<SEC-DOCUMENT>0001654954-20-005509.txt : 20200514
<SEC-HEADER>0001654954-20-005509.hdr.sgml : 20200514
<ACCEPTANCE-DATETIME>20200514172454
ACCESSION NUMBER:		0001654954-20-005509
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200514
DATE AS OF CHANGE:		20200514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENDRA Life Sciences Inc.
		CENTRAL INDEX KEY:			0001681682
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				260579295
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37969
		FILM NUMBER:		20879136

	BUSINESS ADDRESS:	
		STREET 1:		3600 GREEN COURT
		STREET 2:		SUITE 350
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48105
		BUSINESS PHONE:		734-335-0468

	MAIL ADDRESS:	
		STREET 1:		3600 GREEN COURT
		STREET 2:		SUITE 350
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Endra Inc.
		DATE OF NAME CHANGE:	20160805
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ndra_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>ndra_10q</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="font-weight: bold; font-size: 13px">UNITED
STATES</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Washington, D.C. 20549</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM&#xA0;10-Q</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
(Mark One)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font>
&#x2612;</font> <font style="font-weight: bold">QUARTERLY REPORT
PURSUANT TO SECTION&#xA0;13 OR 15(d)&#xA0;OF THE SECURITIES
EXCHANGE ACT OF 1934</font></font></div>
<div style="text-align: left; margin-left: 36px; margin-right: 0px; text-indent: -36px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -36px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">FOR
THE QUARTERLY PERIOD ENDED MARCH 31, 2020</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -36px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">OR</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -36px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font>&#x2610;</font> TRANSITION REPORT PURSUANT TO
SECTION&#xA0;13 OR 15(d)&#xA0;OF THE SECURITIES EXCHANGE ACT OF
1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
COMMISSION FILE NUMBER 001-37969</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA LIFE SCIENCES INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="font-style: italic">(Exact
name of registrant as specified in its charter)</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 49%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Delaware</font></div>
</td>
<td style="vertical-align: middle; width: 2%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 49%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
26-0579295</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 49%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
(State of incorporation)</font></div>
</td>
<td style="vertical-align: middle; width: 2%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 49%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
(I.R.S. Employer Identification No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
3600 Green Court, Suite 350, Ann Arbor, MI 48105-1570</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">
(Address of principal executive office)</font> ( <font style="font-style: italic">Zip code</font> )</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(734)&#xA0;335-0468</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
(Registrant&#x2019;s telephone number, including area
code)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities registered pursuant to Section 12(b) of the
Act:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 32%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Title of each class</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Trading Symbol(s)</font></div>
</td>
<td style="vertical-align: top; width: 33%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Name of each exchange on which registered</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 32%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock, par value $0.0001 per share</font></div>
</td>
<td style="vertical-align: top; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
NDRA</font></div>
</td>
<td style="vertical-align: top; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Nasdaq Stock Market LLC</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 32%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrants, each to purchase one share of Common Stock</font></div>
</td>
<td style="vertical-align: top; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
NDRAW</font></div>
</td>
<td style="vertical-align: top; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Nasdaq Stock Market LLC</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate by check
mark whether the registrant (1)&#xA0;has filed all reports required
to be filed by Section&#xA0;13 or 15(d)&#xA0;of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2)&#xA0;has been subject to such filing requirements
for the past 90 days. Yes <font>&#x2612;</font> No
<font>&#x2610;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate by check
mark whether the registrant has submitted electronically every
Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (&#xA7;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes <font>&#x2612;</font> No <font>&#x2610;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate by check
mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, smaller reporting
company or an emerging growth company. See the definitions of
&#x201C;large accelerated filer,&#x201D; &#x201C;accelerated
filer,&#x201D; &#x201C;smaller reporting company&#x201D; and
&#x201C;emerging growth company&#x201D; in Rule&#xA0;12b-2 of the
Exchange Act:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: bottom; width: 41%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Large
accelerated filer</font></div>
</td>
<td style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2610;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Accelerated
filer</font></div>
</td>
<td style="vertical-align: bottom; width: 7%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2610;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 41%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Non-accelerated
filer</font></div>
</td>
<td style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2612;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Smaller
reporting company</font></div>
</td>
<td style="vertical-align: bottom; width: 7%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2612;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company</font></div>
</td>
<td style="vertical-align: bottom; width: 7%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2612;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <font style="color: #000000">&#x2610;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Indicate by check mark whether the registrant is a
shell company (as defined in Rule&#xA0;12b-2 of the Exchange Act).
Yes</font> <font style="color: #000000">&#x2610;</font> <font style="color: #000000">No</font> <font>&#x2612;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">As of May 14, 2020, there were 14,504,764</font>
shares <font style="color: #000000">of our common stock, par value
$0.0001 per share, outstanding.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; break-after: page; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA LIFE SCIENCES INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 10-Q</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FOR THE THREE MONTHS ENDED MARCH 31, 2020</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
INDEX</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="FIS_PART_I"><!--anchor--></a><a href="#p1">PART I - FINANCIAL INFORMATION&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PAGE</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: top; width: 100%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#i1">Item 1. Financial Statements</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;3</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#i2">Item 2. Management&#x2019;s Discussion and Analysis of
Financial Condition and Results of
Operations&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;19</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#i3">Item 3. Quantitative and Qualitative Disclosure About
Market Risk&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;25</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#i4">Item 4. Controls and
Procedures&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;25</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2">PART&#xA0;II &#x2013; OTHER
INFORMATION</a>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2-i1">Item 1. Legal Proceedings</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2_i1a">Item 1A. Risk Factors&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2_i2">Item 2. Recent Sales of Unregistered Securities;
Use of Proceeds from Registered Securities&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2_i3">Item 3. Defaults Upon Senior
Securities&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2_i4">Item 4. Mine Safety
Disclosures&#xA0;</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#p2_i5">Item 5. Other Information</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a href="#i6">Item 6. Exhibits</a></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;26</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;28</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT INDEX</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: right"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;27</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p1">P</a>ART I - FINANCIAL
INFORMATION</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="i1">I</a>tem 1.&#xA0;Financial
Statements</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA&#xA0;Life&#xA0;Sciences<font style="color: #000000">&#xA0;Inc.</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Condensed Consolidated Balance Sheets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman;">March
31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman;">December
31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman;">2020</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman;">2019</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">(unaudited)</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Cash</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,102,728</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,174,207</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Prepaid
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">373,254</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">116,749</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Inventory</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">174,935</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">113,442</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Other current
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">121,951</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">130,701</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total Current
Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,772,868</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,535,099</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Other
Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Fixed assets,
net</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">237,015</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">236,251</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Right of use
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">389,004</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">404,919</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Total
Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,398,887</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,176,269</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Liabilities
and Stockholders&#x2019; Equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Current
Liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accounts payable
and accrued liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,444,035</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,708,525</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Convertible notes
payable, net of discount</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">38,402</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">298,069</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Lease liabilities,
current portion</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">68,608</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">66,193</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total Current
Liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,551,045</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,072,787</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Long
Term Debt</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Lease
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">325,804</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">342,812</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total Long Term
Debt</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">325,804</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">342,812</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Total
Liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">1,876,849</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">2,415,599</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Stockholders&#x2019;
Equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Preferred stock
series A, $0.0001 par value; 10,000 shares authorized; 2,441.92
shares issued and outstanding</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Preferred stock
series B, $0.0001 par value; 1,000 shares authorized; 121.58 shares
issued and outstanding</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Common stock,
$0.0001 par value; 50,000,000 shares authorized; 13,553,005 and
8,421,401shares issued and outstanding</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,355</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">842</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Additional paid in
capital</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">50,982,080</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">49,933,736</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock
payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">78,836</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">43,528</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accumulated
deficit</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(48,540,234</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(45,217,437</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:60px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total
Stockholders&#x2019; Equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">2,522,038</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">4,760,670</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Total
Liabilities and Stockholders&#x2019; Equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,398,887</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,176,269</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA&#xA0;Life&#xA0;Sciences<font style="color: #000000">&#xA0;Inc.</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Condensed Consolidated Statements of Operations</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;(Unaudited)</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; font-weight: bold;">Three Months
Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; font-weight: bold;">Three Months
Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; font-weight: bold;">March
31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; font-weight: bold;">March
31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; font-weight: bold;">2020</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; font-weight: bold;">2019</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Operating
Expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Research and
development</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,518,146</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,773,498</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Sales and
marketing</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">114,955</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">56,818</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">General and
administrative</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">1,467,745</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">916,903</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total operating
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">3,100,846</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">2,747,219</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Operating
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(3,100,846</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(2,747,219</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Other
Expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Amortization of
debt discount</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(228,568</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Other income
(expense)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">6,617</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(1,517</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total other
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(221,951</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(1,517</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Loss from
operations before income taxes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3,322,797</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2,748,736</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Provision for
income taxes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Net
Loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(3,322,797</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,748,736</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Net
loss per share &#x2013; basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.29</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.37</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Weighted
average common shares &#x2013; basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">11,508,843</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">7,422,642</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying notes are an integral part of these unaudited
condensed&#xA0;consolidated financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA&#xA0;Life&#xA0;Sciences<font style="color: #000000">&#xA0;Inc.</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Condensed Consolidated Statements of Stockholders&#x2019;
Equity</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;(Unaudited)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; margin: 0px auto 0px 0px; width: 100%; font-size: inherit;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Three Months Ended March 31, 2019</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 16%;">
<div><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Series A
Convertible</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 16%;">
<div><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Series B
Convertible</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;"><br></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 16%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Preferred
Stock</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 16%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Preferred
Stock</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 16%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Common
stock</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;"><br></font></font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;"><br></font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;"><br></font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">&#xA0;Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Amount</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">&#xA0;Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Amount</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">&#xA0;Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Amount</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">&#xA0; <font style="font-family:Times New Roman;font-weight:bold;">Additional</font>
Paid in Capital</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Stock
Payable</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Accumulated</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Deficit</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Total</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Stockholders'
Equity</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">&#xA0;Balance as
of December 31, 2018</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">7,422,642</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">742</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">33,939,162</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">(27,691,696</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">6,248,208</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;Fair value of vested stock
options</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">302,268</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:11px;font-family:Times New Roman;display:inline-block;">302,268</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:11px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;Net loss</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(2,748,736</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(2,748,736</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:11px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">&#xA0;Balance as
of March 31, 2019</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:double 4px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:double 4px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:double 4px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:double 4px #000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:5%;border-bottom:double 4px #000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:11px;display:inline-block;width:75%;border-bottom:double 4px #000;">7,422,642</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">742</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">34,241,430</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">(30,440,432</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:11px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:11px;">3,801,740</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:11px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font>&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; margin: 0px auto 0px 0px; width: 100%; font-size: inherit;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman">
Three Months Ended March 31, 2020</font></font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 16%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Series A
Convertible</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 16%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Series B
Convertible</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-family:Times New Roman;">&#xA0;</font><font style="font-family:Times New Roman;font-weight:bold;">Additional</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-family:Times New Roman;">&#xA0;</font><font style="font-family:Times New Roman;font-weight:bold;">Total</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 16%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Preferred
Stock</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 16%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Preferred
Stock</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 16%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Common
stock</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">
<div><font style="font-family:Times New Roman;">&#xA0;</font>
<font style="font-family:Times New Roman;font-weight:bold;">Paid
in</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">
<div><font style="font-family:Times New Roman;">&#xA0;</font><font style="font-family:Times New Roman;font-weight:bold;">Stock</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">
<div><font style="font-family:Times New Roman;">&#xA0;</font><font style="font-family:Times New Roman;font-weight:bold;">Accumulated</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">
<div><font style="font-family:Times New Roman;">&#xA0;</font><font style="font-family:Times New Roman;font-weight:bold;">Stockholders'</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Shares</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Amount</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Shares</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Amount</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Shares</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-family:Times New Roman;font-weight:bold;">Amount</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div>&#xA0; <font style="font-family:Times New Roman;font-weight:bold;">Capital</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div>&#xA0; <font style="font-family:Times New Roman;font-weight:bold;">Payable</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div>&#xA0; <font style="font-family:Times New Roman;font-weight:bold;">Deficit</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div>&#xA0; <font style="font-family:Times New Roman;font-weight:bold;">Equity</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-weight: bold; font-family: Times New Roman">Balance as of
December 31, 2019</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">6,338.490</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">1</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">351.711</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">8,421,401</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">842</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">49,933,736</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">43,528</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">(45,217,437</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">4,760,670</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Series A Convertible Preferred Stock
converted to common stock</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">(3,896.570</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">4,520,982</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">452</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">37,471</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">(37,923</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Series B Convertible Preferred Stock
converted to common stock</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">(230.133</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">234,080</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">23</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">811</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">(835</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Common stock issued for note
conversions</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">331,441</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">33</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">493,814</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">493,847</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Common stock issued for warrant
exercise</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">45,101</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">5</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">39,233</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">39,238</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Fair value of vested stock
options</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">511,080</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">511,080</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Stock to be issued, Preferred
Dividend<br></font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">(34,066</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">34,066</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font></font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Stock to be issued,
Consultant<br></font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">40,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">40,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-family: Times New Roman">Net loss</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">(3,322,797</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">(3,322,797</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">)</font></font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-size: 11px;"><font style="font-weight: bold; font-family: Times New Roman">Balance as of
March 31, 2020</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">2,441.920</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">1</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">121.578</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">-</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">13,553,005</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">1,355</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">50,982,080</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">78,836</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">(48,540,234</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%;">$</font><font style="text-align: right; font-family: Times New Roman; border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%;">2,522,038</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px;">&#xA0;</font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<br>
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying notes are an integral part of these unaudited
condensed&#xA0;consolidated&#xA0;financial statements.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA&#xA0;Life&#xA0;Sciences<font style="color: #000000">&#xA0;Inc.</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Condensed Consolidated Statements of Cash Flows</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
&#xA0;(Unaudited)</font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Three Months Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Three Months Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2020</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2019</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Cash
Flows from Operating Activities</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3,322,797</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2,748,736</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Adjustments to
reconcile net loss to net cash used in operating
activities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Depreciation and
amortization</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">21,586</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19,632</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Common stock,
options and warrants issued for services</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">511,080</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">302,268</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Amortization of
debt discount</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">228,568</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Amortization of
right of use assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,915</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock payable for
investor relations</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">40,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Changes in
operating assets and liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Decrease (increase)
in prepaid expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(256,505</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">40,354</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Decrease in lease
liability</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(14,593</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in
inventory</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(61,493</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(14,831</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in other
asset</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8,750</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in
accounts payable and accrued liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(256,878</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(139,349</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net cash used in
operating activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(3,088,367</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(2,540,662</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Cash
Flows from Investing Activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Purchases of fixed
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(22,350</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(5,239</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net cash used in
investing activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(22,350</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(5,239</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Cash
Flows from Financing Activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Proceeds from
warrant exercise</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">39,238</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net cash provided
by financing activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">39,238</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net decrease in
cash</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3,071,479</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2,545,901</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Cash, beginning of
period</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,174,207</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,471,375</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Cash,
end of period</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,102,728</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,925,474</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Supplemental
disclosures of cash items</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Interest
paid</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,920</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Income tax
paid</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Supplemental
disclosures of non-cash items</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Conversion of
convertible notes and accrued interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">493,814</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Conversion of
Series A Convertible Preferred Stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(452</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Conversion of
Series B Convertible Preferred Stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(23</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock dividend
payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34,066</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Right of use
asset</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">389,004</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Lease
liability</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">394,412</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying notes are an integral part of these unaudited
condensed&#xA0;consolidated&#xA0;financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA Life Sciences Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Notes to Condensed Consolidated Financial Statements</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For the three months ended March 31, 2020 and 2019</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
(Unaudited)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Note 1 &#x2013; Nature of the Business</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
ENDRA Life Sciences Inc. (&#x201C;ENDRA&#x201D; or the
&#x201C;Company&#x201D;) has developed and is continuing to develop
technology for increasing the capabilities of clinical diagnostic
ultrasound, to broaden patient access to the safe diagnosis and
treatment of a number of significant medical conditions in
circumstances where expensive X-ray computed tomography
(&#x201C;CT&#x201D;) and magnetic resonance imaging
(&#x201C;MRI&#x201D;) technology is unavailable or
impractical.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
ENDRA was incorporated on July 18, 2007 as a Delaware
corporation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
ENDRA Life Sciences Canada Inc. was organized under the laws of
Ontario, Canada on July 6, 2017, and is wholly owned by the
Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Note 2 &#x2013; Summary of Significant Accounting
Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Use of Estimates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The preparation of the financial statements in conformity with
accounting principles generally accepted in the United States
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, and disclosure of
contingent liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Management makes estimates that affect certain accounts including
deferred income tax assets, accrued expenses, fair value of equity
instruments and reserves for any other commitments or
contingencies. Any adjustments applied to estimates are recognized
in the period in which such adjustments are
determined.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Principles of Consolidation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
The Company&#x2019;s consolidated financial statements include all
accounts of the Company and its consolidated subsidiary and/or
entities as of reporting period ending date(s) and for the
reporting period(s) then ended. All inter-company balances and
transactions have been eliminated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Basis of Presentation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
The accompanying unaudited condensed consolidated financial
statements and related notes have been prepared pursuant to the
rules and regulations of the Securities and Exchange Commission
(the &#x201C;SEC&#x201D;). Accordingly, certain information and
footnote disclosures normally included in financial statements
prepared in accordance with generally accepted accounting
principles have been omitted pursuant to such rules and
regulations. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for
a fair presentation have been included. Operating results for the
three months ended March 31, 2020 are not necessarily indicative of
the results that may be expected for the year ended December 31,
2020. The balance sheet at December 31, 2019 has been derived from
the audited financial statements at that date. For further
information, refer to the financial statements and footnotes
thereto included in ENDRA Life Sciences Inc. annual financial
statements for the twelve months ended December 31, 2019 included
in the Company&#x2019;s Annual Report on Form 10-K filed with the
SEC on March 26, 2020.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Cash and Cash Equivalents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
The Company considers all cash on hand and in banks, including
accounts in book overdraft positions, certificates of deposit and
other highly-liquid investments with maturities of one year or
less, when purchased, to be cash. As of March 31, 2020 and December
31, 2019, the Company had no cash equivalents. The Company
maintains its cash in bank deposit accounts which, at times, may
exceed federally insured limits. The Company has not experienced
any losses in such accounts and periodically evaluates the credit
worthiness of the financial institutions and has determined the
credit exposure to be negligible.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">7</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="text-decoration: underline; color: #000000">Inventory</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
The Company&#x2019;s inventory is stated at the lower of cost or
estimated net realizable value, with cost primarily determined on a
weighted-average cost basis on the first-in, first-out method. The
Company periodically determines whether a reserve should be taken
for devaluation or obsolescence of inventory.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Capitalization of Fixed Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
The Company capitalizes expenditures related to property and
equipment, subject to a minimum rule, that have a useful life
greater than one year for: (1) assets purchased; (2) existing
assets that are replaced, improved or the useful lives have been
extended; or (3) all land, regardless of cost. Acquisitions of new
assets, additions, replacements and improvements (other than land)
costing less than the minimum rule in addition to maintenance and
repair costs, including any planned major maintenance activities,
are expensed as incurred.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Revenue Recognition</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In May 2014, the Financial Accounting Standards Board
(&#x201C;FASB&#x201D;) issued Accounting Standards Update
(&#x201C;ASU&#x201D;) No. 2014-09, &#x201C;Revenue from Contracts with
Customers&#x201D; (&#x201C;ASC Topic 606&#x201D;). This standard
provides a single set of guidelines for revenue recognition to be
used across all industries and requires additional disclosures. The
updated guidance introduces a five-step model to achieve its core
principal of the entity recognizing revenue to depict the transfer
of goods or services to customers at an amount that reflects the
consideration to which the entity expects to be entitled in
exchange for those goods or services. The Company adopted the
updated guidance effective January 1, 2018 using the full
retrospective method. The new standard did not have a material
impact on its financial position and results of operations, as it
did not change the manner or timing of recognizing
revenue.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Under ASC Topic 606, in order to recognize revenue, the Company is
required to identify an approved contract with commitments to
perform respective obligations, identify rights of each party in
the transaction regarding goods to be transferred, identify the
payment terms for the goods transferred, verify that the contract
has commercial substance and verify that collection of
substantially all consideration is probable. The adoption of ASC
Topic 606 did not have an impact on the Company&#x2019;s operations
or cash flows.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Research and Development Costs</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company follows FASB Accounting Standards Codification
(&#x201C;ASC&#x201D;) Subtopic 730-10, &#x201C;Research and
Development&#x201D;. Research and development costs are charged to
the statement of operations as incurred. During the three months
ended March 31, 2020 and 2019, the Company incurred $1,518,146 and
$1,773,498 of expenses related to research and development costs,
respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Net Earnings (Loss) Per Common Share</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The Company computes earnings per share under ASC Subtopic 260-10,
&#x201C;Earnings Per Share&#x201D;. Basic earnings (loss) per share
is computed by dividing the net income (loss) attributable to the
common stockholders (the numerator) by the weighted average number
of shares of common stock outstanding (the denominator) during the
reporting periods. Diluted loss per share is computed by increasing
the denominator by the weighted average number of additional shares
that could have been outstanding from securities convertible into
common stock (using the &#x201C;treasury stock&#x201D; method),
unless their effect on net loss per share is anti-dilutive. There
were 19,992,774</font>&#xA0;<font style="color: #000000">and
24</font>,949,725 <font style="color: #000000">potentially dilutive
shares, which include shares of common stock issuable upon the
exercise or conversion of outstanding preferred stock, stock
options, warrants, and convertible notes, as of March 31, 2020
and&#xA0;</font>December 31, 2019,&#xA0;<font style="color: #000000">respectively.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The potentially dilutive shares, which are excluded from the
determination of basic and diluted net loss per share as their
effect is anti-dilutive, are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">March
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2020</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2019</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Options to purchase
common stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,579,737</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,449,319</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Warrants to
purchase common stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,451,823</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,496,924</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Shares issuable
upon conversion of notes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">31,603</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">362,568</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Shares issuable
upon conversion of Series A Preferred Stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,806,805</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7,285,651</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Shares issuable
upon conversion of Series B Preferred&#xA0;Stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">122,806</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">355,263</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Potentially
dilutive shares excluded</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,992,774</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,949,725</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">8</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Fair Value Measurements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Disclosures about fair value of financial instruments require
disclosure of the fair value information, whether or not recognized
in the balance sheet, where it is practicable to estimate that
value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
In accordance with ASC Topic 820, &#x201C;Fair Value Measurements
and Disclosures,&#x201D; the Company measures certain financial
instruments at fair value on a recurring basis. ASC Topic 820
defines fair value, established a framework for measuring fair
value in accordance with accounting principles generally accepted
in the United States, and expands disclosures about fair value
measurements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Fair value is defined as the price that would be received to sell
an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. ASC Topic 820
established a three-tier fair value hierarchy, which prioritizes
the inputs used in measuring fair value. The hierarchy gives the
highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (Level 1 measurements) and the
lowest priority to unobservable inputs (Level 3 measurements).
These tiers include:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#x25CF;</font> <font style="color: #000000; background-color: #FFFFFF">Level 1, defined as
observable inputs such as quoted prices for identical instruments
in active markets;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#x25CF;</font> <font style="color: #000000; background-color: #FFFFFF">Level 2, defined as
inputs other than quoted prices in active markets that are either
directly or indirectly observable such as quoted prices for similar
instruments in active markets or quoted prices for identical or
similar instruments in markets that are not active;
and</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#x25CF;</font> <font style="color: #000000; background-color: #FFFFFF">Level 3, defined as
unobservable inputs in which little or no market data exists,
therefore requiring an entity to develop its own assumptions, such
as valuations derived from valuation techniques in which one or
more significant inputs or significant value drivers are
unobservable.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Financial assets are considered Level 3 when their fair values are
determined using pricing models, discounted cash flow methodologies
or similar techniques and at least one significant model assumption
or input is unobservable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The carrying amounts of the Company&#x2019;s financial assets and
liabilities, including cash, accounts receivable, prepaid expenses,
accounts payable, accrued expenses, and other current liabilities,
approximate their fair values because of the short maturity of
these instruments. The fair value of notes payable and convertible
notes approximates their fair values since the current interest
rates and terms on these obligations are the same as prevailing
market rates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Share-based Compensation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company&#x2019;s 2016 Omnibus Incentive Plan (the &#x201C;Omnibus
Plan&#x201D;) permits the grant of stock options and other
share-based awards to its employees, consultants and non-employee
members of the board of directors. Each January 1 the pool of
shares available for issuance under the Omnibus Plan automatically
increases by an amount equal to the lesser of (i) the number of
shares necessary such that the aggregate number of shares available
under the Omnibus Plan equals 25% of the number of fully-diluted
outstanding shares on the increase date (assuming the conversion of
all outstanding shares of preferred stock and other outstanding
convertible securities and exercise of all outstanding options and
warrants to purchase shares) and (ii) if the board of directors
takes action to set a lower amount, the amount determined by the
board. On January 1, 2020, the pool of shares issuable under the
Omnibus Plan automatically increased by 3,202,280 shares from
2,649,378 shares to 5,861,658. As of March 31, 2020, there were
2,281,921 shares of common stock remaining available for issuance
under the Omnibus Plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company records share-based compensation in accordance with the
provisions of the Share-based Compensation Topic of the FASB
Codification. The guidance requires the use of option-pricing
models that require the input of highly subjective assumptions,
including the option&#x2019;s expected life and the price volatility
of the underlying stock. The fair value of each option grant is
estimated on the date of grant using the Black-Scholes option
valuation model, and the resulting charge is expensed using the
straight-line attribution method over the vesting
period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Stock compensation expense recognized during the period is based on
the value of share-based awards that were expected to vest during
the period adjusted for estimated forfeitures. The estimated fair
value of grants of stock options and warrants to non-employees of
the Company is charged to expense, if applicable, in the financial
statements. These options vest in the same manner as the employee
options granted under the stock incentive plan as described
above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="text-decoration: underline; color: #000000">Debt
Discount</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company determines if its outstanding convertible promissory
notes should be accounted for as liability or equity under ASC
Topic 480, &#x201C;Liabilities &#x2014; Distinguishing Liabilities
from Equity.&#x201D; ASC Topic 480 applies to certain contracts
involving a company&#x2019;s own equity, and requires that issuers
classify the following freestanding financial instruments as
liabilities: mandatorily redeemable financial instruments,
obligations that require or may require repurchase of the
issuer&#x2019;s equity shares by transferring assets (e.g., written
put options and forward purchase contracts), and certain
obligations where at inception the monetary value of the obligation
is based solely or predominantly on:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#x25CF; A fixed monetary amount known at inception (for example, a
payable settleable with a variable number of the issuer&#x2019;s
equity shares with an issuance date fair value equal to a fixed
dollar amount);</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#x25CF; Variations in something other than the fair value of the
issuer&#x2019;s equity shares (for example, a financial instrument
indexed to the S&amp;P 500 and settleable with a variable number of
the issuer&#x2019;s equity shares); or</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#x25CF; Variations inversely related to changes in the fair value
of the issuer&#x2019;s equity shares (for example, a written put
that could be net share settled).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">9</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Beneficial Conversion Feature</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If the
conversion feature of conventional convertible debt provides for a
rate of conversion that is below market value on the date of
issuance, this feature is characterized as a beneficial conversion
feature (&#x201C;BCF&#x201D;). A BCF is recorded by the Company as a
debt discount pursuant to ASC Topic 470-20 &#x201C;Debt with
Conversion and Other Options.&#x201D; In those circumstances, the
convertible debt is recorded net of the discount related to the BCF
and the Company amortizes the discount to interest expense over the
life of the debt using the effective interest method.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If the Company determines the instrument meets the guidance under
ASC Topic 480, the instrument is accounted for as a liability with
a respective debt discount. The Company has previously recorded
debt discounts in connection with raising funds through the
issuance of promissory notes. These costs are amortized to noncash
interest expense over the life of the debt. If a conversion of the
underlying debt occurs, a proportionate share of the unamortized
amounts is immediately expensed. See Note 6, Convertible Notes, for
further discussion on the Company&#x2019;s accounting treatment for
the convertible notes.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Going Concern</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s financial statements are prepared using accounting
principles generally accepted in the United States (&#x201C;U.S.
GAAP&#x201D;) applicable to a going concern, which contemplates the
realization of assets and liquidation of liabilities in the normal
course of business. The Company has limited commercial experience
and had a cumulative net loss from inception to March 31, 2020 of
$48,540,234. The Company had working capital of $2,221,823 as of
March 31, 2020. The Company has not established an ongoing source
of revenue sufficient to cover its operating costs and to allow it
to continue as a going concern. The accompanying financial
statements for the period ended March 31, 2020 have been prepared
assuming the Company will continue as a going concern. The
Company&#x2019;s cash resources will likely be insufficient to meet
its anticipated needs during the next twelve months. The Company
will require additional financing to fund its future planned
operations, including research and development and
commercialization of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
ability of the Company to continue as a going concern is dependent
on the Company obtaining adequate capital to fund operating losses
until it establishes a revenue stream and becomes profitable.
Management&#x2019;s plans to continue as a going concern include
raising additional capital through sales of equity securities and
borrowing. However, management cannot provide any assurances that
the Company will be successful in accomplishing any of its plans.
As described further below under &#x201C;Item 2. Management&#x2019;s
Discussion and Analysis of Financial Condition and Results of
Operations&#x201D; the COVID-19 pandemic has impacted our business
operations to some extent and is expected to continue to do so and,
in light of the effect of such pandemic on financial markets, these
impacts may include reduced access to capital. If the Company is
not able to obtain the necessary additional financing on a timely
basis, the Company will be required to delay, reduce the scope of
or eliminate one or more of the Company&#x2019;s research and
development activities or commercialization efforts or perhaps even
cease the operation of its business. The ability of the Company to
continue as a going concern is dependent upon its ability to
successfully secure other sources of financing and attain
profitable operations. There is substantial doubt about the ability
of the Company to continue as a going concern for one year from the
issuance of the accompanying consolidated financial statements. The
accompanying consolidated financial statements do not include any
adjustments that might be necessary if the Company is unable to
continue as a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Recent Accounting Pronouncements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
In May 2014, the FASB issued ASU No. 2014-09, &#x201C;Revenue from
Contracts with Customers.&#x201D; ASU 2014-09 is a comprehensive
revenue recognition standard that superseded nearly all previous
revenue recognition guidance under U.S. GAAP and replaced it with a
principle-based approach for determining revenue recognition. Under
ASU 2014-09, revenue is recognized when a customer obtains control
of promised goods or services and is recognized in an amount that
reflects the consideration which the entity expects to receive in
exchange for those goods or services. In addition, the standard
requires disclosure of the nature, amount, timing, and uncertainty
of revenue and cash flows arising from contracts with customers.
The FASB has since issued ASU 2016-08, ASU 2016-10, ASU 2016-11,
ASU 2016-12, and ASU 2016-20, all of which clarify certain
implementation guidance within ASU 2014-09. ASU 2014-09 is
effective for interim and annual periods beginning after December
15, 2017. The standard can be adopted either retrospectively to
each prior reporting period presented (full retrospective method),
or retrospectively with the cumulative effect of initially applying
the guidance recognized at the date of initial application (the
cumulative catch-up transition method). The Company has reviewed
ASU 2014-09 and using the full retrospective method has determined
that its adoption has had no impact on its financial position,
results of operations or cash flows. The Company adopted the
provisions of this standard in the first quarter of fiscal
2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In February 2016, the FASB issued ASU No. 2016-02,
&#x201C;Leases.&#x201D; ASU 2016-02 requires a lessee to record a
right of use asset and a corresponding lease liability on the
balance sheet for all leases with terms longer than 12 months. ASU
2016-02 is effective for all interim and annual reporting periods
beginning after December 15, 2018. Early adoption is permitted. A
modified retrospective transition approach is required for lessees
for capital and operating leases existing at, or entered into
after, the beginning of the earliest period presented in the
financial statements. The Company evaluated the impact that the
application of the new standard has on its consolidated financial
statements and related disclosures, and determined that it should
record a total lease liability of $431,363, with a corresponding
right of use asset valued at $430,681. The Company adopted the
provisions of this standard in the first quarter of fiscal
2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Other recent accounting pronouncements issued by the FASB,
including its Emerging Issues Task Force, the American Institute of
Certified Public Accountants, and the SEC, did not or in
management&#x2019;s opinion will not have a material impact on the
Company&#x2019;s present or future consolidated financial
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">10</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 3 &#x2013; Inventory</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
As of March 31, 2020 and December 31, 2019, inventory consisted of
raw materials and subassemblies to be used in the assembly of a
TAEUS system. As of March 31, 2020, the Company had no orders
pending for the sale of a TAEUS system.</font> <font style="background-color: #FFFFFF">As of March 31, 2020 and December 31,
2019, the Company had</font> <font style="color: #000000; background-color: #FFFFFF">inventory valued at
$174,935 and $113,442, respectively.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 4 &#x2013; Fixed Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As of
March 31, 2020 and December 31, 2019, fixed assets consisted of the
following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">March
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">2020</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">2019</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Property, leasehold
and capitalized software</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">684,418</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">679,179</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">TAEUS development
and testing</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">60,708</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">43,596</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accumulated
depreciation</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(508,111</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(486,524</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Fixed assets,
net</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">237,015</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">236,251</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Depreciation
expense for the three months ended March 31, 2020 and 2019 was
$21,586 and $19,632, respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 5 &#x2013; Accounts Payable and Accrued
Liabilities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As of
March 31, 2020 and December 31, 2019, current liabilities consisted
of the following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">March
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">2020</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">2019</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accounts
payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,240,687</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,278,431</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accrued
payroll</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">95,656</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">94,862</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accrued
bonuses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">97,114</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">295,794</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accrued employee
benefits</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,750</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,750</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accrued
interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,828</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,738</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Insurance premium
financing</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">23,950</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,444,035</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,708,525</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 6 &#x2013; Convertible Notes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
July 2019 Notes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On July 26, 2019 the Company conducted a private placement offering
in which the Company sold senior secured convertible promissory
notes (the &#x201C;July 2019 Notes&#x201D;) and warrants exercisable
for shares of the Company&#x2019;s common stock (the &#x201C;July
2019 Warrants&#x201D;) to accredited investors for a purchase price
approximately $2.8 million. The purchase price covered the purchase
of $2,587,895 aggregate principal amount of July 2019 Notes and
July 2019 Warrants exercisable for an aggregate of 1,736,843 shares
of common stock. The net proceeds to the Company were approximately
$2.5 million, after deducting placement agent fees and other
offering expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company sold the July 2019 Notes and July 2019 Warrants
pursuant to a Securities Purchase Agreement, dated July 26, 2019,
between the Company and each purchaser. The July 2019 Notes bore
interest at a rate of 10% per annum until maturity on April 26,
2020. Interest was paid in arrears on the outstanding principal
amount on the three month anniversary of the issuance of the July
2019 Notes, and each three month period thereafter, and finally on
the maturity date. Holders of July 2019 Notes were entitled to
convert principal and accrued, unpaid interest on the July 2019
Notes into shares of common stock. The July 2019 Notes were
convertible into common stock at a conversion price per share equal
to $1.49 and were initially convertible into 1,736,843 shares of
common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Each July 2019 Warrant entitles the holder to purchase one share of
common stock for an exercise price per share equal to $1.49. The
July 2019 Warrants are exercisable for an aggregate of 1,736,843
shares of common stock commencing immediately upon issuance and
expire July 26, 2022. The July 2019 Warrants provide for cashless
exercise and customary anti-dilution protection. The terms of the
Placement Agent Warrant (as defined below) are the same as those of
the July 2019 Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">
National Securities Corporation (the &#x201C;Placement Agent&#x201D;)
acted as placement agent in the offering pursuant to a Placement
Agent Agreement, dated July 9, 2019 (the &#x201C;Placement Agent
Agreement&#x201D;). Pursuant to the Placement Agent Agreement, the
Company paid to the Placement Agent a commission of 10% of the
gross proceeds from the offering, reimbursed $30,000 of the
Placement Agent&#x2019;s expenses and issued to the Placement Agent
a warrant exercisable for 173,685 shares of common stock (the
&#x201C;Placement Agent
Warrant&#x201D;).</font>&#xA0;<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">11</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The July 2019 Notes and July 2019 Warrants include embedded
derivatives that require bifurcation from the host contract under
the provisions of ASC 815-40, &#x201C;Derivatives and
Hedging.&#x201D; The estimated fair value of the derivative warrant
instruments was calculated using a Black-Scholes valuation model.
At inception, the aggregate relative fair value of the 1,910,538
warrants issued to the investors and the Placement Agent in July
2019 was determined to be $1,993,714 using the Black-Scholes-Merton
Option Pricing model with the following average assumptions: (i)
volatility rate of 111%, (ii) discount rate of 0%, (iii) zero
expected dividend yield, and (iv) expected life of three years. Out
of such amount, $1,126,138 was recorded as debt discount upon
issuance using allocation of proceeds.</font>&#xA0;<font style="color: #000000; background-color: #FFFFFF">At the issuance of the
July 2019 Notes, the effective conversion price was analyzed at
$0.84 per share of common stock and the market price of the shares
on the date of conversion was $1.54 per share. As a result, the
Company recognized aggregate beneficial conversion features of
$1,440,638.</font>&#xA0;<font style="color: #000000">$1,147,257 was
recorded as debt discount upon issuance of the July 2019 Notes
using allocation of proceeds.</font>&#xA0;<font style="color: #000000; background-color: #FFFFFF">As a result, the
Company recorded a note discount of $2,587,895 to account for the
funding cost of $314,500 and the relative fair values of the
warrants&#x2019; and the notes&#x2019; beneficial conversion
features, which will be amortized as interest over the terms of the
warrants and the notes or in full upon exercise of the warrants and
conversion of the notes.</font>&#xA0;<font style="color: #000000">During the three months ended March 31, 2020, the
Company amortized $228,568 of such discount to interest expense,
and the unamortized discount as of March 31, 2020 was
$3,858.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On December 11, 2019, the Company completed an offering of its
Series A Convertible Preferred Stock (&#x201C;Series A Preferred
Stock&#x201D;), described below under Note 7. In connection with the
offering, the Company retired $1,919,008 aggregate principal amount
of the July 2019 Notes and $24,184 in accrued interest, which
amounts were used by the noteholders to purchase an aggregate of
1,690.58 shares of Series A Preferred Stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of March 31, 2020, the Company had a total of $42,260 in
principal amount of July 2019 Notes outstanding, and unamortized
debt discount of $3,858, for a net balance of $38,402 amount of the
July 2019 Notes remaining outstanding.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 7 &#x2013; Capital Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">At
March 31, 2020, the authorized capital of the Company consisted of
60,000,000 shares of capital stock, consisting of 50,000,000 shares
of common stock with a par value of $0.0001 per share and
10,000,000 shares of preferred stock with a par value of $0.0001
per share. The Company has designated 10,000 shares of its
preferred stock as Series A Preferred Stock and 1,000 shares of its
preferred stock as Series B Preferred Stock, and the remainder of
9,989,000 shares remain authorized but undesignated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As of
March 31, 2020, there were 13,553,005 shares of common stock,
2,441.92 shares of Series A Preferred Stock, and 121.578 shares of
Series B Preferred Stock issued and outstanding, and a stock
payable balance of $78,836.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
During the three months ended March 31, 2020, the Company issued
4,520,982 shares of its common stock upon the conversion of
3,896.570 shares of its</font> Series A Preferred Stock, and
<font style="color: #000000">234,080 shares of its common stock
upon the conversion of 230.133 shares of its</font> Series B
Preferred Stock<font style="color: #000000">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
During the three months ended March 31, 2020, the Company issued
331,441 shares of its common stock upon the conversion of $493,847
principal amount of, and in respect of accrued interest on, July
2019 Notes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
During the three months ended March 31, 2020, the Company issued
45,101 shares of its common stock upon warrant exercises
valued</font> at $39,238.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
<font style="font-weight: bold">December 2019 Offering of Series A
Preferred Stoc</font>k<font style="font-weight: bold">, Common
Stock and Warrants</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 11, 2019, the Company completed a private placement
offering in which the Company sold 6,338.49 shares of its Series A
Preferred Stock and 904,526 shares of its common stock, along with
warrants (the &#x201C;December 11, 2019 Warrants&#x201D;) exercisable
for an aggregate of 8,190,225 shares of common stock, for
approximately $7.9 million of gross proceeds. The offering was made
pursuant to a Securities Purchase Agreement (the &#x201C;Purchase
Agreement&#x201D;), dated as of December 5, 2019, between the
Company and the investors. Pursuant to the Purchase Agreement, each
investor elected whether to receive shares of Series A Preferred
Stock or shares of common stock in the offering. The Company used
approximately $1.9 million of the net proceeds from the offering to
repay debt represented by July 2019 Notes and plans to use the
remaining net proceeds for working capital and general corporate
purposes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">12</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the closing of the offering, the Company filed a
Certificate of Designations of Series A Convertible Preferred Stock
(the &#x201C;Series A Certificate of Designations&#x201D;) with the
Secretary of State of the State of Delaware setting forth the
rights and preferences of the Series A Preferred Stock. Each share
of Series A Preferred Stock has a $1,000 issue price (the
&#x201C;Issue Price&#x201D;). Dividends accrue on the Issue Price at
a rate of 6.0% per annum and are payable to holders of Series A
Preferred Stock as, when and if declared by the Company&#x2019;s
Board of Directors. Shares of Series A Preferred Stock, including
accrued but unpaid dividends, are convertible into common stock at
a conversion price of $0.87 per share. The conversion price is
subject to proportional adjustment for certain transactions
relating to the Company&#x2019;s capital stock, including stock
splits, stock dividends and similar transactions. Holders of shares
of Series A Preferred Stock vote with the holders of common stock
and are entitled to a number of votes equal to the number of shares
of common stock into which such holder&#x2019;s shares of Series A
Preferred Stock are then convertible. Holders of Series A Preferred
Stock are entitled to a liquidation preference in the event of any
liquidation, dissolution or winding up of the Company based on
their shares&#x2019; aggregate Issue Price and accrued and unpaid
dividends thereon. Holders may convert their shares of Series A
Preferred Stock into common stock at any time and the Company has
the right to cause each holder to convert their shares of Series A
Preferred Stock if at any time (i) the simple average of the daily
volume-weighted average price of Common Stock for 10 consecutive
trading days is greater than $1.74 (as adjusted for stock splits,
stock dividends and similar transactions) and (ii) there is then an
effective registration statement registering under the Securities
Act of 1933, as amended (the &#x201C;Securities Act&#x201D;), the
resale of the shares of common stock issuable upon such conversion
of Series A Preferred Stock (the &#x201C;Series A Forced Conversion
Conditions&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
simple average of the Daily VWAP (as defined in the Series A
Certificate of Designations) for the 10 consecutive trading days
from January 8, 2020 to January 22, 2020, inclusive, was $1.82,
satisfying the first Forced Conversion Condition. On January 27,
2020, the SEC declared effective the Company&#x2019;s Registration
Statement on Form S-3 (File No. 333-235883) registering under the
Securities Act the resale of the shares of common stock issuable
upon the conversion of Series A Preferred Stock, shares of common
stock issued in the offering, and shares of common stock issuable
upon the exercise of December 11, 2019 Warrants and December 11,
2019 Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Each
December 11, 2019 Warrant entitles the holder to purchase a share
of common stock for an exercise price equal to $0.87. The December
11, 2019 Warrants are exercisable commencing immediately upon
issuance and expire on the date five years after the date of
issuance, unless earlier terminated pursuant to the terms of the
December 11, 2019 Warrant. If, during the term of the December 11,
2019 Warrants, the Series A Forced Conversion Conditions are met,
the Company may deliver notice thereof to the holders of the
December 11, 2019 Warrants and, after a 30-day period following
such notice, any unexercised December 11, 2019 Warrants will be
forfeited. The December 11, 2019 Warrants provide for cashless
exercise only if there is no effective registration statement
registering under the Securities Act the resale of the shares of
Common Stock issuable upon exercise of the December 11, 2019
Warrants. As described in the preceding paragraph, the Series A
Forced Conversion Conditions have been met with respect to the
December 11, 2019 Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Securities Purchase Agreement, dated December 5, 2019, includes
customary representations, warranties and covenants. In connection
with the offering, the Company paid to the placement agent a
commission of 8.0% of the gross proceeds from the offering, will
reimburse up to $35,000 of the placement agent&#x2019;s documented
expenses and issued to the placement agent and its designees
warrants exercisable for an aggregate of 327,606 shares of Common
Stock (the &#x201C;Series A Placement Agent Warrant&#x201D;). The
terms of the Series A Placement Agent Warrant are the same as those
of the December 11, 2019 Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Series A Preferred Stock Deemed Dividend, Beneficial Conversion
Calculation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">After
factoring in the relative fair value of the warrants issued in
conjunction with the Series A Preferred Stock, the effective
conversion price is $0.45 per share, compared to the market price
of $0.90 per share on the date of issuance. As a result, a
$4,208,612 beneficial conversion feature was recorded as
a&#xA0;deemed dividend&#xA0;in the consolidated statement of
operations because the Series A Preferred Stock is immediately
convertible, with a credit to additional paid-in capital. The
relative fair value of the warrants issued with the Series A
Preferred Stock of $2,766,941 was recorded as a reduction to the
carrying amount of the preferred stock in the consolidated balance
sheet. The value of the warrants was determined utilizing the
binomial option pricing model using a term of 5 years, a volatility
of 114%, a risk-free interest rate of 1.64%, a 6% rate of
dividends, and a call multiple of 2.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
December 2019 Offering of Series B Preferred Stock and
Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 19, 2019, the Company completed a private placement
offering in which the Company sold 351.711 shares of its Series B
Preferred Stock and warrants (the &#x201C;December 19, 2019
Warrants&#x201D;) exercisable for an aggregate of 426,316 shares of
the Company&#x2019;s common stock to the investors for approximately
$405,000 of gross proceeds. The Company plans to use the net
proceeds from the offering for working capital and general
corporate purposes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the closing of the offering, the Company filed a
Certificate of Designations of Series B Convertible Preferred Stock
(the &#x201C;Series B Certificate of Designations&#x201D;) with the
Secretary of State of the State of Delaware setting forth the
rights and preferences of the Series B Preferred Stock. The Series
B Preferred Stock has substantially the same rights and preferences
as the Series A Preferred Stock, except for a different conversion
price and trading price of common stock at which the Series B
Preferred Stock becomes subject to automatic conversion. Each share
of Series B Preferred Stock has a $1,000 issue price (the
&#x201C;Issue Price&#x201D;). Dividends accrue on the Issue Price at
a rate of 6.0% per annum and are payable to holders of Preferred
Stock as, when and if declared by the Company&#x2019;s Board of
Directors. Shares of Series B Preferred Stock, including accrued
but unpaid dividends, are convertible into Common Stock at a
conversion price of $0.99 per share of common stock. The conversion
price is subject to proportional adjustment for certain
transactions relating to the Company&#x2019;s capital stock,
including stock splits, stock dividends and similar transactions.
Holders of shares of Series B Preferred Stock vote with the holders
of common stock and are entitled to a number of votes equal to the
number of shares of common stock into which such holder&#x2019;s
shares of Series A Preferred Stock are then convertible. Holders of
Series B Preferred Stock are entitled to a liquidation preference
in the event of any liquidation, dissolution or winding up of the
Company based on their shares&#x2019; aggregate Issue Price and
accrued and unpaid dividends. Such liquidation preference of Series
B Preferred Stock holders is on a pari passu basis with holders of
Series A Preferred Stock. Holders may convert their shares of
Series B Preferred Stock into common stock at any time and the
Company has the right to cause each holder to convert their shares
of Series B Preferred Stock in the event that (i) the average of
the daily volume-weighted average price of Common Stock over any 10
consecutive trading days is greater than $1.98 (as adjusted for
stock splits, stock dividends and similar transactions) and (ii)
there is then an effective registration statement registering under
the Securities Act the resale of the shares of Common Stock
issuable upon such conversion of Preferred Stock (together, the
&#x201C;Series B Forced Conversion Conditions&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
average daily VWAP requirement of the Series B Forced Conversion
Conditions relating to daily volume-weighted average price of our
Common Stock has not yet been satisfied. On January 27, 2020, the
SEC declared effective the Company&#x2019;s Registration Statement
on Form S-3 (File No. 333-235883) registering under the Securities
Act the resale of the shares of common stock issuable upon the
conversion of Series B Preferred Stock and upon the exercise of
December 19, 2019 Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Each
December 19, 2019 Warrant entitles the holder to purchase a share
of common stock for an exercise price equal to $0.99. The December
19, 2019 Warrants are exercisable commencing immediately upon
issuance and expire on the date five years after the date of
issuance, unless earlier terminated pursuant to the terms of the
December 19, 2019 Warrant. If, during the term of the December 19,
2019 Warrants, the Series B Forced Conversion Conditions are met,
the Company may deliver notice thereof to the holders of the
December 19, 2019 Warrants and, after a 30-day period following
such notice, any unexercised December 19, 2019 Warrants will be
forfeited. The December 19, 2019 Warrants provide for cashless
exercise in the event there is no effective registration statement
registering under the Securities Act the resale of the shares of
common stock issuable upon exercise of such December 19, 2019
Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Securities Purchase Agreement, dated December 19, 2019, includes
customary representations, warranties and covenants. In connection
with the closing of the offering, the Company paid to the placement
agent in the offering a commission of approximately 8.0% of the
gross proceeds from the offering and issued to the placement agent
and its designees warrants exercisable for an aggregate of 14,211
shares of common stock (the &#x201C;Series B Placement Agent
Warrant&#x201D;). The terms of the Series B Placement Agent Warrant
are the same as those of the Warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Series B Preferred Stock Deemed Dividend, Beneficial Conversion
Calculation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">After
factoring in the relative fair value of the warrants issued in
conjunction with the Series B Preferred Stock, the effective
conversion price is $0.03 per share, compared to the market price
of $1.36 per share on the date of issuance. As a result, a $11,165
beneficial conversion feature was recorded as a deemed dividend in
the consolidated statement of operations because the Series B
Preferred Stock is immediately convertible, with a credit to
additional paid-in capital. The relative fair value of the warrants
issued with the Series B Preferred Stock of $364,355 was recorded
as a reduction to the carrying amount of the preferred stock in the
consolidated balance sheet. The value of the warrants was
determined utilizing the binomial option pricing model using a term
of 5 years, a volatility of 118%, a risk-free interest rate of
1.75%, a 0% rate of dividends, and a call multiple of
2.</font></div>
&#xA0;&#xA0;</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">14</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 8 &#x2013; Common Stock Options</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Stock
options are awarded to the Company&#x2019;s employees, consultants
and non-employee members of the board of directors under the 2016
Omnibus Incentive Plan (the &#x201C;Omnibus Plan&#x201D;) and are
generally <font style="color: #000000">granted with an exercise
price equal to the market price of the Company&#x2019;s common stock
at the date of grant. The aggregate fair value of these stock
options granted by the Company during the three months ended March
31, 2020 was determined to be $185,602 using the
Black-Scholes-Merton option-pricing model based on the following
assumptions: (i) volatility rate of 116% to 119%, (ii) discount
rate of 0%, (iii) zero expected dividend yield, and (iv) expected
life of 10 years. A summary of option activity under the
Company&#x2019;s Omnibus Plan as of March 31, 2020, and changes
during the year then ended, is presented below:</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:64%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman;">Number of
Options</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman;">Weighted</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman;">Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman;">Exercise
Price</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman;">Weighted</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman;">Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman;">Remaining</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman;">Contractual Term
(Years)</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Balance outstanding
at December 31, 2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,449,319</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.32</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8.26</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">130,418</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">0.24</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.01</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Cancelled or
expired</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Balance outstanding
at March 31, 2020</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,579,737</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.24</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7.79</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Exercisable at
March 31, 2020</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">856,172</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4.77</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5.20</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 9 &#x2013; Common Stock Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
During the three months ended March 31, 2020, the Company issued an
aggregate of 45,101 shares of its common stock upon warrant
exercises valued at $39,238.</font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following table summarizes all stock warrant activity of the
Company for the three months ended March 31, 2020:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:57%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Number of
Warrants</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Weighted Average
Exercise Price</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Weighted</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Average</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Remaining</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Contractual Term
(Years)</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Balance outstanding
at December 31, 2019</font></div>
</td>
<td style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,496,924</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.02</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4.07</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(45,101</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">0.87</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4.70</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:30%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:2%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Balance outstanding
at March 31, 2020</font></div>
</td>
<td style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,451,823</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.03</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3.82</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:57%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Exercisable at
March 31, 2020</font></div>
</td>
<td style="vertical-align:bottom;width:19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,451,823</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:11%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.03</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3.82</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">15</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Note 10 &#x2013; Commitments &amp; Contingencies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Office Lease</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Effective January 1, 2015, the Company entered into an office lease
agreement with Green Court, LLC, a Michigan limited liability
company, for approximately 3,657 rentable square feet of space, for
the initial monthly rent of $5,986, which commenced on January 1,
2015 for an initial term of 60 months. On October 10, 2017 this
lease was amended increasing the rentable square feet of space to
3,950 and the monthly rent to $7,798. On July 16, 2019, the Company
exercised its option to extend the lease for an additional 5 years
past the initial term originally expiring on December 31, 2019,
such that the lease now expires on December 31, 2024.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company records the lease asset and lease liability at the present
value of lease payments over the lease term. The lease typically
does not provide an implicit rate; therefore, the Company uses its
estimated incremental borrowing rate at the time of lease
commencement to discount the present value of lease payments. The
Company&#x2019;s discount rate for operating leases at March 31,
2020 was 10%. Lease expense is recognized on a straight-line basis
over the lease term to the extent that collection is considered
probable. As a result, the Company has been recognizing rents as
they become payable based on the adoption of ASC Topic 842. The
weighted-average remaining lease term is 4.67 years.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As of
March 31, 2020, the maturities of operating lease liabilities are
as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:88%;">
<div style="margin-left:0px;"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;">&#xA0;</font></font></div>
<div><font style="font-size:11px;"><font style="font-family:Times New Roman;font-weight:bold;">Operating
Lease</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">74,092</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">101,752</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2022</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">104,793</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2023</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">107,954</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2024 and
beyond</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">111,192</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">499,784</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Less: amount
representing interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(105,371</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Present value of
future minimum lease payments</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">394,412</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Less: current
obligations under leases</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">68,608</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Long-term lease
obligations</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">325,804</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
For the three months ended March 31, 2020 and 2019, the Company
incurred rent expenses of $30,288 and $23,188,
respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Employment and Consulting Agreements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000">
Francois Michelon</font> <font style="color: #000000">&#x2013;
Effective May 12, 2017, the Company entered into an amended and
restated employment agreement with Francois Michelon, the
Company&#x2019;s Chief Executive Officer and Chairman of the board
of directors. The term of the employment agreement runs through
December 31, 2019 and continues on a year-to-year basis thereafter.
The employment agreement provides for an annual base salary that is
subject to adjustment at the board of directors&#x2019; discretion.
The annual base salary in effect during the period covered by this
Form 10-Q was $355,350. Under the employment agreement, Mr.
Michelon is eligible for an annual cash bonus based upon
achievement of performance-based objectives established by the
board of directors. Pursuant to Mr. Michelon&#x2019;s employment
agreement, in connection with the closing of the Company&#x2019;s
initial public offering he was granted options to purchase an
aggregate 339,270 shares of common stock. The options have a
weighted average exercise price of $4.96 per share of common stock
and vest in three equal annual installments beginning on May 12,
2018. Upon termination without cause, any portion of Mr.
Michelon&#x2019;s option award scheduled to vest within 12 months
will automatically vest, and upon termination without cause within
12 months following a change of control, the entire unvested
portion of the option award will automatically vest. Upon
termination for any other reason, the entire unvested portion of
the option award will terminate.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If Mr. Michelon&#x2019;s employment is terminated by the Company
without cause, Mr. Michelon will be entitled to receive 12
months&#x2019; continuation of his current base salary and a lump
sum payment equal to 12 months of continued healthcare coverage (or
24 months&#x2019; continuation of his current base salary and a lump
sum payment equal to 24 months of continued healthcare coverage if
such termination occurs within one year following a change in
control).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Under his employment agreement, Mr. Michelon is eligible to receive
benefits that are substantially similar to those of the
Company&#x2019;s other senior executive officers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On December 27, 2019, the Company entered into an amendment to Mr.
Michelon&#x2019;s employment agreement to provide that (i) Mr.
Michelon&#x2019;s employment with the Company will continue until
terminated under the terms the employment agreements, and (ii) Mr.
Michelon will each receive certain payments if he is terminated by
the Company without Cause (as defined in the employment agreement
amendment) or he resigns for Good Reason (as defined in the
employment agreement amendment).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">16</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000">
Michael Thornton</font> <font style="color: #000000">&#x2013;
Effective May 12, 2017, the Company entered into an amended and
restated employment agreement with Michael Thornton, the
Company&#x2019;s Chief Technology Officer. The term of the
employment agreement runs through December 31, 2019 and continues
on a year-to-year basis thereafter. The employment agreement
provides for an annual base salary that is subject to adjustment at
the board of directors&#x2019; discretion. The annual base salary in
effect during the period covered by this Form 10-Q was $267,800.
Under the employment agreement, Mr. Thornton is eligible for an
annual cash bonus based upon achievement of performance-based
objectives established by the board of directors. Pursuant to Mr.
Thornton&#x2019;s employment agreement, in connection with the
closing of the Company&#x2019;s initial public offering he was
granted options to purchase an aggregate 345,298 shares of common
stock. The options have a weighted average exercise price of $4.96
per share of common stock and vest in three equal annual
installments beginning on May 12, 2018. Upon termination without
cause, any portion of Mr. Thornton&#x2019;s option award scheduled
to vest within 12 months will automatically vest, and upon
termination without cause within 12 months following a change of
control, the entire unvested portion of the option award will
automatically vest. Upon termination for any other reason, the
entire unvested portion of the option award will
terminate.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If Mr. Thornton&#x2019;s employment is terminated by the Company
without cause, Mr. Thornton will be entitled to receive 12
months&#x2019; continuation of his current base salary and a lump
sum payment equal to 12 months of continued healthcare coverage (or
24 months&#x2019; continuation of his current base salary and a lump
sum payment equal to 24 months of continued healthcare coverage if
such termination occurs within one year following a change in
control).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Under his employment agreement, Mr. Thornton is eligible to receive
benefits that are substantially similar to those of the
Company&#x2019;s other senior executive officers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On December 27, 2019, the Company entered into an amendment to Mr.
Thornton&#x2019;s employment agreement to provide that (i) Mr.
Thornton&#x2019;s employment with the Company will continue until
terminated under the terms the employment agreements, and (ii) Mr.
Thornton will each receive certain payments if he is terminated by
the Company without Cause (as defined in the employment agreement
amendment) or he resigns for Good Reason (as defined in the
employment agreement amendment).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000">
David Wells</font> <font style="color: #000000">&#x2013; On May 12,
2017, the Company entered into a consulting agreement with
StoryCorp Consulting (&#x201C;StoryCorp&#x201D;), pursuant to which
David Wells provided services to the Company as its Chief Financial
Officer. Pursuant to the consulting agreement, the Company paid to
StoryCorp a monthly fee of $9,000, and in May 2018 this monthly fee
was increased to $9,540. Additionally, pursuant to the consulting
agreement, the Company granted to Mr. Wells a stock option to
purchase 15,000 shares of common stock in connection with the
closing of the Company&#x2019;s initial public offering, having an
exercise price per share equal to $5.00 and vesting in twelve equal
quarterly installments, and, for so long as the consulting
agreement was in place, granted to Mr. Wells a stock option to
purchase the same number of shares of common stock with the same
terms on each annual anniversary of the date of the consulting
agreement. In May 2018, the annual stock option amount was
increased and on December 13, 2018, Mr. Wells was granted options
to purchase an additional 35,000 shares of common
stock.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On May
13, 2019, the Company entered into an employment agreement with
David Wells that supersedes the consulting agreement between the
Company and StoryCorp. The employment agreement provides for an
annual base salary of $230,000 and eligibility for an annual cash
bonus to be paid based on attainment of Company and individual
performance objectives to be established by the Company&#x2019;s
board of directors (in 2019, the amount of such cash bonus if all
goals were achieved would be 30% of the base salary plus base fees
paid to StoryCorp under the consulting agreement). The employment
agreement also provides for eligibility to receive benefits
substantially similar to those of the Company&#x2019;s other senior
executive officers.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the employment agreement, on May 13, 2019 Mr. Wells was granted
stock options to purchase 56,000 shares of the Company&#x2019;s
common stock. The stock options have an exercise price of $1.38 per
share, and vest in three equal annual installments beginning on the
first anniversary of the grant date.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Litigation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
From time to time the Company may become a party to litigation in
the normal course of business. There are currently no legal matters
that management believes would have a material effect on the
Company&#x2019;s financial position or results of
operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">17</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 12 &#x2013; Subsequent Events</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
COVID-19</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
COVID-19 outbreak, which the World Health Organization has
classified as a pandemic, has prompted governments and regulatory
bodies throughout the world to issue &#x201C;stay-at-home&#x201D; or
similar orders, and enact restrictions on the performance of
&#x201C;non-essential&#x201D; services, public gatherings and
travel.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Beginning
in March 2020, we undertook temporary precautionary measures
intended to help minimize the risk of the virus to our employees,
including temporarily requiring most employees to work remotely,
pausing all non-essential travel worldwide for our employees, and
limiting employee attendance at industry events and in-person
work-related meetings, to the extent those events and meetings are
continuing. To date we do not believe these actions have had a
significant negative impact on our operations. However, these
actions or additional measures we may undertake may ultimately
delay progress our developmental goals or otherwise negatively
affect our business. In addition, third-party actions taken to
contain its spread and mitigate its public health effects of
COVID-19 may negatively affect our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Paycheck Protection Program</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Subsequent
to the period ended Mach 31, 2020, the Company issued a U.S. Small
Business Administration (&#x201C;SBA&#x201D;) Paycheck Protection
Program Note (the &#x201C;Note&#x201D;) to First Republic Bank (the
&#x201C;Lender&#x201D;) for a loan in the amount of $308,600.00 (the
&#x201C;Loan&#x201D;) under the Paycheck Protection Program
(&#x201C;PPP&#x201D;) promulgated under the Coronavirus Aid, Relief
and Economic Security Act of 2020. The Loan bears interest at a
rate per annum of 1.00%. The term of the Loan is two years, ending
April 22, 2022 (the &#x201C;Maturity Date&#x201D;). No payments are
due on the Loan until seven months from April 22, 2020, the date of
first disbursement of the Loan (the &#x201C;Deferment
Period&#x201D;), but interest will accrue during the Deferment
Period. Following the Deferment Period, the Company must pay
monthly principal and interest payments on the outstanding
principal balance of the Loan amortized over the term of the Loan
(the &#x201C;Loan Payments&#x201D;), unless forgiven in whole or in
part in accordance with the PPP regulations. These repayments will
begin following the Deferment Period and until the Maturity
Date.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company may apply to the Lender for the Loan to be forgiven
partially or fully if the funding received is used during the
8-week period following disbursement for payroll costs, covered
rent, and covered utilities, provided that at least 75% of the
forgiven amount has been used for payroll costs. Forgiveness is
based on the Company&#x2019;s maintaining, or quickly rehiring,
employees and maintaining applicable salary levels. Forgiveness
will be reduced if full-time headcount declines, or if salaries and
wages decrease. <font style="color: #000000">No assurance is
provided that the Company will obtain forgiveness of the Loan in
full or in part.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company may prepay the principal of the Loan at any time without
incurring any prepayment charges. The Company may prepay 20% or
less of the unpaid principal balance at any time without notice. If
the Company prepays more than 20% and the Loan has been sold on the
secondary market, the Company must provide the Lender with written
notice, pay all accrued interest and comply with the other
requirements described in the Note for such repayment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company did not provide any collateral or personal guarantees for
the Loan, nor did the Company pay any facility charge to the
government or to the Lender.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Note also provides for customary events of default, including,
among others, events of default relating to failure to make payment
or comply with the covenants contained in the Note and related loan
documents, defaults on any other loan with the Lender, defaults on
any loan or agreement with another creditor (if the Lender believes
the default may materially affect the Company&#x2019;s ability pay
the Note), failure to pay any taxes when due, bankruptcy, breaches
of representations, judgment, reorganization, merger, consolidation
or other changes in ownership or business structure without the
Lender&#x2019;s prior written consent, and material adverse changes
in financial condition or business operation. Upon an event of
default the Lender may require immediate payment of all amounts
owing under the Note, collect all amounts owing from the Company,
or file suit and obtain judgment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Common Stock Issued</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Subsequent
to the period ended March 31, 2020,&#xA0;the Company issued a total
of 929,650 shares of common stock&#xA0;upon&#xA0;the conversion
of&#xA0;an aggregate of&#xA0;808.796 shares of Series A Convertible
Preferred Stock at the request
of&#xA0;its&#xA0;holder.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Subsequent
to the period ended March 31, 2020 the Company issued a total of
22,099 shares of common stock to a vendor for services which were
valued at $40,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="i2">I</a>tem 2. Management&#x2019;s Discussion and
Analysis of Financial Condition and Results of
Operations</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As used
in this Quarterly Report on Form 10-Q (this &#x201C;Form
10-Q&#x201D;), unless the context otherwise requires, the terms
&#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D;
&#x201C;ENDRA&#x201D; and the &#x201C;Company&#x201D; refer to ENDRA
Life Sciences Inc., a Delaware corporation, and its wholly-owned
subsidiary. The following discussion and analysis of our financial
condition and results of operations should be read in conjunction
with our historical financial statements and related notes thereto
in this Form 10-Q. This Form 10-Q contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that are intended to be covered by the
&#x201C;safe harbor&#x201D; created by those sections.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of forward-looking terms such as
&#x201C;believe,&#x201D; &#x201C;expect,&#x201D; &#x201C;may,&#x201D;
&#x201C;will,&#x201D; &#x201C;should,&#x201D; &#x201C;could,&#x201D;
&#x201C;seek,&#x201D; &#x201C;intend,&#x201D; &#x201C;plan,&#x201D;
&#x201C;estimate,&#x201D; &#x201C;anticipate&#x201D; or other
comparable terms. All statements other than statements of
historical facts included in this Form 10-Q regarding our
strategies, prospects, financial condition, operations, costs,
plans and objectives are forward-looking statements. Examples of
forward-looking statements include, among others, statements we
make regarding expectations for revenues, cash flows and financial
performance, the anticipated results of our development efforts and
the timing for receipt of required regulatory approvals and product
launches. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: our limited commercial
experience, limited cash and history of losses; our ability to
obtain adequate financing to fund our business operations in the
future; our ability to achieve profitability; our ability to
develop a commercially feasible application based on our
Thermo-Acoustic Enhanced Ultrasound (&#x201C;TAEUS&#x201D;)
technology; market acceptance of our technology; uncertainties
associated with COVID-19 or coronavirus, including its possible
effects on our operations; results of our human studies, which may
be negative or inconclusive; our ability to find and maintain
development partners; our reliance on collaborations and strategic
alliances and licensing arrangements; the amount and nature of
competition in our industry; our ability to protect our
intellectual property; potential changes in the healthcare industry
or third-party reimbursement practices; delays and changes in
regulatory requirements, policy and guidelines including potential
delays in submitting required regulatory applications for CE mark
certification or Food and Drug Administration (&#x201C;FDA&#x201D;)
approval; our ability to obtain CE mark certification and secure
required FDA and other governmental approvals for our TAEUS
applications; our ability to comply with regulation by various
federal, state, local and foreign governmental agencies and to
maintain necessary regulatory clearances or approvals; and the
other risks and uncertainties described in the Risk Factors section
of our Annual Report on Form 10-K for the period ended December 31,
2019, as filed with the SEC on March 26, 2020, and in the
Management&#x2019;s Discussion and Analysis of Financial Condition
and Results of Operations section of this Form 10-Q. We undertake
no obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">
<font style="color: #000000; font-size: 13px">From time to time, we
use press releases, Twitter (@endralifesci) and LinkedIn
(www.linkedin.com/company/endra-inc) to distribute material
information. Our press releases and financial and other material
information are routinely posted to and accessible on the Investors
section of our website, www.endrainc.com. Accordingly, investors
should monitor these channels, in addition to our SEC filings and
public conference calls and webcasts. In addition, investors may
automatically receive e-mail alerts and other information about the
Company by enrolling their e-mail addresses by visiting the
&#x201C;Email Alerts&#x201D; section of our website
a</font><font style="color: #000000; font-family: Times New Roman">t
investors.endrainc.com</font><font style="color: #000000; font-size: 13px">. Information that is contained
in and can be accessed through our website, Twitter posts and
LinkedIn are not incorporated into, and do not form a part of, this
Quarterly Report or any other report or document we file with the
SEC.</font></font><br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Overview</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are leveraging experience with pre-clinical enhanced ultrasound
devices to develop technology for increasing the capabilities of
clinical diagnostic ultrasound, to broaden patient access to the
safe diagnosis and treatment of a number of significant medical
conditions in circumstances where expensive X-ray computed
tomography (&#x201C;CT&#x201D;) and magnetic resonance imaging
(&#x201C;MRI&#x201D;) technology, or other diagnostic technologies
such as surgical biopsy, are unavailable or
impractical.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In 2010, we began marketing and selling our Nexus 128 system, which
combined light-based thermoacoustics and ultrasound to address the
imaging needs of researchers studying disease models in
pre-clinical applications. Building on this expertise in
thermoacoustics, we have developed a next-generation technology
platform &#x2014; Thermo Acoustic Enhanced Ultrasound, or TAEUS
&#x2014; which is intended to enhance the capability of clinical
ultrasound technology and support the diagnosis and treatment of a
number of significant medical conditions that currently require the
use of expensive CT or MRI imaging or where imaging is not
practical using existing technology. We ceased production of our
Nexus 128 system as of January 1, 2019 and stopped providing
service support and parts for all existing Nexus 128 systems as of
July 1, 2019 in order to focus our resources on the development of
our TAEUS technology.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Unlike the near-infrared light pulses used in our legacy Nexus 128
system, our TAEUS technology uses radio frequency
(&#x201C;RF&#x201D;) pulses to stimulate tissues, using a small
fraction (less than 1%) of the energy that would be transmitted
into the body during an MRI scan. The use of RF energy allows our
TAEUS technology to penetrate deep into tissue, enabling the
imaging of human anatomy at depths equivalent to those of
conventional ultrasound. The RF pulses are absorbed by tissue and
converted into ultrasound signals, which are detected by an
external ultrasound receiver and a digital acquisition system that
is part of the TAEUS system. The detected ultrasound is processed
into images and other forms of data using our proprietary
algorithms and displayed to complement conventional gray-scale
ultrasound images.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>

<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We expect that the first-generation TAEUS application will be a
standalone ultrasound accessory designed to cost-effectively
quantify fat in the liver and stage progression of nonalcoholic
fatty liver disease (&#x201C;NAFLD&#x201D;), which can only be
achieved today with impractical surgical biopsies or MRI scans.
Subsequent TAEUS offerings are expected to be implemented via a
second generation hardware platform that can run multiple clinical
software applications that we will offer TAEUS users for a one-time
licensing fee &#x2013; adding ongoing customer value to the TAEUS
platform and a growing software revenue stream for our
Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In April 2016, we entered into a Collaborative Research Agreement
with General Electric Company, acting through its GE Healthcare
business unit and the GE Global Research Center (collectively,
&#x201C;GE Healthcare&#x201D;). Under the terms of the agreement, GE
Healthcare has agreed to assist us in our efforts to commercialize
our TAEUS technology for use in a fatty liver application by, among
other things, providing equipment and technical advice, and
facilitating introductions to GE Healthcare clinical ultrasound
customers. In return for this assistance, we have agreed to afford
GE Healthcare certain rights of first offer with respect to
manufacturing and licensing rights for the target application. On
January 13, 2020, we and GE Healthcare entered into an amendment to
our agreement, extending its term by 12 months to January 14, 2021
and modifying GE Healthcare&#x2019;s rights of first
offer.</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In November 2017, we engaged two firms that specialize in medical
device software development to commence productization of our TAEUS
device targeting NAFLD. The agreements call for these vendors to
provide us with the specialized engineering resources necessary to
translate our current prototype TAEUS device into a clinical
product that meets CE regulatory requirements required for
commercial launch in the European Union followed by FDA submission
for the U.S. market.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Each of our TAEUS platform applications will require regulatory
approvals before we are able to sell or license the application.
Based on certain factors, such as the installed base of ultrasound
systems, availability of other imaging technologies, such as CT and
MRI, economic strength and applicable regulatory requirements, we
intend to seek initial approval of our applications for sale in the
European Union and the United States, followed by
China.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
March, 2020, we received Conformit&#xE9; Europ&#xE9;ene
(&#x201C;CE&#x201D;) mark approval for our TAEUS FLIP (Fatty Liver
Imaging Probe) System. The CE marking indicates that TAEUS FLIP
System complies with all applicable European Directives and
Regulations in the European Union and other CE mark geographies,
including the 27 EU member states. We next intend to submit to the
FDA an application for approval of the TAEUS FLIP.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Financial Operations Overview</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Revenue</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
No revenue has been generated by our TAEUS technology, which we
have not yet commercially sold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Cost of Goods Sold</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
No cost of goods sold has been generated by our TAEUS technology,
which we have not yet commercially sold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Research and Development Expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our research and development expenses primarily include wages, fees
and equipment for the development of our TAEUS technology platform
and the proposed applications. Additionally, we incur certain costs
associated with the protection of our products and inventions
through a combination of patents, licenses, applications and
disclosures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Sales and Marketing Expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Sales and marketing expenses consist primarily of headcount and
consulting costs, and marketing and tradeshow expenses. Currently,
our marketing efforts are through our website and attendance of key
industry meetings and conferences. In connection with the
commercialization of our&#xA0;TAEUS applications, we expect to
build a small sales and marketing team to train and support global
ultrasound distributors, as well as execute traditional marketing
activities such as promotional materials, electronic media and
participation in industry events and conferences.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
General and Administrative Expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
General and administrative expenses consist primarily of salaries
and related expenses for our management and personnel, and
professional fees, such as accounting, consulting and
legal.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Critical Accounting Policies and Estimates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Use of Estimates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The preparation of the financial statements in conformity with
accounting principles generally accepted in the United States
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, and disclosure of
contingent liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Management makes estimates that affect certain accounts including
deferred income tax assets, accrued expenses, fair value of equity
instruments and reserves for any other commitments or
contingencies. Any adjustments applied to estimates are recognized
in the period in which such adjustments are
determined.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Share-based Compensation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our 2016 Omnibus Incentive Plan (the &#x201C;Omnibus Plan&#x201D;)
permits the grant of stock options and other stock awards to our
employees, consultants and non-employee members of our board of
directors. Each January 1 the pool of shares available for issuance
under the Omnibus Plan automatically increases by an amount equal
to the lesser of (i) the number of shares necessary such that the
aggregate number of shares available under the Omnibus Plan equals
25% of the number of fully-diluted outstanding shares on the
increase date (assuming the conversion of all outstanding shares of
preferred stock and other outstanding convertible securities and
exercise of all outstanding options and&#xA0;warrants to purchase
shares) and (ii) if the board of directors takes action to set a
lower amount, the amount determined by the board. On January 1,
2020, the pool of shares issuable under the Omnibus Plan
automatically increased by 3,202,280 shares from 2,649,378 shares
to 5,861,658. As of March 31, 2020, there were 2,281,921 shares of
common stock remaining available for issuance under the Omnibus
Plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We record share-based compensation in accordance with the
provisions of the Share-based Compensation Topic of the FASB
Codification. The guidance requires the use of option-pricing
models that require the input of highly subjective assumptions,
including the option&#x2019;s expected life and the price volatility
of the underlying stock. The fair value of each option grant is
estimated on the date of grant using the Black-Scholes option
valuation model which uses certain assumptions related to risk-free
interest rates, expected volatility, expected life of the common
stock options, and future dividends, and the resulting charge is
expensed using the straight-line attribution method over the
vesting period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Stock compensation expense recognized during the period is based on
the value of share-based awards that were expected to vest during
the period adjusted for estimated forfeitures. The estimated fair
value of grants of stock options and warrants to non-employees is
charged to expense, if applicable, in the financial
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Debt Discount and Detachable Debt-Related Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company accounts for debt discounts originating in connection with
conversion features that are embedded in the notes related warrants
in accordance with ASC Subtopic 470-20,&#xA0;<font style="font-style: italic">Debt with Conversion and Other Options</font>.
These costs are classified on the consolidated balance sheet as a
direct deduction from the debt liability. The Company amortizes
these costs over the term of the securities as interest
expense-debt discount in the consolidated statement of operations.
Debt discounts relate to the relative fair value of warrants issued
in conjunction with the debt and are also recorded as a reduction
to the debt balance and accreted over the expected term of the
securities to interest expense.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Recent Accounting Pronouncements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
See Note 2 of the accompanying financial statements for a
discussion of recently issued accounting standards.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Results of Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-style: italic; font-family: Times New Roman; font-size: 13px">
Three months ended March 31, 2020 and 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Revenue</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We had
no revenue during the three months ended March 31, 2020 and
2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Cost of Goods Sold</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">There
was no cost of goods sold for each of the three months ended March
31, 2020 and 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Research and Development</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Research
and development expenses were $1,518,146 for the three months ended
March 31, 2020, as compared to $1,773,498 for the three months
ended March 31, 2019, a decrease of $255,352, or 14%. The costs
include primarily wages, fees and equipment for the development of
our TAEUS product line. Research and development expenses decreased
from the same period for the prior year as we completed development
of the TAEUS product and began focusing our spending on
commercialization of the product that has been
developed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Sales and Marketing</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sales
and marketing expenses were $114,955 for the three months ended
March 31, 2020, as compared to $56,818 for the three months ended
March 31, 2019, an increase of $58,137, or 102%. The increase was
primarily due to additional headcount and pre-selling activities
for our TAEUS product line. Currently, our marketing efforts are
through our website and attendance of key industry meetings. We
expect that our future clinical business will involve hiring and
training additional staff to support our sales efforts. As we seek
to complete the development and commercialization of our TAEUS
applications, we intend to build a small sales and marketing team
to train and support global ultrasound distributors, as well as
execute traditional marketing activities such as promotional
materials, electronic media and participation in industry
conferences.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
General and Administrative</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Our
general and administrative expenses for the three months ended
March 31, 2020 were $1,467,745, compared to $916,903 for the three
months ended March 31, 2019, an increase of $550,842, or 60%. Our
wage and related expenses for the three months ended March 31, 2020
were $647,442, compared to $408,345 for the three months ended
March 31, 2019. Wage and related expenses in the three months ended
March 31, 2020 included $66,193 for bonuses and $249,585 of stock
compensation expense related to the issuance and vesting of
options, compared to $34,372 for bonuses, $171,837 of stock
compensation expense related to the issuance and vesting of options
for the three months ended March 31, 2019. Our professional fees,
which include legal, audit, and investor relations, for the three
months ended March 31, 2020 were $669,275, compared to $357,837 for
the three months ended March 31, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Amortization of Debt Discount</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2020, we incurred non-cash
expenses of $228,568 related to the amortization of debt discount
incurred as result of our issuance of our convertible notes and
warrants issued in July 2019. There were no such expenses during
the three months ended March 31, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Net Loss</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As a
result of the foregoing, for the three months ended March 31, 2020,
we recorded a net loss of $3,322,797, compared to a net loss of
$2,748,736 for the three months ended March 31, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Liquidity and Capital Resources</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">To date
we have funded our operations through private and public sales of
our securities. As of March 31, 2020, we had $3,102,728 in cash. We
have completed the following financing events from January 2019
through March 31, 2020:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
July 2019, we completed a private placement of senior secured
convertible promissory notes and warrants, raising net proceeds of
approximately $2.5 million after deducting offering expenses of
approximately $314,500 payable by us. The promissory notes accrued
interest at a rate of 10% per annum until maturity on April 26,
2020.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In December 2019,</font>&#xA0;we completed private
placements of shares of Series A Preferred Stock, shares of Series
B Preferred Stock, shares of common stock and warrants, raising net
proceeds of approximately $5.8 million after using approximately
$1.9 million to repay debt represented by convertible promissory
notes issued in July 2019 and deducting offering expenses of
approximately $766,000 payable by us.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">In March 2020, we
entered into an at-the-market equity offering sales agreement (the
&#x201C;ATM Agreement&#x201D;) with H.C. Wainwright &amp; Co., LLC
(&#x201C;Wainwright&#x201D;) to sell shares of our common stock for
aggregate gross proceeds of up to $7.2 million, from time to time,
through an &#x201C;at-the-market&#x201D; equity offering program
under which Wainwright acts as sales agent. Pursuant to the ATM
Agreement, Wainwright may sell the shares in sales deemed to be
&#x201C;at-the-market&#x201D; equity offerings as defined in Rule 415
under the Securities Act, including sales made directly on or
through the Nasdaq Capital Market. If agreed to in a separate terms
agreement, we may sell shares to Wainwright as principal at a
purchase price agreed upon by Wainwright and the Company.
Wainwright may also sell shares in negotiated transactions with our
prior approval. The offer and sale of the shares pursuant to the
ATM Agreement will terminate upon the earlier of (a) the issuance
and sale of all of the shares subject to the ATM Agreement or (b)
the termination of the ATM Agreement by Wainwright or us pursuant
to its terms. As of March 31, 2020, we had not sold any shares of
common stock under the ATM Agreement.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">22</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
believe that cash on hand at March 31, 2020 will only be sufficient
to fund our current operations into the third quarter of 2020. We
will need additional capital to execute our commercialization plan
and if we do not raise additional capital in the next several
months we will need to significantly slow or pause our business
activities until such time as we are able to raise additional
capital. We continue to evaluate and manage our capital needs to
support our clinical, regulatory and operational activities and
prepare for the results of our human studies data and EU
commercialization. We are currently exploring potential financing
options that may be available to us, including additional sales of
our common stock through the ATM Agreement and by causing the
mandatory exercise of our warrants issued on December 11, 2019 for
cash. However, we have no commitments to obtain any additional
funds, and there can be no assurance funds will be available in
sufficient amounts or on acceptable terms. If we are unable to
obtain sufficient additional financing in a timely fashion and on
terms acceptable to us, our financial condition and results of
operations may be materially adversely affected and we may not be
able to continue operations or execute our stated commercialization
plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
financial statements included in this Form 10-Q have been prepared
assuming we will continue as a going concern, which contemplates
the realization of assets and the settlement of liabilities and
commitments in the normal course of business. As reflected in the
accompanying financial statements, during the three months ended
March 31, 2020, we incurred net losses of $3,322,797 and used cash
in operations of $3,088, 295. These and other factors raise
substantial doubt about our ability to continue as a going concern
for one year from the issuance of the accompanying financial
statements. The financial statements do not include any adjustments
that might be necessary should we be unable to continue as a going
concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Operating Activities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2020, we used $3,088,367 of cash
in operating activities primarily as a result of our net loss of
$3,322,797, offset by share-based compensation of $511,080,
amortization of debt discount of $228,568, depreciation expense of
$21,586, amortization of Right of Use assets of $15,915, stock
payable for investor relations of $40,000, and net changes in
operating assets and liabilities of $(582,719).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2019, we used $2,540,662 of cash
in operating activities primarily as a result of our net loss of
$2,748,736, which included non-cash charges for share-based
compensation of $302,268, depreciation expenses of $19,632, and net
changes in operating assets and liabilities of
$113,826.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Investing Activities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2020, the Company used $22,350 in
investing activities related to purchases of
equipment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2019, the Company used $5,239 in
investing activities related to purchases of
equipment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Financing Activities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2020, financing activities
provided $39,238, in proceeds from warrant exercises.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2019, there were no cash flows
from financing activities.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Funding Requirements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We have
not completed the commercialization of any of our TAEUS technology
platform applications. We expect to continue to incur significant
expenses for the foreseeable future. We anticipate that our
expenses will increase substantially as we:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">advance the
engineering design and development of our NAFLD TAEUS
application;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">acquire parts and
build finished goods inventory of the TAEUS FLIP
system;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">prepare regulatory
filings required for marketing approval of our NAFLD TAEUS
application in the United States;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">seek to hire a
small internal marketing team to engage and support channel
partners and clinical customers for our NAFLD TAEUS
application;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">commence marketing
of our NAFLD TAEUS application;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">advance development
of our other TAEUS applications; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">add operational,
financial and management information systems and personnel,
including personnel to support our product development, planned
commercialization efforts and our operation as a public
company.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">23</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">It is
possible that we will not achieve the progress that we expect
because the actual costs and timing of completing the development
and regulatory approvals for a new medical device are difficult to
predict and are subject to substantial risks and delays. We have no
committed external sources of funds. We do not expect that our
existing cash will be sufficient for us to complete the
commercialization of our NAFLD TAEUS application or to complete the
development of any other TAEUS application and we will need to
raise substantial additional capital for those purposes. As a
result, we will need to finance our future cash needs through
public or private equity offerings, debt financings, corporate
collaboration and licensing arrangements or other financing
alternatives. Our forecast of the period of time through which our
financial resources will be adequate to support our operations is a
forward-looking statement and involves risks and uncertainties, and
actual results could vary as a result of a number of factors,
including the factors discussed in the section of this Quarterly
Report on Form 10-Q entitled &#x201C;Risk Factors&#x201D; and such
section of our most recently filed Annual Report on Form 10-K. We
have based this estimate on assumptions that may prove to be wrong,
and we could utilize our available capital resources sooner than we
currently expect.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Until
we can generate a sufficient amount of revenue from our TAEUS
platform applications, if ever, we expect to finance future cash
needs through public or private equity offerings, debt financings
or corporate collaborations and licensing arrangements. Additional
funds may not be available when we need them on terms that are
acceptable to us, or at all. As described above, the COVID-19
pandemic has impacted our business operations to some extent and is
expected to continue to do so and, in light of the effect of such
pandemic on financial markets, these impacts may include reduced
access to capital. If adequate funds are not available, we may be
required to delay, reduce the scope of or eliminate one or more of
our research or development programs or our commercialization
efforts or perhaps even cease the operation of our business. To the
extent that we raise additional funds by issuing equity securities,
our stockholders may experience additional dilution, and debt
financing, if available, may involve restrictive covenants. To the
extent that we raise additional funds through collaborations and
licensing arrangements, it may be necessary to relinquish some
rights to our technologies or applications or grant licenses on
terms that may not be favorable to us. We may seek to access the
public or private capital markets whenever conditions are
favorable, even if we do not have an immediate need for additional
capital at that time.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Coronavirus (&#x201C;COVID-19&#x201D;) Pandemic</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
COVID-19 outbreak, which the World Health Organization has
classified as a pandemic, has prompted governments and regulatory
bodies throughout the world to issue &#x201C;stay-at-home&#x201D; or
similar orders, and enact restrictions on the performance of
&#x201C;non-essential&#x201D; services, public gatherings and
travel.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Beginning
in March 2020, we undertook temporary precautionary measures
intended to help minimize the risk of the virus to our employees,
including temporarily requiring most employees to work remotely,
pausing all non-essential travel worldwide for our employees, and
limiting employee attendance at industry events and in-person
work-related meetings, to the extent those events and meetings are
continuing. As a cash-conserving measure taken in light of the
adverse economic conditions caused by the COVID-19 pandemic, in
April 2020 we reduced the cash salaries of members of management by
33% for the remainder of 2020, including the salaries of our
executive officers. In lieu of cash, the Company is paying this
portion of management salaries in the form of restricted stock
units that vest over the remainder of the year. Additionally, we
amended our Non-Employee Director Compensation Policy to provide
that our non-employee directors&#x2019; annual retainers for the
second, third and fourth fiscal quarters of 2020 shall be paid in
in the form of restricted stock units rather than cash. To date we
do not believe these actions have had a significant negative impact
on our operations. However, these actions or additional measures we
may undertake may ultimately delay progress on our developmental
goals or otherwise negatively affect our business. In addition,
third-party actions taken to contain its spread and mitigate its
public health effects of COVID-19 may negatively affect our
business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Nasdaq Capital Market Listing</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Our
common stock is currently traded on the Nasdaq Capital Market. The
Nasdaq Capital Market imposes, among other requirements, listing
maintenance standards including minimum bid price and
stockholders&#x2019; equity requirements. In particular, Nasdaq
rules require a listed company&#x2019;s primary equity securities to
have a minimum bid price of at least $1.00 per share.&#xA0;On April
24, 2020, we received a notification letter from the Listing
Qualifications Department of The Nasdaq Stock Market LLC
(&#x201C;Nasdaq&#x201D;) notifying us that, because the
closing&#xA0;bid price&#xA0;for our common stock listed on Nasdaq
was below $1.00 for 30 consecutive trading days, we no longer met
the minimum bid price&#xA0;requirement for continued listing on The
Nasdaq Capital Market under Nasdaq Marketplace Rule
5550(a)(2).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
notification has no immediate effect on the listing of our common
stock. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A) and
the rule change filed by Nasdaq with the Securities and Exchange
Commission on April 16, 2020, we have a period of 180 calendar days
from July 1, 2020, or until December 28, 2020, to regain compliance
with the minimum&#xA0;bid price&#xA0;requirement. The notification
letter also stated that, in the event we do not regain compliance
with the minimum&#xA0;bid price&#xA0;requirement by December 28,
2020, we may be eligible for additional time. To qualify for
additional time, we would be required to meet the continued listing
requirement for market value of publicly held shares and all other
initial listing standards for The Nasdaq Capital Market, with the
exception of the&#xA0;bid price&#xA0;requirement, and would need to
provide written notice of our intention to cure the deficiency
during the second compliance period, by effecting a reverse stock
split, if necessary. If we meet these requirements, Nasdaq will
inform us that we have been granted an additional 180 calendar days
to regain compliance. However, if it appears to the staff of Nasdaq
(the &#x201C;Staff&#x201D;) that we will not be able to cure the
deficiency, or if we are otherwise not eligible, the Staff would
notify us that our securities will be subject to delisting. In the
event of such notification, we may appeal the Staff&#x2019;s
determination to delist its securities, but there can be no
assurance the Staff would grant our request for continued
listing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
intend to continue actively monitoring the bid price for our common
stock between now and December 28, 2020 and will consider available
options to resolve the deficiency and regain compliance with
the&#xA0;minimum bid price&#xA0;requirement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Off-Balance Sheet Transactions</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">At
March 31, 2020, the Company did not have any transactions,
obligations or relationships that could be considered off-balance
sheet arrangements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">24</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="i3">I</a>tem 3. Quantitative and Qualitative
Disclosure About Market Risk</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As a
smaller reporting company, we are not required to provide the
information required by this Item 3.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="i4">I</a>tem 4. Controls and
Procedures</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Evaluation of Disclosure Controls and Procedures</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of the end of the period covered by this Form 10-Q, management
performed, with the participation of our principal executive
officer and principal financial officer, an evaluation of the
effectiveness of our disclosure controls and procedures as defined
in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act
of 1934, as amended (the &#x201C;Exchange Act&#x201D;). Our
disclosure controls and procedures are designed to ensure that
information required to be disclosed in the reports we file or
submit under the Exchange Act is recorded, processed, summarized,
and reported within the time periods specified in the SEC&#x2019;s
forms, and that such information is accumulated and communicated to
our management, including our principal executive officer and
principal financial officer, to allow timely decisions regarding
required disclosures. Based on the evaluation, our principal
executive officer and principal financial officer concluded that,
as of March 31, 2020, our disclosure controls and procedures were
not effective.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
A material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented
or detected on a timely basis. We identified the following material
weakness as of March 31, 2020: insufficient personnel resources
within the accounting function to segregate the duties over
financial transaction processing and reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
To remediate our internal control weaknesses, management intends to
implement the following measures, as finances allow:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: justify; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Adding
sufficient accounting personnel or outside consultants to properly
segregate duties and to effect a timely, accurate preparation of
the financial statements.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: justify; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Upon
the hiring of additional accounting personnel or outside
consultants, develop and maintain adequate written accounting
policies and procedures.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
additional hiring is contingent upon our efforts to obtain
additional funding and the results of our operations. Management
expects to secure funds in the coming fiscal year but provides no
assurances that it will be able to do so.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Changes in Internal Control over Financial Reporting</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">There
were no changes to our internal control over financial reporting or
in other factors that could affect these controls during the three
months ended&#xA0;March 31, 2020<font style="color: #000000">&#xA0;that</font>&#xA0;has materially affected, or
is reasonably likely to materially affect, our internal control
over financial reporting. However, our management is currently
seeking to improve our controls and procedures in an effort to
remediate the deficiency described above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">25</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2">P</a>ART&#xA0;II &#x2013; OTHER
INFORMATION</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2-i1">I</a>tem 1. Legal
Proceedings</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We are
not currently a party to any pending legal proceedings that we
believe will have a material adverse effect on our business or
financial condition. We may, however, be subject to various claims
and legal actions arising in the ordinary course of business from
time to time.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2_i1a">I</a>tem 1A. Risk Factors</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition to the risk factors and uncertainties described below and
the other information set forth in this report, you should
carefully consider the factors discussed under &#x201C;Risk
Factors&#x201D; in our Annual Report on Form 10-K for the period
ended December 31, 2019, as filed with the Securities and Exchange
Commission on March 26, 2020. These factors could materially
adversely affect our business, financial condition, liquidity,
results of operations and capital position, and could cause our
actual results to differ materially from our historical results or
the results contemplated by any forward-looking statements
contained in this report.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
The outbreak of the novel strain of coronavirus, SARS-CoV-2, which
causes COVID-19, could adversely impact our business, including our
pre-sales activities, clinical trials and ability to obtain
regulatory approvals.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Public
health crises such as pandemics or similar outbreaks could
adversely impact our business. In December 2019, a novel strain of
coronavirus, SARS-CoV-2, which causes coronavirus disease 2019
(&#x201C;COVID-19&#x201D;), surfaced in Wuhan, China. Since then,
COVID-19 has spread to countries around the world and has been
declared a pandemic by the World Health Organization. Beginning in
March 2020, we undertook temporary precautionary measures to help
minimize the risk of the virus to our employees, including by
temporarily requiring most employees to work remotely, pausing all
non-essential travel worldwide for our employees, and limiting
employee attendance at industry events and in-person work-related
meetings, to the extent those events and meetings are continuing.
As a cash-conserving measure taken in light of the adverse economic
conditions caused by the COVID-19 pandemic, in April 2020 we
reduced the cash salaries of members of management by 33% for the
remainder of 2020, including the salaries of our executive
officers. In lieu of cash, the Company is paying this portion of
management salaries in the form of restricted stock units that vest
over the remainder of the year. Additionally, we amended our
Non-Employee Director Compensation Policy to provide that our
non-employee directors&#x2019; annual retainers for the second,
third and fourth fiscal quarters of 2020 shall be paid in in the
form of restricted stock units rather than cash. We may take
additional measures, any of which could negatively affect our
business. In addition, third-party actions taken to contain its
spread and mitigate its public health effects of COVID-19 may
negatively affect our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As a
result of the COVID-19 outbreak, or similar pandemics, we have and
may in the future experience disruptions that could severely impact
our business, preclinical studies and clinical trials,
including:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">interruption of key
clinical trial activities and attendance at industry events due to
limitations on travel imposed or recommended by federal or state
governments, employers and others or interruption of clinical trial
subject visits and study procedures;&#xA0;<br></font></div>
</div>
</div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-size: 13px">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">delays or
difficulties in enrolling patients in clinical trials of our TAEUS
FLIP device;</font>&#xA0;<br></div>
</div>
</div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">interruption or
delays in the operations of the FDA and comparable foreign
regulatory agencies, which may impact approval timelines; (ISSUER
DIRECT&#x2026;.PLEASE FORMAT BULLETS CORRECTLY, REMOVE THIS
NOTE)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">absenteeism or loss
of employees at the Company, or at our collaborator companies, due
to health reasons or government restrictions or otherwise, that are
needed to develop, validate, manufacture and perform other
necessary functions for our operations;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">supply chain
disruptions making it difficult for our collaborator companies to
order and receive materials needed for the manufacture of our TAEUS
product;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">government
responses including orders that make it difficult for us, our
supplier and our potential customers to remain open for business,
and other seen and unforeseen actions taken by government
agencies;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">equipment failures,
loss of utilities and other disruptions that could impact our
operations or render them inoperable; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 24px;">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">effects of a local
or global recession or depression that could depress economic
conditions for a prolonged period and limit access to capital by
the Company.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0;<br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">These
and other factors arising from the COVID-19 pandemic could worsen
in the United States or locally at the location of our offices or
clinical trials, each of which could further adversely impact our
business generally, and could have a material adverse impact on our
operations and financial condition and results.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2_i2">I</a>tem 2. Recent Sales of Unregistered
Securities; Use of Proceeds from Registered Securities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2_i3">I</a>tem 3. Defaults Upon Senior
Securities</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2_i4">I</a>tem 4. Mine Safety
Disclosures</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="p2_i5">I</a>tem 5. Other
Information</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">26</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="i6">I</a>tem 6. Exhibits</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 6%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Exhibit Number</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Description</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex32.htm">
3.1</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Fourth
Amended and Restated Certificate of Incorporation of the Company
(incorporated by reference to Exhibit 3.2 to the Company&#x2019;s
Current Report on Form 8-K filed on May 12, 2017)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex32.htm">
3.2</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Amended
and Restated Bylaws of the Company (incorporated by reference to
Exhibit 3.4 to the Company&#x2019;s Registration Statement on Form
S-1 (File No. 333-214724), as amended, originally filed on November
21, 2016)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex41.htm">
4.1</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Specimen
Certificate representing shares of common stock of the Company
(incorporated by reference to Exhibit 4.1 to the Company&#x2019;s
Registration Statement on Form S-1 (File No. 333-214724), as
amended, originally filed on November 21, 2016)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419008564/ndra_ex4-1.htm">
4.2</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form of
Convertible Promissory Note (incorporated by reference to Exhibit
4.1 to the Company&#x2019;s Current Report on Form 8-K filed on July
29, 2019)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419008564/ndra_ex4-2.htm">
4.3</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form of
Warrant (incorporated by reference to Exhibit 4.1 to the
Company&#x2019;s Current Report on Form 8-K filed on July 29,
2019)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419013822/ndra_ex41.htm">
<font style="font-family: Times New Roman; font-size: 13px">4.4</font></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certificate
of Designations of Series A Convertible Preferred Stock
(incorporated by reference to Exhibit 4.1 to the Company&#x2019;s
Current Report on Form 8-K filed on December 11, 2019)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419013822/ndra_ex42.htm">
<font style="font-family: Times New Roman; font-size: 13px">4.5</font></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form of
Warrant issued in December 2019 Series A Convertible Preferred
Stock Offering (incorporated by reference to Exhibit 4.2 to the
Company&#x2019;s Current Report on Form 8-K filed on December 11,
2019)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014235/ndra_ex41.htm">
<font style="font-family: Times New Roman; font-size: 13px">4.6</font></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certificate
of Designations of Series B Convertible Preferred Stock
(incorporated by reference to Exhibit 4.1 to the Company&#x2019;s
Current Report on Form 8-K filed on December 26, 2019)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014235/ndra_ex42.htm">
<font style="font-family: Times New Roman; font-size: 13px">4.7</font></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form of
Warrant issued in December 2019 Series B Convertible Preferred
Stock Offering (incorporated by reference to Exhibit 4.2 to the
Company&#x2019;s Current Report on Form 8-K filed on December 26,
2019)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420000453/ndra_ex101.htm">
10.1</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Amendment
3 to Collaborative Research Agreement, dated January 13, 2020, by
and between the Company and General Electric Company (incorporated
by reference to Exhibit 10.1 to the Company&#x2019;s Current Report
on Form 8-K filed on January 15, 2020)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="ndra_ex102.htm"><font style="font-size: 13px; font-family: Times New Roman;">10.2</font></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">U.S.
Small Business Administration Paycheck Protection Program Note,
issued by the Company to First Republic Bank (filed
herewith)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="ndra_ex311.htm">
31.1</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certification
of Periodic Report by Chief Executive Officer pursuant to Rule
13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002 (filed herewith)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="ndra_ex312.htm">
31.2</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certification
of Periodic Report by Chief Financial Officer pursuant to Rule
13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002 (filed herewith)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman;"><a href="ndra_ex321.htm">
32.1</a></font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certification
of Periodic Report by Chief Executive Officer and Chief Financial
Officer pursuant to U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (furnished
herewith)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.INS</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Instance Document (filed herewith)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.SCH</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Taxonomy Schema (filed herewith)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.CAL</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Taxonomy Extension Calculation Linkbase (filed
herewith)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.DEF</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Taxonomy Extension Definition Linkbase (filed
herewith)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 6%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.LAB</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Taxonomy Extension Label Linkbase (filed herewith)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 6%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.PRE</font></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Taxonomy Extension Presentation Linkbase (filed
herewith)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">*
Indicates management compensatory plan, contract or
arrangement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">27</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA LIFE SCIENCES INC.</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
May 14, 2020</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: top; width: 46%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">/s/&#xA0;<font style="font-style: italic">Francois
Michelon</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Francois
Michelon</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer and Chairman</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Principal
Executive Officer)</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA LIFE SCIENCES INC.</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
May 14, 2020</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: top; width: 46%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">/s/&#xA0;<font style="font-style: italic">David
Wells</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">David
Wells</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Financial Officer</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Principal
Financial and Accounting Officer)</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">28</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>ndra_ex102.htm
<DESCRIPTION>U.S. SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM NOTE, ISSUED BY THE COMPANY TO FIRST REPUBLIC BANK
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>ndra_ex102</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;<font style="font-weight: bold"><font style="font-size: 13px">Exhibit
10.1</font></font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px"><img src="ndra_ex102000.jpg"></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px"><img src="ndra_ex102001.jpg"></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px"><img src="ndra_ex102002.jpg"></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px"><img src="ndra_ex102003.jpg"></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px"><img src="ndra_ex102004.jpg"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5<br></font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ndra_ex311.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>ndra_ex311</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 31.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
Francois Michelon, certify that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1.
<font style="color: #000000">I have reviewed this Quarterly Report
on Form 10-Q of ENDRA Life Sciences Inc.</font>:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the
period covered by this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;The
registrant&#x2019;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Designed such
disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Designed such
internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">c)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Evaluated the
effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">d)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Disclosed in this
report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in
the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal
control over financial reporting; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;The
registrant&#x2019;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the
audit committee of the registrant's board of directors (or persons
performing the equivalent functions):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">All significant
deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record,
process, summarize and report financial information;
and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Any fraud, whether
or not material, that involves management or other employees who
have a significant role in the registrant's internal control over
financial reporting.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 40%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA LIFE SCIENCES INC.</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Registrant)&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
May 14, 2020</font></div>
</td>
<td style="vertical-align: top; width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: top; width: 46%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">/s/&#xA0;<font style="font-style: italic">Francois
Michelon</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 5%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Francois
Michelon</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 5%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer and Chairman</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Principal
Executive Officer)</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ndra_ex312.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>ndra_ex312</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 31.2</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
David Wells, certify that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
1. I have reviewed this Quarterly Report on Form 10-Q of ENDRA Life
Sciences Inc.&#xA0;</font>:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the
period covered by this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;The
registrant&#x2019;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Designed such
disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Designed such
internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">c)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Evaluated the
effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">d)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Disclosed in this
report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in
the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal
control over financial reporting; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;The
registrant&#x2019;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the
audit committee of the registrant's board of directors (or persons
performing the equivalent functions):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">All significant
deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record,
process, summarize and report financial information;
and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Any fraud, whether
or not material, that involves management or other employees who
have a significant role in the registrant's internal control over
financial reporting.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ENDRA LIFE SCIENCES INC.</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
May 14, 2020</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: top; width: 46%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">/s/&#xA0;<font style="font-style: italic">David
Wells</font></font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 4px double #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">David
Wells</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 41%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 46%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Financial Officer</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Principal
Financial and Accounting Officer)</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ndra_ex321.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>ndra_ex321</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 32.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CERTIFICATION PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
18 U.S.C. SECTION 1350,</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AS ADOPTED PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the Quarterly Report of ENDRA Life Sciences Inc.
(the &#x201C;Company&#x201D;) on Form 10-Q for the period March 31,
2020 as filed with the Securities and Exchange Commission on the
date hereof (the &#x201C;Report&#x201D;), we, Francois Michelon,
Chief Executive Officer and Chairman of the Company, and David
Wells, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the
Sarbanes-Oxley Act of 2002, that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(1) The
Report fully complies with the requirements of section 13(a) or
15(d) of the Securities&#xA0;Exchange Act of 1934; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(2) The
information contained in the Report fairly presents, in all
material respects, the financial&#xA0;condition and results of
operations of the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A
signed original of this written statement required by Section 906
has been provided to ENDRA Life Sciences Inc. and will be retained
by ENDRA Life Sciences Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">/s/&#xA0;<font style="font-style: italic">Francois
Michelon</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 6%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">/s/&#xA0;<font style="font-style: italic">David
Wells</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Francois
Michelon</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 6%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">David
Wells</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 35%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer and Chairman</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 6%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Financial Officer</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ndra_ex102000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 ndra_ex102000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ K<# 2(  A$! Q$!_\0
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M$LC;8Q(PV\CKQ]>#Q4,>C6L=RT@/R#9MCSP"O3/KR<U-I]BEBLQ#*9)Y3(Y
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M:).C$;6F9T /13VJY134$G<BIB9U(\KV"BBBK.<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^WT^6_ENXA:Q,4>4'(#!MI''?=Q]:H6_C'P_=-(L&I1R-$65PJ-\I498'CJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ-M . %#-@99L "@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:*RO*U__ )^M/_[\/_\ %4>5K_\ S]:?_P!^'_\ BJ -6BLKRM?_ .?K3_\
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M7_\ GZT__OP__P 51Y6O_P#/UI__ 'X?_P"*H U:*RO*U_\ Y^M/_P"_#_\
MQ5'E:_\ \_6G_P#?A_\ XJ@#5HK*\K7_ /GZT_\ [\/_ /%4>5K_ /S]:?\
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M*VMXX((UCBB4(B*.% X H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,56-H.IW]U>646IZC:)>/IXDFTZ)0Q+;\>:'!^Z>F.E=/0!1_LJ#_GM>?\
M@7)_\51_94'_ #VO/_ N3_XJKU% %'^RH/\ GM>?^!<G_P 51_94'_/:\_\
M N3_ .*J]10!SFA:?;_V,TLD]RBK/<9/VIU  F?GK5NT32;\L+/5'N"HRPAU
M!WQ^34: R)H3O*0(UGN2Q;H!YSYKSKPM8E?#MCXG>^BM[32K:[1/L=L6F)=S
M]_/#!1@@8QDYH ]/_LJ#_GM>?^!<G_Q5-;3+9$9WN+M549)-W( !_P!]5P=A
MKNL&*34&N[R>UTW4O*E@"HSS6TD:%&)4?,5=NW;/I6O!?7D'B$Z=JFLRVS6R
MPO"C1J1>*PS)DXYP<KQC&,]Z .@L[;3]0LXKNSO;F>WE&Z.1+R0JP]0=U3_V
M5!_SVO/_  +D_P#BJ\ITOQ)?Z3X=LH=+O1)YNGRRB$P[A!MN%7< !DX1G)'^
MSGM700ZOJ(6SMK[Q&$M)C,8M2MX.'<;=D9+ @X!8YXW8QVH ZVUATV]:=;6_
MN)C;R&*79>2'8X )4_-UY%,E_L>"Z^RS:LT=QQ^Z?46#\].-V:Y'2-90>.;Z
MT-VT%G+>[DEA 'GS"),HX(^4$#(QU((SQRSQ-I_]O?$"^T>VELDENM#\B5KB
M$N5!D/*XQ\X!R,^U '>_V5!_SVO/_ N3_P"*H_LJ#_GM>?\ @7)_\57#/JVI
MZ=!K2Q:I-<QZ9<V]H"(@3! 0@>0C&791N.?K5=K_ %)]>TR8:C=75G#=W,=E
M(ORK=CR RJ^!AB'W+GC.* /0?[*@_P">UY_X%R?_ !5-DTVVBC9WGO0JC)Q=
M2G^M>?:=XAUJ2WMYKW7$-E=21K=2PVQ5[%B&RI)X7+!5Y''XT[6=3N],U&]O
M8?$%PS+HL4D,CQ QRL)7#'9C&<8_.@#T :7 0")[S!Y_X^I/_BJ7^RH/^>UY
M_P"!<G_Q5<8WB'4YM898+]H[A;U(ULFB!1[0H#YV<9]6W9QQBG^$/$=U?ZCI
ML5SJXO&O+&65U\L(-Z28!4 <97/'M0!TD?\ 8\MT;6/5F>X!(,2ZBQ<$=L;L
MU<_LJ#_GM>?^!<G_ ,57G8T?_A(_%?B""VO+2W@MM5M[J641$S@QQH?D;@ %
ME()_WA5FTU^_?2-(N+S6Y1;7\UPEU?I$JB%D)\M5&,*&]3G.!ZT =W_94'_/
M:\_\"Y/_ (JC^RH/^>UY_P"!<G_Q5>>2Z_KUT^FVESJ3V5W-#"^8Q'&I!E8,
MTF[D;D ("YP35R#7+I]$GGN==NI)I-3FLHGMXD0,$9MG)&%R "6YSVZT =O_
M &5!_P ]KS_P+D_^*IDNGVD$32S75U'&@RSO>2  >I.ZO-K+QEJL^G-=W>MB
M&>"*Q<P?9P,,[;95;C)[GVKK-+U=+K0?$"7=\MS'93SP^;(!GR]N1NP,'J1G
MVH V[>SL;N!9[:]N)H6^[)'>NRGZ$-4O]E0?\]KS_P "Y/\ XJN(T3Q-!8_#
M'3[;2&2YUB'20\=JB$D,J#<2/8]NYXIDGB*Y59HX-:N[BPF>);2[CB4.TS(Y
M:(L1A0,*V<9YVT =U_94'_/:\_\  N3_ .*H_LJ#_GM>?^!<G_Q5>8P^-=5?
M37O;C6!'+#:6$YMQ !B1Y"DJ-QD\#/;&:];!#*&!R",@T 4O[*@_Y[7G_@7)
M_P#%4?V5!_SVO/\ P+D_^*J]10!1_LJ#_GM>?^!<G_Q5']E0?\]KS_P+D_\
MBJO44 4?[*@_Y[7G_@7)_P#%4?V5!_SVO/\ P+D_^*J]10!1_LJ#_GM>?^!<
MG_Q5']E0?\]KS_P+D_\ BJO44 4?[*@_Y[7G_@7)_P#%4?V5!_SVO/\ P+D_
M^*J]10!1_LJ#_GM>?^!<G_Q5']E0?\]KS_P+D_\ BJO44 4?[*@_Y[7G_@7)
M_P#%4?V5!_SVO/\ P+D_^*J]10!1_LJ#_GM>?^!<G_Q5']E0?\]KS_P+D_\
MBJO44 4?[*@_Y[7G_@7)_P#%4?V5!_SVO/\ P+D_^*J]10!1_LJ#_GM>?^!<
MG_Q5']E0?\]KS_P+D_\ BJO44 4?[*@_Y[7G_@7)_P#%4?V5!_SVO/\ P+D_
M^*J]10!1_LJ#_GM>?^!<G_Q5']E0?\]KS_P+D_\ BJO44 8&IV4=M>Z.Z27#
M$WP&))W<?ZN3L2:WZR-;_P"/G1O^O\?^BY*UZ "BBB@ HHHH **** "BBB@
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MC;'4$9% %+_A(]&!R+Q.?]AO\*7_ (231P,"]3_OEO\ "M3:/0?E1M'H/RH
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M^5 &7_PDNC_\_J_]\M_A1_PDNC_\_J_]\M_A6IM'H/RHVCT'Y4 9?_"2Z/\
M\_J_]\M_A1_PDNC_ //ZO_?+?X5J;1Z#\J-H]!^5 &7_ ,)+H_\ S^K_ -\M
M_A1_PDNC_P#/ZO\ WRW^%:FT>@_*C:/0?E0!E_\ "2Z/_P _J_\ ?+?X4?\
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MMH?M<  VIMR_SY'(SP#756\]U%JFIB"S,ZF9<MYJK@[!Q@U<^V:A_P! L_\
M?]: //[3P=XCA\6"_D$;N-1GO7O3(!YT#PA5ML9W8#=ONCJ.:P)? 7B:3P_K
MUN=#@2;4;*S5((IHEC2:.0E\<\?+CGDGUKU_[9J'_0+/_?\ 6C[9J'_0+/\
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MJ'_0+/\ W_6C[9J'_0+/_?\ 6@#0HK/^V:A_T"S_ -_UH^V:A_T"S_W_ %H
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MAM'O;>Q33X$28A'4-DR$E?E)XPO/UK>^V:A_T"S_ -_UH^V:A_T"S_W_ %H
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M*S_MFH?] L_]_P!:/MFH?] L_P#?]: -"BL_[9J'_0+/_?\ 6C[9J'_0+/\
MW_6@#0HK/^V:A_T"S_W_ %H^V:A_T"S_ -_UH T**S_MFH?] L_]_P!:/MFH
M?] L_P#?]: -"BL_[9J'_0+/_?\ 6C[9J'_0+/\ W_6@#0HK/^V:A_T"S_W_
M %H^V:A_T"S_ -_UH T**S_MFH?] L_]_P!:/MFH?] L_P#?]: -"BL_[9J'
M_0+/_?\ 6C[9J'_0+/\ W_6@#0HK/^V:A_T"S_W_ %H^V:A_T"S_ -_UH T*
M*S_MFH?] L_]_P!:/MFH?] L_P#?]: -"BL_[9J'_0+/_?\ 6C[9J'_0+/\
MW_6@#0HK/^V:A_T"S_W_ %H^V:A_T"S_ -_UH T**S_MFH?] L_]_P!:/MFH
M?] L_P#?]: -"BL_[9J'_0+/_?\ 6C[9J'_0+/\ W_6@"#6_^/G1O^O\?^BY
M*UZY[4I[J6^T=9[(P+]N!#>:&Y\N3C KH: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#-TW_D(ZI_UW7_T 5B>&/$&K:MXF\0Z=
M?)9+;Z5.L*-"K!G+*&!.3C@''UK;TW_D(ZI_UW7_ - %<[#X+U6TO->N;3Q"
ML4FLRB25OL0)BPNT;/F]/7ZT ;">+M%DUEM*6[)N1*\&?+;8957<T8?&"X7D
MC.:I2?$/P[%9WUT]S.L=B(VN UM(&19#A&VD9P3WJE;_  WM+;55NH[^<01W
MDNH10A1E;B2,(S;NXXR!Z]ZSF^%.[2]1LSKLSO?VMO;33/;@L?*<N&Z\DD\Y
MH [71M>T_7H[E["5G^S3&"97C9&1P 2"& /0BLF;Q:;?X@VOAR6V"VMW;.T%
MT6^_.G+1_@IS4GAOPM-X>DUJ4:@)Y=3N3=$F#:(W*A3QGD<"LC4/ARU^FEW/
M]J+#K%C=_:FU%+;YY6]"N[ ![COB@#4'Q \/_;GLC/<+.EVUD5-K)S,J[M@.
M.21T]:<_C[PXEC:7GVYFANH6G0I"[%8U.UG< 94 \$FL0?#:?^U!?MK8+_VO
M_:Y46O'F[-@7[WW<5%%\*HH]*ALQJ\@<6<UA/*(!^\@DDWD $_*P).#[]* .
M@?QYH$=ZUHUS*)5OH[ _N6QYSC<@SC&".0>E-M?B!X?N[UK.*XG^T*\T>QK9
MQEXAEU!(P2!SBL>[^&$4FIFZL]5DMX?[0MM06!H0X$D";%&<@X(HL_AHUKKD
M.HMK)<1WUS>&/[.!DSJ%9<[NP'!H U_#7C6T\0:3IEX;:YMVU*258$:!R,(3
MR6Q@<#J>,\5U%<UX>\+W7AS2M*TRVUB1[2Q:3>C0)F9&R54GJ,$YR.M=+0 4
M444 %%%% !1110!C:$91H$AA56E$]UL#' +>=)C/M7.>%M9UB_T[5([[46&I
M6[OYUL;4>;;D-T10<.IP<'FNCT&-9M!>)L[7GN5.TX.#,_>JFG^$5TY[F:/5
M;Y[J7*I/(RLT2%MQ49&#D]2>30!EV/B#5=5L-(M[>]CBNKA;AYK@V_S*(FP$
M:,_=?D;AV(.*JKXNU6XU;1P9X+2*^CMVCB:/,<A8GS59^J-@'8/XL?6NGE\+
MV;V\*1S7$$\3R.+F-_WC&3_69.,'=]/3&,5 _@S3#<1M&T\4"B /;(_[N3R<
M>7G//&!T(SCF@"#Q7K][I\L=AIL,K3F![J>6*-9&BA0@$JK, S$GI]:HOXFO
M<R:E!<I+IMK-:VYB,(#3^;LS)G^$CS 0!Z&MJZ\-B_E6>YOKE;E1)$)82$)A
M?&8SQ@C@8.,C'6G'PMI_VR.9/-2%#&S6RM^Z=H_]6Q'J,#ZX&>E &;H.N:C=
M7NGM>2QR0:I%--'$L>W[/L88&?XL@\Y[BFS:_J,6I2W7F)]@CU(:>;7RQDC:
M"9-W7.X].F!6I:>&;6QF>6VGG5E1X[<%@PME<AF" CN0.N>F.E./ANS;4Q>L
M\Q'FBX:#=^[:8+M\PCUQ^'?&: ,OP]KU_>7NF_:Y4EBU:R>^A18POV<*4^3/
M\7$@Y]0:ZVLC3/#MGI=SY\3S/LC,4"2-E8(R<E4]LXZ]@!VK7H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV5?_ /0<NO\ OW'_ /$T?V5?_P#0<NO^_<?_ ,37'W7Q#U>UM-%+:/#)=:Q
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M)K6HH R?[*O_ /H.77_?N/\ ^)H_LJ__ .@Y=?\ ?N/_ .)K6HH R?[*O_\
MH.77_?N/_P")H_LJ_P#^@Y=?]^X__B:UJ* ,G^RK_P#Z#EU_W[C_ /B:/[*O
M_P#H.77_ '[C_P#B:UJ* ,G^RK__ *#EU_W[C_\ B:/[*O\ _H.77_?N/_XF
MM:B@#)_LJ_\ ^@Y=?]^X_P#XFC^RK_\ Z#EU_P!^X_\ XFM:B@#)_LJ__P"@
MY=?]^X__ (FC^RK_ /Z#EU_W[C_^)K6HH R?[*O_ /H.77_?N/\ ^)H_LJ__
M .@Y=?\ ?N/_ .)K6HH R?[*O_\ H.77_?N/_P")H_LJ_P#^@Y=?]^X__B:U
MJ* ,G^RK_P#Z#EU_W[C_ /B:/[*O_P#H.77_ '[C_P#B:UJ* ,G^RK__ *#E
MU_W[C_\ B:/[*O\ _H.77_?N/_XFM:B@#)_LJ_\ ^@Y=?]^X_P#XFC^RK_\
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M;T22:^E;3K???KMNB!CS1C!W?AQFK/\ 8^F?] ^U_P"_2_X4?V/IG_0/M?\
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M_P"CGI\/A_1K?[9Y-A!']M8/<[1CS6!R"WJ:S]$T_3%T-YY[*W*I/<%F,0.
M)7]NP%1V^K>#[M(WMQ9RI(K/&RVQ(< 9./EYX!H VUTS3DU)]26U@%ZZ[&G"
MC<1]:2UTK3;%;A;6T@A6X8M*$4#>3ZUE_;/"AT^UOT%C):W3;()8X0P=O08'
M7@_E4%OK/@NZDBCBET[,TABC+1!0[@X*@D $YXQ0!N76E:;>RVTMS:02R6K;
MH&=03&?;]/RJ"]\/Z-J-^E]>6%O-=(AC65URP4]0#Z<UF_VGX/%Z]HS6"SI,
M(&5X0H60]%)(QDY&!WK0N;;0K.:VAN+:QBDN9/*A5HU!D;!.!QUP#0!$/"7A
MT6<EF-(L_LTL:Q/%L&UD4Y52/0'FK$>@:-%/-,FGVHDFB\J5M@^=,8P?7@8J
M'4T\/:-9->:A;V=O;J0&D:$8!/3H*G_L[2O(69--@=6 (VP#)!]L>] #M-T7
M2M'W_P!G6-O:EP%<Q( 6 Z GOC-7]P]16$3H7]KC3%TY'GSAF2TS&C;=VUFQ
M@$CGFK=U9:)8VLES=6EE%#&,L[Q* /TH TMP]11N'J*R;*#0-11GM+:SE"'#
M;8A\I]#QP:G_ +*TSS3'_9MOPH;=Y"X^F?6@"_N'J*-P]15/^Q],_P"@?:_]
M^5_PH_L?3/\ H'VO_?E?\* +FX>HHW#U%4_['TS_ *!]K_WY7_"J.ICP[H\,
M<NH6]G!'(XC1F@!RQZ#@=30!M;AZBC</45272-+90PT^UP1D?N5_PI?['TS_
M *!]K_WY7_"@"YN'J*-P]15/^Q],_P"@?:_]^5_PH_L?3/\ H'VO_?E?\* +
MFX>HHW#U%4_['TS_ *!]K_WY7_"C^Q],_P"@?:_]^5_PH N;AZBC</453_L?
M3/\ H'VO_?E?\*/['TS_ *!]K_WY7_"@"YN'J*-P]15/^Q],_P"@?:_]^5_P
MH_L?3/\ H'VO_?E?\* +FX>HHW#U%4_['TS_ *!]K_WY7_"C^Q],_P"@?:_]
M^5_PH N;AZBC</453_L?3/\ H'VO_?E?\*/['TS_ *!]K_WY7_"@"YN'J*-P
M]15/^Q],_P"@?:_]^5_PH_L?3/\ H'VO_?E?\* +FX>HHW#U%4_['TS_ *!]
MK_WY7_"C^Q],_P"@?:_]^5_PH N;AZBC</453_L?3/\ H'VO_?E?\*/['TS_
M *!]K_WY7_"@"YN'J*-P]15/^Q],_P"@?:_]^5_PH_L?3/\ H'VO_?E?\* +
MFX>HHW#U%4_['TS_ *!]K_WY7_"C^Q],_P"@?:_]^5_PH N;AZBC</453_L?
M3/\ H'VO_?E?\*/['TS_ *!]K_WY7_"@"YN'J*-P]15/^Q],_P"@?:_]^5_P
MH_L?3/\ H'VO_?E?\* +FX>HHR/453_L?3/^@?:_]^5_PK)\0Z9:0Z;YEO9V
MZ88!RL2YQ^5 &R^HVJ7:6IF4S.<!1SCZ^E6=P]17F<4%O'.DAMXB%8$@H.:[
MY=)TMT5AI]KAAD?N5_PH KZT0;K1L'_E_'_HN2M>L#4["SM;W1Y+>UAB<WP!
M:- IQY<G'%;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!FZ;_R$=4_Z[K_ .@"O&=?M;N_O/%/V."_N9)M9@FMM.^RMY5Z$5 2
MS8!"@J><@<"O68M3AL=5U..2*Y<F53F*!G'W!W JS_PD%K_S[7__ ("2?X4
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M%'_"06O_ #[7_P#X"2?X4 :U%9/_  D%K_S[7_\ X"2?X4?\)!:_\^U__P"
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M*/\ A(+7_GVO_P#P$D_PH \_EMKZ/5M=DLAJL$,^L(;F5(W8FW\H@L@/5?,
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M UJ*R?\ A(+7_GVO_P#P$D_PH_X2"U_Y]K__ ,!)/\* -:BLG_A(+7_GVO\
M_P !)/\ "C_A(+7_ )]K_P#\!)/\* -:BLG_ (2"U_Y]K_\ \!)/\*/^$@M?
M^?:__P# 23_"@#6HK)_X2"U_Y]K_ /\  23_  H_X2"U_P"?:_\ _ 23_"@#
M6HK)_P"$@M?^?:__ / 23_"C_A(+7_GVO_\ P$D_PH UJ*R?^$@M?^?>^_\
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MI&*7H\Z9),X\N,I\S#!XSZ<UU$NL:=;W<5K/>0Q7$J[UBD8!L8S7)ZGX*O\
M4_$FIZL7L89R()-,N5W-+!+%NQN&!\K!B& /3]$/A&YEUF;6=8M=)G:7RYI6
M DD:!XQC]V"/F! [X*DG&: .C'BK0&5F76+,JI3)$HQ\YPOYGBJ&H>,K*RUB
MS@$]JU@\D\-U<F7F"6-0VPC'OS^%<KH_AB_U_P )6LFZVM6@LFM[1#$Z$YE1
MSY@(!4#RP,#/4FMM?"VMQ:N=62XT]Y_MTERMNP<(!)"L3 OR21M!'RC//3/
M!I2^)MFKWMLTMC#91V4-U!>22Y5_,=EYZ#&5&,'G-:PUC36U4Z6+Z WP7=]G
MWC?CZ5Q-]X$U8VEU96<FG/;OIT-I&TY<$.DID+;0I 'S' !XP*Z/1](U'3;^
MX$HL9+.6YENUD^;SD>0Y9<8Q@$D!LYQ@8H S=7\<W&DZOJEF^F6K1Z? EPSO
MJ"QO*C!C\B%>6^4\9].>:WD\1:49K.WEO(X+J[C62*WF8+)@C(!'8]>/8US.
ML>$M6U#Q!K%X+/0KB"^MX[>(W9=GA"AOFQLZ_-T!'0<T77@[6W72X%U&WGM]
M.:TD0S%E:9XN'\S .[(Z$GCT[T :^K^+K2#2+RXT>XL[^[MXA-Y(FX*;L%LC
M.1UK:L]2L[]YX[6XCF>W?RY@ASL;T/O7 MX)\0G1H;!3HZ>78SVIVO(%S)(&
MR %X  _.NM\,:?J>DZ>UA?R6\D,+8M7B9B_E^CY R1TSW[\T ;=%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M.>*9;B)80DK+"^0RCC)KEZ[3Q'!YVDNX',3!_P#&N3L'C6^B\U0T3-M<'T/%
M %G2M6ETV;N\#'YT_J/>NUM[B*Z@6:%PR,."*XO5M(DTV7<,O;L?E?T]C3-+
MU2739\C+0L?G3U]Q[T =Y145M<Q7<"S0N&1N]2T <SXKM\&"Y'NC?S%9N@7'
MD:O$"?EDRA_'I73ZW;_:=)F4#+*-Z_45P\;F.1)%ZJP8?A0!V6M_\?.C?]?X
M_P#1<E:]8NK2"630Y%Z/>JP_&*2MJ@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Q7M-9@O[J6R>P,,[AP)@^X84#MQVIW_%2>ND
M_E)6Q10!C_\ %2>ND_E)1_Q4GKI/Y25L44 8_P#Q4GKI/Y24?\5)ZZ3^4E;%
M% &/_P 5)ZZ3^4E'_%2>ND_E)6Q10!C_ /%2>ND_E)1_Q4GKI/Y25L44 8__
M !4GKI/Y24?\5)ZZ3^4E;%% &/\ \5)ZZ3^4E'_%2>ND_E)6Q10!C_\ %2>N
MD_E)1_Q4GKI/Y25L44 8_P#Q4GKI/Y24?\5)ZZ3^4E;%% '/6%EXBL+7R$DT
MME\R23)60??<L1^&[%6?^*D]=)_*2MBB@#'_ .*D]=)_*2C_ (J3UTG\I*V*
M* ,?_BI/72?RDH_XJ3UTG\I*V** ,?\ XJ3UTG\I*/\ BI/72?RDK8HH Q_^
M*D]=)_*2C_BI/72?RDK8HH Q_P#BI/72?RDH_P"*D]=)_*2MBB@#'_XJ3UTG
M\I*/^*D]=)_*2MBB@#'_ .*D]=)_*2C_ (J3UTG\I*V** ,?_BI/72?RDH_X
MJ3UTG\I*V** ,?\ XJ3UTG\I*/\ BI/72?RDK8HH Q_^*D]=)_*2C_BI/72?
MRDK8HH Q_P#BI/72?RDH_P"*D]=)_*2MBB@#'_XJ3UTG\I*/^*D]=)_*2MBB
M@#'_ .*D]=)_*2C_ (J3UTG\I*V** ,?_BI/72?RDH_XJ3UTG\I*V** ,?\
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MM+,16$L41#NQ:8,5!;CA>IXYJ'4=::3Q'97-RJAM*U&ZB*P.?GC%H[_,N>O
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M3]B-Q;RR_:[J.U0QIN",YP"Q[#- '/>$-?N-1U-[:?45N]^F6M[MV@%'?=O
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MR*>2#C/*COZ&NJ\1Z:+:Y%U$@$<IPV!T;_Z]<UYML+SYIR9,[ N20#WP.F:
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MA@O7BO0XM>4W)BN+.XM4,R0I++C#LRAEZ'C).WGOQW%:] '*3:7J%MX"33[
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MX)TG^R=.G58=1@BF<.(;Z1"R-C#8" *!P.G4Y-;;:A$6A\AX9DDD*,RS+\N
M2?J1CH*+75;"\M8;JWO(9()_]4X<8?Z4 <MI5MJ5II/_  CDNE7.Y;B0_; R
M>28VE+ALYSG!^[CK5SQ-:?VM'"S:9J.;9Y#'<V<JQW$+# #1\X8-D\'MU%;$
M6LVETZK9RQ7 %PUO(1(!L90<]>I!XP/6K9O+8!R;F$",@/\ ./ESTSZ4 9OA
MU]432K6VUA'>^6(M+/M4*WS$ '!^_MP3@8SG%<S!+K%GJ/BE8?#E].^HW.;5
MG,:Q,!$J99MV0,J>V<5W4,\-Q'YD$J2IDC<C!AD=>12RS10)OED2-?[SL *
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M?K5A]6L(Y[>%KR#S+C=Y2[Q\^T?-CZ4 <#JR:DEW>6T[:GMLY-UM\C/'-!L
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M@6*-VB$'DL%. -OWCSWR:T]6AUJ!9+:%KN)I=/,MM);AC_II<DA]O4<K][C
M:F:%JHLKR)I&"QS@!UW ]>X]<5U&J:[;:;9K<#;<+YT<+B.1?DWM@$^PH QM
M%TZ\OKK6_P"U9;PL)PD2.[>4%,49)13P1OWX/UKCI+>>RU@I$LJYN2+BWDC.
MP>LBGMZ^]>E3Z[;QZCI=I$!.FH-(J31."B[%W'ZUF^(;:&ZC^W6LB2&,[)=C
M X],XH X;1UOIKG08$6>?[+J)F-K*FV-%.[,F[ .5#9 R<YZ5T.H)J":E9^+
M8K21S'>&%H4A?SVM6.PKLQV($E4H;Q8[D^5,!-"0QY^[Z5Z%IU]'J-C'<QD$
M,.<'.#WH R->$K:YX;?G[&+MS-QQN,3>7G_@7ZXK"^U:Z^FZJT<6J+K=N95:
M-@?(D0RY4QYX+>7]W;SGK793WFG2*\4US;-CED+@D8/7'L:P=1\61[62Q= H
MX,KL/T% &)?27<.H022R7,NFIK$$]J)@QD2/RF\S.[YMH8\9]:QUU/4TLK>R
MBDNK:W+3$-"AW%VD+#=[8/':M&6\661I);E7<\EFD%68;=?+:ZN[B&UL4C$C
M3O(.A.!@=<'L>E '.NEU=P7D+)=M=;9 %3.UQ_#CU./3WK=LM/UK[+JL=J]]
M;21VT%Q;*=ZAW&6*Y]\8(_VA77Z9)HMLUS#:W,+26VT3N7!*[AD9/;BI-;UV
MVT72FOWVS*"NU$D4%PS!<C/7K0!S&J2ZW)+8ACJEI;W\#NS6T9E>VG)4HAP?
ME 7(Y^7(.>M)<IJ5FNNZC;BY6:SU".Y6/)C6[18U#)GH0><=L@5W<DB1(7D=
M44=68X%4KR+3+IHI;LP.;67<A=\!'QWYZ_6@"#2[KRI(]-N7G>^:#[4Y=6*X
M+8(#=."0,?2N.O-+NCK5VC0W^V3Q#!/O7>0(?) +*>P#9&1TKT'SK;[0R^9%
MYP7)&X;@O\\4^*:*9=T4B2*#C*,",T ><03>('6PL[B;6(86CD2*XC@9Y/-6
M=L"0DC@Q[,%N#SWKO;S2;#4F1[VTCF=8WC!8=%<88?0BK'VB 2M$9H_,4;BN
MX9 ]<50T765UN'[5;P$6;J&AG\Q2)!DC&!R",?K0!R%IX92_\4:TNHP7UKI0
MN+:2W@,D:PW/E(H&X EB R@@9'09I-$T,RS7^IZI!J*R6VI7-[96,DD6QF?.
MV10#DM@D?,V!FNBM!H6J+>7=UI5C$T5U);R/<11DLR]\X[U<.C^'ED6,Z;I8
M=AE5,$>2/;B@#G/ ?AQ++3]+OM2^UC5;:T^RI!<R(1;KD%@@3C!P.22< 5W-
M9EE9:$MSOL+;3A/&,[H(TW*#].16G0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <%X@\/IJ/BJ[N[RYCBC:SCBMI(HG,UO*CETE
M5@N,Y/3/0>]5UTM[K5EU+5)["XGECB2?_0Y2$:,DJ\8([YY!Z$9!KI-1\866
MF7]W:RVE\RV:QO<S)$/+C1^C9)!(&.< XJ./QI:3AQ#87[/]JDLXHRBJTTJ9
MW!06' "DY..* .-LK?\ M&WOK:4S0K=VMS;1^9;S*;-9"6V[2F.3C^(].#6E
M)87CZD]\=2M"TUW:W+Q?9)@%\E=I ..<^X&*Z*W\8V=X(A965_<R,"9HHXAO
MM\.4.\$CD,#P,]":JGXBZ&MQ>1M]H$=LKGS_ "P4<HVUE'.<YX&<9H YZ70+
MFYDNKBYUH27,]ND.3;R[,QSB5"%QA1@8(%6WT^X_M>;4XK^V29+\7D""UEV.
M#%Y3J_'!(Y!&<'UK0NO'$%_H-XVF0WR7XAGVH(D+P[ ,R<G:5!9>A.<]*O>%
M_$::E:V=E(99;U+.&2XE.T LR!LXSGG/7&* .9?0VB6X6TN[0?:+"XMW=[64
M'S)9-Y(POW1T K9T"R:UUT7 O5598BLMO#'*(Y).,-AAA3@<D8SGFM34?%5M
MI>JQV-S97@$I98IE12LC+&9"JC.X\*1G&,\5!;^-K"XM_.^R7L>^"*X@1XP&
MG60[5"C/7/&#C\J )_%=K+J5A:Z?;Y\Z6\@DW#_EFL<BNS?DO'N16GIMS<W5
MJ9+JU^S2"1U"!]P*AB V?<8-<WX<U+4=0TGQ&]S<3)/!?7$4!E1-\"A5*K@<
M';GWS3=/\916FAV3WR75U)':02WUS$BE8=XX9QD'GDX4' YH K_\(I=OJ<4T
MUG:O FH7=SL8@Y26/:O!&,YZTW0O#.K:;<627=K97< MK52\DF6M9(1CY!CD
M'@CD8.<UJ:AXWL-+N+J*[L[Y/(MY+A2L:L94C(#%5#9QR#D@<<UI:9KL.J27
MT,=M<13V;*'BE4 D,NY2,$C!% '(S^$M8.E+!';VKRR:??6,F^3A?-;<C9QR
M.Q'O4R>&=:COH_,@M)XQJ%M>+.9/FB1$"M'TR<$$CMS3/#_BJYFC_M*ZAU6:
MYO#/Y>F((F"QQ2$%UY&,<*<DY-;"^.]+DCN)XH+V2UM[5+J2X$6$V.I*XR<D
MG&.!P: ,!O!%_+IBVTEI:%TTR]M%R00KRR!T(XZ #\#TJ)1GQDJ36@G\BY@<
MH)@)5E6(1E@K#)C 8YP<<9]JZ*+QC;W5Y]DET_4[69+U;3!5,-(4\P D,1M*
MX_.I?^$PLDTI=5N;&ZMX1YJRF14W0E&V;6PW4MP,=_2@#:TVXN+O3H9KNV^S
M3N#OBW;MO/KW]?QKD!X(NH=466WEMTM(KF5(XMO_ "Z3?-*A]]_3VJ[#\0-/
MN(U\G3]2DF83'RA"/^68!;YMVT\$$8/-/'Q T9]1M[.-;ES*J$R+'E8RR;U#
M#.>F.@(&10!3E\*WIU62ZC@MO+768KZ-"0,QB$QGMP<G/X52;P9JCV0AB6WM
M;AK:]B>X5N2995=,X&2/EP?3/%= GC/3I+.QNECF*7K[(?F3DXSUW8Z=LY]J
MZ('*@X(R.AH XB3PSJ)U!=6@MK>.47MO<&RW@*-D;QNP(& 2''X**?X4\+ZA
MHM]9S7,-J0EG)!(8VY0F=Y%QQR"'Q^%=K10!@ZSI=U>Z]I=Y#&CP6T=PLH9L
M9WH .._2N4E\#ZE-I/V9K6U,PT6VL58L#B6-\D@XX&.AKTFB@#BX_#-['KOV
ME+6W2V_M;[8H# ;8S!Y;<8ZEN?>LJ3P;K?\ 85EIR6NG@VUNL?FJ^UBR3*X.
M<="%Z>O6O2:* .(B\*ZA'/;_ +JW41:U+?&6-L'RWC=>..H+_I6;=>!M3N=(
M2!DM_M,-E]C=@^%NCYR.';Z!#UYRQKTFB@#FM)M+W1=1NHH]/B^RW^HO,/+<
M#R4\I1G;C'+(?^^LU-XITR]U2UMX;2&VD =Q+YQP55HV7*G!QR1GOC.*WZ*
M//SX5UDV%U$8H#)+IUC;+^]XWPN2W;I@\5V.LV\UYH-_;0(#//;/&BLV!EE(
MY/XU?HH XJ]\(NW@-M-L[*W74YK>WBF<MPWEE3RW7'RG ]Z=XHT-(['3VT_3
MHU6+44O;H XW85@<GJ3R.?:NSH(!&",@T ><^>4C2*!5MX(SF.*$;50YSD#U
MSWJCI5A+%K*ZI&L)U(7TDVV9_DGBDP&'HL@QD'ZCO77ZOX=SNN+%>>K1#O\
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MED<,0[*%)48P.@XQ5"#P+8P1QQB]O60V\=M<J7&+E(R2F_CJ,XR,9'!KJ:*
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M7:V5]!?P"6%L_P!Y3U4^] %FN.\3Q;-5#_\ /2,'\N*[&N:\61?+;38Z$J:
M(_"<F)KF+U4-^7_ZZZFN+\-R;-85>SH1_6NTH **** *][:)>VDEN_1AP?0]
MC7G\T+V\SPR##H<$5Z17-^)]/RJWT8Y'RR8].QH ;X8U#[UC(?\ :CS^HKIJ
MXG2M)O;F:.>/,**0PD8?R'>NV[4 %106T%LI$,2H&.3M'6I:* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'B_P_<WDEI#JULUQ%$9I(RV"B 9W'/08[T2>,/#T-D]Y)J]LMN@4O(6X4,2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<C+<6EVBPM&MT^T%;8R'Y-^#[@G&< BJI\::9?1*O]F7TJ2K.8U>  N86VR
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M6I/!D#:C+J;:I>K>-*DR3*R@QLL?EGM@AEZ@T  \=:?):2W45M=O%':BZ/R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*R;ZWUF6ZE^S3VHM66,*L@8,"&_>#([%>AZYK!\$W,>F^!Y+RXDGDVW%T?WL
MS2.^V5PJ@L2<X4 #VH [2BN(@\8:E(B>:FFQB]L5OK.8R-LC4NJ[).Y;YQC;
MC)XXZU4@\<ZS=VH,%E9"1+>]DDDD\Q07MW4$!#RH8,.IX/TY /0J*P+>VO\
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M^6XCB9K<!1.<C*JR[NG? (H ]+HKET\9;A"6TJYC^U211V;2?*DQDR0,D<$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&944LS!5'))/
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MMNDBPR2W#NWSXW9)/.0 .:XP:9!;W&[RV61%$;*6.#MX&1W(Z5ZI7*>)M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVQAHXW*QMY?$9*]"5P,?04 9<'C*^N(M/=/#\J_;[B2"(/<H-I3=G?QQ]TX
MS2/XVG=4DMM'DEM[EYX+.83@>;+%NRI&/D!V/@\].V:U+?PIIUM'8I&]UML9
MGGAS.3AFSG/J.3U]:6/0=%TB[?4L" >8\H$DQ$4<C_>95)P"W]?>@#@3XCN+
M_:T@D??#',@>7J&ZCV([UJ:-XRDLM(G9='NID$T(C8,%4B5P@R3TP2#WX-5K
MO3K"SU1HX45/*ED\I2W/S'+#W'\JT]!\,Z?J%A<V\HG6)9(V79*05VMO !]
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M<XK-;P5HTC&$S7A810H5%TWW8CF/\C0!=TCQ!%K%_?V:1B*2TD:-T,@\P8.
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MT5%]I@\U(O/C\QQN1-XRP]0.]2T %%%% !1110 4444 %%%% !1110 4444
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MF*PM@G]L&\&&4'R3%L*].I/;I69_P@^JG14M6LK0W$>BBQ1_,!VRB3<"#C@
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M0WA6<1LP 5(QP0Q;+9&2!Q7HMO=V]VKM;3QS"-S&YC8-M8=0<=QZ4 34444
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M>*!]-M&AA),:&%<)GK@8XS3_ .RM/^S_ &?[#;>3L\O9Y0QMSG;CTSSBKE%
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M2@#IO[?TGY_]/A^14=N>S_</XTVS\0:;?ZS=:5;3^9=6L:22 *<8;.,'H?\
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MO" [QR,N=PDS@X(/&.G6LR]\"ZBZWR6":/:QW.F?8PB1NH1S(7)X'(^8^^:
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M(^]]*U/&&JM=_"R;4K?4%M_/AC8RM%MW!B 5VL>,YKJUT;2U#!=-LP&3RVQ
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M(+RX0,@9-I"8) R02>O13BN=\-WMQK_C<SZE-;@G2;6X^P/"I,;EI.A)W#!
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M)N;(S_M K]ZO2J* /,=3T[4[VSU:SN[;4+V 7,5S'*&D1\"?)3;G!PO(*'&
M,@&NJ\36ES]GTW4+)+N22RG4O;QR,#+$PVLI /)&0<GIBNDHH \R^P:UIUA
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ndra_ex102001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 ndra_ex102001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ K<# 2(  A$! Q$!_\0
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M$LC;8Q(PV\CKQ]>#Q4,>C6L=RT@/R#9MCSP"O3/KR<U-I]BEBLQ#*9)Y3(Y
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M:).C$;6F9T /13VJY134$G<BIB9U(\KV"BBBK.<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2PAMHS$C$J\:D;B"<$<]/:L:/P3KBWRWLVH6-Q</+:2S&6-R-T)?.WGY00_
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M58EF8[^$1AE2W]T$=,XS3Y]<T.98;>YN[=ENSL2.4<29.!D$=">!GKVKE8_
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MOIEM=SZ9&MG?&\:YMH7$[$NS;%)/ .<'KD4 =4_B?0HS<"35;5/LXS*7D"@
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MY(Y66&6%G:1&#!MRQ#C('!!/'Y@&I_PF]MODSIFH")&N(PQC7<SP@EE"YSR
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M1RLJ;TAEV[MC%<CH?O=,\58U3Q;:Z7=W$;6UQ-#:>7]MGB"E;;?]W<"<GU.
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M?C0!<HJ@NMZ2\'GKJ=F8=^SS!.NW=Z9SU]JMS3Q6\+33RI%$@RSNP50/4DT
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M723JHGO1=1ZA=/<E?)V;"_!&<G(P!66/$^JW&KV5E%8V\6-1EL[O?*6X6(2
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M,'C&* -%_$FC1SP0OJ, ><(8^>"'^YD]!N[9Z]J@;Q5I$EC+<6NH0RJI,:.
MS(S\\ @?-C!SC.,<UFW/A*[N+R\W7L!L]0,$EW&83N5XL?ZLYX!VCKG':FVG
MA;5+.VT]H;VS6ZM+BX?'DL8GCF))&,Y##(P<_P Z )_#_C*SO]$TF?4KB""^
MOH4<Q)G:"Q(7GL"0<9/.*T;?Q3H5T"8-4MG41/+O#_*44X8ANAP>N.E<K'X"
MUA=*T[37UR&2WL?(>(>0R#S(Y=^2 WS C YZ8]Z'\!:I<6MK;3ZA9)'#]L):
M&!LYFD$@P"<84@#!ZB@#J'\5Z''9&[DU&)(0YC)8$$,!DY!&1@<DXZ<U<NM7
ML+/[&9[@*+R01V[*I82,1D $ CFN?U/POJ&KW-A?7DNF2W5L)(WADMF>"2-P
MN>"V0P*@@YZ9%:NJ:(;WP\NG0S+#-"(VMYMG$<D9#*<#MD#@=J (I?%FB?8E
MG&J111R.\:2R(P4.C!6!R!@@D#!QDFLW4?&T4&HI:VBJRV^I165\TT;KM#IN
M!3C!/05#>^"+E]-UVTM+V!5U)E>(2Q$K"Y(,K<'G<R@^U2WGA75)]6:\BOK,
M1OJ-O?NCPL2#'$(RH(;OC(H W+GQ#IUOX>FUT3&6QBC:0O$I8D X(QUSGC%9
M=AXNAFUFYM[R2&"V=;=K,X8,_F@_?R/E.1@=*=9>&[R/PA?Z+=74!FN6N&66
M*,A5\UV;D$YX+>M4+CPKKDYNR;[3LS_9/^6#\>2<G^+O^E '2VFN:9?7\UC:
MWL4MS""7C4\@ X)'J >#CH:T*Y?PSX3/A^;YFLY%B#I%,EOMG=&;.)&R<X]L
M9ZFNHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ#V[*ZSHX5V8*1D\8.<GC&*R4\%6$<D=Q%=WT5Z'D>2[24"2;?C<'XP0=J]
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MYGO9;2ZDL?L4:Q[6A\T<@]"!G&<\\XJQ>>/[4?VG#8VEU--:P3O')Y9$<C1
M[ANZ#VSUP<5S']F(;DS?:;A"TD;DJPX*'(QD5VI\(V4MI?0Q7M]%:WPD;R4E
M&R(R#YR@QQG)X.0,G% $WA+[5-H-O?7<UTTMY&DYCN'5_+)49VE1T/7';-;M
M9FE:5)I44%LE]//:P6ZPHLV"?EZ$D <XP/PK3H **** "BBB@ HHHH ****
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M$CV%NR(-VZ,?-&IQ_",_2@#)T6[OOLOAC4[FYCGO;UC!=-"FT2H59ER,GE2
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MYVC'09YQ5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9)U?3T17D&]BY &W&.<'C&.U=^\XQ^ZVRL& *AP,#."?PIPEC;&UU.>!@]:
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M"3[5MC4, 2,YR-O'<56U_5]+^W:X'D57;6K"3:8R3A%BWG@?PE6R>V#7KE%
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M 93F0;<DH"HW*#@9!SUR!7-^+]0O8_%4J26DMQ8:?I+ZBL4%XT+LZ..>.#@
MC!.,$T >A45R5QXQNX$DV:2DLEO:+>W:+<\QQ,3C;E?F;"L<<#CKS21>,KRY
MN42'13Y4MW)9QO)<@$N$WJQ !PI'OD>E '745A1>)H3X2379X&BW1[C;AP3O
MSC:#WY[UQ$?B?5+34-=N,;#/)$_ER7)=8 (^0A(Z$CH!U- 'I%]J=KIZ9FD^
M;LB\L:Y74->NKW*(?)A/\*GD_4UR?]N3RRR3O%YD;I$8QN)=F?/!X]OTK=MK
M>0:'<ZOJ<,ME;6L;R3(RY?"C)P/<>M %K1;J2UU*,QJSASM=5&217=UYGK6N
M7NG^'K^TM-+2ROO+MI5D%UNWPRRA,[PH(;.01[Y!K9\3K=^'O OE:6C!VGBC
M8273L4$DJA@'.6Q\Q ] >.E &[K.CIJ$?FQ +<J.#_>]C7&2(\<C1R*5=3@J
M>U:5IK4FC,VFV>BS-*+];/\ ?7Q=06C\P-N;)V]0!C/%9_B37#=1W_DV<46H
MV,Z1/&\N'9&D5 VTJ,@[N",C'Y4 =%H.MYVV=T_/2-S_ "-=+7E]Y)+:2QP&
M'-P\GEA"V,'J>?PJ?PIXGDM=/6WN;6XNIX+>YFCD,Q9I")!^[QU)]_;@4 >D
MURWBN#$MO< ?>!0_SK*;Q!=7FLV.K:8BW@;3IRUJMX1$2CKD_=^_U'(!^E-U
M+Q9_:NF2NEAMB2YM!&YEY9)T#*V,<'Y@"/UH T?"\_EZB\)/$J<?45U]>3Z?
MK[VTEE?/;"-'DP-TG ZC#'&!FND;QY<-]OGM] NY[&V2?9<*VT2/$2&7D #)
M#8()Z4 =C+$DT31R*&1A@@]ZXO6-'?3I/,CRUNQX;^[[&K2^,+Q9G6;1U1(I
M[=)&%R#B.;&U@-O)!/(_(FJ#>/I;G3I[O_A&[J73GV>3,S[5D5I1'D[@,'D-
MQF@!-,U*73;C>N6C;[Z>H_QK?UX1W^BI=P'<J$,"/0\&N&N+F[&IB!;6.%$N
MY;>53+O(**K<' R,..U7!K\^F"XM(;7[6KP-+)"9-G'3(.#S0!H:+/\ 9]6@
M;^%CL/XUW=>.V,SWNK2W!#". 1O"1(01E2>1T.>_TKUVVF%Q;13#^-0U $M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %9.JZ1I=TTMYJ;'R?L[P3"28K$8F'S;AG'XFM:N%\8S%-:DBNM0\O3WT:Y
M+6LBKY<K#USWQ_*@#3?P=X:>YM=2\@@QVJV<)69@GD$8"8!QM.?QHC^'OAB*
MRGM$TT"&=(4<>:W(B_U?.>"O8US5KXJN["*RM!JME)$K:8,-& 1%-\K*.>V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F20Q3#$L:/P1\R@]>M/HH K_8+/(/V2#(QC]V.W2I5BC0L415+=2!C-/HH
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M) EQ-=B)49%W$-E3VQ@UU-<?XL\)7'B;7M'FECL)M,LQ*MQ!<;BTHD78<8&
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MAZ]O8]0@FGL8Y4&F>4"_R_=<X.[I\QXP1TQ2V_B/6C)ID$^OZ.T=Y=,BW%N
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M/;/%<N66);?8HECD&< Y$F01DD@BMG0M%EM?AS>:5;V$MM<-%<1B*5C\SG<
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M5)& P[>] "T5P>D>++RRL%CU#[;JU[,UY)&RQ11J$@E*%<C:,X //K5^?QU
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M*V/&%Y>3>&],NH)9++[1/$LL.U'.UQG!.#R/8UR/]IOI6H-%>2&XC6-9D94
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MI%4HV,Y*G<!G'>LO6?%<]U!/:0)=:9>VES9RLI>-FDADG5"&VD[<C.0<'D4
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M2+,MN75FX;/!ZYXYX]*[N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+DF1LH9"R%@0!@=S^%0Z[KFHV^L:S;Q:M<Q)%>Z>(E2 '".<2H#CICYB>HH
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MT/T]Z[?3?%6FW-O;K-=(D\C2188$ O&I9N>WR@FN'O?"VI:>L=G)<PRN]HL
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MQG&1ZC((R*TJYOPSX7/AY5B,EM(D,9BBD2#9*R9R-[9Y(Z<8SUKI* "BBB@
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M<KM)W(F_(&>0P'%0P^-;6XCT^[;3]1C2ZLIKVW&U3OC158@@'[V&&!7+1Z?
MES%*9;H+%-YZHDQ7#[2N?R/>NJM?"NG7&G:7Y%_>B&QM9+:$B0 ['&T[N.H
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MI]EK:7QG<W;1-%$)9 3MSD@=R!QUSBMF@ HHHH **** "BBB@ HHHH ****
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MY[N1 US;>6I9E&""R]QT(S5H^']&8Y.DV)/S<_9U[]>W? _*@#F&\4:P\\B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAF^@,TD[R"?R3@!I3)C&>N21F@#1D\6:'#=0VTU_'%-* 520%2,Y(!ST)P<
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M6_NM66X6VL#8+&ML$WIN#*Q.3R,8XXH N+XLT5,;M3CE:6>:*)$0EBT0RZ
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MRK*1(KAMP<-UW9YH Y#3?%MWI&D:U?:G#<W,=MJ=RK&2:,&&-=N$!) 8@$X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH[4
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MC[^?D)' '  J5/#NNW=_:FZTG4);*U\3O<Q1S-DK:O'@$9;H&'([9]Z]IHH
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M0 4444 %%%% !1110 4V1=\;)N9=P(W*>1[BG4R8R""0Q!3(%.S?TSCC..U
M')6GPVT2V:T$DU_=0VET;V*"XN"T?GDD^81@9.23SZU(GP[T*,7*QBZ5)H9H
M$43'%NDQW2"/^[N-89\>:O:Z5;7L\5C<M>67G(D&56W<2+'\[$X*?/G)QC::
MOV?B#Q/)J-G87T>FV\C+-)*8LRNZQ[2 %#84E6]3@T ;+>#].:+0HS-=[=$8
M-:?ON>%VC=Q\WR\?C2/X+T9]=_M9HY?-^TB\,/F'RC<!-@EV_P!X+QFL.;Q9
MK4>A6.HQ-IMPVJO$EM''\OV=G#'#EFPP&,?P_,<57N/&/B*TANC=Q:7#+96,
M=W*B,TGF'S61ESD!<[<@\X]Z .DB\%:'!?PWL=LPGAOI;]&WGB61=K'Z8[5&
M/ ^D)!J]O$UU%;ZJ9&N(4F(4-(,.R#^$GO2:#?WYG\0O>WJ7:VUXXAACBVLB
M!%./O'/4=ASGUKGI/&^MKI=O?0?V9.E[8K>QX# 6V712CX)W'Y^#\O*D4 =Y
M86D&D:7:V,<K&&WC6&-IGRQ &!D]S7+Q?#/1(;E+B.YU$2)<SW2G[1TEF7:[
M=.I%6O%<)_L73/MTD4TT>HVQ\T)L7=Y@&0,G'!]36-%XO\272WMU!I]E]E)D
M2V4S*90Z2!""NX;FQD[3MYP,\YH NO\ "[P\]K!;,]^8X+>.V0?:3]Q)/,0?
M@U;.G:.__"0W>M7UI;1WK1_9(I(9&8O &+*6R!AN>WYUCP>,+B6]TO.T6-T!
M&\WV=AMF,A78XW9C.!@9!!)//',OB'Q-?V&HZA;V/V5&TZQ6^>.X4EKI26!1
M""-N-N,X/+ 8H @\8Z%=ZWXJ\,26MS%"+"6:64"Y\N8JZ;,H,'I6C9>#-&TR
M_P!(GM6GADTV&2"VC\[Y6#\N6!^\2>2?:LSPW!+J/C'Q!=WKVL\EK<1BVS;X
MDM\Q @;MQQ@,01QDY/M6+:W&I7%SI%]/J5G/JJOJ"QSO!CRT4'Y2H?GIZC /
MY@&EXE^'22>"]:T;P[F-]1?>D,\Q$,),BNQ48. <=*TT\ Z5<6R/>?:S>M<Q
M7LLWVDE_-C7:HW8&5 ) &*SM-\9:WJVJVPMK&S%B@MQ=EY@&_>H&W)SG&2 !
M@YP>1BK/B;Q1J.BW>LK'+9K%:6=O=Q>;&<_-*R.&.X9X7@\8SWH GB\&P6XT
MG28[:.31M-E%W!+-.S3),&8@8Q@K\WK70:QI-IKNCW6EWRLUK=1F.0*V#@^A
M[5R1\6:R9G9#IC(;RYM(XQN(.R,NC%\^W( [\&F6WB[572..>ZTU6N[&WNH9
MDA=A&TC!3%M#?.QZKRO?/3- %G4/AMH.I3,MS=:AYDEK%;E1=8+1Q,"O;LP!
MS[U<7P5I3QZM +R]<:C(7NU^T9R2H4C&.. *P++Q_>RZ<E]<6]B'%B[YY5ED
M%P(B6&3M3HQ&3]:T/!YDBUCQE&L]I/>+>1NQC&Q&8P(02N20">O)[T =3=:3
M#<Z,=+26>V@\M8U:!]KJHQ@ \^E5KKP_I.H7MM->1+<7=K;O"'=LNT<B[6#>
MH.#^-<;-XYUV#1([X#2Y9+C3_M850X6 K(B,I.3NSOXZ<J16AJ?B36-*N-7B
M/]F336?V';*49"Z32,C9&3R,<#..<^U %H_#3P\VFSV3B[=)4AB$C7!WQ1PG
M,:(>RJ:T[+PSI=GK]WJEI),MS/L-S$)<H[@8#LO]['?O6);^)=8O-1ETB.YT
MZ*[AN+A/M,D3;)1&$(4)NX/S\\G &<<TDWB;54U.YMHAI<9_M2"S,WS-\DD(
M=6ZC<V3CJ!B@#;\0^$=,\32PR:@;@-#%+"ODS%,I(NU@?PHTKPQI6DZF^IV<
MDWG?98K.0M-N4K$,+N']X#O7+W?CG4[73H[AI+%YK><Q7$4<+MYR"X\GS5.[
M$:$<C.[GCD<UHZ3;6DGA#Q+;)'&UL;J]!13D8.210!?UKP/HOB/4&U&[:Y\V
M2&.(F&<JI5)/,0X]FYJK/\/M%FUA]0-S?"\DO4U';]IP#*@VJ<8Z '&*R=*\
M0:G9:/IMC]MT\"73[22WF\AG*%AM\LH&^=SC(.5[YZ5'8^(/MMS8^()FM+2]
MDT:;S'E!"*RS!>5!)QGL.><4 ==X?T=[*:_U*[M;>WU+475[E;>0NA*+M4@D
M#MST[TNH>%M.U'6?[6D-Q'>?9'LR\4I4&-N<$>H).#7+6/C'6[Z9;%7L(IEN
M;NV>:6%E8F) ZMY6[@'//S5HZ)XGU'7'%Q')8P06T<)N('5B\N^,-N1L\#)P
M.#D@\T 1R?"S09;<0-<:EY8L1I^W[3U@#;@O3U[U9?X=:)*+@R27SR37$5R)
M3/\ /%+&NU60XX.W@^HH\'>(=9UYOM%_:VD-E<0">V\J8-(O."K $]..3@YR
M,5S>L^,M9<WMG::C:+F%+B"[@MFVJ!<I$R LWS\-R<#H?K0!Z;! MO;I"I9E
M48RQR3[FL/3O!6B:5<V-Q9VS1RV*SI V[.!*VY_KST]*A\5ZW>:/I,4MG=VG
MVDQ22!6@:5I]B9(1 PX]23P/6L6W\;:I=N)P+&*V^T6*>7AF9DN54Y)R "I;
M/0YQ^- &O8?#_1M.N+*X@DO?.LI)Y(7:X.1YQRX/J">?K5*#X8>&K)(UD>\D
MA$$MH(Y[G*LDS99>G=CD>^*OZ#JNK7M_)87LUM]JL9I%O1';LH*G'E%<L<;E
M(;OW'&*R_P"VM6M=;OHY[RRNK<ZQ!:QPRQ%6A1E!!7DY.2.H]3[4 :)^'FB-
M;E&>\:X-S%<_:S.?.#Q+MC^;T XQCO18?#S1--;36@:\W:=<RW-NS7!)#2??
M!]0?2LF+Q7KT]K%*9=*C>>VNY%"H["-X'QUW#<&'TQ[]*GTSQ?K6KZY$MO96
M:Z;&\45R7F DR\2ON49R>6P!CD \\4 6_'GAW4O$2:$NG&-38ZI%>RLTQC;:
M@884@'GYOTJ2/P'H%K/821&>&\MWE=)Q/B28R'=('/\ $#U/]*K^)M>U[2=1
MN[:S-I(9++[381O Q:1T8>:A.\9^4J01CKWQ5>Y\2ZC/+8RVD]BUIJ,%U+:3
M& ^9%LBW*<;L-SG/3M0!<?X?Z')K;7QNKX79O5U$H+GCS -JMC'3'%1+\+_#
MT<5Q&C7RK/:263_Z23^Z>0R,H_X$37-IJE[IERVMQW=G<7R^'[6>ZD>,_OAY
MC?*<-P<'&>>>U;DWB[5I#+/:FR$37-S9I T;-+ \2L0[?-\P.WE<# 8')H T
MV\)QZ7)<W^D0BXOKF"&UF2\N&$<L:#;DX!^;;WQ6A8>&[/3K'2;2V>>&'3%Q
M%'%*51_EP=P_B'.<&N/U3Q7JT]NL5MJEC;2O%IURI2+<P$LH60$;^5_+@X]Z
MZ;7-5U*TO]+L[&:Q5;U)MT\REB&2,L"J@C(XYYH NZWX?M]=>R>>YNX6LYO/
MB-O+L^?! )XYP"?SK/\ ^$,TB($M<7@O9KH7(O6N3YYE"%1AO39D;<8QFL./
MQSJ5U9->P): 6D=JT]LRDM<>=C)C(/ &<#@Y((XING>)-6M+>W:_N+342U_?
M(W[K9*GE>9M51DCG9^ XYZT ='_PANG!9UCGO(UGLVLW"S?P,26;I]XEB2?>
MEF\'Z;.MMF6[1H+7[&SQS%3-#_<?U'Z\FL2Y\3ZY;Z/87$3Z;=S:J\0M3%\B
MP[T9B&+-AONX!RN2>E=5H=W>7FCV\VHQ017I4B:."3>@8$@X/IQ0!2U3POHM
MXMW->H4BFLOL<H\S8@B!R#Z CLW:G?\ "-Z=<72W]O<7*;X4C<P3D).J_<+>
MI&>#7!:I9K;SWL>FRVUN;CQ+;03>8AE#*=C!2-PXW$DCODUK>--&M5OO"5E:
M65@<7,L2P2LT4)3R78C"YXR 0,'D"@#M=(TN'1M,AL+>2:2*($*TS[FZYY-9
M$7@JQAN8[A+[4A)'=37:G[1TDE!#]NF"<#MFN5\-ZY?6<7]@0W$$%T^I74(G
MF8SV\&Q5D$49W L,-P"01AN.,5;@\9>(+RQU*\2+3K?[%I:WRPR!V\QLRJ<M
MD;5S'D<'((H V+;X?:/:);A);Z4VQB:'S;@G:8R=G...I%:VBZ4+&2^O)+>*
M"YOYO.F2)RR@X ZD#GCG@5S5YXJUBWBF6.:P,]KI@U-Q+"RBX4Y_=I\W&-N"
MW/+#BH[CQ?J]A<2?:VM?+M[V-KE?L[*R6<JC:_W_ +RL<'MU]* -74O#<^K^
M+)+BZW+I;62P,(KDJ92'+%77'*D''7^=6CX/T]K.6V,]Y\]Y]M2438>&7U0X
MX&.,>G%847B;Q/)K3V,=OITD=JT:7,DK^5N\Q-RL%W%@!D#H<X;I6MH^L:M>
M^!CK<K6;W<UJ;B*)498T.W.TG))&1UXH JS>$9;OQ0\MP\QTLV"6[%;H[YV$
MC.PD&.0=WKV]ZO1>$K'3;_\ M2Q2:6\C,K11RSX3]YC<I.#\O QG.,5SA\9:
M]YFE1*^EO_:*6<ID"-_HXFRI7;N^8Y&0<CC/I4LOBWQ)]KU-K:ST]K.Q,UNS
M3R[&,L:Y#;02<-C[N.A!S0!U^A:3%HNE):1(J?.TC*I) 9F+$#V&<#V IBZ(
MHU)KTZA?MO?>T)E'EGC&,8Z>U<NWBS55<VKW>G"6:W@N898X'?\ UBL3$$#?
M,_RY!R/E.>U,TOQ;K6HP:;,TEG"NKV2M9#[.S;;@,!(K'?R N6 X[\\<@'5:
M5X=L='N'FMS,S%/*C$LFX0QYSL3T7/;V'I6M7.:%KMU?:Q>Z??*D<T.YXT6,
M@/&'*AE<$AAQST()QCC-='0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,E5GA=4?8[*0K8SM/KCO3ZBN3B
MTF.]DPC?.@R5XZCWH R- \,66AZ/]@*07+.NR>9K=$:<<XW@#G@XYJ]#HNE6
M\D$D&FV<<ENI2%D@4&-3U"G' ^E>917VI_V1ODU+7S</HYF.5<,+E7PO&W@D
M=5Z&M,WFN75XTWGZG;W@NR654;R/L)3[X4C&X#_@6X8Q0!W/]AZ2([F,:79;
M+HYN%\A<2GK\W'/XU#<>'M!D4FXTC3G!C$1WVR'*+R%Z=!C@>U<"!KT^A^'P
M=5U:VBN;,O<78C>247>% 5AQM'WL _+FNF\26TTMSX6NY1>G[/>AI_()&,PO
MRRKVW8'XT ;>B2Z5>V*ZEI$4(@NN?-CBV&3;\HSP#QC'/I2MH&C/%/$VDV+1
MW#AYD-NF)&'(+#')^M>=:=?SV5E;;6UORYK2X\Z"*-U*,)QM*@C"'!8YZXR:
MCM[W73.MK?W6KV\4?V\ 1&1MR (T+>9M#$\L!TZ8Q0!Z3JT6D#3U;5H;1K2%
M@RBXC#*A'0@$=?I5*2?PM%;C47.F"+4L#S]J8N.XR?XL>_2H[+61!X0TK4=0
M65[I[>,-NA;=YI7#9 &1SG/%<_Y$=CY-Q;0W%Q82Z?=6R;+=OFN))-Y^4C@,
M2P!Z4 =JFD:8AMV33[13;#]P1"H\K_=XX_"I+C3K&\GAGN;.WFF@.Z*22,,T
M9]5)Z?A7(ZPMYI.@>%;>XO[R#9)#;7GV4DF0>40V2!NP"N<BL9/^$FFFLH9]
M1U2TMPC/92^09))B)FVK+R!N,>S[W'+=Z /1+72=.LKJ>ZM+"U@N+@YFEBA5
M6D.<Y8@9//K44GA_1I9?-DTFQ>3+-N:W0G+?>.<=^_K7$6DM^;-)KN_UI[23
M49XKN5=PDCC!;RL #*IG&2H]*FN/[9?Q'$@U74[>TAC@:T*P%_M*8/F>8>%W
M>NX=,$4 =G%HVDVCPS0Z=90O;(4B=(54Q+W ..!UJ6XTRPO)UGN;*VFE52BO
M)$K,%/49(Z>U>4S/J&H^'_LLUUKEQ)=:9,9E=9%)=)1MX &UBN>!U%=KXFEF
M70K&&R&IF28[(FBD9"#Y;;?-8 L!G';DXSWH T;KPMH\UM,EOIMC;3ON9)TM
M4+1NPP7''WO>J-AIOA_2(K'PM<Q6MQ=7$/FX>T4?:/*P-[8&W<,KUYKC8M6U
ML6LMS=7>L+=PP:;(L/E.$#[RLXP%^8;<$Y]:T],:]N/&VBW5S#JDEPOVV.[\
MV-O)MR=NS;V"D+P1UX[T =5?0>&M)N();FPL8IKN46<;"V4L[29^0D#H><YX
MK0@TNSLK::'3K:WLO,7&88549 P"0.N!C\J\]UNTD@\2ZF774MMSJVGR(ZAW
M0(NW<RXR!C#?3%0M<Z[>>3;+J>JVMC'-=Q172P.\C.LW[D-T)!CZ$Y![T =/
M:Z1X:\-Z7::'JK6$\MXP0&XMD#7;*<KN &&(K<G\.Z)=/(]QH]A,\JJLC26R
M,7"XV@Y'.,#'IBL'Q3<_9]3\*RSK,?)O&EG9(6;8/)=23M!QRP'XU7UG5IM2
MN[5HSJMOHSQS(+BTC=)#< KLR,9VGYL9&"0* .F/AW1"CH=(L"KR^<P^S)AI
M/[QX^][]:S]7\(6&IR0M#';6G^DI<7(2T1OM6W.%?(Y')KDY[WQ"E[I#3?VI
M'=Q&!=2*,3%M:)MQ2,*5.&QDYX8# Q6AX,O[Y]0T^.[N]3G-QII:;[6C "59
M,#J %8KGCO0!T=E#X>UJ.1K:RLYTLW:R.;88CVXW(,CITZ<5I6>G6.G)(EE9
MV]LLC%W6&((&8]2<=3[UYZ;^:RU:YN86U;#ZM<+)##"Y#Q>3P0N,$[E&&]:K
M07GB".VU%D?41!%-!<VR3R2N98S$=R>8%RIW8.,$!N.AH [B]A\.:6EK8W-C
M91)?W02&$6P*R3<L#@#&>"<FK3>'M%=BS:18,Q1HR3;)]UCEATZ$DDBL3Q0D
MUSH6AW#PW<:Q7MO/<A,F6%=IW$[><@GG%<[M\2O?6UO-J6J6MHH9[&7R3(\V
M)3M24@@;BF/O=B>] '>-X=T1G5VT>P+)PK&V3(XQQQZ#'TJ2+0](MY+>2'2[
M*-[9=L#) H,0]%P.!R>E>;7DWB6/2]8O)=5U:'4$+JUI#;,53]\/+*$Y&"O'
MRCD$YZ5UV@7<[2^([<7%Z\,%QFUDG1F8*8E)VEA\P#[\#\* .AMM/LK*2:2U
MM(('G;?*T484R-ZMCJ:S$M?#DFJ7.DII]D;H0^;/%]E7!21N<G&#DKR/;FN1
M@O=:\BUMM1_M)+"*X:&\O;9I"[_N\HRY&]1NR&'.#CDBHENM>A24RI>OJBZ3
M&KR)#^\*>>V<'&/-\L@X'.?>@#N89=%UV>>!88+I],G\EQ)!GR9-HX7(]".1
M2_\ ",:!DG^Q-.Y96/\ HJ<E>%/3J.WI7,^%TO(!XNDL(;QWDG$ME+>JW[\_
M9T Y;D_,,<UC2W>M)I!N+:^UR-&AMC<B6-FE2Y\P!T7() V[MP' XQ0!Z/I]
MB]H)9)Y_M%S,V9)O+"9 X P.P']:H-%X<U;6;JRDLK*ZOH%BGF\RW#$9!V-N
M(Y. <>E9FF-/?Z)XCL#-?2B.>:.!Y2PD*% 1M8\D9+ &N3ADEL+59+9M8AFM
M-+LE3]W(2[A_F4\?-@'IZ4 >C#PSH(  T33@ &4 6J<!OO#IW[^M6(-&TNVF
MAF@TZTBEAC\N)TA561/[H(' ]JY/PN=:F\03W&H7]YOW3)-9- 1"J[LQNK$X
M^Z!C:.<G/2J^HWGB*&?78;$75Q(R-);R@/\ NE#@%0A&"=N[:5/..0* .]>"
M&26.62*-Y(\['902N1@X/;(JM_8VE^9;2?V;:;[4%;=O(7,(/4)Q\H^E<+!]
MOB^S0WNL:U-I$OFM'>11/'(LGR[4/5]H^?&[@G@]J>9];?5&+7&J0W4=[(LR
M[3Y/V':=L@&-N[&T\<[LC% '7MX9T!P0VB:<P,8B(-JGW <A>G3/.*CT@Z#?
MSW5WIEM;&:"1K.:5;<(V4P"F< D#@>E>?66J:XEK9*USK4PGTRWDOB4<R1D2
MA92G'ROLR2!SW'-,)U*#2-:M[&#7$N9M0O)[.8,\0D_=J4+, 68_W0>#@YH
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M* "BBB@"E?:59ZE+:RW41=[27SH2'9=C],\'G\:NT44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 07=I#>P>3<*6C)!*ABN<?3M[5, %4*H  & !VI:* "BBB@ HHHH 0*H)
M( !/4^M+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\GI[T <ZOCN^8WVVVL9$L)+9KF2.1RJP2D@LN5&XJ5/3@CFNG_M.X_L6YU
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MI9(K2,3F 0R=2#&<\$'@@\T <_\ \)CJEM9BXU+1A:Q>8N9MY=%B*D[B%!(
M/RY(QWJ_H&IZMJ.IZRD[V;6]O>(D'EYXC,,;GGO][.?>KR>%]%CL_LB:?$(!
MP$!/3&,=>F.,>E2G0=/65Y8(!;R2/&[O"2I;8 %Z=L #Z"@#*\7>*9/#,*W
M2VDC50\B/(WF,-P!VJ >Q)R>.,51?QQ=6TLLMWIT4=I%>W-HVR8L^8HVD#=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ndra_ex102002.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 ndra_ex102002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ K<# 2(  A$! Q$!_\0
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M$LC;8Q(PV\CKQ]>#Q4,>C6L=RT@/R#9MCSP"O3/KR<U-I]BEBLQ#*9)Y3(Y
MP,GL*%SWU"?U?E?)>^A7?7;4>6RL?+8@,Q7@?(6_, 4W_A(K$0M*PE50I/*=
M<8/'OS4L6FZ9)"$B1&C29VPK<;R"&'ZD4'3]/#06TF797\V-7<DY48_( CBE
M[Y?^S7M9DG]JVYMFG7>R"01+M'+L<<#\ZBBU5KC4HK:&$A"CM(S\%2IQC'UJ
M==.LX[%;)4 A0Y4 \J<Y!SZYIT%C;6\JRQ@^8%9<ELDY.3GWS3]XSO12=D^M
MOT,XZ^RS*&M)/+WS*V.3B/'(_.KD&L6MS>?9HBY;LVWY<X!Q^M-33["9FEC.
M\,T@X?(RW#8_*E6"QL+A6#%'*DA-Q(X R<>N,4ES=67+V#5HQ=[$8U@?VO+:
M&,>4BG$@/)<#++CZ&A]:CQ#Y,,DAD,7&,8#YP?TJ8:79#!$0W+(9-V?FR<YR
M??/2FQZ-9QKA _5"#O.1LSMQ],T6F*^'[,K6?B".>V1YH9$E< JBC._+;1M_
M'UJ2378!'+LCEWQQ-(X*?<VD@@\]<BIET>S6-$$9 1=J'<<K\V[(]\TO]DV?
MER)L.)(S&_S'+ G)_')HM.PW+#<UTGN5O[?BCBGEGAD1(Y-@(Q\WRAL]??I2
M'756=T:%PBR,@(&=X";N/PJQ)HME*6+(_P V<@.>Z[3^8 _*GKI5HEPLP1MR
MG< 6XSMVYQ]*+3#FPUMF02Z_91-C]XPR1E5R"!C)^G(J>XNYOM:6MJD;2-&9
M2TA( &<=J:NCV210QQQLBQ9"[6(."<D'VJ>XLX;EE=MRNH*AT8J<'J,^E/WN
MI#=!-<J?7?\  @;58HI/*E1PRE5D91E58C(&?\]:CCURU<QADFC$@4J77 PV
M<'Z<5,^E6K-N"$' XW$@D# )'<BJK:!"=.^R;R2R+&[MDG:IS@>E)\Y4?JS6
MM^G_  26?5O+BLIHX'=+EL;<?,!M)Z?A4;>(+0_+$'9S'O7*\9VE@#Z=*OR6
MD,IA++_J3E,'IQC^1JNFCV<?W$< IL(#G!XQR/7!IM3Z"C+#V]Y,I_V_NMH'
M2 EG*AS_  *2F[&?RHJW_8MD-H", N,*'.,@;<X]<44K3[EN>&Z1_K[S0HHH
MK0X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .=FT>=6GD8*JEIGW1DEVW?
M=&/8X-61IT]QX>D@FV_:K@&1]W0,3G'X<"MFBH]FCI>+J-+R=SGI-"N&\YHW
M2&25Y265CT90 /S%6ETR8:-/:JP221MP&\D#D<9]\?K6O11[- \74:2?0YQM
M"NGD9OW:HTC-Y:R$!<[<'..HP:<VBWGFW)25=DK C+$GAP>OTS70T4O9Q*^N
MU3DQIEW<N\(A*$*P:1R1O/FAN?P%6KG1+UR5A>-8Q*SH-Q!7+ ^GH*Z*BCV2
M*>.J7NCG6T*X,^04$?F.<*Y7&YMP;IU XJS9Z7/;ZBD[B,A/-S(&)9]Q!&?I
MTK9HIJFD9RQ=22LS#.E70$FT1&02^8)2YRXW[L'TXXIAT>\:6VE\Q \<C,WS
M$C!?=C&/3Z5OT4>S0UBZB.=&AW2QLB^3@AU7YB-A+[@X]\<?A39]"O)"X5HM
MQ64><6.Y]Y!&?3%=)12]G$:QM5.YS<^B:A-+.WFQ@2*5X8C/S@CMZ UL:?:O
M:).C$;6F9T /13VJY134$G<BIB9U(\KV"BBBK.<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&.U&;!.!G ZFEI&)5&8*6
M(&<#J: .;7QG:3Z?#<6MG=/-<7#VUO;RA8VED0,6 R< #8PSZC%2W'BVWM;\
MV,FG:D;E;5;ITC@#[8SUZ'D@Y! SR*Y*VT349;KPZ]YX;F866IWD\S2-$VR.
M4R%#][GEU./8UH>)-'GU#QA-<2Z)J%W9?V9]E62UNEB+.7W$ [U/0]30!VEC
MJ%KJ-A;WMI,LEO<H'B<<;@1D=:L%U!P6 (&<9[5Y>/"_B/\ LR&TO;,7,S:4
MEM:S0S*GV"=2V&/([%#N4$_(1CFI[GPQ=NMTS:1<S3'7(IQ(9QEX 5WG[WW"
M WR>XXH ](WI_>7IGKV]:3S8\9\Q>F>O:N%D\-ZA)KLBM8X U%+B"_650B6H
M4 PE<YZ KMQ@YS5>/PCJ-O<VR16<9M[:YGL>7'[RQF.\M]4.%"GL#ZT >B!U
M)P&!.,\&@.I7<&!4=\\5Y==^#]1\C6"UCJ$UXRSI"\-ZJ131N?W8"Y!!7C@X
M P<=:ZS6--NCX:L8-/L=R13127-BK*AFC'+IDG&<X/)P<8[T :.B:[;ZW:W$
M\44D*P74EJ5FP"60X)X/0]JU-PW;<C=C.,\UY;9^%]7@%PESH)ET^6:]\FT2
MY0-$965HY/O8& "O!)7J*M6?A+5X]5,FI_;[NXB53#>07@1-HA",A!^;=G/;
M!R"><T >D AAD$$>U&]<$[AA>ISTKC+#2M4C\&ZUIMU:,[-')':["L4LP*8!
M.UMJG/<$9ZX%84.@ZXCP;='G%JMO8M=V[3)_I+1AQ(OWN6^9#SPVS'I0!Z4U
MY;+=1VK3QB>52Z1[AN91U('IS4VX9QD9/05PFC>&;JP\1Z=?RZ8#$JW2Q[Y%
M9K)'<,B9SDC&X87.,XZ5GMIS:AXGUF&PM9)98=4AF>Z2Z'[I=BF1 -VX%AE<
M 8^;MB@#TKS$_OKP<=>]+N&<9&3T%>7IX1U)_#_A^VN=/O/(2"2*_M[>Y1)A
M*<!)"Q.&P 1G.1N!'2BSTJ:XUK4;:QMY)KJTU*&5KMKS=Y8$2EXR2V[YAE>F
M/FSVH ].\V/^^O7'7OZ4ID0 DNH ."<]Z\L3PYJ"VVI7-]I]OIP,-K<V,1=2
ML5U$7RGWCN+#:"W>NPN_#JZIX.N;*2".*\NU:Y; X2Y;Y@?P; ^@H Z+S$[,
MI.<8SW]*R=4\1VND6$T\Z-)/ B/+;0,&=59MH/7IGO[5S,'AS4'N]1FN]-'V
M>^MQ?&%)%S%>;#&47!]#NW9Z]ZS)?#FK#3IY5T!WNKC1+:T8^;'Y@D1VWJ3N
M[@KSGM0!Z:9&Q&8U#AFPQW#Y1SS[U(&!) (R.HKSL:1J,?B"&:#0[R.TCU4S
M@+.@41-;F-SMW_WR#^M/\&:/JFEW^DFXTJYMU6PG@NI'F5_G\T-'N^8EOE#8
M/;=0!UYUVS349+*830LD;2B26,JCJOWB#[9IVEZU::MY@@$J.@5]DT91BC?=
M8 ]C7.ZMX?N]:UF]E@BN+))[">QN'FD#).&7"%5!.,'G.!^-7-&L-0DU2XU*
MYMFL9/L,5E&CLKDE"Q+_ "D\9;COQVH TVUR!?$L>A^5+YSVK70EXV85@I7K
MG/(/3H:TA)&<8=3NZ<]:\PCT'7(KI+G_ (1H32KIDUM=[[M1]IE,B,&!#9((
M4GG'H:?:Z!J6G1I<O#;Q:I#JDALHG90'MIE5655!. I);';:?6@#TP.K?=8'
M(SP:RI->3^W3I5O:R7#Q!#<R(R@0!]VTD$Y(^4YQTX]:QK/0[S2_%T#V-J?[
M,\L1N9-N(@L94&,@[AD]5((Y)X-8&N^'+ZZUKQ)/!H$S&ZELC;SQR(A?RV_>
M'(8'!!Z'K0!Z:'0XPRG=TYZT%U&<L!CKSTK@[[PYJ$NLW2Q6#!'FMY;&]BE5
M1:1IC>FW.1T;@ AMW-9=OX=U!+.")_#]V6-K>Q3;[A&+%FS""2_/L>U 'I5S
M>V]F8A/*J-,^R)20#(V"=H]3@&JVA:Q#KVCV^HPQ21),"1'+@.N&*\@?0USU
M_I5[?:5X4N)M+-Q=6%Q')<0RNA=/W3*3DG!^8J>#VKF8/#GB(:7%;VNF7%E=
M2:?=13R>>BY=IQ(BDACC*AP#VW?6@#U=6##*D$'N#67I^O6^HZEJEDD<D;:=
M*D<CR8"ON4,"O/3FL&WT*^MO!FIVFF0W=K<7#^9'!=W"LW\.]05.$# ,!@\9
MS6#_ ,(YJC7&KB'PPD-GJ$T;PK+*C& B H6*!L?>]SC.<4 >E+>6SW4MJL\9
MGB4/)&&Y4'."1VZ&J^L:O;Z+I%QJERLKVT";W\E=Q"]SBO/!X5UX:;,5TTK?
M365BEQ*DZ+)/Y1Q+%OSG<PQR>/4UMWFAW4'PUU32M/LKR2:YCE6"VGG5I%W]
MB<[0 2> < 4 =E;W"W%K'<;'C5T#[9!@J#ZU)N7 .X8/0YZUQ>MIKFMZ*EE;
MZ3=VR0M#),K3QH]PH8;HT(8@' /WL \"N?O/"=_$MS'9Z1J$L;:1-%!YUXKE
M)C+NC'WL*1R<C@<#/% 'H6IZW#IFH:99R0RN^H3F!&0#:A"EOFYSSM.*TMZX
M)W# .#STKS:;0M?NM3L;@Z41>Q:@9VOY)T^6%H64#&<Y0L!MQCC(/-5+?PA?
MQZ?I[2Z7J3WBWEJ;T27RNDFPGS' # $$$]>3D<<4 >J;U"ABPP>AS1O7YOF'
MR]>>E<OJ^CR7/B[0IHK%GL[>"=)'W#RHR0OE_)GD@@\XXKF+'PIK-O8>;+:7
MLM\KQB_CDO%,=\JR;CL&>XR?FQ_=Z4 >G[UPIW##=.>M1I*2S+(H0[L)\P.X
M>M<#JWA>XOKJS$6FWT.FB!TCM[:[6-K:8R;@YYZ'_9)*XQCFGVV@WZ6C7BZ5
M)]OL-6DN+1)YE8RPO\K8;)QP2P![J* .^#H<893GISUI=RX)W# ZG/2N!E\)
MW:>*HY#!<O9Q""2SDM;@1QP,I)D5U/S88DGC.<X/2M+PMI-_9#4K.\MC]CD4
M")Y]ID?.[*L5)# 9^\0"<\YH UH?$5G<ZO#80;I%FMFN4N5(,3 ,%P#GDY-:
MVX;MN1NQG&>:\M3PUJ$.DVUE_P (W(/L^DW$"B.2,+YY<%2,-U.W.?I6IH?A
M_5!XF&I:G;WPN%D\R.?[4OE")HP/+90<EE.1CH3SF@#OMP! )&3T%17%W;VL
M$L]Q-''%$,R.S !1[UP-_HVIC7M0N[72;HN^IV\T%QYRG"!<.R@MP/\ 9[^E
M4O\ A$M7NM&EMY],V7"Z=+;W>Z9634)BZLCCG_98Y;!&['T /3$FW%FPHAVA
MEDW##9_E4FY<@;A\W3GK7G9T74_MMVR:'.MA]HM97LS.F)D6,JRJ-V!M)4[3
M@'%.G\+WD^OV\AL;V*P2*(V20WBH+1T8EA)R20>#\N>/EH [76-5@T/2;G4[
MI)6M[=-\GE+N8*.IQ[56T[Q%9ZC?FP\JYMKSR1.L-S%M+QDXW \@C/'7-4?$
M_P!JUKP+JUO8V$[W5Q!);QP,55BQRN<DXQWSGI7*OX9UN6ZNY-(L;G3HY-*-
MO+]LN@YFE!4JJ$,Q08#@G('S#CC- 'IN]-F_<NW^]GB@N@SEE&!DY/2O.O\
MA&KJ76;2[&C3P6#WT<C6)G4I$!&5=F4-M()*\#/W<XYHMO#=_;Z6I32)&CCU
MB6::TDF4O<6Q9]@W%L$+N4[2<<4 >BF2,=74<9Z]J/,09RZ\8SSTSTKSX>#;
MS[/99M@PF^TVEQ$\@9K>UE)9.3]XQD   _Q<<"JTOA/59].TS[?92R;"T%[%
M9W"K)(BIY<4F6P#P,D$Y!;(Z4 >E[ANVY&X\XS2UR'@_0Y=+OM3>ZLIT=G00
MSW$_G,RB-0V&))QD'TS77T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M![4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"H*O<#*#Y@/4<\\5J)8VD;Q.EK K1+MC81@%!Z#T%++';W:/!*D4R@@/&X#
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M*UM;((DP',:C8H]^P'- '$:;XEU6XL-'U.XU.V-K=FXLY1;P K]I#L(B#DD
M[3QZ[?6GS>)M0M+V\TJYU:R62*ZM[9KT1J/(#Q[BSKG&2PP,X'-=3I]UI5Q=
MWNF6<,:OI\B>=&(=BJ[#<I'&#QW%7&T^R?SMUI;MYW^MS$#YG^]QS^- 'E&@
M:]/I/AZYAM-5M(84M]0EB'DJ )X[AC\H[@J1\HZ \5LW'B]KG6K6V_M&WN=,
MO$E@N(S"JI$PMS(!N)R2<>FW!]:] -E:,(PUK"1&24S&/E)ZX],TV6SL3OEF
MMK?D9=WC7H!CD^PS0!F>#)(I/!>C-"Z/']DC"E"".GM7%ZSKCW]K+::G/;+<
MV^J6DENQ"&-0;D*K(P/7:#D-ANO:O3((H8852W2-(@/E6, +CVQ4$UEIX222
M>UM=I8.[/&N,CH3GN/6@#SF_\<:A;Z5=-#K%O+>Z?<7"M'' A-Q''(HW,<X4
M;3SCGN.AJU>>*]96/59[?4+%TBU-+"/: L<".JL)'<[B"-VWD8SVKO/[-TZ,
M%OL5JH&YB?*48R.3T[CK52UN-'N-1O\ 2K>"(RQHCW*"#"N'SC)QALX/K0!Y
M]<:Q?65]/J4^I:5#J\&D;YY(<,DZK.=O7'!'<#KTK7C\4W=_??-<6KVLE[+8
MW.FNJDQPA6/G%O[I !.?EPU=I+IVF[-TMG:;50)EXEP%'0=.E2?8;3<S_98-
MS1^43Y8R4_N_3VH \>U+54G^&$&FF^M8+6'1()U1U5_M1S@[2>FPJ.G(-;5S
MXR\0%-9O;6[TF&TLX[A4@G<F5#&N4?;@'YL9Y;!##%>C?V=8[(T^QV^V+/EC
MREPF>N..,TVYMK$)/<7%K"V8_P!ZQB#%E'.#QD].E $6D3M)8P">^CNKB2(3
M$@*I*MTP!V[9K0K-TF73=3L[35["-?*F@'D/Y>TB,\@8[#VK2H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X3Q@
M;TZQ<+"^M^4-)E:-;-)/+%P&!3!0??\ 8GIU%=W4,MU!#*D+S1+,XRD;. S?
M0=Z /,KV36YI[B"VDUN&PDE@ENI3;3.ZAHCOV X;'F;=RH>.<#K1?+K%JERA
MNO$EU+;V5JUO*()!NE$GS'"#!8IC<#GKSS7;:!XFMM8T=+RX:"SN '::V:=6
M,(5V3)/I\O7I6B-7TTPQS#4+7RI21&_G+AR.H!SS0!P,D4DM^PGM]<DTVUU*
M4AA'/YBQO!@;#]\KOSTZ>PJ"TLO%1U2S75=2U:!H(HV@^S0&195YWK(X^4/C
MKN'/&WFNVUGQ%#IUE)-:>3>20SQ0SQI.H,0=PNYOIGI5]M6TU+07;:A:+;%M
MHF,R[,^F<XS0!D>"(94\-P371OVO)<F<WQD\PD$@?*_W>,= !6'?+K4GB"Z!
M_M.*ZCOHVMY(0_V<V6!O!QE"V-_!&[.,5U$6NJVMZA931I#;6EO'.+II1M=7
MW9/L!MZDU6T;Q5:ZE97EU=-;V45O?26B.]PI63:>&#<#D'.* (O L4Z^%K6:
M\-^;V4$SF^+^86!(&5?[O&.@ KGI'U%O$6H1VD^L3W<&J(R89O)6W**9$_N=
M"=H/.2N.]=^E[:27+6R74+7"C+1+("P^HZ]ZHI;Z)H,]U<[K:RDO&\Z=Y)=O
MF$<;CN/N/TH \XB.MFX\MHO$$.GW%U8R(@^T.^PEUG$C$97@*3MVC."*MRZ9
M<:5XCN([:'7(X9]:C:5H6GDCEMC H.6YX#9Y!!'KP*](_M&QV3/]MM]L&/./
MFKB//3=SQ^-,?5=.C2-WU"U59 &1C,H# G (YY!/% 'FD">(M0CTR.2[URRM
MHPZPNMK(TAE6=MHDW8(!C\O#."I&<\UUW@N*<PZC<7CZB]P;V9%:],@)B#DI
MM5L#&#U J]J?B2WL)K$1&">WGNS;3SBX4+;G:6^;WXQCBM'^T[#_ $?_ $ZV
M_P!)_P!1^]7][_N\_-^% '&:\FMR^(+^.(:BDX\AM(E@W^0/^>HDV_+ZYW]L
M;>:M^ +2.U&ND6U_ TNIS.OVM9@&C+'8R^9QR,\CGIGM75P7MK=,ZV]S#,T9
MPXCD#%3[XZ5&-5TX^?B_M3Y!Q-^^7]WV^;GC\: ///$D$ESXMU\%O$%O#-IL
M-O&UA9.Z3N/,RI.P@\..X')YI!#XC%O!;36M[::A'9VG]F+9[_LT3A0)4DP2
MO&/X^W0YKT@WUH+9;DW4(@8@+*9!M.3@8/3K4+:QIB112MJ-H(YB5B<SKAR#
M@@'//- 'G]M;7DR6)GE\1,9=9GBGW>>N^WW/L+8 VK@I@C'Z<7+:TU>^U46]
MQ_:D-T;N>*];S)%@>T(81F-@=H8?N\%2&R&S76:AXDT72\"]U.UB8RK#M,HW
M!V. ".U7$U"RDN/(2\MVFP3Y:RJ6P.O&<\4 <!IVGZXUW8Q72ZGY$\)TZ[S/
M*-KQ-D3@YXWJ",C&3CUK,^S^(X])NKBYU#Q ;]I(4N+:&V<*&$PR489W*4W<
MI@8QGFO3O[8TPP>?_:-IY6\IO\]=N[TSGK[5++?V<#[)KJ"-C&90'D .P=6^
M@]: &>3!;Z680)S D1& [M)MQZYW$_K7EN@V=[:>'M,M)+37X+(VLX981.LL
M=YO&PD?>"[>G\&<YKU6.^M)9%CCNH'=D#JJR DJ1D$#T([U&FK:=)'YB:A:M
M'O\ +W"92-W7;G/7VH YGPA!J)U;4)-8EU"2[B2%0TN]8=QC'F>6,!&&X'GG
MZU5\9?;CK4RP-K1B_L:X:-;-9?+%R&4Q<H/O\-P3VQWYZW4-9L-,FLX;NY2.
M6]E\FW5CCS'VDX_(?RJGX=\1P:WI$=U-Y-K<[7::U,ZLT05V4D^WR]>E '(Q
M/KEY<":3^V8-0\^-U<1R+";,QC<"N-H?.[@C?NQCBG^&IM;$]HL(U+[5/I@,
MS:K%-Y7G+)_%D85MN>F,\5V]SJL*:-<:E9[;V.&-G @D4[]O4 YQGBC2-475
M=#M-4:%K:.Y@6<)(P)56&1DCCIS0!PVH_P!L2:]J%LESJ+ZJILY+86S/]FB8
MD^8#V"%0<A^O;FJRV6L:O?ZG%&-9L+:>R::%IYY@4N8Y3C<<@ ,#C:ORE3WQ
MFNWMV\.VL]UKT%S9(UR1'/=BX&URO0$YQD58O9](O(DM;NZMF65D*(9PN\GE
M<8/.>WK0!QUR+NZNM"O9AK4$.I--+>VUN\KK$AA(0,4SM(;;C!'))]ZQXKCQ
M(^GP+ -=6XN-+B-XTEO*65UE ?:&P _E[N 06'OBO4KB]LM/0?:;JWMD X\V
M14&!]>U!U&Q$QB-Y;^8%WE/-7(7&<XSTQWH \UFM]2MXO(>^\2WD(TZX>%Q!
M-'^\W*8ONC=N^\ &.2!S71>#+5XM6UNZFMKZ.2\>"??<"0*V8(\X#< [PX(
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M612&SP!CFN2T3PQ+XA\)QBV@L+:&.QO+2%DY,S2,0H<8X"X![\]*]8HP!T%
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M.#*HVGT//%*=1L1*(C>0"0IY@3S!G;C.<>F*XH^$+D1L!I5BQ&N+J +,,F,
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M-JJ"F5RI^7G!P0!QFI=3T.?6[^^BNH5AMC'&UI=QR9EBF0DJX&.""?7GD=Z
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M983'Y;[%.[.\#^*@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%<%X@M=9N/$%\L<=_YI6!M'N(&;R86!_>"3!Q]=PY'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]EG2&P^88DMXY=PY/&2,CT.T4^;0]4.O27RZ,=W]M)<+(LRY^SB 1MW[D=*
M.^2;]T'FVQG)&"P(ZXZ_E2O/#$P625$9N@9@":\L@\)ZH-.M89=#9GATF]LP
M&N58*[R!HN_8 \]LTY+,7'B6W;4(@S6L]HTBB1))DE6)5VCG(3)R0 <X)[\
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M(QD<'CZ5TNG>'=*TFZ-S8VOE2F!+<MYC']VGW5Y/053D\$>&Y8C$^EQ[""N
M[C@MOQUX&X9Q0!1D\67UM=1B[M+:*UBU V5W/YI(CRH9&''0Y .>AK0N]<N=
M.T"UO+JVC^V74T<$<*N0@>1L+EB.  <G\J2?PM9F.>WMH84MKV42WPDW.TI&
M,8R< \"M:_T^TU.RDL[V!)K>0 -&W3CD?0CUH XF]\0ZQJ%X=*:""V11=07I
M21MQV1AE:)AC&0P//(-)8^+;W2-%L+.?3_/N)+6T%ILDW&1I-R_/G'(V$]><
MUU#^%M%DMH;=[!#'"79/G;(+C#$G.22/6H/^$)\.^7Y9TU63R4@ :1SA$.5
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M(-T(E#8 QWP1FMC_ (1+0S!%";$%8I6F1C(Y8,W#'=G/(ZC.*1O!^@M<-.;
M>8URMT3YCX\U1@-C..!QZ8H Y"7Q+=6'BF75[FW)6YT>!K:UBG+!C).%3(/
M/S#)'%;VF>)]:OM:M]+N=$6RE:*2:2268'*HZ+\JC)Y#@C)J\G@KPW&L@728
M,20M;L&R<1D[BHR>!GG QCM5JV\-Z59WL-[;VNVYAB:%)#(Q(5CD@Y/.2!U]
M!0!I0^;Y*^?L\W'S;,[<^V:?4%G:K96J6Z.[JF<%VR>3GK4] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UW6-"[L%4=23@"F1
M7,,SND4JNT9PP4YQ5'6=,;4;;$;E9$Y49^5O8T 1'Q)9?;%@4L8R<&7L#_A6
MP"",@Y!KS:2-XI&CD4JZG!4]JW]!UKRBMG=-^[/$;G^'V/M0!U5%%% $=Q$)
M[:2(]'4K7G+*R,5/#*<?0UZ57!ZU!]GU>=<8#'>/QH ["U,>H:5$95#I)&-P
M-<GJ^D2:;+N7+6['Y6]/8UN>%Y_,TYXB>8G_ $//^-;,L4<\312J&1A@@]Z
M.%TS4YM-GW)\T;??3/7_ .O7;VMU%>6ZS0MN5OT]C7':OH\FG2;TR]NQ^5O[
MOL:@TW4IM-N-Z<H?OIV(_P : .]8!E*GH1@UYW=P&VO)H#_ Y'X5WUI=PWMN
MLT+;E/Y@^AKEO$]OY6HK,!Q*GZC_ "* -SP_<>?I$0)RT9*'\*U*Y?PI/B2X
MMR>H#C^1KJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEQ@'.,9^M34 %%5I-0LXED+W4(\HX?YQE3Z&N;U#Q7YO[JQ=$4G D+#<?H*
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MY9$*/-'+&L;3[QD'GISN4ALC'(KT>B@#SJX\-ZHOA?5=/CT&"34WBDB6^6=
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MCPY([Z0BNK#82H)'4=J2W\.V4%PTK R#.51^B_XUK  # & * %HHHH ****
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M@#%\1Z=]JM/M$:_O81DX[KWKC@2""#@CD&O2^HP:X76M/-A?L%'[J3YD_J*
M.JT?4!J%BKD_O4^60>_K^-:%<)HVH?V??JS']T_RO]/7\*[L$$9'(- !15*^
MU2UT]?WSY?LB\DURNH:[=7V44^3"?X%/)^IH Z#4/$%M9YCB_?3#LIX'U-<K
M>ZC<W[[IY"5[(.%'X5!%#)/((XD9W/15%='I_ACI)?-G_IDI_F: *WAB6X2\
M9$C9H''SD=%/8UUU,BBCAC$<2*B#H%&!3Z "BBB@#(UG1EOT,T("W*CKV?V-
M<>K36EP"-T<T;?B#7H]8^M:,M^GG0@+<J/\ OL>AH P]4O$U.S@N@ L\?[N5
M?Y'Z=:?X9G\K4S&3Q*A'XCG_ !K'96C=D=2K*<$'M4ME.;:]@F'\#@T >B44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #))8X8VDE=8XU&69C@#ZFHK>^M+MBMM=03,!DB.0,0/PJIXB
M\@>&M3^T>7Y/V63=Y@!7[IZYKSNT73)M+\#+H4<)UR(VC3/:J R0",>=YI'\
M..,'OC% 'J]1_:(1<"W,T?G%=PCW#=CUQUQ2Q2QSQ++%(LD;<JRG(-<1XRBC
M_M^SO[-H_P"V=-MVNX(UQYDR!OWD?J0R;N/7!H [9KB%)TA::-97&50L S?0
M=Z9)>VL-Y!:27$:7-P&,418!G"\M@=\5YU>:S8#Q(VN2W:VT\ND-);NT(>6"
M,R)LPAZ$@D_CSQ63>^);_P [3KF=MVH65[?0K(ZH91!Y6=X"_*Q"G.!P<"@#
MV*BO/$\0:O/XA2"SUJU-A"D#QF:/+7T;@[G&U><'CY2,;>16UX4UZ:\BF@U2
MX'VJ.14#ED\N4L"1Y97&>/X2 P[T =317$>*->U2SU:\M;:[^Q-;V2W-DAA#
MB^DRV8^1GLHPIS\V>U:/A>_OM1U#6&O-1686UVT"6\:*%B&%."1R2"2,YH Z
M:BO*[[QGJ<$VJM::N3;_ &&2>WGN;9 JRI,JE54?-]TD8;GH:TYM>U*.6_GA
MUAKJUTB]BDN4CBC+2VSH"PX'\).01S@$4 >@T5YUJNMZY837%L=4:"ZALDN[
M1)+=6%[(SMF(\?PC8F!@_-DYIJ>*]5CU)C)J4,S#6)+$62QJH*&#>JYZ[@_R
MYSSS0!Z/17'>!M4U?5(GGU+4;6Z66".4111D-;R'.]&^48Y_A.2,=:P9O&6J
M1:C?_8[R:ZM&M7DCDDMD B99U1RJK\V$1B<-R=N: /3Z9%+'/&)(F#(>A%</
M<SS_ -K^'I5\42W%J9[@&5$0)(=@*J^T8..>1CJ:PX_&6KSZ1;SMKUNDG]AW
M-XVR!,O/%* .N< C(VCT- 'J]%>=_P#"0:IJ'BBUM[?5TA@,\#-&@C$;0M"&
M89;YBY<C '&"/>M3Q7K-]9ZJME%?'38C8R7$-QY2N)IU/$7(/;!P.3GCI0!V
M%,:5%E2(L [@E5]0.O\ ,5YROBS51?,]WJD%NT5Y91R60B4!1-&"Z,3SD$GD
M8QWK8\5:G=QZK+I=OJ/V=9](N942-!YHD3&&!/L3Q0!V-017MK<75Q:PW$4D
M]OM\Z-6!:/<,C<.V17$^']<O8]5TNQFOFO+.:VB6-T"EMWE;CY@P&Y/(89'0
M'!J+4KBZTWQGK4MA/Y-U+]A,=L(5/VSEU8<C/ /)!XP,T =W=WMK80>?>7$<
M$6X+OD8*,DX ^I-3UY)J6MZIJ&CZA+JU_9+#YI3[$T?[RUD2=0A^Z,?+ZDYZ
MBM#5/%5_#I^J6]KK4DE_:W%PMOY,$1:4+$'4,2-H )[<MC H ] .J6 :[4WD
M&ZSQ]I&\?N<C(W>G'-/LKZUU*T6ZLIXYX'R%D0Y!P<']:\DUG5([JP\0W,>H
M+9SSOI,DABV@DDKN'([<G\/2NZ\0ZA/I\F@P6NJQ6T=]<F*64QHS2@QLVX'H
M#D YQWH ZFH'O;6.^BLGN(ENI4:2.$L-[*,9('H,C\Z\VMO&5VMK927?B 8N
MK-]QCMT++(DRH&48X+ G.>!UZ"LRX\47OGZ3>W+[+^W_ +0MYIRB&:* /'B3
M:/E8A><#@X)YH ]CHKSRVU_6;C7YEBUBT%E;-L6*:/<UQ$8MRS#:O0GG(.!@
MC%;OA37)+ZT>'49L7L<OE'>R;9&V[OW97 88[8!'<4 =!-=06\D<<LR(\N0B
MD\M@9.!["DM[RVNC(()TD,9 <*<E<C(SZ<5RNHW=Q;ZCXJNQ*D%S9Z>ALY9
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M18[9U@NH<27:./G( !Y!XX( QD\5>\5ZYJ-EJEQ:VUZ;'R;#[5:?N0XO)MS
MQ<CV48&#\^>U &2002",$<$5JKK]XE@EK&0I48\S^+':L.VEO;ZZU2[NIXF,
M=Z8#%$@ B_=HV#W)!9AGOM-8\>H7#A<WZY<3#Y448V?=(H WS(9)6W,6D/)S
MR3FM/3=)6\O6M9KF.*9(Q*T&X>:$)(#;>P)!Y/I6%IFJ7*KJ#6E[:27*6ME-
M"&"JR%]_FJ&((!.T8+# R.G6GWOB.5=2GU73SMOI-%MRYFC&^-3<E7=@N<[5
M)/&1CGD4 >DVEC;6,>RWC"^I[GZFEGOK2VN;>WGN(HYKEBL,;, TA R0H[X'
M->;ZMXEUO3=$!76EN[^$/,GV6!#'-$'499F W8!((09/7M3;W6FU'Q/HUS<7
MPBEAU*YB6U:#(ME$;A')QG##:V2<'=[4 >GQRI-&)(V#(>A%/KR9_&NKMICW
M0URW#1:+%?;4@3YYO,*L#G/#<<#!%;=EK>IZAXW6W36$%G'=2K) HC$;Q!?W
M84GYR^[K^..,4 =]17 Z]XCU*PUK6$M]05DMK:-K:V2%2 S9#%SR3C@X&*HV
MWB'6A_9:WGB*WCM;FZGBDN4@7<%\DNF6(VY!'8=^: /3**\RL_$_B*2VU:XD
MO%EGLM,AN8[1+<*69MX+,.6Z*KX&.H&*D7Q'K=C;0SW&KV^H6OFDL]HB^848
M+C&Y0'VDG*KAN1UQ0!V6KZ(FHD2Q$1SC@L1PP]ZDT_0[6PP^/-F_OL.GT':N
M#NO$_B(0:]>C5;.U%K%=*MG)#N>!H^8V(VCJ!U)(.X8I)=;O+KQ'902:](UO
M;ZA;2%HE0926WD8JV!RNX #_ 'O7% 'J%,25)'=58%HSM8>AQG^1%>3ZCXBU
M*_CU&VCUF\%D8(;B*Z$,:,"+@HX  R%VXR&YX]ZV&\4WYN+FT?542V76&M'O
MXXES;1>2KH""".7RNXT >AT5Y3<>+]>@M[UI]7AB:UTQKJ)1;J#,R3LBLP/:
M10IP,=>.M=/XJN[B/4O#=U:WLR0M/(6CAQLG/DLR*3@]2 !]: .OHKBO"6NZ
MCJ=_:F2^^V07-EY]S&81&;.;<!Y? 'J1ALGY<]Z[6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $95=2K*&4]01D4V.&*+
M/EQHF>NU0,T^B@!%544*JA5'0 5F7&L:;;Z_:Z7-N_M"XC9X0(6.5'4[L8&,
M^O<>M:E<CK;W$'CS1[U;"]GM;>SN$ED@A+A6<IM''^Z: .J,$);<8D+8QDJ,
MXH,$1()B0XZ94<5P6J6FL:WK]K>21:Q9V;0H;6.W*AHI5D);S.?EW+MY.1C(
MZUF06>OPB(V-MK"WLG]I1M+<.V,,Q:#)8X'48..* /0+/4[&ZUB^TN&%EN-.
M"&3=%M4"0$C:>_0YJ^]M!(5+1(=C[UXZ-Z_6O*I-%U8ZC?2V.F:K::5.;,S@
MMNF=%20.H!8L<,4)&>0#CWZ'PWI%Q;>*&^U#5YH(=/A6"6]D8KO#/GH=N[:4
MSU_2@#MV16*EE!*G()'2DVQ0AW"H@ZLV /Q-</?:=K$_B2Y?RKP7(OH9;*\B
MD(A2U&WS$89QG DX(R2PQ[:'@ZREM/"<AN;6\:[=IO,2]=C)(-[; =Q/52!0
M!;;Q3H'V2>Y:0F&*)KAR;9_FC!&7 V_,O3D9IMMJFAZ]=1V=O<312F,7'V=H
MFA\^/CGYE&Y>1T]1GK7*R:9JUEI>K6-A:ZF^FRZ7.BV5THD:WF=<+'"^<LO)
MR.0,=>U&E6U_IFKV.IV^FZS<I:Z4T-T+U=S!L+M2$'G)8'=CC '/% '?V^HV
M%]?W5I#*DMS8LHF3',989'Z>E6?L\.[=Y,>[.<[1U]:X6RM-9TCQ3I>I2P-=
M0ZA;M;WGV>V93$=V]'DR3R"S+]#[5-XJT_5;S5[H)!>2QO9 :9+:RE!;W0+9
M+X(X/R')!& 1WH [=45<[5 W')P.IJC;7]O<RRBV@>14E\II50!2W\6#W (P
M3ZUA^$;"Y@DUJ6Z6]%R]]*(I;IF.Z,@8*@G&W.<8[5D60N$T?PK%##?&6SNF
MAOH[=B?+PK!O, Z\D$?7- '9)>VJ7<-C);M \@9H@Z *V"<@$<9QSCT/UJW]
MF@_YX1^GW!7$:;]I?1/#-C/'=)J,=^9"MUDRK&IDR[9[%2%S_M"E\56NJS^)
M+.?3K"Z+6L]M(TZR/M>/>=ZJH8*, \Y!R#[4 :6JV^F:1?I</'?74UU)OCL8
M,/N9 "64'!&  < X]JU]3U:TTZ.Q>[BE(N[F.WB BW;9'^Z6_NCWKG/%E@UQ
MXOT"\72[VZ6VCN"[P;@%)4;!D' .X=?SKG[6PUF"5M^EWXM)-1T^ZAB&^3R@
MI_>YW,3D8Y/?KCF@#U$P0L23%&23DDJ*<8T+ARBE@,!L<UYK>Z=XC,=W;Q1W
MKV9NXYIID!%P\19MR8+%7Q\IRN.!C&:WKC3]4M_ *6=@U[/<1LN5GD GDA$@
M++GLQ3('.1P,YH ZP1H""$4$# ..@ICD>?'^Y+$@XD 'R?\ ZZ\[M]&O?^$C
MT[,&K+HK7DKQ6[R28BC,('[SG(!EY )XYK8\5Q7SZS%]EBU1HGTVZB9K0G:K
MD#9TZ/D'!H ZYH8F+%HT.[&<J.<=*000CI$@YSPHZUYI#9ZJDD,8L-7-BT%I
M)?QLS[I2%82!23G<"4) QD ]:MZKI6H2,T%K::H;8V 72G6=@UM<AFYD);/=
M#EL\*1]0#OS;0-G,,9SUR@IS11L%#1H0O3*]*\U31KPV!:YBUN2X;6E,S"23
M,D&03T/^KZ\#VJ5=#U]-5U:6*;4DOE,ZVF) +=H2N(QN)ZC  '4'GI0!Z Z6
MD;(CI"K.=J @ MWP*D,$3'+1(3ZE17!#0[>:^\/WL&C:F!;79:5;F1RT3&/&
M[ENF0,GH?QK5U^UU%_$UA/:P37-NRK!-$=RH%+99PRL-I Z@@@@ #F@#IH#;
M31)-;^4\97"/'@C'L1VIJQVEP^56)V@D/W<'8^.?H<']:\J?0M8MO"&G:=I^
MCWL%]:0EUE\U]H=9@2% ;&2!D%N". .:M77AW4%FN(HK/4K:PGU*>6[^RMN=
MPZ+Y;@;N0#NSCH<>E 'I,VGVT][%=NG[Z-2FX'[RG^%AW'?GH:(-.MK>\FNT
M3]]* I8G.U1T5?0=\#O7G#Z;JL.HW#-#KL[1W]CY4KR.V8]JK/C:0N,!L\=3
MQ47]D:W=S);RKK=OIL4UTEJ(2?,1O.W1$ECG;LX#'('(- 'J96--TA"KW+$?
MKFF!+:X42A(I%D (? .X=N>]>9C3-2DN9$DL]8E\[4KR)VF9R#;R0,%SSC9Y
MFW'IBMU-/U2'X5VUCIMK/;W\5K$C0%]LAVE?,4$G@L P'/<=* .Q$$(.1$@.
M<\*.M.\M,$;%P1@C'4>E><1Z-=-K5EBWUA-&DOMT=J\DF(D\DAR_S9"E\$ G
M@@GH:Z#Q%:2SZS:?:;6^N=,,#*HLW8&.?<"&;:0>G /0<YZT 7O$MK&VE;UB
M7<C+R%'3ICZ5R-O*L%W$X4%T8,$ &2,U!?:+J\DVN7-VVL&YQ/Y8B;]R\+?Z
ML @\D?*,  @@GI6+=63J3+#;S[FLMH9&.X/G/KUH ]-O=5M(;U=.@L;N2Y:-
M6=K2%2;8/N"LQ)XR5;UZ<UKVENEK;)#'N(&22YRQ)Y))]237EUW874UYX@O[
M73-6$]SIUHMO/ '5GD4MO .?=?UK>:WNOMVIW-UIFJW%Y\SV;03,B-"8@!'U
MPK9W#!&<D$4 ;/B/3[=K5)D6))5; 7 !?O@>I')_.N24 \^7M/N!4%IH.I/>
MP27VDW+VMOJR7$"(S_NX7MF5L;G+<28SFLQK#4(K> 7MG?K&T<JHKDK(K[_E
M8\^G0T >K:1>)J%E'*RKYT?RMQT/M]:NOAID1H2W!8/@84C^O/Z5X]:?;K74
M8IG-X9([NU=I$+8*@@2X ."",C!]:ZOQA!J,VJ7GV*/57CFT*XA1K1F""<LI
MCQCHW#<^E '8W5C!<VLT)15\P<D#G/8UP$]J;:=X9(U#H<'Y:V/"L=Y;ZGJR
M/:W\=O);VTL0N-V&EV$28+'@YVY^E<7=:7K(GDN6TN]MK.1;>0(&=G1M["02
M,6))QCD8!XH [KPQ=1!WLI$0;AE#M'/J*Z<11!MPC0-C;G:.GI7C<4=Q R7,
M*S)+%<ND:NQ&8V)P1D\XZUW&H1&?0=(2TM[F?389@MY;V\C>:4"D=<[F 8J2
M,Y- '6>5& H\M,*,*-HXIKF!)%$AC5Y3M7.,MQT]^*\^N=+O5UZ">6;5[?3X
M(X6L2LGW N=Z2L23D^X.00.HK$CMX]FCW!MKV6\M+J9VGN)G9\,6VGD]@1^5
M 'HNJ:QIVD0Q-<63M),S*D$<2LY"]3C/3I^8KDY'22Y>>W^T11/(95BD8$HQ
M[@XR/IG KFA%/-)I\ES#>221K,KR.6+#)^7)S6MI>B:A<M8F^L[\0/$JQNJG
M*."<[N>,\<GC@T 6SA<N<#/5C6]IWA1GO;.^O'>+[*[210(1@EE*G<,8Z$BN
M.OO#FHWDUV#H=U]ADMQF NQ<RQW"MDG=@DIDC;@<XYQ70:=IFI6_BNYO[PZJ
MHAE=H50@P-;%!M0\G+#^[C.><XH [T1H'+A%#G@MCDU \UE 6C=X(S$OFLK$
M#:N?O8[#(/-8WB5I+_1+7[-8W%TL\R?*K.GE@@_,ZJ0Q4'&5R/TK@CX5U6\T
M>[%]I=U+J$V@K;&0N?FECD?@_-U(V$9ZT >N&*)\DHC;A@D@<BH]MK%*B8B2
M23[BX +8]/I7GZ:-JDNNW$[_ -LVRH#]C6!QL$!BQM))/S@YX/.<'-16NCZG
M]OT:ZN]*N)S8R7,:R1LR,P:-=K%68[<L".I&1D=: /1I#;0*/-,48=@@W8&Y
MF/ ]R30B1NL@-N$!8A@RCY_?W%>5Q:#JMRX:YTB\^QB]L+R* R.S18)$H)9L
MEAQDC /7%7X;/5)(H([ZPUB?2EO[WS8C(XFPS9@?A@S( 2.#QQZ4 >CM!"YR
MT4;$C&2HZ4_:N -HPO08Z5Y9_9^N6PG:[@UJYO85L6BD5V90ZM^\VX.#A<!N
MQ.:Z/Q99WEYJEL7M;ZZTMK.5 EG(4>.Y)4HYP0>@(!Z GF@#KU15+%5 +')P
M.IIU<9X*TV_MKS4)=7^VRWRF-?/N&8H_[M0^P9VXW ]!79T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[O5M/L
M)XH+N]@@EE(")(X!;)P/UX^M7*Y/Q=X<U7Q QBM+NW@MC$O52',BR!AD@9*\
M=!CGGF@#8F\1Z+;WC6DVJ6D<ZYW(TH&W'7/ICOZ4X^(-($<,AU*U"3-MC8RC
M#GIQZ]1S[UP2:5/J=[J4(MED>0W<<4$J.BP-*-K.P*\@XS][OQ6M<>"KBYDT
MUYH["X2+3TLIX9PQ5"I!$B8Z\]0?:@#J9-=TF&:>*74K2.2 9E#S*-@SCG)]
M2/S%$>NZ3-*D4>HVK222&)5$HR7'.WZ^U<5<_#VY;2=4LHXM,FFG\[[/=S*W
MF8E?<0W88]1UPO2K5WX4UBYO[N<"P19]1M;L;6;*K$@5@..IV\?6@#JO^$@T
M?,G_ !-+,>6ZQMF91AF. .O<U#_PD^CF]L+1+Z.26_+B (<AMGWN>W/%<C%X
M O+72K:VB@TIKFVFM\7!5]TR12AP6ZX8XQ@<9)-:FF>&=4M-7CO9'L@JW]U.
M57<?W<VW&/\ :!7Z<T ='/JEG:W$JW%]:1+"BM('E 9-QP"<G@'MZTQ]?TA+
M0W3ZE:K )#$7,HQO'5?J!S].:YSQ'X7U+5K_ %62WBTXQ7EK!"OG;MV^.3?E
ML#WP*8OAC64\03:N!IS$SR,ENY8JR/&BG/'# QCMR"10!M6GB2*36+VSNFMX
M8DEABM)!+G[09$W#\?0#-)K'BFQT_P .W.J6US:SLB2&!'FVB5TSE<_48-9-
MYX8U:XO[NX0V"#[59W-NHW8_<]5/H#VQ5)O!6MJM\5N].D:\CO82CHX6)9Y#
M(&'JP)(/J,>E '6V&NV5U'91RW5O'>W,"3?9_,&X94-@#Z<_3FJ&D^(+?4?%
MVIZ?:1VKPQ6T,_VJ%]QD+%EPV/3;[\5@VOP]N4-Q'=264K3(K+>!&\V!_*$9
M" G&WCCN 2*UO#WA_5=/UY]1OI+ 1MIT-F8K5&&6C9B&YZ ANE &I_:^CP2/
M=37^GJ[L\2R+(N6"<LN<\E><@=*NR:E916*WTEU"MJP#+,7&U@>F#WS7(0>%
M=6AU&WN/(TLK#J%U= 9;(25"H XX.3DUH6VBZS;>#+'2XIK..^MV0.X!9-H;
M)VDCAL=#@X- &LWB/15BCE;5K,)(@D4^<O*DXW=>F>,U)%K>F3%Q%?0N4G^S
M-M;.)?[A]ZX2+P#K%M9W5LLFGS>9IMW8I-)NWGSIBZEN/X0:Z#2-+8>))KI6
M A6&,W$0C(0W:J4+*QZ_)P?P/6@#1.MS#Q@NA?8_D-F;O[1Y@Z!@N-N.N35Z
MXU73[2[BM;B]@BN)B!'&\@#-G@<>YX'K6'>Z9K(\9?VU9)9/"M@;14ED96)+
MA\\#IQBJ%WX0U.^GO_M-S:O'JL=O]J8!@\#Q]?*]O3/0\\T =)_PD&C[IU.J
M6@-OCS<S*-F3M&>?7CZ\5/%J-O>6D\^GS171B++A'&-X'W2>W;\ZX+5? VOZ
MD]U-+=Z?+)-;/;"-E*QJ/.21&4 <$!3Z\G.:ZG2=,U&QN=>GE2US?3B:!(V.
M!B)4PW'J@/'K0!EVOCJ<Z5IVKZAHSVVF7KK&;A)UD^SEFVJ7''REL#(SC-=,
MNL:8UW+:+?VQN(5+21^:,J!U)^G?TKC[7PAK=QX:TWPYJ4UA'IUNZ/=-!O9Y
MPC[PBYP%!(&3R?2DD\!W]U:K8W%[;B&VDN9+:Y16\U_-W863L0-W/][ Z4 =
M7%XAT><H(M2MG+E@H60$DJ,M^0Y^E'_"1:+B,_VK9_O K)^^7D-PI^A[5ESZ
M/JUPVFW1BTR*ZM)R[H@;8ZF,H3G&<\C ]!BN;;P%K8T^[MM^ER23:=%9K*%9
M>4E9\D8/9L?A0!W3Z]I*6K7+:C;"!)#$SF08#CJOU'7Z4O\ ;ND_:!;C4K4S
M%@FP2J3N(W ?4CFN0O/!6HWNN7&HSQZ?)&UVTHM79]CHT*1') X8; ?<$B@>
M#-3@N[AK:/34A:^L;A H9?E@"@C&.IVC% '4:;XGT;5;."ZM;Z(QSEA'N.TM
MM.#P??'YBI[_ %+[-9-<01&<!BI*]%(.#G\:Y2'P9JD%EIL<5U;175C(X2XC
M+#,;2;RK*>&!'8]#C!KL[5YI8Y/M$"Q$.RJ V0R]C^/I0!P]WJ=W>RB269A@
MY55. OTKH-'\0";;;WC!9.BR=F^OO46K^'<[KBQ7GJT0[_3_  KF2""0001U
M![4 >ET5RFC^(&@VV]XQ:+HLAZK]?:NJ5E=0RD%2,@CO0 M%%% ".H=&4]&&
M#7F\B&.5T/56(->DUP.KQ>3JURO8ON'X\T =9H,GF:-;_P"R"OY&M*L+PK)N
MT^6/^Y)_,5NT %9^L:>-0L611^]3YD/OZ?C6A10!YH002",$<$5V/AW4/M5G
M]GD;,L(QSW7M63XCT_[-=_:8Q^[F/S8[-_\ 7K,L;M[&\CN$_A/S#U'<4 >A
MTV1%EC:-QE6&"#W%)%*D\*2QG*.,@T^@#SS4M.%CJ+(Z E>8W(_A-6-,U:73
M!*$4.KCA2> ?6ND\0:=]LLO-C&9H>1[CN*X^""6YE$<,;.Y[ 4 27=[<7LF^
MXD+>@[#Z"GV6FW5^^((_E[N>%%;VG^&43$E\V]O^>:G@?4]ZZ!$2- B*%4=
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M!^-.!# $$$'D$4 +12%U#*I8!FZ GDTM !1110 4444 %%%% !1110 4444
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MJ%+L<#.![ #Z 5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3=P/I[UJ%[?5;&1(+IU$BE?,A;:Z9[@]C4UK;1V=M';Q9V(,98Y)]23W)]:
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MB@ HHHH **** "BBB@ HHHH **HZS)<0Z+>RVLPAN(X'>.1DW $#/3OTKG?
MVK:GK5G%>7E_),'MHI)(I-/-N%=U#?(3]Y>HS].: .PHHKB?%VMZII?B/3K6
MVOY8+.YMII'6#3S<R!H]N, =B&.<C P/6@#MJ*YYO$BZ9<6-AJ45S)+.RPB]
M6 )$\C D  MG) _A! /&:S?^$F N],U*.[N?[(DL[N>6*:(!SY9!R>XQR *
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU]Y,4LTB6JR (C2@B09QD@[B<$\9K-FC\JXDC_N,1^M=/X4<FTN$[+(,?B*
M**_#^T"QLVJ:D;B&&&&&82*/+\DDQL%"[21DCD<@G/6M^ULKJVFBS?RS0K&P
ME$JKF1R<[L@#'T''M5^B@ IDD4<R%)45U/4,,BGT4 <EKVC1V:+<VRD1DX=<
MYV^A^E8L$SVTZ31G#H<BO1)H4N(7AD&4<8(KS^]M'LKN2W?JIX/J.QH [RSN
MDO+2.>/[KC./0]Q4]<CX;U#R+DVDA_=RGY<]F_\ KUUU !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9MKX@TB]O&M+;4;>6=6*%%<$DC.0/7H>GI3?$MI
M>7_AC5+/3Y/+O)[62.%LXPQ4@<]OK7*6^L331^&M/TK2_LTT,J1W=I=Z>Y:T
M0(=S*^0H(QMR"<[Z ._K)U+Q/HFCW:6NHZE!;7#IO6-V^8KZ@>E:-O<1W5ND
M\))C<94LI4_D>:X;QA<"+QOHK?;;^Q2*SN?,N;6T,VW<4VJ?D9>=I]^* .YM
M[F"\MX[BVF2:&0;DDC8%6'L:EKR&SCUZ#0]*LDN+W1[,&X,,\5G([SR>;F-I
M$# H74EL-\O)R!Q6[]JUDQ:M(D^I?\)'#'<"&S*'[.Z_\LF QLSC:>#G<2#D
M4 >@T5YA)?7Z3V[VNHZX-)FNK8-YL4C2[R6\Y22I94 VD] #T-0_VMK4-K&-
M-N=6N+YH[RW1+B&5E(1LQ,=P W8SAB1NZ9H ]5J.::.WB:25PB*"Q)] ,G]!
M7F?VC6;'2(+J'5]0U*W6=G"2036[N"H&P,=S9#9(#_*2>H %;_BLPG6O#5])
M)=B*WN9#(+9W^7,+XW*G7G _''>@#I]-U&UU;3;?4+*3S+6XC$D3E2-RGH<'
MFK5>.Z9J&KV>A6]OI4FIAY-(1GC:VD81.LRJ^Q2  PCW_*""<9ZXKM-,34%\
M#WZKK%W<S%93;7LEHRR*".,(Q+M@YP2<G\J .NKAM9>SGU.[:RE#M!((KI0I
M'ER$9'YBLB2^U=K0.QU>+S-/O;=/)DED5YT*M$R$J&!/SX+ $XP2>*26#4+^
MYDVC5+?4;M;&2)'1E1U"J)C)QMX&[AN0<8H N6%X]I<QW,88;3R",9'<5Z!%
M/'-;K.C#RV7=DGM7B_F7DT%H!>S)&0X$ZQER\BR,,'&.P[\5H SW^A:Y8RW.
MIB]>RN%CM8G81M\I*@ <9^AR>0<T >NUGZMK-EHMNLUX\GSDA$BC:1VP"QPJ
M@DX )/L*P=7N+BV\,Z0;4ZA]A:6-;R5-YN$@*GYO[_WMN2.<9KFPEU+XD\*M
MJ,^JND=U=>3*!*"8""(6EVC 8]#NP2.M 'J$<BRQ)(ARCJ&4XZ@U#>WD=C:O
M/(>@X'J>PKAO%>L75IXHMS8RW^^VF@,T?FD0/$2VX*BC#'IDL>.,5D^(M5NK
M[4QYMS<)&8&,44&<*X(QT_KQ0!>=B[L[=6))KK_#-NT6F&1ACS7+#Z=*\WMX
M=2EBN[EEO9H[>:(7 B5LK$0OF% !\Q'/3)K9AFODE2"\O=8B\/M+(+&ZA63S
MCPFP2$+NV@[\;ASCGM0!Z32,P12S'  R37F]Q-XG?Q#J,D&H7B7,"O\ 9+ V
MC&.XB\OY6+EM@;<<GC=D8Z5#87&JQV5NUYJVL76F7,ZB\E2UEAFM6V'Y1RS[
M2^-Q' XQP30!Z!I6LV6M65O>Z>[S6UPK-'+Y; $!MIZCCD5?KQO2[[5M,\,O
M9K-K-G-'I,S1QBS8E9OM#$$?(<LRD?AZ5IWFL74'VRWCNM7FMQ=0-L_>I(ZM
M%EPDFW*@,,X'N.,T >HUB>(].^TVOVF-?WL(YQW6L/9>Q?"U7AU&^NK^&)96
MN(Y)&E9E8%AR Q[C&.?2LJ74;R7Q D+7>NQ:;<:C(2?)DVO UOGAMNY0'Q@<
M?>_( 9/=1V<)N)7V(A'S =#VKT#2-0&H6"R$_O%^5Q[UXZ_V^YT.#[2E\TLU
MNIB40NK2.'(<,",Y&!U^M;=L-9M3K$AO=0LIX[>;%O':,WR^63&ZGE3\V!P"
MV3C% 'JU%<S;3O:^ %NW?5)I6M%ED*;FN-Q4;MH89!SGC''I7'66H:F;N*RO
MK[6H;7[7= ;!,Y:$PJT9,NS=PQ./RH ]7JG)JEG%JT.EO,!>31M+'%@\HN 3
MGIW%<-IO]K70TF5[O57CUBR6WF)D>,VLT?S,X4X*EE##..J_[5:GBZ'&K:5+
M(^H16RPSQ&>S#EU=@NP97)&2/IQS0!V-4M4U:RT:S%U?S>5"9$B!VDY9F"J,
M#U)KSV?4=?AU#2_/?54NXA#'J3*&:(!H&RR1JI0X?&6.3GCI63>:G?MX=\N2
MXU:ZGN=/MY'%S;3.HG6X7G:%^7Y020,9 H ]EHKS6RO)[_6]'M6O==B\Z2Y_
MM"%O.5%E&-NU]HPF0=H! (K.N]0UNVTJ)4O-<CN;:TOXKB4JS!&256B+%AM)
M*9 89R#UH ]:+!<9(&3@9/4TM>7W,=U?W5G<"?6)])AU6V>)R91(&,;B3CAM
M@;RQSP"6QQ5^SM[_ %G0;Q/[3UJUU[RMUQ$SO''%.I)PIP!M/3Y3@CGKS0!Z
M#17,V\^J3^%-0U:RBN%U&[MVFMK6X<MY3!,*N#P#D<]B:Y*XO-3%EYUIJ.N+
M8R26?F^;'(9EF,H$R#*E@GEY)QP".#S0!ZA+*(@I*NVY@OR*6QGN<=O>GUS'
MB:XETJ'1%@NKY4%[''+Y:-,7CP<[S@G X.37)Z=J6IR6]L@U/6#=75E<I(\]
MO+A9%E C.T* IVYY&#CGL* /4ZIV6J6>H3WD-K-YDEG-Y$XVD;'P&QSUX(Z5
MY]+J>K75M;+<G5K2W:UE%M-:F1R]VKX7<=H8H1C < 'G-+!_:<JZU>N;^/4+
M*\M;JXBMA)&MP%@C65!QAQE7'&>1[T >F45YWK*:W_:]I';ZKJ-C:S1FY@80
M/<;IV?)B;# * N %;Y>O0UG'5M;C)DLKO5KJ_>>]AC2>!PC*!F/Y=H4'.-K=
M^F: /5:0D*I8G  R:X.;>NBPZOI.H:[=+8W"3RVUQ)(K3)P'CPP!)_BP<C/
MX.*[#38'L]-19Y99),&21I'+D$\D#/.!T ]!0 [3-2M-8T^*_L)A-:S F.0
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M<[!5W,S'@#DFMG3O"0FNTOKX-&ZKM50QR1Z$=!71V&E6NGK^Z3,G>1N2:NT
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MP7/N <-]#FK-%% !1110 @50Q8*-QX)QR:6BB@ HHHH **** "BBB@ HHHH
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M]A0!7LM/N;]]L$>0.K'@#\:WH/"B!<W%RQ;TC&!^M=!%#'!$L<2!$48  I]
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M<!UVB+*\9^8<9^7!KL/%VG^=X,CBBFOY$CG@E+Q2-YK*)%))(Y/'./:NMHH
M\L^WZA;75Q-I,M_]JEU&\CC@>-A$_P"Z.QF!&.7"X8UT_@C[<UK/)=ZE=WJR
M!&VW,#1F%\?.GS')YZCH.U=910!Y-9#Q#8>'#'HYU$74%K,EW!)&2L+^:"IC
M4]7VES@'D8]JLM/J4-S8P-X@U:XLYHKQ_,2!HSPBE/F(+9#;@,^XKU"B@#S'
M1[_7M2U*RN;[4[ZU58;=Q MLVR>,QCS23P P;=GC(P,50\+M<1Z3I6G17>K
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M[H"X7 ;T4@ GN*]-HH J6,T$OGK#,\C)*1('))1O[OTJW2*BKG:H&3D^]+0
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MRP0->S6EY;W$&V3<L98#GIV/'7-;>J:Q;Z4(1+'/--,2(X;>,N[X&20!V H
MT**P;CQ?I=M.D<GVG9F-991"=D#28V+(?X2<CKZC-00>.M$GC$N^YB@:*65)
M98&57$;;7 SSD$CC'>@#I:*X;3O%TCZ_J-MJ,MU#$U_;V]E";7:ZEX?,*/UZ
M\\FM#2_&=GJ*V3W,=UI\EP+EUBFC^4I$<,6;H.,'KZT =317,'QYHRM$DJ7L
M4DS1K#&]LP:42$A&4?W21C/T]:V=*U6WUBR-U;"1561XG25-K(Z,592/4$4
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M;7IYBZZE<101BWVR)"@4\J/[N[D]374:5XCL=:N[F"Q6XD6W;:\S0E8]V <
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M+@;F1 _/H#G /L>*Y.TUK6KF+1YKNXGMX=3M)KNX:.=?W(C"G*?+P,-RO?%
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MQMLY0)&64']T8_,\T<<C'&/7-++XMFB$ _L2]9[B5(H>559-Z%QAB?;!]#0
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M8[F&[>WEC,H)557<).GW2"N/K0!F_P#"#NVHG4'UNY>X>[M[N7=$FUVB38
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MU;QKE(V4M,)_+#?()0H4.%Z;L ?EFM>B@#&L_#&GV/\ 9OD^?C38Y(K<-(2
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M]6_MC3+*_CMWBCN8RY21AN3V('7OTKDD\.:P=7$T]I'Y\>H+>I?QRC/D[ #
M!U]4&>",&J4?AW7WLK)(].-M=KI,]I)(;D85BX95R.Q (W#IF@#M;#Q!;WVJ
M:K9>6T7]G/&KRNR[7WKN!'/3ZU>74+1[R6S6YB-Q"@DDCW#<JG."1^!KSO\
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M&PYJ^L\3$!94).<88<XZUQWB/PW=ZEKUW-'913)=VD$,5RT@!M7CD=BV.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M W,>@'J3Z5-0 44V21(HVDD=411EF8X 'J338)XKF!)X)%DBD&Y'4Y##U!H
MDHJ![RVCN5MGGC6=D,BQ%AN*CJ<=<5+'(LL:R(=R. RGU!H =1110 4444 %
M%%% !1110 444R25(8S)(VU1U- #Z*BN;F"SMI+BYFCA@C&YY)&"JH]2338;
MRVN)I8H;B.22''F(C E,C(R.V1S0!/1110 45EOXDT2/S=^J6B^5((Y,RCY6
M/0&M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPQ@#@ **<D4<0(C14!.3M&,F@#@M6\7WEGXJ^S6%R;Q%DF@DM?*50LBP-(B
MYW%BP'/0YP*KWFK75SI6C7J>*1(DVH6IG-NB+Y(8-N1NO&<8!YXYS7HOEQ[]
M^Q=QYSCF@0Q*"!&@!.X@*.3ZT >?IXMO)WBM9M8M;>&2^N[=]12-=L9CP8TY
M)4$@GKUVG'6L^;QOK45I<7%WJ%G;2V]A:W7V?R@"6>5D8-DYPP 88P1N'X^G
M_9X0I40Q[2<D;1@GUI'MH)&)>&-B>I* YH Q_&,LR^"=9GL[EX)DLI)(YHL9
M&%)R*XBUUM-,UW4+FTU>W99+W389]P3_ $CS$568D=#C)X]*]3P-NW QC&*C
M^RVY.3!%DG/W!0!Y1JOBZ_O(=2M[;6I6M?L\=S'>)$D94K<JCA1R0NT\[N>*
M]$UYX#X/U!YY4DA-DY,DF &^0X)[<UJ^3$,_NTYSGY1SGK3F170HRAE/!!&1
M0!P5IXGM=+^&MG_9$UK<:A!I<<@@C8/L 5=S,J\@#))JHOB/68KO3[6X\2:6
M\-V+EEN+=%8[4C5U.XX4X.<X'I7HD=O!$Q:.&-"1@E5 H^S0$*/(CPH( V#C
M/6@#R34_%#Z_HMA-?WUO%Y=SIDPMU0$R[WC+RCO@,6'R],$&KTGB_P 0M8:C
MJ U33+41ET-G)&6EMG64* PXQE?4G)((KTX00KMQ$@VC"X4<4-!"^[=$C;L;
MLJ.<=,T 5FA+Z+)#+*;O?"P+LH_>9![ 8KS6S\2ZGH_AJV73[N"ZM4L81+(8
MQMT]_,5#N*]@I8D'D;,]*]7  & , 4P1QJ& 10&Y8 =?K0!YK-JUQ!>V=U>:
MKIDFIQ6%\8KN( HR#:4)Z;L=\8!(-6(/%&M:EJ]I!!J-A;0_9[6;;(,O=K(O
MSM&,<D'(&.A'->@&V@( ,$9VC:,H.!Z4X0Q#;B-!L&%PH^7Z4 <%/KVM67AV
M]F^V--J&E.\%V9(%"$M( LI"C(41G=QVZTT>)M6L$LGO=2L[RW:9D>:Q*EF4
MLH0X;&\#)!V<Y[&O0=J_-\H^;KQUIHAB 4"- %^Z-HX^E &'XUU6YT3PI>:C
M:7$%O-"4(>9=RD%P",9')!-<S)XNNK+5'BEUNUE@@UA;)LHGSQO"'R<=U8D#
M'I@UZ&\:2IMD174]F&13/LMOG/D19SG.P=?6@#S6V\5:Q>+J,EIJCSP64=M?
M*_V>,-<0$GS@ ,XX!([CH:] T>66YL!=RS-(MRQFA#*!LC;E5X]L=>>:DN]/
MBNH5A#R0)NRWDD+O'/RGCH<U:50BA5 "@8 ':@#SR#Q1?S:BL$GB"S59-1NK
M+]W&@V*B;E89)^88QSQSTJK%XZN;DZ(\.J1R22RVT5Y%'$@C59&*E]Q.<G@C
M' Z&O2?LMOG/D19SG[@ZTJV\*8VPQC'3"B@#RRS\0ZW#IVFV%MKEL)IEN)&O
M-0QAI4DQY/ ZX))'WO0UI_\ "3ZI'INJW\VLV8-IJR6801*$\LLF1R<[L,1D
MG^$\>GH)BC(P8T(#;A\HZ^OUIIMX"&!AC(8[B-HY/K0!YAXB\3_:EUS3Y+]+
MK39],OO];$B*DL> JKW[G[W4C(JQ%>3B^\1W6AWD8N((K"YE6%5<S1B,[U^I
M7H?7%>D&"%@08HR#URHYJO=:;#<P^6K/;@D;F@PK,!_"3CI0!%HL\MY8?;GG
M:2*Z8S0!E"[(C]T<>W//K7&7/BR?_A)Y["/5=UG)'>1O(8D06TL0! &<G(YR
M6X.,BO0T18T5$4*JC  ' %-,,1SF)#NZY4<T >,Z+<+"?#,L6II>S)X>N)!:
ME8F,C@1XC.!DYP??Y3[UT5EXFUAK.U>\UO3S:7D\8-_;*"+561B5;("@E@%&
M>1NYSQ7H2VMNC!E@B5EZ$( 13O)B\MD\I-C'++M&#0!R6C7%PWC:XBGUQKM3
MIT+1QJBK'(=S!G4#)Z@=#CGZ5V%-"(""%4$# (';TIU !1110 4444 %%%%
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MVB$2>5+'DD;95VMP<=*EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKJ:/4P%DWLI,2XQMC.WY1CZU G@2PC7272_U);K2HVAM[OS@9?+;&48D888
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ndra_ex102003.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 ndra_ex102003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ K<# 2(  A$! Q$!_\0
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M$LC;8Q(PV\CKQ]>#Q4,>C6L=RT@/R#9MCSP"O3/KR<U-I]BEBLQ#*9)Y3(Y
MP,GL*%SWU"?U?E?)>^A7?7;4>6RL?+8@,Q7@?(6_, 4W_A(K$0M*PE50I/*=
M<8/'OS4L6FZ9)"$B1&C29VPK<;R"&'ZD4'3]/#06TF797\V-7<DY48_( CBE
M[Y?^S7M9DG]JVYMFG7>R"01+M'+L<<#\ZBBU5KC4HK:&$A"CM(S\%2IQC'UJ
M==.LX[%;)4 A0Y4 \J<Y!SZYIT%C;6\JRQ@^8%9<ELDY.3GWS3]XSO12=D^M
MOT,XZ^RS*&M)/+WS*V.3B/'(_.KD&L6MS>?9HBY;LVWY<X!Q^M-33["9FEC.
M\,T@X?(RW#8_*E6"QL+A6#%'*DA-Q(X R<>N,4ES=67+V#5HQ=[$8U@?VO+:
M&,>4BG$@/)<#++CZ&A]:CQ#Y,,DAD,7&,8#YP?TJ8:79#!$0W+(9-V?FR<YR
M??/2FQZ-9QKA _5"#O.1LSMQ],T6F*^'[,K6?B".>V1YH9$E< JBC._+;1M_
M'UJ2378!'+LCEWQQ-(X*?<VD@@\]<BIET>S6-$$9 1=J'<<K\V[(]\TO]DV?
MER)L.)(S&_S'+ G)_')HM.PW+#<UTGN5O[?BCBGEGAD1(Y-@(Q\WRAL]??I2
M'756=T:%PBR,@(&=X";N/PJQ)HME*6+(_P V<@.>Z[3^8 _*GKI5HEPLP1MR
MG< 6XSMVYQ]*+3#FPUMF02Z_91-C]XPR1E5R"!C)^G(J>XNYOM:6MJD;2-&9
M2TA( &<=J:NCV210QQQLBQ9"[6(."<D'VJ>XLX;EE=MRNH*AT8J<'J,^E/WN
MI#=!-<J?7?\  @;58HI/*E1PRE5D91E58C(&?\]:CCURU<QADFC$@4J77 PV
M<'Z<5,^E6K-N"$' XW$@D# )'<BJK:!"=.^R;R2R+&[MDG:IS@>E)\Y4?JS6
MM^G_  26?5O+BLIHX'=+EL;<?,!M)Z?A4;>(+0_+$'9S'O7*\9VE@#Z=*OR6
MD,IA++_J3E,'IQC^1JNFCV<?W$< IL(#G!XQR/7!IM3Z"C+#V]Y,I_V_NMH'
M2 EG*AS_  *2F[&?RHJW_8MD-H", N,*'.,@;<X]<44K3[EN>&Z1_K[S0HHH
MK0X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .=FT>=6GD8*JEIGW1DEVW?
M=&/8X-61IT]QX>D@FV_:K@&1]W0,3G'X<"MFBH]FCI>+J-+R=SGI-"N&\YHW
M2&25Y265CT90 /S%6ETR8:-/:JP221MP&\D#D<9]\?K6O11[- \74:2?0YQM
M"NGD9OW:HTC-Y:R$!<[<'..HP:<VBWGFW)25=DK C+$GAP>OTS70T4O9Q*^N
MU3DQIEW<N\(A*$*P:1R1O/FAN?P%6KG1+UR5A>-8Q*SH-Q!7+ ^GH*Z*BCV2
M*>.J7NCG6T*X,^04$?F.<*Y7&YMP;IU XJS9Z7/;ZBD[B,A/-S(&)9]Q!&?I
MTK9HIJFD9RQ=22LS#.E70$FT1&02^8)2YRXW[L'TXXIAT>\:6VE\Q \<C,WS
M$C!?=C&/3Z5OT4>S0UBZB.=&AW2QLB^3@AU7YB-A+[@X]\<?A39]"O)"X5HM
MQ64><6.Y]Y!&?3%=)12]G$:QM5.YS<^B:A-+.WFQ@2*5X8C/S@CMZ UL:?:O
M:).C$;6F9T /13VJY134$G<BIB9U(\KV"BBBK.<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(Z4 :\.LPR^(+K1S#-'-;PQS>8X 20.6 V\\X*G-6X;VUN!(8;B.01R&-RK
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M]>]:/A#2=1TF\DOKW1G%Q-IMG$\N^-I#)&I1P3GGL<^@]>* .\HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *CE@AG"B:*.0*P90Z@X(Z$9[U)10 4V2-)8VC
MD171AAE89!'N*=10!%!;06L?EV\$<*==L:!1^0J6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SKQ;XYGT[Q#/8IY\&F::
M+=M1N;?89 9GVH &_A'!..>>*]%K"U#PAHNJ:J-2NK8M<$1B4!R$F"-N0.O1
MMIY&:T[&PBT])EB>9A+,TS>;*7(9CD@9Z#VH M4444 %<3XKO=2M?'7A*SM=
M2G@M=1FFCN(D"X8)&7')&1D\'VKMJP]7\*V&M:M8ZG<RW:75CN-LT,Y01EA@
MD#U(XH YSQ_J^HZ;K7AU-.O+OR[J[:WN;:U"%G 0N,;NC?C4NOV_BF#1K";0
M=4N'U&,M.;:[1#YZXW>2V!P<< C_ .O6A)X TB:>UGDN-1::UN'N8I#=L2)6
MZL?4XX^G%:-MX;MK:ZAN5O-0>2*5Y?WERS!V8 '<.XP  .U 'FFK>-K[4?".
MI>(]&U:]MFCNK6 VLB+_ *.[,%EC((Z@G^5:&K^(M<TS5O%7A\:G+)]BTG^U
M+*\V*)(L'!C;C##/<C.*['5?!&AZQ;W5O/!)'%=W"W-PL$AC$LBXPQQWX!_"
MD?P/HTEIJ<+K<M)J8"WER9V,TJC@*7ZA<<8&!0!SVFWFL77P_O-9DU'5+>Z&
MF>:GGK'@R",2>8F!]TGC!JIX&\1:SK/B*SMVU&8Q1:9'/J%M?QJKN[J"DD&T
M9*9/)Z=.]=6/!&F_8/L)NM1:V%J;18S=MA8B "!^ QGKBE@\#Z/;7&E7,/VE
M;G2XC!;S"<[_ "O^>;'^)1V!H YW5_&&M>&FL(_$+QVEM.)@=2BMF>%9 ^(E
MD&<HI4Y)Z_2K6L>(M4DU_P )^'K6[AMWU:%[BZOH &!5$W%8LY'S'OV%=)JN
M@_VH]P3>2I%<V_V:: JKQLO/.#_%SP?TJ.7PCH\NEZ;8&!U73 HLY4D*RP[1
MM!5QSTX/8T <;XPU^YT[PKK5SI'BL7-U8B)DCC$9DB^?:P?CG.1U /%;36VL
MW?ABYEM=7U*POIF18/MB1LT+!MN< <JV<XJS<_#OP_=:??6<D5QMU"99KR19
MV$EPPZ;F]!Z# JZWA.U<-OO]39F"*&-VV5"-N 'IR!GUQ0!Q-CXHUC5EO=/O
MKRYT[7]'T^X-];PJOER.H7RYER/NMDFM#PE>:OK/@E=5NM1U.&XDTX.7D6/8
M\C+NWQX';'0_E77:CX<T[4Y9IIHV2XFMC:23Q-LD:(D$KD?3]35"V\$:;:6,
M-C#=ZDMK! UO%%]K;;&C#!Q[XX![4 <7X&\3Z[K6MZ);MJ4Y)L/M6I0WT:J)
ME881[? R?FZ]L5MW7C2:T^*6GZ4US"VDWL4EJJ*/FCND(;+'W!V@>U:D?P^T
M.&#2XX3>1R:7O%G.EPPEC5NJ;NI7V-/O/ >C7^E6.GW#7;Q6,WGP/]H/F!\D
MAB_4D9- &=X1U#4;GQIXNM+W4II[739XH[>.0* H=-YR0.<=/I2>.=3O+#5?
M#;6NIW=O:7MP\,Z6R!RZ["P(&"<Y Z5?'@#2EDU)UNM35]2(-XRW; RX&!G\
M...U7]4\+V&K7NFW5Q)=))IS;[80SE K=,D#KQQSVH X/3?$?B^YO/#?A_5)
M&L+G49+F62Z>)5G:WB^XNW[JNP//I2ZKK/B@'QAH6GZG))>Z-%%?6=T(UWNC
M*2T+C&"< X/7I7H>KZ#I^M_9FO(F\ZUD\VWGC<I)$WJK#D>XZ'O1I6@:=HXN
MC:PL9;M_,N9I7+R3-C&68\GC@#H.U 'G-KXRO7\4:5.-3GDT37-+8VH.W$5V
M%&4# 9[]#WSZ5<N+[6X?B*_A_P#M'59K;^S()LVXC+1R-(4+DD?= &:Z^W\&
MZ%:V.EV<-DJP:7<&YM%R?DD^;GW^\:9/X/L)]>GUH7-_%?SPB!Y(KDK^[!R%
M [#/- '$^,O$6I>'?$UQ ^JZHUBFC"Y+6T4;>7-Y@C#MD<+GD^E7-1U_Q'H]
MMHUSJD\MS9K8^9?W6CPK+LF)^61D(R8MH/W1US[5U$?@G24U,7[&ZFE^R&R9
M9IRZ/">JL#UR>?KS45EX!T;3[06]L]^B"'[.I%V^5BR3Y8.?N\GCMVH V]'N
M5O-%L;E+M+M98$<7"# ER =P';/6KM0VEI;V%G#:6L2Q6\""..-1PJ@8 %34
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+9R0LBJ0#@X/4>M %VBBJVH:A:Z7837U[*(K:%=TCD$[1^% %FBBB@ HHHH
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M8;;59K:0K& LJ?9UE0-SQ@L5]\9ZUO>%M<NM6M+V*]E$=[;!1(0B[%W D,K
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M2.E=50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M--U'4+X2M/->SF8M(BYCRH7:I SC"K^576TZQ<$-96[!G\P@Q*<O_>Z=?>N
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M*@%CN'X** .WN;VTM%1KJYAA#G"&1PN3[9K+U;Q#%INKZ5IZ11S27UQY+XE
M:$;2P8KU.<8JCXTT+4M>M%M+%;18W@FC>611YB%@,!25.%..<8/ YK$7P=KS
M3V0;[ 'AOS=O>EV,NUHV4J/EZJ3QSC '2@#J;?Q#%<>+IM$ABC=8[/[2;A)0
MV6W["A4="*W*XOPYX=U;3_$-K?75MIT$,.F?89?L[L6E<.&#CY1P1G.>>:[2
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M? 5Y#IYM!KF5^P26(;[*N0'??NZ]1TQ0!NS>*=*B>Y5II0D"N9)U@=HP5&6
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M (1_3I;3[9)=>9<RW&]U"X,C%B !VR30!K8&<XZ4M%% !1110 4444 %%%%
M!1110 4444 %%%% !2!0"2  3UXI:*  @'J**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+VW%U930'^-"!]>U3T4 >:$$$@]1P:[K0[C[1I$#$Y91L/X5RFLV_P!FU:=
M,*QWCZ&MCPI/E+BW)Z$./Y'^E '24444 %%%% !1110 4444 %%%% !1110
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MA(E)PJ@#EF/X "JNH>+=5L-2TS1)-,MQK&IW,L=N!.3$L,:AFE8XSTSA<9H
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M6,D\=J[AC;XW;TR.3MY(-9NN?$2]M- O-?TE-.O=-C-L8"6<,XE.WG'0@]J
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MRMW;2W&I6TD<<KL\2VVT;"H4(O/&.3GOFL2Y^&&DR:%KND6DTMI;:K<I= (
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M/?9B@#TUW6.-G<X51DX&:4$,H(Z$9KG?$FI7NG^ ;S4H[I;>^AM!*)3#D;P
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MT[B@#T2QO[34[..[L;B.XMY,[)8VRK8.#@_458KD/AU^\\!6\2/(K+)<)O\
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MOKB:/[7!%=J\:[!'(I.[.-S<X.1@#I72>!KBWE\*(\+HT2W%P"5X _>L?Y4
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MHR#@<=.*, '( R>^*\O_ +$U0PS1PZ/?6P-O:S<K%(DDZ(P?<AD&XGY1G(Y
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M(<ICE$(7&X C /<\9K?\.:/)HWAO5;2+1UAE,]PR1(X3[1DDJ0RGC((&>"*
M.KV+G.T?E2E5(P0#^%>12:;J-A:S6\NDI%!=W=O/;Z>VP1OB(B1&7?\ -@@$
MG/)P>>:F_L"\&G:5!HVBR![$PR"[?:'W+.#*@&_"';GD;MPX)H ]4B9GW%X3
M&58JN2#D>O'K3G9(T9G(5 "6)Z 5YA%HNH27EFMUH6IR6D=_J#21R3*ZM#*"
M4R#)\V21UY&#TI^FZ'K<T&GI=:9*QGT\6EZE]L;9LC8!@ZN3RQ'RD$'.<@T
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MZFNU  & , 4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^F*CUCQQIMO8VK:=?6\DUW=BSC=D9UC<\DLHP>!@XXSFLR]^'U_J$-O8S:K
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M 4444 %%037MK;SQ037,,<TQQ'&\@#.?8'K4] !1110 4444 %%%% !1110
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M*A9X(I0N<"1 V,\=ZK?V;IT!41Z;;CS%\H[(%^YUP>/N^U &3:7%Y>>#;O\
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M5JU\*ZC:Z@KQZ38I&-76Z,BRC<8O*",>1G)/.,_C77QZ]I<T,LD5[&XBE$+
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M]A%-->::BLMU;A1\JX;[P/\ >'%;?_"6V$?V7SK:\B>Z5=N;<XWLI94STW$
MT 0>)="NM1U2UNH+2TNXUM+BT>*Y; 7S-A#=#D#9R.O-96E>")M/UY9[B.*]
M$<D4L-Z\S!XMD0C*[._0XYQ\QS[WXOB'HRZ587NH&6Q:\7>(I5^9$W;=QQVS
M6J;[6?M.Q=,A:(SR()//ZQA04?&.YX([>] &-XA\+WFK:I>F**U,-[!#$+F1
MOGMF1RVY1CD\\8(Y%4;;PGJ5KI]JT-C9J]MJUQ=O9LXV3Q2,Y7+8^\N\$9'4
M5VFFZA!JNG07UL<Q2KD9Z@@X(/N""/PKEU\;3QS3?:+. I'JO]FB*&;,K$D
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M\4Z&OE9U.W'FHCI\W568JI]@2",T 9M_HUZ_P[.CVMI!]M-HD)BWA4W  $Y
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M:TCG:.,(5(:39D=]V>V<8%:6DZLNJ)=YMY;>6TN#;RQR$$A@ V<@D$$,#^-
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M[BP#KCD L<8QUQTXK+T'Q-<7MM8VEI%8V\B6,%U)',[ ,LCLI"')/&T]<Y)
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MTA#$3)N.PCTZ#(Y(/2J7P_U:]-MINEW'EO#)8RW,4F6,@VS;"&)/.=P^F.]
M'47^G2MX9N].MG>>:2V>)'GDY=F4C+-CU/I63;>"[:;1;:*_EN1?I! GVF.;
M$D#1#Y?+8 8 );MSGFF>#W2!?$<LLSE4UB=,R2LVU0%PHR>!ST'K5%O&VIRZ
M,^K6UE:&U?9Y!>7G)F$;*P!SP#G.!@\8H Z)/#5JLTLWVJ]:>6S^QO,9?G*Y
M)W9Q][))S^E5T\':9$ZRPO<0W >5S-$RJS>8 '! &,':#TZC-9$GBN\NGFT:
M2.V2]9[R(R_,(RL*@\#.=Q#COQ@FH?#7B2^DT[2]/M8(I?LUG9_:7GE 8B2(
M'>,G)Q]#DYYH V[CPOH]O%([2S6\)^S_ "K( J^2<H!Q^?K7-MIN@^9<0$ZB
M]O/ ;9W,PSL\PR  8[,3@]<&K5A8:GXMT>RUNZGA220":*")F"C@@@Y-8UO/
M+(UQ%<)Y,L8!*XZ @X;/1@>H(ZT =MJ\;Z_9V]I9-&\#2I)+,9,-'L96^[CG
M.".U-G\&:?/?/=&XO%+323B-91L5Y$V.0,=Q^M>;Q7E[I:2.K-%>);EHKA'+
M),N1\V,\'G]:ZE/'%_%.MK*MO("KIYP4Y5PFX$C.#SU'ZT =,?"]GY=BJ7%W
M&;&T:S@=) &5&"@G..OR+S[54D\#:4WS0R75M(RS)+) X4RK+]]6&,8) / &
M"*S-*\7:G=0V-NL5M<W*6EM->N7$8/F?>VY;J,'L<GCBMCQ'J5]IGA._O \/
MVE6V1O#G"AI @//< Y/N* ,G7_#-C9V&Z.6Y,DOD1[VD&0(00A''7D_G6/;Z
M-;ZA>Q6\SS;9D,$A5\%E/7MUK3UW4R]W)I$'E!-/>))!*Q\Q]Z$[A[=O<YK,
MT:]%O->RRSK"EB92)G4N$4+D$@<G&>E ':#PMIXNFGS,0[1/)$7&R1XP CD8
MZC"]/04:=X7L-+N+2>W>X+VL<L<>]P1B1][9X_O5Q:>--1%E=Q2ZF0(;Y8A>
M"WC,K1-")%*Q@[3\QQZX]P:FM/$GB& 3BYU&VO;FTT9-0:U@C3=+(2X*DJ3P
M,+]W]>X!UVJ^%[#6)[B:Y>X#7$"6[A' &Q7WC''7-7K#2X=/FO98GE9KR;SY
M=[9^;:J\<<<**\Z/BGQ1]GM;<:IHK->N6AU 3?NE&S(C9O+V[B<X&,X[YKH-
M%\1:C/XE6QU&6'$\0:)+90R B-&8$G#J<D_>&",8YS0!>7P5IZ6L]K'=Z@MN
M\HFBB$^5MV#[_P!V".!N['([=*(?!6G6UQ!<6]S?12Q-+EDGP9$D?>T;<<KN
MY'<>M<Q+XWU.UGFF-]979CU&\LDLHE4>8(X6D3!R6W9 4COGUQ4-YX@U6[L$
M,7B&-K23['<M>P1(/(+RA6A;MCOSSP0>M '<1>&;*&^CNTDN/,2[DNP"XQO=
M=K=NF.U3:AH<&HZG9:@]Q<17%F'$)B8 #>,-D$'/%<WXEU6^TKQ#!=6]]))'
M'I5Q/'8!%Q<R+MP.F<\YX]/<U8T'7KJ>:^$VIV]_8QV4=VE]'$ L;-OW1L%X
M. H..N#S0!I?\(M;#4H=06]U!;E!ME=9\?:%W;@L@Q@@$\8QQQ4;>#-+DC6.
M4W$D:_:/D:3@^=]_M^7I7(V_C/5FCU%8[Y+J.WDMIDF*0Q220.C%MBEMO51@
M,0<9[XJ[=^-;ZTEN)8_]*5[+S[.)(UP[+%O8. =Z'OR",# .: -&[\ VTD3O
M'J%])=D)MEFE&[Y 0.0HYP<9[]ZP_L#Z??,SF5;@*$.YO3H?_KU+9:_XAFGT
MNSGU[2-M_<,J7%KB5V3RRP )"KD,.FT\$9YJ33I4?P5J5WJ^MF:>TN[A#=2P
MJ6@Q,R@%5QG(P<'ID=J *$UG'<7"RR%V96#*N>-P[_7FN\733?6MC.US=VL\
M46W,+!2<@9R""#TKSG3-<N%N_LRZC9VDPFO83+,B-+B)0R.!G:!SSCKZUT%C
MKFLWT]DHU,>7K5G%+9/#;HRPR+@S#/.?EY&?4B@#3N_"&@VFFA9;F:RM8[;[
M*SBX"#:7W@DGC=O)/U/2K*>#M-#*SRW4O[V:5@\@P_G+B12,?=/7 [URWQ+U
M0R6&K:;/>06L-O;13K#*@9KK+\E2>?EP/N\YZTR?Q-K6H#6I/[3TZRL8HKJ,
M1%LSP[ =C[2O&X8Y)(.X8YH Z;2=,LS9K;Z1X@NKE;2Z3S&-T)2BI_RQ/'W<
M=CSWS6MJ6F"\N;"[0A;BQF,D9/0@J58'ZJ3^E><Z/K6KP#2;33+[2P@L+:>2
M:YVHUZI&&50B'=L V\$')&:MP^,-6DM(I$UG2YKFZ@NQ''\B(LD4@56!R3R"
M>#QG'O0!V,7ANUM;HWD/FR2I++/!%*^8XI9"2[#C/))ZYZG%2:3IUCI>F1Z&
M9HY7,;O+&Q&Z3>Q+MMZX+,?SKBKKQCK5RUC;Z;=6=M)Y,DKRZEB,3.DFTQC8
M&5L#KL/.<BM'Q5-)9>)8KZWO(-/N_P"RIMDLD2MYK*Z$1\]<^@Y]* .E3PQH
MT<8C6PC""S-@!D_Z@_P=>GZU6'@O05DCD6TD#QR12*PN9<EHP0A)W<X!(YKE
MKCQGJ2:S:)'>0+Y\<D<]M+$%CM)Q;^8H9L[R=W7C&..HJ"7QCKL\%G9VEU:V
MUX6D$MQ?E$0N@4B,,@9&SDGC!QZ$&@#N+O2]#!NXKR&V']K,$F25O^/A@N
M">N!V^M(?"VD-;);O;RO&O7?<2,7Y!PY+9<<#ALC@"N%U#6WU/Q!H4M]=V\,
MEOK2VXL?+&]?W;8D!(W8;/';&.];.K^)=2@UV^@M;B**2RGMHXM/>,%KU)"N
MYP>O&YL8X&PYH ZS4-*LM4%N+R$O]GE$L15V4HP!&05(/0D8Z'-8<7@KPI<0
MW$$%L6CVK;S1Q7DN%"'<J8#\8)SCWK,T'Q3>W>M:?#=:M83K=S7D!AA50 8F
M^5E.2<XZBLZYUM=,37H]*U."VNVU.=EBAB21I76!6V\D*O(R<\GD#F@#N-/T
M[['=WFI78MEN)E5&DCS@1)G;N9N2<$YS27>BZ/KLEO?RQ)<,(]L<T4K /&3G
M:2I&]"><'(KEM-\22Z^LLEWJ=G:VZ0)YEA+&I^TQO"&+@DYQN8CCCY3FE^&V
ML?;[&*V-]&@M;2-(M/78<QX&V8,.2#R,=!T/- '1WGA^W6>;4-/M;<:BQ#*9
MW?R=P 7<4!QNV\;@,^]9VF:1X:DLK$BZM[R;3PMF;B*?!+$C]V^T\@L1\K9'
M-<U/XKU2]T>>?^U(8UNK*Z:XA$:AM,>,< D_WC\OS<Y.16O8W5QIG@WPW<V%
MW;3-=W%E#<S^2N9(W*I@%<#(! R<]* .B_X1;1\7B_9#Y=YN\Z(3/L);[Q"Y
MPI/JH!JNWA/P\9+B%K8F2ZV2.&N)"V8^$=?FRI7U7!KD;OQIJ5C8ACK-HUTB
M:A&ZRPJ!YD))C+ $%3@8QD9S5]?$>JQ7+68U6RN)I]&^W0%PB,)"X'7.",'C
MCZYH W;WPKX<2!KB\B,4,5K)!)(UW(BB)^7W'<,YZECR<#FKC:3I&H:/'I17
MSK. 1[%6=MR;<%#O!W9Z$'->>^(O%$FL^%=0LWOEMD.FW#L;F!";F1"4:(8)
M4XP#E"<[@1TJ_I_BVYDLS:)JME#"EY#:K>H@(MXFMU<;@21N+$KEN,@\4 =8
MWAG0+2(RO;+%%'(9VS,X0MNWY89P1N.<'C-:-]I5EJ;VSWD E:VD\V(EB-K8
M(['D8)&#Q7GNMZ]JFC7.J7J^([>1H-,@DC22)!#(?,*LRC.<G![D9/L!5^Y\
M5ZDVKS"VO;9#%J L_L$B DPLH(N,Y#8YW9^[@$=>: .LTSP_I>C.[V%KY18;
M1\[,$7.=J@D[5SS@8%:=<)X-\57FKZC80WFHVES]MTH7GEQ!5\MPX4A<')!S
MGGIBN[H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,G^PTFU>XO[Z1+GS(&M4B,6%6)CDJW)W9/?CCM3X/#NC6S1M#IEK&T;K(A6
M,9#*,*?J!QGTKE?$%CK5SK^H>4E_YK+;MI-S Y$,+ _O!( <>YW Y7@<UJ>$
M+&18-6:\2_\ ,EOIU5KQWW-"6)3;DX P>,4 ;+:%I3N6;3[<L9&E)*#EF&&/
MU(ZTU_#^CR7YOGTVV-T6#&;RQNR!C.?7!QGTKD)]%U:#0-0LK"&\6YTZ1TLY
M_/8M/%(ZNVTLW+!-R<]QQBL^32;Z&2UB0^(KBS:UO&VN9%"L0IC&%.0=P;&3
MG\#0!Z N@Z2LEI(NFVH>S!6W81C,0/9?05(FCZ;%,LJ6,"R)*\RL$&0[_>8>
MY[UY_!!K?D1.^GZM+<O+I]R<L5P54+-G+ #D'*]^N*UO!VG:M;ZG-=:G-J1N
MF5TNHY>("V_*LG)SQTQC X- '21:+I7E2VRZ7"D/F!BIC&UB.01]#^M3FQTZ
MVM;A&M[>.WN&+3AE 5RW!+>N:X.2WU";7$CFAUYK3^V9VDP9 C6[0D#D<[0^
M-OIS4\^G:AJWPDM[2\L[V6^C\DO#+N64[)E)[Y)VC\: .ETM-$OY)H;2Q53I
MEV8_GAV[)0HRRY]CUK8EMX9S&9HDD,;ATW*#M8="/0UYS+;ZBFJW-U8V&JPW
M)U0"%BC[/*,&W<PS@KNQDG/2MCP)IU_9QRRWTNIF>6)!<1WGW5F'WBG)SGU'
M!&* -N^TS0K47^K7EC:J7@87<[1C+Q@<AO48%0V-CI&L64S/HA@5W5)([JW"
M,VS&P]\@<8->?:IIVLW=KKR_V1J@M;[3'1+<O)(_V@2'&[+8R0?X?EQ]*UTT
M_5&ORL%KJD$B36[:=-YCB*.W 7S$D4GK]_(89.1CV .T/AS166W!TNT(MI#+
M"/*'[MCR2/3-6+K2["]D\RZM(9G\MHMSH"=C=5^A]*\X;1]5ET>P7=KD<#W=
MR+YMSO<$9;R6P2#M /\ #[<<5HF#6[&[G)MM2U&&2S*ON<QS*RQ@?*X.P[C[
M!LDGD4 =K%8V=C*7M[)%>;;&[1H.548&?8#BL>*S\-1ZN_AR+28$E$8U$H+<
M"/[VW<#TW9[#UKE-.M_$-K>0QFVU%$74V>W">8T(A>WXW[B6P).QZ'/%7_"U
MC?1>+[>\FTS48@VE&&[GNGW#[1Y@+8RQX/)&WB@#KXM TB&XMYXM-M4FMX_*
MA=8@"B?W1[5);:1IUE)%);64$+Q(8XV1 "JDY('L3S7(7%GK#2:VT,6H+KFZ
M?[%.9&^SM&5^0==HQTP1D-S[UF30W=E-;7\$6J6]C'=VDIM;B9C*&&\3D*6R
M5P4R.02,B@#O%\/Z/'-YZZ=;+)YOGE@@'[SKN^OO55]/\,VZ3RFUL%6[<2RE
M44^:P.0QQUYYS7G, NY;KRI6U%8$2X2-'N'V8:5F3OUVD#DG@5#8V\]K]@6*
M"41JBQM&V0%P3D@Y_0^V* .^N9?"UPICFTZ*53,9SF ']X1@M]2*N6-GX:N9
M[62VLK19[6/RH/W05HT_NCV]JXF;G3)'B@G=,$!0"K'G!Y/-8T4-TKA)H[K8
M&FP(RVW! *]\]<XH ]8O+W3/"VGVD9@,-M)<):Q1P19"LYP.!T&>]-DM]'TI
M(;%+&,?:V\M((H@2P'4X[*H/)[5YJ\NHZG#9I<6M_=WZ7=HT!$F%$:E=X8$@
M9R"<GDY%=[?BXB\9+*KJOGZ6\-H7/ F#[B/Q&W\C0!A:S8Z'I^I3:=!%)%(M
ML)Y5\@M&L1;;G=Z ]>N!S52XTE+.4/)9*'X*LJ@Y[ @]^*7289[+57U'4M,U
M"*$Z&T5]+=OD-<;\L%RQSNYQMX.16IJ=GJ"_#W1K>2.\FO(9+,RI:J2Q"NI<
M$#G;MW9% &/':6\4T$L=O&LD!S$P7E/I6UIUY8)IMQI=Y:J+6Y9VD*#@ESDG
M';GGBL&3P_<-;>9';ZKYCZL\>QU?_4;CAC_LX]*J3Z)?0ZC/%?B[BRSJI!(C
M,9'RX;/4<>^: .N\0V=D\=C?(L,]T%,0NM@WE0.A-0>%;1$U(KMW J[/N'WB
M>N:Y(PW!MK=WAFPKK'<1HYRR*",CGIG!]2*O^'K9CJ21:A'J$D17_13;NP>-
M@^1O*GTQR<C&<T =CXKL]+M='%]<//:0V9!S:0))U^7!1E92.>XX]JMEM+\/
M/I\'V<K+=R_9HI$A!)8@M\Q X'!]O2N'O=.UV\O]6:#3+^.VN[&XC:*29F+3
M"12IRS;1E<[=H P<5>-E>K=PM'9:D=,FU2&2&&0.[PJ(V61SDDHI8C@GU- '
M>?8;/R#!]E@\DMN,?EC:3ZX]:D$$(F\X1)YI&W?M&['IFN6\+:5-9WD]K.97
MATJ22&UF>=G,JR$/ELGDJ"%Y]\5B:JFK1>*)]0@M[^TLT6ZBN)C*S9'E I(
MS; N1Q@9!SGK0!WXT^R602+9VX<-O#")<AO7IUIXL[98WC%M"$=MSJ$&&/J1
MW->56VFW1,#;-8CFEOK-I[6)[@A8 -LC,6Y*L<D@>U:-SH_B0ZEJ\MK<:E'?
M)YZ605L6[0E,1_,21N''& =W/2@#TAHXVD61D4NF=K$<KGKBHD2UM L4:0PB
M1CA% 7<W4\=S7G2:9J]KI*RV3ZQ,PF\X6UZC %M@!3Y6W+SR#DKG)QBN@\1Z
M;/>ZGX9O5L9I'M;ARX1R?*+1, 6P1D!MN30!TGV"S\LQ_9(-A&"OEC!'IBJF
MF7UAJ=Q=R6L)$MI,UK([P[6R,$@$\E>17+^$K'5XM3LI[B/4()%M'35?M4A:
M.>?<-K1Y)']XY7 P0.V*@N](U?\ MJ^?38;J#46OS/#<ER+<PF, AN=I)(Q@
MC(.#TH [D6-G$J%;2!1$2R;8A\I/4CCK571[[3]>T=;VTA_T6Y9\K+%M+$,5
M;<I]U/6L+P+I][9P327DNIF26-/.CO>BR@88IR<Y[D'!XQ7.+HWB&VTR1=*M
M;Z"^A%V+H-*52=7F+H(\G;NVDX88QGDT >E'3[)B"UG;D@8!,2\=O2HX=,BA
MO?M D<JJ[88-JB.'UV@ 'GODFN)BT^^@U&WO;:UU8:4MZNRVD=VD16A*R$J6
MSMW;>O0@D<5B&RUY;"=7L]?6>+2"L""1V N%F)0@J2"VW!Y)XZT >DZG?Z;;
M:II=G>0>9<7LCQVS>3N"D*6;+?P\#\:([O3+W7-0TW[,&N[>*)K@R0<.CYVC
M<1\P^4_3%<8MGJEQXJTF]GTS4GN(M3D>:9FQ$MNT3B,@$X&-P! &[.<U=\1Z
M3?7'B:]GMK:]\Z:SMELKFWD*HDJ22%MY!Q@!@<,,$9 H [065HHB"VL($1)C
MQ&/DSUQZ4U=.L4(*V5NI7."(E&,_A7,Z1I,UKXCO+)_->Q@F^W0R&X9B'D7!
MC/.<*0Q /&&'I5'6HM6?QE#<V=C?I;PW*K<3+([>9"T1!,:@[  >V"<C- ';
M?8[7RXX_LT.R([HU\L80^H]#3Y8(9MAEA20QMN3<H.T^H]#7EFFZ+J=]86UE
M=#6;>271R9;BXDE 6Z20&,L<\' .<=0>:[C2$EN/#\U_<I):W.H1>=(@E),/
MR8 4YQP.XH UXX+>4_:#:(DKX+%T&[C@9-4+^[TK3[S3=,N+5=U_,RVZK "@
M=5+DGL#@'FN%-MJD^A020P:G=M=Z$J*\4K<SHX().X;6([]Z9?6VKMJ-CJ-Y
M8:E%>6MW<27%QY@\J* PR+&RY;9\NY<XYR#0!Z>;> S^>88_-QCS-HW?G2M!
M"\R3-%&TJ A7*@LH/H>U>4VUE=K9F41ZRE[+/9EK>%YR?+4@2.2W9LDD#T%6
M7M-;AXTJ#6([H7%]#;O,9"B1,I,6[<<8W$8)Y'TH ](33[*-U=+.W5U.598@
M"#[<4GV6P\XI]GMO-)\TKL7=GIN_^O7G5MI-]$^DY/B.2VEO=UW#(74(IA96
M!"DG&[9SG&<D5<\%Z;=IK-GJ-_I]^ER=,^SM/<%@04E? ;)Z[2N..?SH [PV
M5HS*S6L)*+L4F,?*OH/;VHBLK6!P\-M#&X7:&2, @>G':N!U'3M5EDU^:U75
MMYU", EGW-;$+Y@A!(4C(/ YQGUJE=Z5J,$7V=#XANHETBZ$!9G&)MZM#]TY
M###8SS@ &@#N]4O-*TRXM8KNU!?5+A;8%8 P=\$C>?3Y3UJ2ZT2WNIK3<[I;
M6L@E6UC55C+J=RL>,Y!YX('KFN!O+36[ZYTZY;3-2EU*/489EE<D1+!Y1 )4
MG *L3N&-V<^U0V^CZQ'IUH]Q+XBDG>[M/MT66"Y5_P!Z1M))4KG)! /R]Z /
M4#9VK>9NMH3YIS)F,?/]?6L^UO-*N==O-,BM5%Y8Q1F1C   CYVA3W'!Z5QT
M^D>(5UG4YK>?4DNXC*+!4;_1WA,>$!8DC(/8C.X9Z5?\'V$\'B?4[G^S=0MK
M.XL;95DO&)8R+OWKR2<\CVH Z)[W2%U.RTCR$>21))( L(,:;,!AGH#STZU?
M^PV965?LL&V7_6#RQA_KZUYE#H4EFD-B-(U1(XVU%G>(R$%G(,>&#9Y[8[U8
MM+#7;S4+:ZOY=;A,<$#0"$$ @1XE63GAMVX\C)^7% 'HSV5I(H62UA=0NT!H
MP0!Z?2J.G7>F:K->&WMAYEG*UG(TD&T\ $J,CE<$>U<#_8FKS:/HL3OKD,,D
M$GVIHV=IUN<C:S[FR!C.". >HK1&BZA)KL@^SWT<[W\<LEQYI6)[8Q*L@.T[
M2QP1C&<X(P* .ZBL;2"020VL$;J,!DC ('I5BN3\):9/:R2Q7)E==,:2SMI7
MG9_.0MOW-D\M@JI)[@UUE !1110 4444 %%%% !1110 4444 %%%% !1110
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M$@PJJ.!4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !12$@#).![TSSXLX\U,^FX4 244
M@C(.:* "N1\2Z?Y%R+N,?NY3AL=F_P#KUUU07=LEY:R02#Y7&,^A]: ."L[I
M[*[CN(^JGD>H[BO0()DN($FC.4<9!KSR>![:>2&08=#@UO\ AG4-K&QD/#?-
M'GU[B@#J**** "J][>1V-J\\AQ@<#U/856U#6K73P5+>9-VC4_S]*Y"_U"XU
M";S)C\H^Z@Z+0!6=B[L[=6))KK_#$#1:89&&/-<L/ITKG]*TF749^05@4_._
M]![UW"(L<:H@ 51@ =A0 ZBBB@ HHHH *Q/$>G_:;7[3&O[V$<X[K6W2$ C!
M&0: /-02""#@CD$5WFD7XU"Q60G]ZORR#WKE-7TUK+43'&I,<AW1@#/X5L^'
M]+O+.1IYB(T=<&+J3Z$^E '0T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,_X0CP^YM7GT])Y;7'DR2,=R8].:M1^%="B\[9I=L%FB\EUV?+L_N@= #@9
MZT >67^H75MX0\0Z;<QZKH^L6&F"ZCB2_:2)QNQY\4@.>6R"I/X5L65Q/?>+
MM,\.WE[?1:5;Z&E\L:3R"2\E8C<3(#O;;_=![_A7;3>#O#T]K<VTNE0/#<L&
MF0Y^?'0'GH.PZ>U22>%=#ET^VL7TZ(V]J,0#)S$/16SD#\: .+GCB\6Z4Q\*
M>)=56\M[Q_)N)3+&J.J$^0P8 .N5&<@D9K*BUK5=>TW4YH6FTW75N;:RNK&X
MNI(XY9AN,D49SB/>H&&&/KSFO2X_#&BPFR\G3XH_L3%[<1Y4(QZG@\D^IS4]
MUHNF7K.US8P2L[J[%D!RR@A6^H!.#VH PO NJ+J5IJ$;1:A;7=K<>3<65]+Y
MK6S;00JO_$N""#DGFNLJIIVEV.D6OV:PMD@B+%B%ZLQZDD\D^YJW0 4444 (
M54L&*@L.A(Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45D1ZU+)XEN-'^
MP2 10"?[1YB[6!. ,=<Y!_*DL-?@GM/.OQ'I[;F CFG0D@-MW<'IGB@#8HK#
MUWQ'%H]UIMLB1SRWMY';,GF@-&KYP^.I'%:)U33P)";ZV B;;(3*ORGT//6@
M"W16?>ZYINGBS-S=QI]ME$5OS_K&(R,52T/Q)%J^D&YF\BSNE,OF6SSAO+"2
M,F2?3Y>OO0!N,P52S'  R37 :E?-J%Z\Q/RYP@]%KIM:U&)-+DB6>(W#JH*(
M^2-W?Z8S7!K>@ZF+ Q,LKC,1)&V0^F>Q]J .G\/Z2MV_VJ=<PH?E4_Q'_"NO
MZ# K$T?5;:/1K1KL1Z>7)CCCFF7+$'&?Q-6(?$.DSO?(E_!FQE\FX+. $? .
M#^= &G12*ZNBNC!E89!!R"*Y%?':*\K7&ESQ01:A_9\DBRHY63<%!V@Y*Y(Y
M&?I0!U]5;^PAU"W,4HY_A8=5-*=1LEN'MVO(!-&N]XS(-RCU(]*9'JVFRM&L
M=_;.TAP@6526/MSS0!PUW:RV=R\$HPRGKZCUK2T#4OL5WY,C?N93@_[+=C5W
MQ#/IEW9-<1W]J98'$9Q*O)/\/U]*Y87$)Z3)RQ7[W<=OK0!Z?61K^G_;;+S$
M&9H?F7W'<4W2M<LYM*AEGO($;)C):0#<P]/?%:,UU'#-&CS0(I5G8.^&VCN/
M;UH \\KM]"U#[=8 ,?WT7RO[^AKE=96SAO)9;:Y@>W)R2C@A"><'T]1532M=
M73]9!8J+8Q!FDW\,"<?I0!Z315&;5[&.UGG6[MV$)VMF4 !\9"D]B:I:#XCM
M]7T/3;^X,5I-?)N2W:4$YR1@'O0!MT5%#<P7!<0S1R%#APC [3[UG_\ "0:=
M'J-MI\UY;_:KH2/ J/D,J$ \^O/\Z -6BHHKJWGA,T,\<D8&2ZL"/SJ'^U=/
M^7_3K?YD:1?W@Y51DD>P!&: +=%51J5B9((Q>6Y>=0T2^8,R ]"/6D&IV#>?
MMO;<^1_K<2C]W]?2@"W159=0LW\K;=0-YJ[H\2#YQTR/6D.I6(MWN#>0>2AP
MTGF#:#Z9H M454_M.PWQI]MMRTB[T E7++ZCGI[U/!<0W,?F02I*A_B1@10!
M)159]0LH[L6CW<"W!&1$T@#$8ST^E)'J5C-YGE7MN_EKO?;*IVKZGG@>] %J
MBL#2?$IU:+69(;5673[AH8]DP83@*&# ]!G/2KF@:PNNZ!::L('MH[F,2JDC
M D*>F<<=* -.BJ?]K:=Y7F_;[;R\E=WFKC(&2.O85G>)?$UOH&@OJ4?DW+85
MHXA,%\Q2P!*GOC=GB@#=HJJ=1LD>2-[N!9(UWR*T@!0>I]*22^@-D;F&YMS'
MG"R/( A.<=: +=%5AJ%D;D6PNX#.25\L2#=D<D8]169J?B2"SCMGL_)O1)?0
MVDWES#]SYC!=QZYQGI0!N455BU.QG:-8KR!VD#% L@.X+PV/IWK)L/%-M>ZQ
MK%HQ@CM=/6%A="<,LF\$_A@J1B@#H**@6]M7DC1+F%GD7>BAP2R^H]1574M9
MLM(AGN;ZZ@AMH$#2$M\RY.!QZ&@#1HJ"&]M;A]D-Q%(VT-M5P3@C(X^A'YTR
M74K& R"6\@3RL>9ND VYQC/IU'YT 6J*J/JEA''*[WMNJ0OLD)D "-Z'T/M3
MO[1LC/% +R RRKNC3S!EQUR!WH LT54&IV#+(PO;<K&P1R)!\K'H#[U(MY:O
M+Y:W$1DV[]H<9QZ_2@">BJ8U?36A,PU"U,0?87\Y<;O3.>M317EM/(8XKB)W
M4 E5<$C/M0!-150ZI8":6$WMN)85W2(91E!ZGGBE&IV!AEF%[;F*(XD<2#"'
MT)[=10!:HK$\.^(%UO0/[5GBCM%$LJ,#*&50CLN=W Q\N<UH)JEA)#'*E[;M
M'(Q5&$@PQ'4#WH MT54EU"W"2>7=6V]&V$/(  V<8/O39M7TVWNA:S7]M'<'
MI$TH#'\* +M%5%U33W21UOK9ECQO(E4A<],\]ZM(ZR(KHP96&0P.010 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;E.WWXS[YKM-%BU"VTZVM=0\IY8H%5Y8\ ,W?Y0!CM_@*TJ* "BBB@ HHHH
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MUMY;BZLYH#_&I%>>,K([(PPRG!'O5QO'MU]DTFZ\JS"W<D4,T(+LZ,\IC+9
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M]0:WJ* ,2/PO8J<NTK^Q; K3MK&UM!B"!$]P.?SJQ10 4444 %%%% !1110
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M]4TVYDDANTMP/,BD8L\4BY^923QZ5U6I:+-JFH6CW,\3V$*-OM3&?GD(P&W
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M/=VRJ\T0ZH&SMS]<&K= !15:+4;2;4)["*X1[JW56EB!Y0-TS]<59H ****
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M2UM-5D"6H5K2UGA9VOXS'DG?POWLC/\ #BJ5EJGB!M GO'UX3LTD3RQ&%X3
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M"Q1 ")U$@#;OE)<XS\HQQS6.WBG4HIWGM-4GOKHWE[;PVS0[8W54+1# 7KN
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3B@#4\2^&4\30+;3WDL=J8Y(Y80 5DW+@'_>7J#3K?PW';7\5VEY.&2S6U<
M !RN0LA_V@"1^/M7+^)?$D^JZ;9O81306\.H6!N)EN-C*SO&VS:!\R[7&>1U
MJVWQ NC;7%W#X<NI+-0#;SF38L@\P(<EAQUW<;N* 'K\/?+$[QZS,+BX$'GS
M-"K&4Q.7#'_:.<$U+=^ S?P75O>:O-+;74\TTL/DJ$/F*!C'JN,@^YK;U>_O
MK#PM?:@D$(O;>UDF$1D)3<JDXSCD<>E<K;ZYJ-CJUSJ,]NTZS6=B]Q%]I.R'
M>Q4F,$>X)''3K0!LQ>#(HYC_ *?,UO*EN+B%D7$K0J ASU X&1WQU%06O@<V
MTD,XU5VN4\Y'D-NAWQR/O*X/0AB<,/QS5C0O%DVN:F\2:1<Q:>WF>3>MG:Y1
MBI!&!C."1@GIVK%\93ZBGBJ"UL[S5U$VESR)!8$']\K($.",?Q'.>* .FUC0
MI=4O-*N([XVXTZ?SE3R@_F':5P<GIAC60? 48TW[ FJ3>1#'+%9!HE)MUD^]
MSQNXRHST![US$MSXL;4[VVBN]3?6H8+"18(=IM4E<'S@^1@(<'O]*NV5QKS^
M)KB.PNM5N3!K9BE$Q#6R6NQ2P)('(SQCGI0!TOBVROYO#5M:V4<MQ<I=6S%H
M@H("2*S-ACCHIXIUGX4>TUJ#5/[2>291.90T0Q(\NW)Z_* $0 >Q]:I_$"YO
M;2TT>2QFOE=]2CADBLY%5YD96)7GC/ QTK/T?Q3?6/A6TNI/-U6XU&\D2QA)
M)EC0!FV2D+G<NQ@?E]O>@"VO@.X%JT!UV1E-C<6.3;+G;,^YCUZCH*T;/PM<
M6%K=6MOJ\@M[E&+HT*G;(R;2P.> ?O;?7O6==^.+Z(6Z0Z$RW,BP%[>YN/+D
M#2N4PH"G=MQECQ@4FH>);F^TB>T>T:V:XBOH3+#<'=$\(."IQWQG/&* *\/A
M2_;6?[-DN+E=,CTBWL9+D1H!<!'<E>N5.U@,X]?:K-U\/4N9;N?^UIQ<7%O/
M:F9HE9A#*1\ISUVC@>V*2'Q9/IEMX<M)K:*87T5M")6NOWK.Z==F"<9 R2>_
MM46G>,[E--M;[7=/2-_L5S=M-;3%D"QD KMP"21Z^GO0!TE[H;7L.E WCI/I
MTJRK*J#YR$9#D'U#&L1/ UTEO;1+X@G4P0S1*Z0*K$2.'/.?;'TS2S>-;RTO
MH;"YT0BZFEMPGEW09!',Q57+8!R&7!&/>I+7QKYL]E!<62VTEQ)+ S23?)YL
M<GEE%;;AB<$C.#CM0 [2O UMH][;W-K>2IY-U-<"-44*?-5 R^PR@/XFK=YX
M8-[JNHW<MZ&AO;>*![9[=74*A8C.>N=S9^M=!7$2>/IH;N\M7TE);BW\ABEO
M>*X"R2&/YC@ $$ D#/6@#8;PO&?"T&B)>2J(&C>.<C)5D<.O!_A! &/3BL^;
MP'#/%,DNI3NTMXU[O:--T4C8R8R "AXZY/6FWGB:[O;&\TZ'3RNHXN8I%2ZV
MB-$ RZOMSGYEP,=?I5K1;ZZA^&5C?QGS[M-*24&9S\[B//S'KUH C;P/;M:7
MEG]NF6TFD::)510\+EM^0V,L W(!_6M#2/#\NE7.IW;:E+<W6H,KNSQJ%1E0
M*"%'T]:Y&S\2:E8ZA-K%W;M,MQIFGSW$*W)V0^8[H6C4CJ>"1QTZU<U[QU?6
M/]L65K9VHOK6S>YA)N=XVJX4[P%X.""!D^AH MV'@-]/M[=8=:G$T4,MLT@A
M4>9#(V\J1_>#$D-VST-;.AZ NASWABN2\$YC$<10#R@B! ,YYX I=?U"_P!-
M\*WU_;0P&^AMVD6-W.P,!ZXY'X5D?\)E<0KOFTY7M[::"UOIHY^8I9 F-JE?
MF4&1<G(Z].* )_\ A$)(]6COK?59(PE_+?")H58;I(RC#/7&":AT;P,-','E
MZG))MB2.;,"@R;"2I!ZJ<'!QU K:UK5SI?V.*& 3W=[/Y%O&S[%+;68Y;!P
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MT;[U(]CWJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC2XM'BTURC6<B_O[E/*W"10OJQ[<84T =!?^%+=]/U&'3\127SQO*)'<HVS
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*1[Z"[O@\[C?Y9!(WX+$\8'3%.U7P;'+=Z';Z?I]JFEVD\LUS&9W1V+H5)!
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M2VN8+%(;72C92&"4DE_,# @;1Q@?K7;T %%%% !1110 4444 %%%% !1110
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M<?,,@ 9Z"@#HM,U6VU6.=K<2*T$Q@E21-K(X ."/H0?QJ#4O$%GI5Y#;W27
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MJRZ+X=FU&*T-TT"*WE!PF1P#R:H_\(%X;^S^1]@D\K[+]CV?:IL>3NW;/O\
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M4]2&HW4,YNUC\H2Q7<L1"9SCY& QFD_X131!-;2BQ4/;QK$A$C_,BG(#\_.
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M!]C#CJ1WH K:=XINY/L3'2[:TM;MKI&+W)+)/$S#9PN#NVDY![&F?\)IJO\
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MGY3GCIBNJ%M;K]V"(<8X0=*<8HR23&AR-IRO4>GTH <"" 000>012T=!@44
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MGX=#;7U2%#Y1E^<,H"A=QR2, [><=<=JTK#4[/4[(7EI-YENPR)-I4$8SD9
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M'%),(E#& .2!G'7&"3CMS762OY4+R!&?:I;:O4X[#WH Y6;P6TEX)TOR@CU
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M(Z>^H+>K->1RK<O= ).0HD9=K''H1VK>HH YZR\&:78& P27@,40A;-PW[U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ndra_ex102004.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 ndra_ex102004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ K<# 2(  A$! Q$!_\0
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M$LC;8Q(PV\CKQ]>#Q4,>C6L=RT@/R#9MCSP"O3/KR<U-I]BEBLQ#*9)Y3(Y
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M:).C$;6F9T /13VJY134$G<BIB9U(\KV"BBBK.<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD,IW$@-\RE,]3TQQ6K)X3NWU^^FDMK[;N<VLMM=K%&L+1;?+V]0P/08VYP:
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M6,B2>&8&3JW+%,C)ZCBI]8\,ZQJ>HWCIH445O+!=P/&)%(E+!6C8DMSRO P
MOZT >EQS>868 >3M#)(&!#9J3<H7<6&WUSQ7FTFAZU]IU$VNCRQ6;2V,K6C3
MIMN(XU(DB7YL+_"<< [<=Z8WAG45N8S)I-S-:.+TQV_VA2MLDBKY<9&[&=P8
M\9V[NM 'IM)N&[;D;L9QGFL;PU/<_P!D6MG>VEQ!=6UO$LGFD-D[>>03GI7(
MW?AO6)Y;M9;&9KE;JYF:^AN OVFW>-PD(^8$')08. -F0: /1PP;."#C@X-&
MY>?F''7GI7.:9IZV/@".UNH/LL@L-MR"^#O"88E@>N1US7&:7HNJ7^AV=_IM
MDT=M]AM5G@-RI_M#:X9L$,0/E!&6QG.#Q0!ZMO4@$,,'H<]:9)(RQDQJ)'!
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M0C>6,N W3*@'(]CZ51B\*;M5M]7FO6-ZMPD\A\H ,%B:,)C)Q@.QZGFH)/"
MM+27[-(URL$EQ<6=LZJ-DDJL""QX(^=L CO0!<?QIHZ%@7N,JT2X$#$DR@F/
M''.[!Q4S>*]+C9DD>9&6&2;:T+ D1@,X''4!AD5SNA^&M0N+:".[9[>.VGAG
M5I;54E9HB<*<.P9<'@\8["M*Z\%O=:E<7;:M+^]\\!3$"565 I7=GD# (]*
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MK+&Q&,JPR#CZ4 6**** "BJ*ZO:-KCZ.&?[8EN+EEV'&PMMSGH>:O4 %%%%
M!116-'XHTN6ZCMDED,DEV]FH,3 &5!EAG'3'?OVH V:**S[76;6^:Y6U$LIM
MKG[-*!&1M?C/7L,]: -"BJ.JZM::-:)<WKLL;RI"I5"WS.P5>G3D]:6ZU2UL
M]0LK&9F$]ZS+" A()5=QR>@X]: +M%%% !1110 4444 %%%% !1110 4444
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M6M89G<S2J+9X\%EQG*%LCCC."*P+AM4O= DMKR#7YHGAO8X2(Y5D:?<?+\P
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M9+"U2_DOEB'VF10C2$D\#L.P_"@#C_B#_:9MEBTBWU)[Q+:22WD@DD$0=2I
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MP48JT@W(6*L0%.,'OGB@#JJ*YL>,($TR2_N;&YMX8)9H[C>R$P^7P20&YR<
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MFZ?XKT+5;F*WLM2AEFE3S(DY4R+URN0-P^E6==8IH&H$*[DV\@"QJ68DJ0
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M.G31N^_[3O.!+W/&W&_C&<T >AT5YG$VI_VB/MESKC2?VL8I2HD$?D-#\VT
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MI:M;65W=WETXDL8YI8Y;,1HSN <HPZ@8;CT(KI;^T%_I]Q9M*\2SQF,O&?F
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M-MK&H065MI]\LLEO]H8S1!%1=Y0YR>2".WL:K_\ "!6'[DO?7Q:WMX(('\P
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MKOQ')8))9Q1"XB%M<!V>+;DYZ89>01[5T-O="33X[J=1;AHQ(RNP^3(SR>E
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M^E=?10!SFE^%Y-(DF^S:@#%ND>W5[==T9<Y.YNK $G X_2NB&0!DY..32T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37=8T+NP51U). *9%<
MPS.Z12J[1G#!3G%4=9TQM1ML1N5D3E1GY6]C0!$?$EE]L6!2QC)P9>P/^%;
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MVYBDX.2AX(]J]$MIA<6T4P_C4-0!+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %)@9S@9/>EHH .@P*0JI/*@_44M% "  #
M  %!53U4'\*6B@"JMA$+\WA:1I-FQ5+G8@[[5Z GN:AN-(@N=9M-4>2<3VJ.
MD:K(0A#=<KT/0?E6A10 8'I2  #  %+10 4@4 Y  ^@I:* $*J>J@_44;5'1
M1^5+10 A /4 _6EHHH ,8&!1110 @4#H /PI:** $*J3DJ#^%!4'J ?PI:*
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M\D[)<W%U BLT,4+%I%+!=Z\<KDC)'2M)?%&FJUVYN9Y&BECA-J+=O,61DW[
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M*)X!( QE8[O,QO+9/S$X')]!26_A72K6W,%O%-%'NR@2=QY7.<)S\HSS@<4
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MZ;[0+K;YC;/- QOVYQNQ^=02>$] A@@M&WPQ^>K6\?VEEVLIW!4YZ C.T>E
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M*.^LKF2&8-<!0T:J"LF2,8.X?3WJ+P_K-K<26JVVFBYO&N+F 3"Y!B66) P
M..0P(YQQ75S>%='GCN(Y+3(N+>.VD(<@E$.5YSU![^PID/A+2+>_BO8HIEGB
MG:X#"9L&1E"LQ&><@"@#+D\;3PZ197S:5O:Y(B\F*8LR3F0H$^[R.&)('&.A
MJ:V\8N]QIUO>:7)837@8;;I]F'#[=JDC#$CY@#@XQQ6I+X9TF:UN[=[7]W=7
M'VF3#D$2\$.ISE2" >*)/#>F3)"DL4DBQNKX:5B'96W MS\QW<\]Q0!4\6>)
M7\+V'VXVL4T"*SR%[D1GC'"C!+,<G\JK+XNN9+UX5T=EC%Z;)))+@ L_E[T;
M !^4_7(]*UM5\.Z9K4JR7T!D80O <.0&1_O*<'D<#\JI+X-TJ%Q+"MQYBW(N
MU#7+X\T+M!//IQ0 [0/$-SK:P,U@L!\MS=+YVYK>57*^6>.3P>>.G>M^L[2=
M-%@+J9TA6ZO)O.G\H';NP!QGGH!^M:- !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7GWQ(U.1]-U?1S<6UO -'FN
M6$T>XW!Y&U<D 8P#GDY(KT&H9[2VNMOVBWBFVYV^8@;&>#C- '":9XDUB]U3
M[/:SV$&FVY6W;S3F4J8@RRJ.X)(/I@'FN?\ #VLZQ9:)HT.G2Z8US<V+W4EW
M<J$\W;)CRB0<G&6)/7D<5ZTUE:/(9'M86D*>66,8)V_W<^GM4::9I\<4<26-
MLL<;[T585 5O4#'!]Z .'A\7ZO\ ;/WEWII5M2NK%8@NU1LB,B,7)SG( /'?
MM44GC/6KF"SLK)K>'47,B3R7J*B1R(B,$X8J=V[=D'[H/>N\_LC3=^_^SK3=
MO\S=Y"YW?WNG7WIYT^R:'R6M+<Q;]^PQ#;N]<8Z^] '-Z/XCO;GQ'_9]_P"4
M@FCWP"!=\;812PW9W!@2>&4<8Q6.M_-H?B/5WLIK5(Y-6B%Q:&/YG5XUW2Y!
MR-HRQXZ*:] 6V@6<SK#&)B-ID"#<1Z9H-K;FX^T&"(S[=GF;!NV^F>N* /.[
M;QGK$O\ :,4-Q!=^2;66&40K$98I-^[RU+X;[HVY()R:EB\9ZO>ZF9+'[(]C
M;)$TL,H*37"NF=R+U!W< <C@\UW8TVQ6,QBRMPA&TJ(EP1SQC'N?SI_V2V$T
M<PMXO,C78C[!E5] >PH X#POJ*ZC\0(KZ6]M+BXO="24"! I0>;G8>3G;TR>
M?:K$OBG4H;Q;4ZC9>=_:=S9A)(L;@(MT6<'(P<?7/:NWAL[6W=G@MH8F;[S(
M@4GOSBHI]/@E2<I''%/,I!G6,;P<8!SCDCWH \]B\<:NECI\TEY83)J%M:R2
M3QQ82P,CA&+_ #<CDXR1R*M?\)/KQU"'3C?:>BF6\A^V"'/G>5&KJZKNP,$E
M6&>JFNNT;0;/1M$ATM$6:..(1.\D:YE &!NP,$XXJTVF:>XB#V-LPB4K&#"I
MV ]0..!0!STOB.:;P7I&J+=Q6UUJ$<3#9%YNYV0L412P&<@]3V-<Q#X_UFXT
MMM0^T6$2PZ=;7C1&/+,S2M&ZM\WR_=XQTSWKTL6-F+:.W%I ((R"D0C&U2.0
M0.@J)M'TM]V_3;-MXPV8%.1G.#QZT 86G:CJTGB"YTBYNXVEAN!<*ZVX >T9
M?E'7KNRI/^STYJ1M5O;GQ7=Z>M[:6D%F8<PS1Y:Y1QEB#D8_NC /(.:V[2Q%
MM/-,TK2R2<*6  1!G"@#L,U++9VTTR32V\,DL8PCN@++]#VH \NB\32Z!X1L
M?[)NK?$)=WM$@#Y3[3M)+;@%4 D<9.?85L+XHU6;48[2*]TR(2ZW/8M((RQ$
M8A+H0-W+9 !)ZUVBZ5IR*%2PM54 @ 0J ,]>W>F_V1IF[=_9UINW^9GR%SN]
M>G7WH Y;PIXHO]6U#3H[RXM)$O=/EN D2;2KQRJAP<G(8$G';%8MU+<SZQ;B
M[U6&:ZA\3-':F2(9MU\AN ,\CD>E>BPZ7I]M(DD%C:Q/&"$:.%5*@]0"!QFG
M2Z=8S2>9+9V\CAM^YXE)W>N<=?>@#SP^.]0^PZ7<K?6TDIFBBNX([?(VFX,1
MD+%OD! R ,\]>*W_  U++>>&-3&J:@E__I%RCET"A5#L I&>F!^5=%'I6G1
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MO->UF6X@MDUVU>V%S92_;[:$!661CF)AN([!LYY!K?\ $NNWMIJL&G6M[:V
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M::#]X3 1M)0/@ @\\FMC3M=UB[U&*UDNX1_:$$%W9/'!E5CQ^^4G/)!P!_O
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M@6UEAY!YTP_B8<#Z"M:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/Q!X>U35/&'
MA[5K9[-;;29)'*2.V^3S$*$<# P.1ZUF6?P_NM/U>.YM[NW,-E<WE[9*ZMGS
M9QT?_94YZ<GVKOZ* (K7[0+6$71C-QL'FF($*6QSC/.,U+110 5QWBSPK>^(
M?$F@7R"P>RTR5Y)8;G),V]=I&,$<#GFNQHH Y7Q!X6N+S6/#NJZ3+;PRZ*TB
MI;S*1')&ZA2N1RI  QP:J>)O"FIZW!I<:C39!!?B]NDN VR3 QL P>,'J?3I
M7:T4 <;H/A;5O#NFZKHUK=6UQI4F\Z:DS,'MP_\ RS)P<H"3CO64/ >M#X1-
MX+^TV'V@IY/VC<^S9NW9QC.[/&.E>CT4 < G@W5[?QC::];1:1"(--:R:",L
MN]FP=V0OJ/RI_@_PIKOA32+:P1-&:1&8SW4>\/,NYF"GY?5L9)/%=Y10!Y=H
MGPWUG08],OK&ZTZ+6;.>832+O\N\MY'+E'XSE2>#STKM-7TN^U:^M(GDCCTU
M%9IA%,Z2F0@@8(&-N"00?7VK=HH \WT/P'K>F:"NA74^EWFDPW$KI:3HT@DB
M<'$;$CC:QR&'Y5)!\.[B'1(]*F.GW^G!)L6%VK-'$SR;E\M^64(N5'<^U>B4
M4 <);>!]3TJ]\.7]GJ4=W<Z59/93"\W#SD;!R&&2"".,YXI_B'P9>:W?:*94
MTZXLK2>6>[AG# 3&4,K #!Q@,2">]=Q10!P>D>%/$>EZ;!H#ZC;7&BV]SF&7
MS)([E;<'*1Y QE3CG/(&.*CT'PAX@\-3:M!8SV$NFWEZ+N"*>60O"21NYV\Y
MQGZUZ!10!Q-Q\-].FUC7;J.1H+77+%K>[MX^@E)_UJ]@<=?>M+0--\0:1I-I
MID]S83Q64(BCF565YE484,.B]!DC-=)10!P'A+PCKOAG3Q:*-(\V2>1YKV/?
MYNQW+E1\O)!/&35C2/!%Q9>*+'6YY;..Z@@>.[FLXS&U^S #,B]!@C.>23Z5
MV]% !1110 4444 %0W-U!:1&2>144>O>H]2N7M-.FGCQO1<C-<'<W,UU(99Y
M&=O4]OI0!Z%!,MQ!',F=KJ&&1SBI*@LUV6,"^D:C]*GH **** "LC5M#BOP9
M8L1W _B[-]:UZ* /.)X);:9HID*.O4&M'2=:ET]A')E[<GE>Z^X_PKJM0TZ#
M48=DJX8?=<=5KC-0TVXTZ;9*N5/W7'1J .[@GBN85EA<.C="*DK@=.U.?39M
MT9W1G[T9Z'_Z]=K97T%_ )86S_>4]5/O0!9KCO$\6S50_P#STC!_+BNQKFO%
MD7RVTV.A*F@"/PG)B:YB]5#?E_\ KKJ:XOPW)LUA5[.A']:[2@ HHHH KWMH
ME[:26[]&'!]#V->?S0O;S/#(,.AP17I%<WXGT_*K?1CD?+)CT[&@!OAC4/O6
M,A_VH\_J*Z:N)TK2;VYFCGCS"BD,)&'\AWKMNU !44%M!;*1#$J!CD[1UJ6B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(]QL+1@K(4!V@]\#C/4UB6/C+5KZZM++[7:0&2[O+9Y9H0),1H'1MN[ X/-
M'H<LT4"!YI4C4D*"[  D]!3F940N[!549))P *\AUKQ4WB#PS;SWEU8VZP2Z
M;.\)&6=GD0F123PH.0,9Z'-==XPFE75M-@DOTAT^>WNA<6\BC;-B/H2?J>*
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MM-'<Q-$D?[L8#8Y'SCN>I..*Z7QC8"\&C2FVN;A;;48Y'6W+9"X89(4],D4
M:.E3:3K-C#>65M&T,<CI$6@VE"K$-@$9'(-:,L$,X431)(%.Y=Z@X/J*\MSK
M<%JS:1:ZM%?7!O\ *O$P09?<G7Y5)&=I]379^#K>>WT^?S+G49XI)-\8OXO+
M>/(&5"GG&>>>Y.* +$YT+3]5T[37LH$N;T2I;A;8;<*NYQG&!QV[UJ&"UCME
MM3%"L#?((MH"GVQ7F=W'JQUZPO;C2]:GO;6>]%RT (CV-&ZQ&(GY>A7!'.<Y
MHL].U&XU"U>]T[4S:V^JQ3VJEI6\N-X,');!($G7/3)Z T >E'3K(V@M#9VY
MMAR(?+&S\NE++86=Q%'%-:P21Q_<1XP0OT':N0\$V^L+>2W.JW&IFY>-DN[>
MXB"PK*&X:-OX@1T(XQC/-1:U'KDOB"^6%;];A9K=]+EBS]G$?R^:LF./[^=W
M8C% '4#5K&\U*721#+-MW1ROY):$, "49NF<,#@^M17<NB6$VG6$UM &FN/+
MMHT@!5)-I;L,*<<]JQO EHMM>>(V^R7L#3:I)(AN5<!XR% *[NO(:L:;33:Z
M].AT[5-L^NB>26-)&0Q&(C(/89.#B@#I]<\,6VI?+:QFVFSYI=$78Y'9AZG-
M<HVGK8%HIH</&2QW(,Y[X_\ K4FF2:W.1;E]=B#:5)%NFMW*I*)_E.#C+%.O
M.2!ZUU.D6<FJ^'(SJ=I);7,;.H8[BQ /# /\V#V!Y_G0!QWVG3V@>Y_=F,OA
MF$>3N]QC.:]%L[&SGTJW^T64!S" RR1#IU(((Z9YKA(]#NUTZ'4]*L[AFGF$
M%];7$1C<KY@Q,JGD%0.?4'VJ2_L=;U&:\MWBU(7ANKE)^6%O+9E7\L*1QG[F
M,?-G=F@#T%+2R9DG2W@)\O8D@09V8Z ^F*8FDZ;&5*:?:KM7:N(5& >PXZ5Y
MY86.L_;=+@#:S8VEO:VQLTBA)4L!^]24MG:2>/F_AZ5Z-#>1W=DUQ )&7YAM
MVE6R"01@]\B@ 6PM4GBE2%%:%"D>U0 H/4"FRZ7I\\K2RV-M)(Q!9VB4DD=,
MG':O,$;71<;Q;Z_;64L]C*(QYCOQ(1.')&?N\G&!TQ6C;P:I&L-]$NHEK?4K
MBP6"X=TWV\C$1N Q^;9D$'KC(H [Q]/TR&!F>SM5B1C,W[I< ]VZ=?>JFER:
M7JT,\D&FF-&D5V,UKL$IP&5QD?-P1S5?Q%8K'X$U&Q6.YGQ9/&BQ%FD=MN!C
M'S$YQ7$2VNIV>BO#IUCK7[W1[0P1J),K/'(=XY/RMC'!QD4 >FRV5AB,2VUM
MA3A-T:\$]A]:S])_L/6[,:C964#1M*^'>V"-O5BK'!&0<@]>:XI],NK_ $R.
MZNK76+B6'Q )-LOF"06XD.W"@C@ CI5-?[>MX,Z/:ZM#=W#:GE7B95&Z0O$?
MF^53@D@GN: .[N?"5C/>^<C>3"R!&MTBCV8&3\N5RN<G.*N:Q?:1I5M;S:KY
M:Q"011,\1DPYX & >3T]ZXJQL;X:KHL;77B"?3YKF9I4N(FB5%,7 8#D#?C&
M3U)[5N_$%)Y- MHK6&YDE-_;./L\)E*!958L1Z  GF@!\FL^#EBBE_T,BXE,
M:;+4L3(@Y4@+D,H['D46WB?P[IZ[I-9$\ERGVIIRA(9!A=V57:%' ]N]86I^
M'Y]*U#2/LD]]/=W>K/>W=\MH'"$PM&"5 VJ!E1^M0-X3DL]>L]#L;K4(;=M-
MNH[C4!;!P[S2J[Y8C:I/S'CIQ0!W=Q/I.EVD^M2""*'9YDMU''DLGJ2HR14&
MCZCH%])/#I9M_,=!++&L/ELRMT8@@$@^M5=;T^/3/AY>:78P321P:<UK!%&I
M=S\FQ0 .2>E<=9VVMZ1:71@M=0N]2O=-1--OI8R7@ 7YK=^,(0V2I/!SR>*
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M@EM;HB)I+>/[2J"XP,D*W?C)XSTKEI/!.LS:7':N+/<ME8H^)G7S'MR<QEE
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M'J:ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MQM0\3Z9IE[]EN)),H4$TB1ED@WG">8PX7)Z9KG6\;7-QK-CY%K=0V:7MW:7,
M#6Q:6<QQLRE/Q7H!6MJ'A%+[4[VX%Z\=KJ*QK?6OEAA+L^[ANJY'!ZY'IUJO
M_P (;<QZM'>V^LF-([V>\6%K96 :52I&<@\9/Z>E $]QX^\-VSV2RZ@H%Y&D
MD9P>%?[A8=1DC XZUJ:/K=KKUF;NP$WV<_ZN66)D63W7/45S^E>!)-)^S&'5
M]S);QP3%K53Y@C)V,O/R'!P<9SCM6]H.E3:+HD.GR7?VEXMV)O*"9R2>F3ZT
M 8VF>+5M] MY]7D>>\?SG=;6W+$1HY4OM&2%'&3[U>E\9:/#<+&\D_E-&72Y
M$#&)\)YA"MC#'9S@5FVW@BYM$MY(=;=;R))H'F%LN)(97WE2N>"#T;/U!IDO
MP_'VNUFMM6EB%B1]A5X0_P!G7R3$4&3RO.>W/>@#>TGQ'IVMS-%9M+N$,=PO
MF1%!)$^=KKGJ."/PK(U_Q/);:WI-C82-A]12VNW,!:,@HQ*!^@88!QZ5/H'A
M6XT6_M[A]4^TI#IT6GB/[.$RL9)#9R>>345[X+:[U 2#5IHK(7ZZA]F6)2?-
M PPWGG:V3QCC)YH M+XTT5F=3-*GR;X2T+ 7*[@H,7'S_,0./4>M#>,],1)&
MDAOXVCM9;ID>T<,$C8*XP1]X9!QZ'-9R^ $^R6MO+JDT@TX;=+?RU#6N&5AG
ML^-BCD#@>^:N:CX5NM4$3W.KM]H%K<6DTB6Z@/'*!G"Y^4C:O.3W]: )?^$T
MT8W/D))<.PD2)F6W<JKNNY%)QU8<#WXJ&Z\?^'K&UMY[N[: 3LRE)4*O'M;:
MQ=3R #P:IQ^"+Z+(7Q [#SK64&2T4M^X  !((SG'/%.M_ \L%^;[^U@]P\DO
MF%K12&C=]^T GA@2<-[\@T 7CXWT@B3R/M5QM\Y5,=NV'>,99 2/O8Y'K4^D
M^*+354LPMO=13W$"3-&\1_=;N@8]LX./4"LQ?!=WYZM)K9>,7DUR4^R@$B12
MI7.[L">:F@\'-'=:1<2:B9)-.1$600*DC*HQMW \*>X.<^U "^+-<NK"]TK2
MK/[5#-J,KI]JAMA-Y05"V<'CJ!G/;)H7QUHL%L6NKJ7Y(A(LQMV"W*Y +Q==
MPR1T]15G7]!N]4U'3;^WODA_L\R.(&@#B8NA4@G(QP2*X%](E^PPV+WLACM(
MOL]L'0$PIQQ[G  S[4 =7KGC&2/29I]+CV2(A<-<QD=.VWK7%7&O7TK2.T]M
M*RO$&N""4P_;[W!'U_*MS^R;C6H)+""0(\B8:0J.!W.*V+KP(T^E6MM%J:P7
M$,T<KS"V#*^PY VY& 2.: ..AU.>:2UWW=A:VTT\T O)L^4QC3=D$L..W?FN
MRT"?[5X!_MN&U2VOGM9)%,JF10RYPP!P=IQD=.#6GJOAMM2U?1[Q;N**#3G9
MC;&V5UEW#:>2>.,XP.O-:NH6C7FF7-G%*(&FB:-9-F[9D8SCO0!A0>+-/2RL
M8]1=WFE@@:YD2$F*)I -N\CA=QZ9K#UO4='CN+@PBXMS""[K);NJ2*'"%D)'
M(#$ _7/2M2#P,8D\E]5=[>>&&.^B\@ 7!BP%8'/R9  /7/M574/AY-?37=P=
M>F%U<P36K3M;AF\F1U;:>?X=N 1CCM0!A+J< ? ,HD#[=NP[@0-V<>F.:])T
MN\-]IL4^1O(PWU%>8WFB,UQ=I-=!R\N<^2!M(&W(YX/%=MX0\X6=U&\@95D'
ME\<@8[^M '-V'C[5&U..UN9=-FE;5&L&M8K>6)@H<KY@D9BO09V_AUKJI/&>
MBPSRQRS2HD:R,LQA;RY/+^^$;'S%<'('I6/%X"NVM6L+W7C/I\E^;^2)+18V
M9_,\S&_<<+N]!GWJW_PA3*DD*:HXMHVFDLHFA!^SO+NW'.?F W-@'&,]30!:
M@\:Z3<3QPHMX'>'[1\]LZA8>TK$C 3WJ*7QIHDD16:*[*EH\*]JWS)(=J2#(
M^X3QN]Z(?"3[XUN]1\^V&E_V;)$( F]>[9SP?:HXO!2MI\UM?:A)=R&R^PP3
MF)5:*($%3QPS A3GC[HXH Q-3OM*Q+<62W,<<-Q);7"R1$")T ))ST&&&#WS
M6?:>(+5+B"6VD=IMY"HJ$G(&2#CVKK7\$6LO]H>;>7#"^MXXY, #$J]9A_M-
MQGM\HKEKO19['48DFN06MW+'$(42 KC.,\<?K0!W%]XGL=.TV*^G2Y:)T9V\
MB%I/+51EF;'0#U-07_C/2M/O$MG6[F+.D9DM[9I$5G&Y5) X)'-<JVE_V\!I
M5QJ$EO93))&\07<KEUP#U&".H///:K*:!JT/B@/&DO[E8UBED@5X'V(%#G$@
MPW7&4)'8T ;,OQ!\/P:5#J<T\L=K/DPN\14RJ!EF4'DJ!UJ;_A.O#IU5-/&H
MQM,Z[E8<J3LWXSZ[?F^E4[?P0]MI^D1IJ8:[TU9(EG>U5EDC<@E2A.,\+@@]
MOPJU:^$18ZA=36U^RV]PQE:)X%9Q(5"DASSMX!VD=?RH U[+5(;^P^V0Q7&S
M9O"O$58C&1@'KD5@V7C_ $RYT>WU":VOK?S8VF:(P,S11 X,C8Z)[_7TK2\.
M^'T\/0744<^])YC*L:)LCB& ,(N2!TR<=22<"L:W\!O9PQ1V^LS)BV>RE)A4
M^9;LQ(7'9ADX;GJ>* .CU+6M/TG2_P"TKNX5;8[=K@_?+?= ]2>U8O\ PL+0
M6CMY(FNI4N(FDA:*W9A(5;:R+CJX/51S6CJWAZ#4=&M]/BE-M]D:-[9PH?8R
M?=RIX88X(/8UF:EX-GU.WCCDU<QO OF6TD=LH-O<;L^<G/IE0O3!/6@"T?''
MA]=6ETV2_2.XB1W??P!L&77/JHZBI(O%NGRSP0&"_CEGD:*-9;1URP3S,<CN
MH)'K@BJ$/@=/(OK:[OS/:WH=YD6!8W\QQ\[!QSM))8+V)ZXJY)X>U"YBL&NM
M:,MW8W(GBF%LH!&QD(9<\DACSGKCB@"K!X_TJ>9F,-U#8K9K=F\FB*1@,Q4
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M\5W,D"$7'[TLP."$QT! &21U]JS;;X@2/9175UI)A6XLVN(8UN S%UE6(HW
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MJ%M3CD?]V;K$9C55;=NVYR=X&,?C6EJ7A72=7N+B>\AE=[B%8)<3NH9 =P&
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M+9\--'-\LSJ5>,?*1@\8]!ZT <_K.LWVM^#;J_BM7M;&1$FM9X;K$C8E4 ,
M!MR.>">.#4^I>-[K2M/O[BXTZU1K"5TF#7F P"JPV?)DL0W3&!CK6O)X0T62
MSN;,V\@M;AMSPK.X0'=N^4 _+EN3BF-X*T*2[FNI+61YIM_F,\[G<&4*P//0
M@#\A0!1'C29M3: :7BU2]M[0S-.-S><BLCA<=/F&03FLR;Q]>26NH2-H:26L
M%B]RZ+=XD4!]AC?Y<(^,G&3T.,UT)\%Z+EF2"5&::*?B=\"2,8C.,]ACCVK.
MT_P0JV<UEJ,@>TEC,4L4$TH6<'NP)^4_3/7K0!/+XMN(-:FL6TO;;P:A!8M*
M9QN;S5!5PN.F6 ()S3= \67NN:T+7^S(H;4VS3M*+@L\9#[1&Z[<*W?&:L+X
M6T&]\ZX@9Y7>>.5I4NG8>=$-JD_-U7'3VYI/#OANXT>8O).@4 C9#)(5ESW*
ML<*?IGZT 8$FIZW?:MILTR1K-!K=Q;0PPW#+'*@@DP)..<$9S@U?A\;-/:-?
MIHTI==.6ZXE+9S(49<*"<*5)SC..U;,WAG1&OX[EHS'<"Y-TA6=E_>L-I8 '
MN./Q-,LO!FB6#*UO!,I2+RES<2'";MV!S_>)- #-4NO[9\$W5]9WSP,;>26&
MXLI<X*@X(..>1R"/8USO_"03V%T!K]W<QZAHUM++<Q6[[8[R(8V3!>^>A'8Y
M%=BWA_3FT5]($+I9R;MZ)(REBQ+,2P.2222>><TDFGZ/>7:P31V]Q=6UL82K
ML&D6%Q@AN^&V]^N* .;O_%VM0W=M8KIEK#=O=6H;=<%T:&8N."%&&!0@\>XS
M6CH'BNXUW4FC&D3PV#H[07C$[7VMM((('7J,$U=3PGHJ6@MA:;HP\;@M(Q8%
M/N?,3G"Y.!TY-6;#0M-TRXDFL[<1-(S-M#$JI8Y;:,X7)Y..M '%6VJW8\47
M]U=6B27W]J-IVGJMY(J8\K<0XQM V@MG!.>*V].\6WNI:I;:>FD"*1O.%R\E
MP-L;12;'5<+ENN0>*O?\(?HN+O-O(QNK@74C-.Y(E'1U.?E;W&.*LV_A[3;6
M]M[N"%HYK>-HD(D;&&.YLC."2>23SF@#,OO%-W::O=VBZ4&M[66V229IP"RS
M';E5 /0]B16:WCS4);6^O++P_++901R2Q7$DA19!&V''W>N Q &?N]JWKSPG
MI%_=75S<0S&6Z:-IBL[KN,9RG /&#5BUT#3+*>>:"V"F<LSKN)7+?>(4\ GO
MCK0!EV7BFYOM:N--BLX2T4T11_..)('0L9!\O8C;CIGO3;[Q9<V6J7EN=+'V
M6SN((I9VG&667HRJ >A[$BM>RT'3-/FMYK6T6.2WM_LT3 DE8\YV_GS5.\\,
M:)=WMQ-<J_GW4D4L@^TNN]H_N'&>WM0!SVH^/-1&@RWEKID47VK3IKW3IGFW
M@B, D2+M^4[2"!R.V:U+;Q;>SZ\NFC1I9(HI1;7=U$Q*12E W< %>5'7//2M
M"'PEH<$-S#'8J(KB-XGC+,5".<LJC/R@GGC%*-#T33[V.ZV)!/(5B4M*0)7
MPI()PSCL>M #_$6N#0=.CN!;/<S33I;PQ)_$[' Z G'7L:YV?QOJ]LVGI/X?
M6W>_)AA6:YVXG# ;6^7Y5*Y8,?88R1743:)9W>D_V;>A[J#(.97)8$'((;J"
M#T.<U4N?".C7=O/!<6\DD<\(AD!F?)4-OSG/7=R3U- &2?'4BWM]NT:Y.G6;
M3127BGCS(QR,$8P3D#G/J!5\Z[JT-QI\5WI,$7VV<Q*R76_ \LN#]T=P0?S&
M:N1>&-(BFFE%H&,ZD2J[LRN2NTL5)P6(X)ZFFCPMI(M(;8PRM'!(LL6Z=RT9
M4$#!SD  D8Z8- '*/XXU1TO+N;2X)+"+2ENGMX[@A]WFNC?-MZ80G\*V7\77
M$.LRV1TK;;P7\-BTIN!N/FHK(X7'3YAD$YJT_@?PZUJ]LNGB.&2$PNL<C+N0
MMN(.#ZD_F:=)X.T>2224QS>:\\=P6-PY_>1C"-U[#'Y4 4_#_BR\US6C:'38
MH+?[.9RXG+/&0^WRW7: K\9QFNKKD-"TF+PY?00W>I6T,LH,<<"7##[0?78Q
MZC'09Z]:Z^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[%;%Y5V",1+\X'0'CH* .,D\6:[;?:!=:GIGFVMM;S&*",D2L9&5QDGH0,C
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M]IZ7]UIRWMNM];PB62.1]H0-]TDU)=76ESJ]E=7-JV[(>)I1GCD@C/:@#/\
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M8B983>6XE=@JIYHR21D#'N*RW\11-XN@T&...42VTLSRK*#L9&4%"O\ P(4
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M^W5!*T^R4R,K.JC@L.?NY[=JE/BG5+:_U32KU+6*Y3<=.NMK>5.5179&&>'
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M,<D^O-=9XG\//=>#O[#T:SMEC#1*D+ML18T=6(Z'LN/QJGX:)&L*/5&S79T
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M#2D9V@XP:O#4;1K:6Y$ZB&)F1W/ # X(_/BN8U719X[75(6>6634KI)K-[:
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M<IY;<EXQ& G/&  3GK46G^$[ZPM-(*WEL;S39YW!\MA'(DN[((SG(R.?;WH
MV9/$VBPAB^H1;52.0L,D;9#A#D#&">*EFUW3+<.9KQ$".8V+ _*1C.?89&3T
MYKGIO $$MC9VGVMQ%':R6UP-O^N#-O7Z!7^8?E4EQX1NV?39H[NTN9H;=K:[
M^W6_F+.&(9I ,\/D>XYP: -23Q!#<7'V;2&AO;F*=4N(@Y7RTR QSC!(R#CO
M4.H:Y?:;X6?5;FRACN(W DA:4[0I?;D''H<\BI] TB?23J7GRPR"ZO'N$\M"
MNT, ,')]JGU_2VUG1;BP258GDVE79<@$,",CTXH 8OB31WLFNUOXC LC1LPS
M\K+]X$=1@<GVYJ;^VM-%TEM]MA\UQE1NX/R[NO3.WG'IS7-W?@R[EU+^UH;B
MR:]DF9YX+BW+V[JT:I@+G.0$!SWYJ>/PG=QR:I9_;H?[*U#+LBPXEBD,0C.P
MYP%P >F1TZ4 :[>)-'2&29]0B6.-D5BV1@O]S\#V/0T6_B71KJ:.*'4(6>0.
M5!R/N?>'/0CN#S6!/X,OKF"!Y+VW-W$EI!N\IMC1P2%\D9^\2?H*CN/ ][>+
M+%-?6RQ375W.YCC;<%G0K@<]1GKWH Z8>(-*,,DHO$*QML< '<IQNY7&>G/3
MI5FXO[6U@2>:8+&^-A )+=^ .3QZ5RK^#[^ZTJ.WN9M.CND;=]IL[=H65@NU
M9 0V=W7(.00<8K9U'1KFZDTBZANU%YISEMTB?++N0HV0.F0<C'2@"F_C/3X-
M>^R7%S;1V,EI'<077F$AR[E<'C ' YSWJ:+Q$[7EQ!-]F@\K4ELD+NW[T%0W
M''WN>G3CK61_P@+1PS6T-W$+>ZLFM+@-&25W2-(S)S@<N< ],"K,OA6_>\:5
M;NV\O^UHK]08V+;$0+M)SU..M &VWB'2$N&@:_B$BHSD9/W5."<]\'CZ\5'_
M ,)/I)N[.V2YWR7;2+&54X!C^_N./EQQUKC-)TG5IS<06\"VDC),D<LUM*IM
M TGF;/F^5@QX)0DCJ"*U+;P/=12JTE[#M-Q=.X1&^Y.@# $DG<".": .E37M
M+DCD=+V(A&56'.<M]W ZG/;'6J6C^)8;SPP-;OC':PB25'()95"2M&#G&>=H
M/3O6+!X,U.&PL +O35O=.GB>"2.T*+.B*5Q+SDDACR.AZ5H0^%[D>"+S0)[N
M+SIS.5FCC.U3([..">Q;'7M0!J3^(](MI'CFOHT=)O(92#GS-N[;C')V\U1U
MSQ;9Z;X?;4K.6"Z9HEFA3<<.A8#.0#@<]^]9Z>%=6.K+J$UY9%SJ"WSJL3
MB Q;1S[YS69'\/M6@TMK2'5+,^?9):3[X&(&R1G5D^;C[Q!!]C0!V<^OZ5:/
M*ES?0Q-"A>3<>%  +<^V1GTJU97UMJ-L+BTE$L)) < X./K7(2^"KUK;6+5+
MG3VBO1,T$LEL3-$TH^92V>5'..AZ"NPLXG@LH(9"I>.-58H, D#M0!/1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP1QUH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP8+EC@<\$_3\*LT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,FD\F"238\FQ2VQ
M!EFQV'O7.:;XT@U6UBNK31M9:WF1FBD-L 'P#Q][@\$#.*Z*=F2WD98VD8*2
M$7&6/H,X'YUY_P""]-U'0;&S1_#>H1WRQNMS+)>(\6TL7PB^:1N. !@*.>:
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M3VX@%I<F!07RS@ '<1V!SQZBM.@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@-)_A1_PDFG?WKC_P !I/\ "@#6HK)_X233O[UQ_P" TG^%'_"2:=_>N/\
MP&D_PH UJ*R?^$DT[^]<?^ TG^%'_"2:=_>N/_ :3_"@#6HK)_X233O[UQ_X
M#2?X4?\ "2:=_>N/_ :3_"@#6HK)_P"$DT[^]<?^ TG^%'_"2:=_>N/_  &D
M_P * -:BLG_A)-._O7'_ (#2?X4?\))IW]ZX_P# :3_"@#6HK)_X233O[UQ_
MX#2?X4?\))IW]ZX_\!I/\* -:BLG_A)-._O7'_@-)_A1_P ))IW]ZX_\!I/\
M* -:BLI?$6G,P4-/DG _T=_\*U: "BBB@ HHHH **** "BBB@ HHHH ****
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M#R.Q=B!V&2<#TK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!LCB.-G;.%&3M4D_D.:I_VM:_W;K_
M ,!9?_B:-::5-#OI()FAE2!W210"5(!(//TKC(M5UK2M'\+ZS+J;WL6IM:PW
M5K+&N2TR_>C( (()Z="* .S_ +6M?[MU_P" LO\ \31_:UK_ ';K_P !9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>ndrau-20200331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: Source; Value: 200644 03312020 10Q1.xfr; Date: 2020%2D05%2D13T17:42:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8008000C -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:NDRAU="http://endrainc.com/20200331">
    <link:schemaRef xlink:href="ndrau-20200331.xsd" xlink:type="simple" />
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember8019421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember8019421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember8019484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember8019484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_StockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NDRAU:StockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_custom_StockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NDRAU:StockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NDRAU:StockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_StockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NDRAU:StockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_StockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NDRAU:StockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NDRAU:StockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_ConvertibleNotesPayableConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NDRAU:ConvertibleNotesPayableConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_ConvertibleNotesPayableConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NDRAU:ConvertibleNotesPayableConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_SeriesAPreferredStockConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NDRAU:SeriesAPreferredStockConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_SeriesAPreferredStockConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NDRAU:SeriesAPreferredStockConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_SeriesBPreferredStockConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NDRAU:SeriesBPreferredStockConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_SeriesBPreferredStockConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NDRAU:SeriesBPreferredStockConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PropertyLeaseholdAndCapitalizedSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">NDRAU:PropertyLeaseholdAndCapitalizedSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_PropertyLeaseholdAndCapitalizedSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">NDRAU:PropertyLeaseholdAndCapitalizedSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_TAEUSDevelopmentAndTestingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">NDRAU:TAEUSDevelopmentAndTestingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_TAEUSDevelopmentAndTestingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">NDRAU:TAEUSDevelopmentAndTestingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="UsdPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-03-31">ENDRA Life Sciences Inc.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2020-01-01to2020-03-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-03-31">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0001681682</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2020-01-01to2020-03-31">false</dei:EntityExTransitionPeriod>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-03-31">false</dei:EntityShellCompany>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-03-31">001-37969</dei:EntityFileNumber>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-05-14" unitRef="Shares" decimals="INF">14504764</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">6535099</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">3772868</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">130701</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">121951</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">113442</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">174935</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">116749</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">373254</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:Cash contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">6174207</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">6471375</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">3102728</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">3925474</us-gaap:Cash>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7176269</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4398887</us-gaap:Assets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">404919</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">389004</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">236251</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">237015</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2072787</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1551045</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">66193</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">68608</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">298069</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">38402</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1708525</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1444035</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">342812</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">325804</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">342812</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">325804</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2415599</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1876849</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7176269</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4398887</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">4760670</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">6248208</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">2522038</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">3801740</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">842</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">49933736</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">50982080</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">33939162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">34241430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-45217437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-48540234</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-27691696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-30440432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember8019421" unitRef="USD" decimals="0">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember8019421" unitRef="USD" decimals="0">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember8019484" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember8019484" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_StockPayableMember" unitRef="USD" decimals="0">43528</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_custom_StockPayableMember" unitRef="USD" decimals="0">78836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_custom_StockPayableMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_custom_StockPayableMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-45217437</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-48540234</us-gaap:RetainedEarningsAccumulatedDeficit>
    <NDRAU:StockPayable contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-43528</NDRAU:StockPayable>
    <NDRAU:StockPayable contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-78836</NDRAU:StockPayable>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">49933736</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">50982080</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">842</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1355</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="UsdPerShare" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="UsdPerShare" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="UsdPerShare" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="UsdPerShare" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">2441.92</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">2441.92</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">121.58</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">121.58</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">2441.92</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">2441.92</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">121.58</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">121.58</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="UsdPerShare" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="UsdPerShare" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">8421401</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">13553005</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">8421401</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">13553005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-3100846</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-2747219</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">3100846</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">2747219</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1467745</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">916903</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">114955</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">56818</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1518146</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">1773498</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-221951</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-1517</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">6617</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-1517</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">228568</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-3322797</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-2748736</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-3322797</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-2748736</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-3322797</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2748736</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_custom_StockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_custom_StockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">-.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-03-31" unitRef="UsdPerShare" decimals="INF">-.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">11508843</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-03-31" unitRef="Shares" decimals="INF">7422642</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8421401</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">13553005</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7422642</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7422642</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember8019421" unitRef="Shares" decimals="INF">6338.490</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_SeriesAPreferredStockMember8019421" unitRef="Shares" decimals="INF">2441.920</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember8019484" unitRef="Shares" decimals="INF">351.711</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember8019484" unitRef="Shares" decimals="INF">121.578</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">511080</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">302268</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">511080</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">302268</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4520982</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">-3896.570</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">452</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-37471</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2020-01-01to2020-03-31_custom_StockPayableMember" unitRef="USD" decimals="0">-37923</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">234080</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">-230.133</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">23</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">811</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-03-31_custom_StockPayableMember" unitRef="USD" decimals="0">-835</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">331441</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">493847</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">33</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">493814</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <NDRAU:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45101</NDRAU:StockIssuedDuringPeriodSharesWarrantsExercised>
    <NDRAU:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">39238</NDRAU:StockIssuedDuringPeriodValueWarrantsExercised>
    <NDRAU:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5</NDRAU:StockIssuedDuringPeriodValueWarrantsExercised>
    <NDRAU:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">39233</NDRAU:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">15915</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">511080</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">302268</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">21586</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">19632</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-3088367</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-2540662</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-258878</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-139349</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-8750</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">61493</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">14831</us-gaap:IncreaseDecreaseInInventories>
    <NDRAU:IncreaseDecreaseInLeaseLiability contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-14593</NDRAU:IncreaseDecreaseInLeaseLiability>
    <NDRAU:IncreaseDecreaseInLeaseLiability contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</NDRAU:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">256505</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-40354</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-22350</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-5239</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">22350</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">5239</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">39238</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">39238</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-3071479</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-2545901</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:IncomeTaxesPaid contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1920</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">394412</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">34066</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfDividendsCommonStock>
    <NDRAU:ConversionOfSeriesBConvertiblePreferredStock contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-23</NDRAU:ConversionOfSeriesBConvertiblePreferredStock>
    <NDRAU:ConversionOfSeriesBConvertiblePreferredStock contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</NDRAU:ConversionOfSeriesBConvertiblePreferredStock>
    <NDRAU:ConversionOfSeriesAConvertiblePreferredStock contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-452</NDRAU:ConversionOfSeriesAConvertiblePreferredStock>
    <NDRAU:ConversionOfSeriesAConvertiblePreferredStock contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</NDRAU:ConversionOfSeriesAConvertiblePreferredStock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">493814</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NatureOfOperations contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ENDRA Life Sciences Inc. (&amp;#8220;ENDRA&amp;#8221;&#13;or the &amp;#8220;Company&amp;#8221;) has developed and is continuing to develop technology for increasing the capabilities of clinical&#13;diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions&#13;in circumstances where expensive X-ray computed tomography (&amp;#8220;CT&amp;#8221;) and magnetic resonance imaging (&amp;#8220;MRI&amp;#8221;)&#13;technology is unavailable or impractical.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ENDRA was incorporated on July 18, 2007 as a&#13;Delaware corporation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ENDRA Life Sciences Canada Inc. was organized&#13;under the laws of Ontario, Canada on July 6, 2017, and is wholly owned by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the financial statements&#13;in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial&#13;statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management makes estimates that affect certain&#13;accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments&#13;or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&lt;u&gt;Principles&#13;of Consolidation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&amp;#8217;s&#13;consolidated financial statements include all accounts of the Company and its consolidated subsidiary and/or entities as of reporting&#13;period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&lt;u&gt;Basis&#13;of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The accompanying&#13;unaudited condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations&#13;of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Accordingly, certain information and footnote disclosures normally&#13;included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant&#13;to such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered&#13;necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily&#13;indicative of the results that may be expected for the year ended December 31, 2020. The balance sheet at December 31, 2019 has&#13;been derived from the audited financial statements at that date. For further information, refer to the financial statements and&#13;footnotes thereto included in ENDRA Life Sciences Inc. annual financial statements for the twelve months ended December 31, 2019&#13;included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC on March 26, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&lt;u&gt;Cash&#13;and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&#13;considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid&#13;investments with maturities of one year or less, when purchased, to be cash. As of March 31, 2020 and December 31, 2019, the Company&#13;had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured&#13;limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial&#13;institutions and has determined the credit exposure to be negligible.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;u&gt;Inventory&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&amp;#8217;s&#13;inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average&#13;cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation&#13;or obsolescence of inventory.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&lt;u&gt;Capitalization&#13;of Fixed Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&#13;capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one&#13;year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3)&#13;all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less&#13;than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed&#13;as incurred.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the Financial Accounting Standards&#13;Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-09, &amp;#8220;Revenue from Contracts with&#13;Customers&amp;#8221; (&amp;#8220;ASC Topic 606&amp;#8221;). This standard provides a single set of guidelines for revenue recognition to be&#13;used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its&#13;core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects&#13;the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated&#13;guidance effective January 1, 2018 using the full retrospective method. The new standard did not have a material impact on its&#13;financial position and results of operations, as it did not change the manner or timing of recognizing revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under ASC Topic 606, in order to recognize revenue,&#13;the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of&#13;each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that&#13;the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of&#13;ASC Topic 606 did not have an impact on the Company&amp;#8217;s operations or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows FASB Accounting Standards&#13;Codification (&amp;#8220;ASC&amp;#8221;) Subtopic 730-10, &amp;#8220;Research and Development&amp;#8221;. Research and development costs are charged&#13;to the statement of operations as incurred. During the three months ended March 31, 2020 and 2019, the Company incurred $1,518,146&#13;and $1,773,498 of expenses related to research and development costs, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Net Earnings (Loss) Per Common Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes earnings per share under&#13;ASC Subtopic 260-10, &amp;#8220;Earnings Per Share&amp;#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss)&#13;attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the&#13;denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average&#13;number of additional shares that could have been outstanding from securities convertible into common stock (using the &amp;#8220;treasury&#13;stock&amp;#8221; method), unless their effect on net loss per share is anti-dilutive. There were 19,992,774&amp;#160;and 24,949,725 potentially&#13;dilutive shares, which include shares of common stock issuable upon the exercise or conversion of outstanding preferred stock,&#13;stock options, warrants, and convertible notes, as of March 31, 2020 and&amp;#160;December 31, 2019,&amp;#160;respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The potentially dilutive shares, which are excluded&#13;from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,579,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,449,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,496,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,603&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;362,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of Series A Preferred Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,806,805&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,285,651&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of Series B Preferred&amp;#160;Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;122,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;355,263&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Potentially dilutive shares excluded&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;19,992,774&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;24,949,725&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Disclosures&#13;about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance&#13;sheet, where it is practicable to estimate that value.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In accordance&#13;with ASC Topic 820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; the Company measures certain financial instruments at&#13;fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance&#13;with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Fair value&#13;is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between&#13;market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the&#13;inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for&#13;identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These&#13;tiers include:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; &lt;font style="background-color: white"&gt;Level 1, defined as&#13;observable inputs such as quoted prices for identical instruments in active markets;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; &lt;font style="background-color: white"&gt;Level 2, defined as&#13;inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar&#13;instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; &lt;font style="background-color: white"&gt;Level 3, defined as&#13;unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such&#13;as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial assets are considered Level 3 when&#13;their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one&#13;significant model assumption or input is unobservable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of the Company&amp;#8217;s&#13;financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and&#13;other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of&#13;notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations&#13;are the same as prevailing market rates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Share-based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s 2016 Omnibus Incentive Plan&#13;(the &amp;#8220;Omnibus Plan&amp;#8221;) permits the grant of stock options and other share-based awards to its employees, consultants&#13;and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus&#13;Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number&#13;of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming&#13;the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding&#13;options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined&#13;by the board. On January 1, 2020, the pool of shares issuable under the Omnibus Plan automatically increased by 3,202,280 shares&#13;from 2,649,378 shares to 5,861,658. As of March 31, 2020, there were 2,281,921 shares of common stock remaining available for issuance&#13;under the Omnibus Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company records share-based compensation&#13;in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use&#13;of option-pricing models that require the input of highly subjective assumptions, including the option&amp;#8217;s expected life and&#13;the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes&#13;option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock compensation expense recognized during&#13;the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures.&#13;The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable,&#13;in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan&#13;as described above.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;u&gt;Debt Discount&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines if its outstanding convertible&#13;promissory notes should be accounted for as liability or equity under ASC Topic 480, &amp;#8220;Liabilities &amp;#8212; Distinguishing&#13;Liabilities from Equity.&amp;#8221; ASC Topic 480 applies to certain contracts involving a company&amp;#8217;s own equity, and requires&#13;that issuers classify the following freestanding financial instruments as liabilities: mandatorily redeemable financial instruments,&#13;obligations that require or may require repurchase of the issuer&amp;#8217;s equity shares by transferring assets (e.g., written put&#13;options and forward purchase contracts), and certain obligations where at inception the monetary value of the obligation is based&#13;solely or predominantly on:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; A fixed monetary amount known at inception (for example,&#13;a payable settleable with a variable number of the issuer&amp;#8217;s equity shares with an issuance date fair value equal to a fixed&#13;dollar amount);&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#9679; Variations in something other than the&#13;fair value of the issuer&amp;#8217;s equity shares (for example, a financial instrument indexed to the S&amp;#38;P 500 and settleable with&#13;a variable number of the issuer&amp;#8217;s equity shares); or&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#9679; Variations inversely related to changes&#13;in the fair value of the issuer&amp;#8217;s equity shares (for example, a written put that could be net share settled).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Beneficial Conversion Feature&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the conversion feature of conventional convertible&#13;debt provides for a rate of conversion that is below market value on the date of issuance, this feature is characterized as a beneficial&#13;conversion feature (&amp;#8220;BCF&amp;#8221;). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 &amp;#8220;Debt&#13;with Conversion and Other Options.&amp;#8221; In those circumstances, the convertible debt is recorded net of the discount related&#13;to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the Company determines the instrument meets&#13;the guidance under ASC Topic 480, the instrument is accounted for as a liability with a respective debt discount. The Company has&#13;previously recorded debt discounts in connection with raising funds through the issuance of promissory notes. These costs are amortized&#13;to noncash interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of&#13;the unamortized amounts is immediately expensed. See Note 6, Convertible Notes, for further discussion on the Company&amp;#8217;s accounting&#13;treatment for the convertible notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Going Concern&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial statements are&#13;prepared using accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) applicable to a going concern,&#13;which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited&#13;commercial experience and had a cumulative net loss from inception to March 31, 2020 of $48,540,234. The Company had working capital&#13;of $2,221,823 as of March 31, 2020. The Company has not established an ongoing source of revenue sufficient to cover its operating&#13;costs and to allow it to continue as a going concern. The accompanying financial statements for the period ended March 31, 2020&#13;have been prepared assuming the Company will continue as a going concern. The Company&amp;#8217;s cash resources will likely be insufficient&#13;to meet its anticipated needs during the next twelve months. The Company will require additional financing to fund its future planned&#13;operations, including research and development and commercialization of its products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The ability of the Company to continue as a going concern is dependent&#13;on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable.&#13;Management&amp;#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and&#13;borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.&#13;As described further below under &amp;#8220;Item 2. Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of&#13;Operations&amp;#8221; the COVID-19 pandemic has impacted our business operations to some extent and is expected to continue to do so&#13;and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. If the&#13;Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce&#13;the scope of or eliminate one or more of the Company&amp;#8217;s research and development activities or commercialization efforts or&#13;perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its&#13;ability to successfully secure other sources of financing and attain profitable operations. There is substantial doubt about the&#13;ability of the Company to continue as a going concern for one year from the issuance of the accompanying consolidated financial&#13;statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company&#13;is unable to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In May&#13;2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers.&amp;#8221; ASU 2014-09 is a comprehensive revenue&#13;recognition standard that superseded nearly all previous revenue recognition guidance under U.S. GAAP and replaced it with a principle-based&#13;approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised&#13;goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange&#13;for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue&#13;and cash flows arising from contracts with customers. The FASB has since issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12,&#13;and ASU 2016-20, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim&#13;and annual periods beginning after December 15, 2017. The standard can be adopted either retrospectively to each prior reporting&#13;period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance&#13;recognized at the date of initial application (the cumulative catch-up transition method). The Company has reviewed ASU 2014-09&#13;and using the full retrospective method has determined that its adoption has had no impact on its financial position, results of&#13;operations or cash flows. The Company adopted the provisions of this standard in the first quarter of fiscal 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU No. 2016-02,&#13;&amp;#8220;Leases.&amp;#8221; ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance&#13;sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning&#13;after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for&#13;capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial&#13;statements. The Company evaluated the impact that the application of the new standard has on its consolidated financial statements&#13;and related disclosures, and determined that it should record a total lease liability of $431,363, with a corresponding right of&#13;use asset valued at $430,681. The Company adopted the provisions of this standard in the first quarter of fiscal 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other recent accounting pronouncements issued&#13;by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did&#13;not or in management&amp;#8217;s opinion will not have a material impact on the Company&amp;#8217;s present or future consolidated financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020 and&amp;#160;December 31, 2019,&#13;inventory consisted of raw materials and subassemblies to be used in the assembly of a TAEUS system. As of March 31, 2020, the&#13;Company had no orders pending for the sale of a TAEUS system. &lt;font style="background-color: white"&gt;As of March 31, 2020 and December&#13;31, 2019, the Company had&amp;#160;inventory valued at $174,935 and $113,442, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020 and December 31, 2019,&#13;fixed assets consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Property, leasehold and capitalized software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;684,418&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;679,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;TAEUS development and testing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;60,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;43,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(508,111&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(486,524&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fixed assets, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;237,015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;236,251&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense for the three months ended&#13;March 31, 2020 and 2019 was $21,586 and $19,632, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;As of March 31, 2020 and December 31, 2019, current liabilities consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,240,687&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,278,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued payroll&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;95,656&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;94,862&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued bonuses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;97,114&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;295,794&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued employee benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,828&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,738&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Insurance premium financing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,950&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;1,444,035&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;1,708,525&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;July 2019 Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 26, 2019 the Company conducted a private&#13;placement offering in which the Company sold senior secured convertible promissory notes (the &amp;#8220;July 2019 Notes&amp;#8221;) and&#13;warrants exercisable for shares of the Company&amp;#8217;s common stock (the &amp;#8220;July 2019 Warrants&amp;#8221;) to accredited investors&#13;for a purchase price approximately $2.8 million. The purchase price covered the purchase of $2,587,895 aggregate principal amount&#13;of July 2019 Notes and July 2019 Warrants exercisable for an aggregate of 1,736,843 shares of common stock. The net proceeds to&#13;the Company were approximately $2.5 million, after deducting placement agent fees and other offering expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company sold the July 2019 Notes and July&#13;2019 Warrants pursuant to a Securities Purchase Agreement, dated July 26, 2019, between the Company and each purchaser. The July&#13;2019 Notes bore interest at a rate of 10% per annum until maturity on April 26, 2020. Interest was paid in arrears on the outstanding&#13;principal amount on the three month anniversary of the issuance of the July 2019 Notes, and each three month period thereafter,&#13;and finally on the maturity date. Holders of July 2019 Notes were entitled to convert principal and accrued, unpaid interest on&#13;the July 2019 Notes into shares of common stock. The July 2019 Notes were convertible into common stock at a conversion price per&#13;share equal to $1.49 and were initially convertible into 1,736,843 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each July 2019 Warrant entitles the holder to&#13;purchase one share of common stock for an exercise price per share equal to $1.49. The July 2019 Warrants are exercisable for an&#13;aggregate of 1,736,843 shares of common stock commencing immediately upon issuance and expire July 26, 2022. The July 2019 Warrants&#13;provide for cashless exercise and customary anti-dilution protection. The terms of the Placement Agent Warrant (as defined below)&#13;are the same as those of the July 2019 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;National Securities Corporation (the &amp;#8220;Placement&#13;Agent&amp;#8221;) acted as placement agent in the offering pursuant to a Placement Agent Agreement, dated July 9, 2019 (the &amp;#8220;Placement&#13;Agent Agreement&amp;#8221;). Pursuant to the Placement Agent Agreement, the Company paid to the Placement Agent a commission of 10%&#13;of the gross proceeds from the offering, reimbursed $30,000 of the Placement Agent&amp;#8217;s expenses and issued to the Placement&#13;Agent a warrant exercisable for 173,685 shares of common stock (the &amp;#8220;Placement Agent Warrant&amp;#8221;).&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The July 2019 Notes and July 2019 Warrants include&#13;embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815-40, &amp;#8220;Derivatives and&#13;Hedging.&amp;#8221; The estimated fair value of the derivative warrant instruments was calculated using a Black-Scholes valuation model.&#13;At inception, the aggregate relative fair value of the 1,910,538 warrants issued to the investors and the Placement Agent in July&#13;2019 was determined to be $1,993,714 using the Black-Scholes-Merton Option Pricing model with the following average assumptions:&#13;(i) volatility rate of 111%, (ii) discount rate of 0%, (iii) zero expected dividend yield, and (iv) expected life of three years.&#13;Out of such amount, $1,126,138 was recorded as debt discount upon issuance using allocation of proceeds.&amp;#160;&lt;font style="background-color: white"&gt;At&#13;the issuance of the July 2019 Notes, the effective conversion price was analyzed at $0.84 per share of common stock and the market&#13;price of the shares on the date of conversion was $1.54 per share. As a result, the Company recognized aggregate beneficial conversion&#13;features of $1,440,638.&lt;/font&gt;&amp;#160;$1,147,257 was recorded as debt discount upon issuance of the July 2019 Notes using allocation&#13;of proceeds.&amp;#160;&lt;font style="background-color: white"&gt;As a result, the Company recorded a note discount of $2,587,895 to account&#13;for the funding cost of $314,500 and the relative fair values of the warrants&amp;#8217; and the notes&amp;#8217; beneficial conversion&#13;features, which will be amortized as interest over the terms of the warrants and the notes or in full upon exercise of the warrants&#13;and conversion of the notes.&lt;/font&gt;&amp;#160;During the three months ended March 31, 2020, the Company amortized $228,568 of such discount&#13;to interest expense, and the unamortized discount as of March 31, 2020 was $3,858.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 11, 2019, the Company completed&#13;an offering of its Series A Convertible Preferred Stock (&amp;#8220;Series A Preferred Stock&amp;#8221;), described below under Note 7.&#13;In connection with the offering, the Company retired $1,919,008 aggregate principal amount of the July 2019 Notes and $24,184 in&#13;accrued interest, which amounts were used by the noteholders to purchase an aggregate of 1,690.58 shares of Series A Preferred&#13;Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, the Company had a total&#13;of $42,260 in principal amount of July 2019 Notes outstanding, and unamortized debt discount of $3,858, for a net balance of $38,402&#13;amount of the July 2019 Notes remaining outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2020, the authorized capital of&#13;the Company consisted of 60,000,000 shares of capital stock, consisting of 50,000,000 shares of common stock with a par value of&#13;$0.0001 per share and 10,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company has designated 10,000&#13;shares of its preferred stock as Series A Preferred Stock and 1,000 shares of its preferred stock as Series B Preferred Stock,&#13;and the remainder of 9,989,000 shares remain authorized but undesignated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, there were 13,553,005&#13;shares of common stock, 2,441.92 shares of Series A Preferred Stock, and 121.578 shares of Series B Preferred Stock issued and&#13;outstanding, and a stock payable balance of $78,836.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2020,&#13;the Company issued 4,520,982 shares of its common stock upon the conversion of 3,896.570 shares of its Series A Preferred Stock,&#13;and 234,080 shares of its common stock upon the conversion of 230.133 shares of its Series B Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2020,&#13;the Company issued 331,441 shares of its common stock upon the conversion of $493,847 principal amount of, and in respect of accrued&#13;interest on, July 2019 Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2020,&#13;the Company issued 45,101 shares of its common stock upon warrant exercises valued at $39,238.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;December 2019 Offering of Series A Preferred Stoc&lt;/i&gt;&lt;/b&gt;&lt;i&gt;k&lt;b&gt;,&#13;Common Stock and Warrants&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 11, 2019, the Company completed&#13;a private placement offering in which the Company sold 6,338.49 shares of its Series A Preferred Stock and 904,526 shares of its&#13;common stock, along with warrants (the &amp;#8220;December 11, 2019 Warrants&amp;#8221;) exercisable for an aggregate of 8,190,225 shares&#13;of common stock, for approximately $7.9 million of gross proceeds. The offering was made pursuant to a Securities Purchase Agreement&#13;(the &amp;#8220;Purchase Agreement&amp;#8221;), dated as of December 5, 2019, between the Company and the investors. Pursuant to the Purchase&#13;Agreement, each investor elected whether to receive shares of Series A Preferred Stock or shares of common stock in the offering.&#13;The Company used approximately $1.9 million of the net proceeds from the offering to repay debt represented by July 2019 Notes&#13;and plans to use the remaining net proceeds for working capital and general corporate purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the closing of the offering,&#13;the Company filed a Certificate of Designations of Series A Convertible Preferred Stock (the &amp;#8220;Series A Certificate of Designations&amp;#8221;)&#13;with the Secretary of State of the State of Delaware setting forth the rights and preferences of the Series A Preferred Stock.&#13;Each share of Series A Preferred Stock has a $1,000 issue price (the &amp;#8220;Issue Price&amp;#8221;). Dividends accrue on the Issue&#13;Price at a rate of 6.0% per annum and are payable to holders of Series A Preferred Stock as, when and if declared by the Company&amp;#8217;s&#13;Board of Directors. Shares of Series A Preferred Stock, including accrued but unpaid dividends, are convertible into common stock&#13;at a conversion price of $0.87 per share. The conversion price is subject to proportional adjustment for certain transactions relating&#13;to the Company&amp;#8217;s capital stock, including stock splits, stock dividends and similar transactions. Holders of shares of Series&#13;A Preferred Stock vote with the holders of common stock and are entitled to a number of votes equal to the number of shares of&#13;common stock into which such holder&amp;#8217;s shares of Series A Preferred Stock are then convertible. Holders of Series A Preferred&#13;Stock are entitled to a liquidation preference in the event of any liquidation, dissolution or winding up of the Company based&#13;on their shares&amp;#8217; aggregate Issue Price and accrued and unpaid dividends thereon. Holders may convert their shares of Series&#13;A Preferred Stock into common stock at any time and the Company has the right to cause each holder to convert their shares of Series&#13;A Preferred Stock if at any time (i) the simple average of the daily volume-weighted average price of Common Stock for 10 consecutive&#13;trading days is greater than $1.74 (as adjusted for stock splits, stock dividends and similar transactions) and (ii) there is then&#13;an effective registration statement registering under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;),&#13;the resale of the shares of common stock issuable upon such conversion of Series A Preferred Stock (the &amp;#8220;Series A Forced&#13;Conversion Conditions&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The simple average of the Daily VWAP (as defined&#13;in the Series A Certificate of Designations) for the 10 consecutive trading days from January 8, 2020 to January 22, 2020, inclusive,&#13;was $1.82, satisfying the first Forced Conversion Condition. On January 27, 2020, the SEC declared effective the Company&amp;#8217;s&#13;Registration Statement on Form S-3 (File No. 333-235883) registering under the Securities Act the resale of the shares of common&#13;stock issuable upon the conversion of Series A Preferred Stock, shares of common stock issued in the offering, and shares of common&#13;stock issuable upon the exercise of December 11, 2019 Warrants and December 11, 2019 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each December 11, 2019 Warrant entitles the&#13;holder to purchase a share of common stock for an exercise price equal to $0.87. The December 11, 2019 Warrants are exercisable&#13;commencing immediately upon issuance and expire on the date five years after the date of issuance, unless earlier terminated pursuant&#13;to the terms of the December 11, 2019 Warrant. If, during the term of the December 11, 2019 Warrants, the Series A Forced Conversion&#13;Conditions are met, the Company may deliver notice thereof to the holders of the December 11, 2019 Warrants and, after a 30-day&#13;period following such notice, any unexercised December 11, 2019 Warrants will be forfeited. The December 11, 2019 Warrants provide&#13;for cashless exercise only if there is no effective registration statement registering under the Securities Act the resale of the&#13;shares of Common Stock issuable upon exercise of the December 11, 2019 Warrants. As described in the preceding paragraph, the Series&#13;A Forced Conversion Conditions have been met with respect to the December 11, 2019 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Securities Purchase Agreement, dated December&#13;5, 2019, includes customary representations, warranties and covenants. In connection with the offering, the Company paid to the&#13;placement agent a commission of 8.0% of the gross proceeds from the offering, will reimburse up to $35,000 of the placement agent&amp;#8217;s&#13;documented expenses and issued to the placement agent and its designees warrants exercisable for an aggregate of 327,606 shares&#13;of Common Stock (the &amp;#8220;Series A Placement Agent Warrant&amp;#8221;). The terms of the Series A Placement Agent Warrant are the&#13;same as those of the December 11, 2019 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series A Preferred Stock Deemed Dividend,&#13;Beneficial Conversion Calculation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;After factoring in the relative fair value of&#13;the warrants issued in conjunction with the Series A Preferred Stock, the effective conversion price is $0.45 per share, compared&#13;to the market price of $0.90 per share on the date of issuance. As a result, a $4,208,612 beneficial conversion feature was recorded&#13;as a&amp;#160;deemed dividend&amp;#160;in the consolidated statement of operations because the Series A Preferred Stock is immediately&#13;convertible, with a credit to additional paid-in capital. The relative fair value of the warrants issued with the Series A Preferred&#13;Stock of $2,766,941 was recorded as a reduction to the carrying amount of the preferred stock in the consolidated balance sheet.&#13;The value of the warrants was determined utilizing the binomial option pricing model using a term of 5 years, a volatility of 114%,&#13;a risk-free interest rate of 1.64%, a 6% rate of dividends, and a call multiple of 2.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;December 2019 Offering of Series B Preferred&#13;Stock and Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 19, 2019, the Company completed&#13;a private placement offering in which the Company sold 351.711 shares of its Series B Preferred Stock and warrants (the &amp;#8220;December&#13;19, 2019 Warrants&amp;#8221;) exercisable for an aggregate of 426,316 shares of the Company&amp;#8217;s common stock to the investors for&#13;approximately $405,000 of gross proceeds. The Company plans to use the net proceeds from the offering for working capital and general&#13;corporate purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the closing of the offering,&#13;the Company filed a Certificate of Designations of Series B Convertible Preferred Stock (the &amp;#8220;Series B Certificate of Designations&amp;#8221;)&#13;with the Secretary of State of the State of Delaware setting forth the rights and preferences of the Series B Preferred Stock.&#13;The Series B Preferred Stock has substantially the same rights and preferences as the Series A Preferred Stock, except for a different&#13;conversion price and trading price of common stock at which the Series B Preferred Stock becomes subject to automatic conversion.&#13;Each share of Series B Preferred Stock has a $1,000 issue price (the &amp;#8220;Issue Price&amp;#8221;). Dividends accrue on the Issue&#13;Price at a rate of 6.0% per annum and are payable to holders of Preferred Stock as, when and if declared by the Company&amp;#8217;s&#13;Board of Directors. Shares of Series B Preferred Stock, including accrued but unpaid dividends, are convertible into Common Stock&#13;at a conversion price of $0.99 per share of common stock. The conversion price is subject to proportional adjustment for certain&#13;transactions relating to the Company&amp;#8217;s capital stock, including stock splits, stock dividends and similar transactions. Holders&#13;of shares of Series B Preferred Stock vote with the holders of common stock and are entitled to a number of votes equal to the&#13;number of shares of common stock into which such holder&amp;#8217;s shares of Series A Preferred Stock are then convertible. Holders&#13;of Series B Preferred Stock are entitled to a liquidation preference in the event of any liquidation, dissolution or winding up&#13;of the Company based on their shares&amp;#8217; aggregate Issue Price and accrued and unpaid dividends. Such liquidation preference&#13;of Series B Preferred Stock holders is on a pari passu basis with holders of Series A Preferred Stock. Holders may convert their&#13;shares of Series B Preferred Stock into common stock at any time and the Company has the right to cause each holder to convert&#13;their shares of Series B Preferred Stock in the event that (i) the average of the daily volume-weighted average price of Common&#13;Stock over any 10 consecutive trading days is greater than $1.98 (as adjusted for stock splits, stock dividends and similar transactions)&#13;and (ii) there is then an effective registration statement registering under the Securities Act the resale of the shares of Common&#13;Stock issuable upon such conversion of Preferred Stock (together, the &amp;#8220;Series B Forced Conversion Conditions&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The average daily VWAP requirement of the Series&#13;B Forced Conversion Conditions relating to daily volume-weighted average price of our Common Stock has not yet been satisfied.&#13;On January 27, 2020, the SEC declared effective the Company&amp;#8217;s Registration Statement on Form S-3 (File No. 333-235883) registering&#13;under the Securities Act the resale of the shares of common stock issuable upon the conversion of Series B Preferred Stock and&#13;upon the exercise of December 19, 2019 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each December 19, 2019 Warrant entitles the&#13;holder to purchase a share of common stock for an exercise price equal to $0.99. The December 19, 2019 Warrants are exercisable&#13;commencing immediately upon issuance and expire on the date five years after the date of issuance, unless earlier terminated pursuant&#13;to the terms of the December 19, 2019 Warrant. If, during the term of the December 19, 2019 Warrants, the Series B Forced Conversion&#13;Conditions are met, the Company may deliver notice thereof to the holders of the December 19, 2019 Warrants and, after a 30-day&#13;period following such notice, any unexercised December 19, 2019 Warrants will be forfeited. The December 19, 2019 Warrants provide&#13;for cashless exercise in the event there is no effective registration statement registering under the Securities Act the resale&#13;of the shares of common stock issuable upon exercise of such December 19, 2019 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Securities Purchase Agreement, dated December&#13;19, 2019, includes customary representations, warranties and covenants. In connection with the closing of the offering, the Company&#13;paid to the placement agent in the offering a commission of approximately 8.0% of the gross proceeds from the offering and issued&#13;to the placement agent and its designees warrants exercisable for an aggregate of 14,211 shares of common stock (the &amp;#8220;Series&#13;B Placement Agent Warrant&amp;#8221;). The terms of the Series B Placement Agent Warrant are the same as those of the Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series B Preferred Stock Deemed Dividend,&#13;Beneficial Conversion Calculation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;After factoring in the relative fair value of&#13;the warrants issued in conjunction with the Series B Preferred Stock, the effective conversion price is $0.03 per share, compared&#13;to the market price of $1.36 per share on the date of issuance. As a result, a $11,165 beneficial conversion feature was recorded&#13;as a deemed dividend in the consolidated statement of operations because the Series B Preferred Stock is immediately convertible,&#13;with a credit to additional paid-in capital. The relative fair value of the warrants issued with the Series B Preferred Stock of&#13;$364,355 was recorded as a reduction to the carrying amount of the preferred stock in the consolidated balance sheet. The value&#13;of the warrants was determined utilizing the binomial option pricing model using a term of 5 years, a volatility of 118%, a risk-free&#13;interest rate of 1.75%, a 0% rate of dividends, and a call multiple of 2.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <NDRAU:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock options are awarded to the Company&amp;#8217;s&#13;employees, consultants and non-employee members of the board of directors under the 2016 Omnibus Incentive Plan (the &amp;#8220;Omnibus&#13;Plan&amp;#8221;) and are generally granted with an exercise price equal to the market price of the Company&amp;#8217;s common stock at&#13;the date of grant. The aggregate fair value of these stock options granted by the Company during the three months ended March 31,&#13;2020 was determined to be $185,602 using the Black-Scholes-Merton option-pricing model based on the following assumptions: (i)&#13;volatility rate of 116% to 119%, (ii) discount rate of 0%, (iii) zero expected dividend yield, and (iv) expected life of 10 years.&#13;A summary of option activity under the Company&amp;#8217;s Omnibus Plan as of March 31, 2020, and changes during the year then ended,&#13;is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 64%"&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,449,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;130,418&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Cancelled or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,579,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Exercisable at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;856,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</NDRAU:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock>
    <NDRAU:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2020,&#13;the Company issued an aggregate of 45,101 shares of its common stock upon warrant exercises valued at $39,238.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes all stock warrant&#13;activity of the Company for the three months ended March 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 57%"&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,496,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(45,101&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.82&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Exercisable at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.82&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;</NDRAU:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Office Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective January 1, 2015, the Company entered&#13;into an office lease agreement with Green Court, LLC, a Michigan limited liability company, for approximately 3,657 rentable square&#13;feet of space, for the initial monthly rent of $5,986, which commenced on January 1, 2015 for an initial term of 60 months. On&#13;October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On&#13;July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally&#13;expiring on December 31, 2019, such that the lease now expires on December 31, 2024.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company records the lease asset and lease&#13;liability at the present value of lease payments over the lease term. The lease typically does not provide an implicit rate; therefore,&#13;the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease&#13;payments. The Company&amp;#8217;s discount rate for operating leases at March 31, 2020 was 10%. Lease expense is recognized on a straight-line&#13;basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents&#13;as they become payable based on the adoption of ASC Topic 842. The weighted-average remaining lease term is 4.67 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, the maturities of operating&#13;lease liabilities are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 88%"&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,092&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;101,752&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;104,793&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;107,954&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2024 and beyond&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;111,192&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;499,784&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: amount representing interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(105,371&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Present value of future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;394,412&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: current obligations under leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;68,608&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Long-term lease obligations&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;325,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three months ended March 31, 2020 and&#13;2019, the Company incurred rent expenses of $30,288 and $23,188, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employment and Consulting Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Francois Michelon&lt;/i&gt;&lt;/b&gt; &amp;#8211; Effective&#13;May 12, 2017, the Company entered into an amended and restated employment agreement with Francois Michelon, the Company&amp;#8217;s&#13;Chief Executive Officer and Chairman of the board of directors. The term of the employment agreement runs through December 31,&#13;2019 and continues on a year-to-year basis thereafter. The employment agreement provides for an annual base salary that is subject&#13;to adjustment at the board of directors&amp;#8217; discretion. The annual base salary in effect during the period covered by this Form&#13;10-Q was $355,350. Under the employment agreement, Mr. Michelon is eligible for an annual cash bonus based upon achievement of&#13;performance-based objectives established by the board of directors. Pursuant to Mr. Michelon&amp;#8217;s employment agreement, in connection&#13;with the closing of the Company&amp;#8217;s initial public offering he was granted options to purchase an aggregate 339,270 shares&#13;of common stock. The options have a weighted average exercise price of $4.96 per share of common stock and vest in three equal&#13;annual installments beginning on May 12, 2018. Upon termination without cause, any portion of Mr. Michelon&amp;#8217;s option award&#13;scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change&#13;of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the&#13;entire unvested portion of the option award will terminate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If Mr. Michelon&amp;#8217;s employment is terminated&#13;by the Company without cause, Mr. Michelon will be entitled to receive 12 months&amp;#8217; continuation of his current base salary&#13;and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&amp;#8217; continuation of his current base&#13;salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following&#13;a change in control).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under his employment agreement, Mr. Michelon&#13;is eligible to receive benefits that are substantially similar to those of the Company&amp;#8217;s other senior executive officers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 27, 2019, the Company entered into&#13;an amendment to Mr. Michelon&amp;#8217;s employment agreement to provide that (i) Mr. Michelon&amp;#8217;s employment with the Company&#13;will continue until terminated under the terms the employment agreements, and (ii) Mr. Michelon will each receive certain payments&#13;if he is terminated by the Company without Cause (as defined in the employment agreement amendment) or he resigns for Good Reason&#13;(as defined in the employment agreement amendment).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;b&gt;&lt;i&gt;Michael Thornton&lt;/i&gt;&lt;/b&gt; &amp;#8211;&#13;Effective May 12, 2017, the Company entered into an amended and restated employment agreement with Michael Thornton, the Company&amp;#8217;s&#13;Chief Technology Officer. The term of the employment agreement runs through December 31, 2019 and continues on a year-to-year basis&#13;thereafter. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors&amp;#8217;&#13;discretion. The annual base salary in effect during the period covered by this Form 10-Q was $267,800. Under the employment agreement,&#13;Mr. Thornton is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board&#13;of directors. Pursuant to Mr. Thornton&amp;#8217;s employment agreement, in connection with the closing of the Company&amp;#8217;s initial&#13;public offering he was granted options to purchase an aggregate 345,298 shares of common stock. The options have a weighted average&#13;exercise price of $4.96 per share of common stock and vest in three equal annual installments beginning on May 12, 2018. Upon termination&#13;without cause, any portion of Mr. Thornton&amp;#8217;s option award scheduled to vest within 12 months will automatically vest, and&#13;upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award&#13;will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If Mr. Thornton&amp;#8217;s employment is terminated&#13;by the Company without cause, Mr. Thornton will be entitled to receive 12 months&amp;#8217; continuation of his current base salary&#13;and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&amp;#8217; continuation of his current base&#13;salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following&#13;a change in control).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under his employment agreement, Mr. Thornton&#13;is eligible to receive benefits that are substantially similar to those of the Company&amp;#8217;s other senior executive officers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 27, 2019, the Company entered into&#13;an amendment to Mr. Thornton&amp;#8217;s employment agreement to provide that (i) Mr. Thornton&amp;#8217;s employment with the Company&#13;will continue until terminated under the terms the employment agreements, and (ii) Mr. Thornton will each receive certain payments&#13;if he is terminated by the Company without Cause (as defined in the employment agreement amendment) or he resigns for Good Reason&#13;(as defined in the employment agreement amendment).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;David Wells&lt;/i&gt;&lt;/b&gt; &amp;#8211; On May 12,&#13;2017, the Company entered into a consulting agreement with StoryCorp Consulting (&amp;#8220;StoryCorp&amp;#8221;), pursuant to which David&#13;Wells provided services to the Company as its Chief Financial Officer. Pursuant to the consulting agreement, the Company paid to&#13;StoryCorp a monthly fee of $9,000, and in May 2018 this monthly fee was increased to $9,540. Additionally, pursuant to the consulting&#13;agreement, the Company granted to Mr. Wells a stock option to purchase 15,000 shares of common stock in connection with the closing&#13;of the Company&amp;#8217;s initial public offering, having an exercise price per share equal to $5.00 and vesting in twelve equal quarterly&#13;installments, and, for so long as the consulting agreement was in place, granted to Mr. Wells a stock option to purchase the same&#13;number of shares of common stock with the same terms on each annual anniversary of the date of the consulting agreement. In May&#13;2018, the annual stock option amount was increased and on December 13, 2018, Mr. Wells was granted options to purchase an additional&#13;35,000 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 13, 2019, the Company entered into an&#13;employment agreement with David Wells that supersedes the consulting agreement between the Company and StoryCorp. The employment&#13;agreement provides for an annual base salary of $230,000 and eligibility for an annual cash bonus to be paid based on attainment&#13;of Company and individual performance objectives to be established by the Company&amp;#8217;s board of directors (in 2019, the amount&#13;of such cash bonus if all goals were achieved would be 30% of the base salary plus base fees paid to StoryCorp under the consulting&#13;agreement). The employment agreement also provides for eligibility to receive benefits substantially similar to those of the Company&amp;#8217;s&#13;other senior executive officers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the employment agreement, on May&#13;13, 2019 Mr. Wells was granted stock options to purchase 56,000 shares of the Company&amp;#8217;s common stock. The stock options have&#13;an exercise price of $1.38 per share, and vest in three equal annual installments beginning on the first anniversary of the grant&#13;date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;From time&#13;to time the Company may become a party to litigation in the normal course of business. There are currently no legal matters that&#13;management believes would have a material effect on the Company&amp;#8217;s financial position or results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the financial statements&#13;in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial&#13;statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management makes estimates that affect certain&#13;accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments&#13;or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&amp;#8217;s&#13;consolidated financial statements include all accounts of the Company and its consolidated subsidiary and/or entities as of reporting&#13;period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The accompanying&#13;unaudited condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations&#13;of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Accordingly, certain information and footnote disclosures normally&#13;included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant&#13;to such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered&#13;necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily&#13;indicative of the results that may be expected for the year ended December 31, 2020. The balance sheet at December 31, 2019 has&#13;been derived from the audited financial statements at that date. For further information, refer to the financial statements and&#13;footnotes thereto included in ENDRA Life Sciences Inc. annual financial statements for the twelve months ended December 31, 2019&#13;included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC on March 26, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&#13;considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid&#13;investments with maturities of one year or less, when purchased, to be cash. As of March 31, 2020 and December 31, 2019, the Company&#13;had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured&#13;limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial&#13;institutions and has determined the credit exposure to be negligible.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&amp;#8217;s&#13;inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average&#13;cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation&#13;or obsolescence of inventory.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&#13;capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one&#13;year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3)&#13;all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less&#13;than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed&#13;as incurred.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the Financial Accounting Standards&#13;Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-09, &amp;#8220;Revenue from Contracts with&#13;Customers&amp;#8221; (&amp;#8220;ASC Topic 606&amp;#8221;). This standard provides a single set of guidelines for revenue recognition to be&#13;used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its&#13;core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects&#13;the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated&#13;guidance effective January 1, 2018 using the full retrospective method. The new standard did not have a material impact on its&#13;financial position and results of operations, as it did not change the manner or timing of recognizing revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under ASC Topic 606, in order to recognize revenue,&#13;the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of&#13;each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that&#13;the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of&#13;ASC Topic 606 did not have an impact on the Company&amp;#8217;s operations or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows FASB Accounting Standards&#13;Codification (&amp;#8220;ASC&amp;#8221;) Subtopic 730-10, &amp;#8220;Research and Development&amp;#8221;. Research and development costs are charged&#13;to the statement of operations as incurred. During the three months ended March 31, 2020 and 2019, the Company incurred $1,518,146&#13;and $1,773,498 of expenses related to research and development costs, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes earnings per share under&#13;ASC Subtopic 260-10, &amp;#8220;Earnings Per Share&amp;#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss)&#13;attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the&#13;denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average&#13;number of additional shares that could have been outstanding from securities convertible into common stock (using the &amp;#8220;treasury&#13;stock&amp;#8221; method), unless their effect on net loss per share is anti-dilutive. There were 19,992,774&amp;#160;and 24,949,725 potentially&#13;dilutive shares, which include shares of common stock issuable upon the exercise or conversion of outstanding preferred stock,&#13;stock options, warrants, and convertible notes, as of March 31, 2020 and&amp;#160;December 31, 2019,&amp;#160;respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The potentially dilutive shares, which are excluded&#13;from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,579,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,449,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,496,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,603&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;362,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of Series A Preferred Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,806,805&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,285,651&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of Series B Preferred&amp;#160;Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;122,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;355,263&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Potentially dilutive shares excluded&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;19,992,774&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;24,949,725&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Disclosures&#13;about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance&#13;sheet, where it is practicable to estimate that value.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In accordance&#13;with ASC Topic 820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; the Company measures certain financial instruments at&#13;fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance&#13;with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Fair value&#13;is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between&#13;market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the&#13;inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for&#13;identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These&#13;tiers include:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; &lt;font style="background-color: white"&gt;Level 1, defined as&#13;observable inputs such as quoted prices for identical instruments in active markets;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; &lt;font style="background-color: white"&gt;Level 2, defined as&#13;inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar&#13;instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; &lt;font style="background-color: white"&gt;Level 3, defined as&#13;unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such&#13;as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial assets are considered Level 3 when&#13;their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one&#13;significant model assumption or input is unobservable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of the Company&amp;#8217;s&#13;financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and&#13;other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of&#13;notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations&#13;are the same as prevailing market rates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s 2016 Omnibus Incentive Plan&#13;(the &amp;#8220;Omnibus Plan&amp;#8221;) permits the grant of stock options and other share-based awards to its employees, consultants&#13;and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus&#13;Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number&#13;of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming&#13;the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding&#13;options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined&#13;by the board. On January 1, 2020, the pool of shares issuable under the Omnibus Plan automatically increased by 3,202,280 shares&#13;from 2,649,378 shares to 5,861,658. As of March 31, 2020, there were 2,281,921 shares of common stock remaining available for issuance&#13;under the Omnibus Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company records share-based compensation&#13;in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use&#13;of option-pricing models that require the input of highly subjective assumptions, including the option&amp;#8217;s expected life and&#13;the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes&#13;option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock compensation expense recognized during&#13;the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures.&#13;The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable,&#13;in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan&#13;as described above.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines if its outstanding convertible&#13;promissory notes should be accounted for as liability or equity under ASC Topic 480, &amp;#8220;Liabilities &amp;#8212; Distinguishing&#13;Liabilities from Equity.&amp;#8221; ASC Topic 480 applies to certain contracts involving a company&amp;#8217;s own equity, and requires&#13;that issuers classify the following freestanding financial instruments as liabilities: mandatorily redeemable financial instruments,&#13;obligations that require or may require repurchase of the issuer&amp;#8217;s equity shares by transferring assets (e.g., written put&#13;options and forward purchase contracts), and certain obligations where at inception the monetary value of the obligation is based&#13;solely or predominantly on:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#9679; A fixed monetary amount known at inception (for example,&#13;a payable settleable with a variable number of the issuer&amp;#8217;s equity shares with an issuance date fair value equal to a fixed&#13;dollar amount);&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#9679; Variations in something other than the&#13;fair value of the issuer&amp;#8217;s equity shares (for example, a financial instrument indexed to the S&amp;#38;P 500 and settleable with&#13;a variable number of the issuer&amp;#8217;s equity shares); or&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#9679; Variations inversely related to changes&#13;in the fair value of the issuer&amp;#8217;s equity shares (for example, a written put that could be net share settled).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <NDRAU:BeneficialConversionFeaturePolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the conversion feature of conventional convertible&#13;debt provides for a rate of conversion that is below market value on the date of issuance, this feature is characterized as a beneficial&#13;conversion feature (&amp;#8220;BCF&amp;#8221;). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 &amp;#8220;Debt&#13;with Conversion and Other Options.&amp;#8221; In those circumstances, the convertible debt is recorded net of the discount related&#13;to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the Company determines the instrument meets&#13;the guidance under ASC Topic 480, the instrument is accounted for as a liability with a respective debt discount. The Company has&#13;previously recorded debt discounts in connection with raising funds through the issuance of promissory notes. These costs are amortized&#13;to noncash interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of&#13;the unamortized amounts is immediately expensed. See Note 6, Convertible Notes, for further discussion on the Company&amp;#8217;s accounting&#13;treatment for the convertible notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</NDRAU:BeneficialConversionFeaturePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In May&#13;2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers.&amp;#8221; ASU 2014-09 is a comprehensive revenue&#13;recognition standard that superseded nearly all previous revenue recognition guidance under U.S. GAAP and replaced it with a principle-based&#13;approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised&#13;goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange&#13;for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue&#13;and cash flows arising from contracts with customers. The FASB has since issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12,&#13;and ASU 2016-20, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim&#13;and annual periods beginning after December 15, 2017. The standard can be adopted either retrospectively to each prior reporting&#13;period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance&#13;recognized at the date of initial application (the cumulative catch-up transition method). The Company has reviewed ASU 2014-09&#13;and using the full retrospective method has determined that its adoption has had no impact on its financial position, results of&#13;operations or cash flows. The Company adopted the provisions of this standard in the first quarter of fiscal 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU No. 2016-02,&#13;&amp;#8220;Leases.&amp;#8221; ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance&#13;sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning&#13;after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for&#13;capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial&#13;statements. The Company evaluated the impact that the application of the new standard has on its consolidated financial statements&#13;and related disclosures, and determined that it should record a total lease liability of $431,363, with a corresponding right of&#13;use asset valued at $430,681. The Company adopted the provisions of this standard in the first quarter of fiscal 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other recent accounting pronouncements issued&#13;by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did&#13;not or in management&amp;#8217;s opinion will not have a material impact on the Company&amp;#8217;s present or future consolidated financial&#13;statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,579,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,449,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,496,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,603&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;362,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of Series A Preferred Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,806,805&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,285,651&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon conversion of Series B Preferred&amp;#160;Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;122,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;355,263&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Potentially dilutive shares excluded&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;19,992,774&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;24,949,725&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Property, leasehold and capitalized software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;684,418&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;679,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;TAEUS development and testing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;60,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;43,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(508,111&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(486,524&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fixed assets, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;237,015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;236,251&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,240,687&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,278,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued payroll&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;95,656&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;94,862&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued bonuses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;97,114&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;295,794&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued employee benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accrued interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,828&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,738&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Insurance premium financing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,950&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;1,444,035&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;1,708,525&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 64%"&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,449,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;130,418&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Cancelled or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,579,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Exercisable at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;856,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 57%"&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,496,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(45,101&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Balance outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.82&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Exercisable at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,451,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.82&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 88%"&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,092&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;101,752&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;104,793&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;107,954&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2024 and beyond&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;111,192&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;499,784&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: amount representing interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(105,371&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Present value of future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;394,412&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: current obligations under leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;68,608&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Long-term lease obligations&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;325,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2020-01-01to2020-03-31">2007-07-18</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">19992774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">3579737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">3449319</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13496924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">24949725</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13451823</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_custom_ConvertibleNotesPayableConversionMember" unitRef="Shares" decimals="INF">31603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_custom_ConvertibleNotesPayableConversionMember" unitRef="Shares" decimals="INF">362568</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_custom_SeriesAPreferredStockConversionMember" unitRef="Shares" decimals="INF">2806805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_custom_SeriesAPreferredStockConversionMember" unitRef="Shares" decimals="INF">7285651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_custom_SeriesBPreferredStockConversionMember" unitRef="Shares" decimals="INF">122806</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_custom_SeriesBPreferredStockConversionMember" unitRef="Shares" decimals="INF">355263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">2281921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <NDRAU:WorkingCapitalDeficit contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-2221823</NDRAU:WorkingCapitalDeficit>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31_custom_PropertyLeaseholdAndCapitalizedSoftwareMember" unitRef="USD" decimals="0">684418</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_custom_PropertyLeaseholdAndCapitalizedSoftwareMember" unitRef="USD" decimals="0">679179</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31_custom_TAEUSDevelopmentAndTestingMember" unitRef="USD" decimals="0">60708</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_custom_TAEUSDevelopmentAndTestingMember" unitRef="USD" decimals="0">43596</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">486524</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">508111</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">21586</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">19632</us-gaap:Depreciation>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1708525</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1444035</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccruedInsuranceCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">23950</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">0</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">9738</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4828</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">5750</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">5750</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">295794</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">97114</us-gaap:AccruedBonusesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">94862</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">95656</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1278431</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1240687</us-gaap:AccountsPayableCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">3449319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">3579737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">130418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <NDRAU:NumberOfOptionsExercised contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">0</NDRAU:NumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">856172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31" unitRef="UsdPerShare" decimals="INF">2.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31" unitRef="UsdPerShare" decimals="INF">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-03-31" unitRef="UsdPerShare" decimals="INF">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-03-31">P8Y3M4D</NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2020-01-01to2020-03-31">P2Y4D</NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-03-31">P7Y9M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-03-31">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">13496924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">13451823</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">45101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">0</NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">13451823</NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31" unitRef="UsdPerShare" decimals="INF">2.02</NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31" unitRef="UsdPerShare" decimals="INF">2.03</NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.00</NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.87</NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.00</NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice>
    <NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31" unitRef="UsdPerShare" decimals="INF">.00</NDRAU:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-03-31" unitRef="UsdPerShare" decimals="INF">2.03</NDRAU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2020-01-01to2020-03-31">P4Y25D</NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
    <NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm contextRef="From2020-01-01to2020-03-31">P4Y8M12D</NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm>
    <NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2020-01-01to2020-03-31">P3Y9M25D</NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm contextRef="From2020-01-01to2020-03-31">P3Y9M25D</NDRAU:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">74092</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">101752</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">104793</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">107954</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">111192</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">499784</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">105371</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LeaseAndRentalExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">30288</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">23188</us-gaap:LeaseAndRentalExpense>
    <us-gaap:DividendsPreferredStockStock contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">0</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-34066</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="From2020-01-01to2020-03-31_custom_StockPayableMember" unitRef="USD" decimals="0">34066</us-gaap:DividendsPreferredStockStock>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">40000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-03-31_custom_StockPayableMember" unitRef="USD" decimals="0">40000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <NDRAU:StockPayableForInvestorRelations contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">40000</NDRAU:StockPayableForInvestorRelations>
    <NDRAU:StockPayableForInvestorRelations contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">0</NDRAU:StockPayableForInvestorRelations>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial statements are&#13;prepared using accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) applicable to a going concern,&#13;which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited&#13;commercial experience and had a cumulative net loss from inception to March 31, 2020 of $48,540,234. The Company had working capital&#13;of $2,221,823 as of March 31, 2020. The Company has not established an ongoing source of revenue sufficient to cover its operating&#13;costs and to allow it to continue as a going concern. The accompanying financial statements for the period ended March 31, 2020&#13;have been prepared assuming the Company will continue as a going concern. The Company&amp;#8217;s cash resources will likely be insufficient&#13;to meet its anticipated needs during the next twelve months. The Company will require additional financing to fund its future planned&#13;operations, including research and development and commercialization of its products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The ability of the Company to continue as a going concern is dependent&#13;on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable.&#13;Management&amp;#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and&#13;borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.&#13;As described further below under &amp;#8220;Item 2. Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of&#13;Operations&amp;#8221; the COVID-19 pandemic has impacted our business operations to some extent and is expected to continue to do so&#13;and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. If the&#13;Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce&#13;the scope of or eliminate one or more of the Company&amp;#8217;s research and development activities or commercialization efforts or&#13;perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its&#13;ability to successfully secure other sources of financing and attain profitable operations. There is substantial doubt about the&#13;ability of the Company to continue as a going concern for one year from the issuance of the accompanying consolidated financial&#13;statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company&#13;is unable to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The COVID-19 outbreak, which the World Health&#13;Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to issue &amp;#8220;stay-at-home&amp;#8221;&#13;or similar orders, and enact restrictions on the performance of &amp;#8220;non-essential&amp;#8221; services, public gatherings and travel.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beginning in March 2020, we undertook temporary&#13;precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring most employees&#13;to work remotely, pausing all non-essential travel worldwide for our employees, and limiting employee attendance at industry events&#13;and in-person work-related meetings, to the extent those events and meetings are continuing. To date we do not believe these actions&#13;have had a significant negative impact on our operations. However, these actions or additional measures we may undertake may ultimately&#13;delay progress our developmental goals or otherwise negatively affect our business. In addition, third-party actions taken to contain&#13;its spread and mitigate its public health effects of COVID-19 may negatively affect our business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Paycheck Protection Program&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to the period ended Mach 31, 2020,&#13;the Company issued a U.S. Small Business Administration (&amp;#8220;SBA&amp;#8221;) Paycheck Protection Program Note (the &amp;#8220;Note&amp;#8221;)&#13;to First Republic Bank (the &amp;#8220;Lender&amp;#8221;) for a loan in the amount of $308,600.00 (the &amp;#8220;Loan&amp;#8221;) under the Paycheck&#13;Protection Program (&amp;#8220;PPP&amp;#8221;) promulgated under the Coronavirus Aid, Relief and Economic Security Act of 2020. The Loan&#13;bears interest at a rate per annum of 1.00%. The term of the Loan is two years, ending April 22, 2022 (the &amp;#8220;Maturity Date&amp;#8221;).&#13;No payments are due on the Loan until seven months from April 22, 2020, the date of first disbursement of the Loan (the &amp;#8220;Deferment&#13;Period&amp;#8221;), but interest will accrue during the Deferment Period. Following the Deferment Period, the Company must pay monthly&#13;principal and interest payments on the outstanding principal balance of the Loan amortized over the term of the Loan (the &amp;#8220;Loan&#13;Payments&amp;#8221;), unless forgiven in whole or in part in accordance with the PPP regulations. These repayments will begin following&#13;the Deferment Period and until the Maturity Date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may apply to the Lender for the&#13;Loan to be forgiven partially or fully if the funding received is used during the 8-week period following disbursement for payroll&#13;costs, covered rent, and covered utilities, provided that at least 75% of the forgiven amount has been used for payroll costs.&#13;Forgiveness is based on the Company&amp;#8217;s maintaining, or quickly rehiring, employees and maintaining applicable salary levels.&#13;Forgiveness will be reduced if full-time headcount declines, or if salaries and wages decrease. No assurance is provided that the&#13;Company will obtain forgiveness of the Loan in full or in part.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may prepay the principal of the&#13;Loan at any time without incurring any prepayment charges. The Company may prepay 20% or less of the unpaid principal balance at&#13;any time without notice. If the Company prepays more than 20% and the Loan has been sold on the secondary market, the Company must&#13;provide the Lender with written notice, pay all accrued interest and comply with the other requirements described in the Note for&#13;such repayment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company did not provide any collateral or&#13;personal guarantees for the Loan, nor did the Company pay any facility charge to the government or to the Lender.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Note also provides for customary events&#13;of default, including, among others, events of default relating to failure to make payment or comply with the covenants contained&#13;in the Note and related loan documents, defaults on any other loan with the Lender, defaults on any loan or agreement with another&#13;creditor (if the Lender believes the default may materially affect the Company&amp;#8217;s ability pay the Note), failure to pay any&#13;taxes when due, bankruptcy, breaches of representations, judgment, reorganization, merger, consolidation or other changes in ownership&#13;or business structure without the Lender&amp;#8217;s prior written consent, and material adverse changes in financial condition or&#13;business operation. Upon an event of default the Lender may require immediate payment of all amounts owing under the Note, collect&#13;all amounts owing from the Company, or file suit and obtain judgment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Subsequent to the period ended March 31, 2020,&amp;#160;the Company issued&#13;a total of 929,650 shares of common stock&amp;#160;upon&amp;#160;the conversion of&amp;#160;an aggregate of&amp;#160;808.796 shares of Series A&#13;Convertible Preferred Stock at the request of&amp;#160;its&amp;#160;holder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Subsequent to the period ended March 31, 2020 the Company issued&#13;a total of 22,099 shares of common stock to a vendor for services which were valued at $40,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>ndrau-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: Source; Value: 200644 03312020 10Q1.xfr; Date: 2020%2D05%2D13T17:42:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8008000C -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9605o7xRiXgOn8uMbX9cWaCBSaP9wJl++Zkxvm51bZmaDyEtonPPeSZ427w2UVIF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:NDRAU="http://endrainc.com/20200331" elementFormDefault="qualified" targetNamespace="http://endrainc.com/20200331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://endrainc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/NatureOfBusiness" id="NatureOfBusiness">
	  <link:definition>00000007 - Disclosure - Nature of the Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - Inventory</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/FixedAssets" id="FixedAssets">
	  <link:definition>00000010 - Disclosure - Fixed Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
	  <link:definition>00000011 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/ConvertibleNotes" id="ConvertibleNotes">
	  <link:definition>00000012 - Disclosure - Convertible Notes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CapitalStock" id="CapitalStock">
	  <link:definition>00000013 - Disclosure - Capital Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommonStockOptions" id="CommonStockOptions">
	  <link:definition>00000014 - Disclosure - Common Stock Options</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommonStockWarrants" id="CommonStockWarrants">
	  <link:definition>00000015 - Disclosure - Common Stock Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommitmentsContingencies" id="CommitmentsContingencies">
	  <link:definition>00000016 - Disclosure - Commitments &amp; Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000017 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/FixedAssetsTables" id="FixedAssetsTables">
	  <link:definition>00000020 - Disclosure - Fixed Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
	  <link:definition>00000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommonStockOptionsTables" id="CommonStockOptionsTables">
	  <link:definition>00000022 - Disclosure - Common Stock Options (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommonStockWarrantsTables" id="CommonStockWarrantsTables">
	  <link:definition>00000023 - Disclosure - Common Stock Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommitmentsContingenciesTables" id="CommitmentsContingenciesTables">
	  <link:definition>00000024 - Disclosure - Commitments &amp; Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Nature of the Business (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/InventoryDetailsNarrative" id="InventoryDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Inventory (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
	  <link:definition>00000029 - Disclosure - Fixed Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/FixedAssetsDetailsNarrative" id="FixedAssetsDetailsNarrative">
	  <link:definition>00000030 - Disclosure - Fixed Assets (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" id="AccountsPayableAndAccruedLiabilitiesDetails">
	  <link:definition>00000031 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Capital Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommonStockOptionsDetails" id="CommonStockOptionsDetails">
	  <link:definition>00000033 - Disclosure - Common Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommonStockWarrantsDetails" id="CommonStockWarrantsDetails">
	  <link:definition>00000034 - Disclosure - Common Stock Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommitmentsContingenciesDetails" id="CommitmentsContingenciesDetails">
	  <link:definition>00000035 - Disclosure - Commitments &amp; Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" id="CommitmentsContingenciesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Commitments &amp; Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ndrau-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ndrau-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ndrau-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ndrau-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="NDRAU_StockPayable" name="StockPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ConversionOfSeriesBConvertiblePreferredStock" name="ConversionOfSeriesBConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ConversionOfSeriesAConvertiblePreferredStock" name="ConversionOfSeriesAConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" name="ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_BeneficialConversionFeaturePolicyTextBlock" name="BeneficialConversionFeaturePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_NumberOfOptionsExercised" name="NumberOfOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_StockPayableForInvestorRelations" name="StockPayableForInvestorRelations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_PotentialequivalentsharesexcludedMember" name="PotentialequivalentsharesexcludedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_StockPayableMember" name="StockPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_ConvertibleNotesPayableConversionMember" name="ConvertibleNotesPayableConversionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SeriesAPreferredStockConversionMember" name="SeriesAPreferredStockConversionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_SeriesBPreferredStockConversionMember" name="SeriesBPreferredStockConversionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember" name="PropertyLeaseholdAndCapitalizedSoftwareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_TAEUSDevelopmentAndTestingMember" name="TAEUSDevelopmentAndTestingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NDRAU_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>ndrau-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: Source; Value: 200644 03312020 10Q1.xfr; Date: 2020%2D05%2D13T17:42:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8008000C -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://endrainc.com/role/DocumentAndEntityInformation" xlink:href="ndrau-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/BalanceSheets" xlink:href="ndrau-20200331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/BalanceSheetsParenthetical" xlink:href="ndrau-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfOperations" xlink:href="ndrau-20200331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfStockholdersEquity" xlink:href="ndrau-20200331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfCashFlows" xlink:href="ndrau-20200331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/NatureOfBusiness" xlink:href="ndrau-20200331.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/Inventory" xlink:href="ndrau-20200331.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssets" xlink:href="ndrau-20200331.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/ConvertibleNotes" xlink:href="ndrau-20200331.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CapitalStock" xlink:href="ndrau-20200331.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptions" xlink:href="ndrau-20200331.xsd#CommonStockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrants" xlink:href="ndrau-20200331.xsd#CommonStockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingencies" xlink:href="ndrau-20200331.xsd#CommitmentsContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SubsequentEvents" xlink:href="ndrau-20200331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsTables" xlink:href="ndrau-20200331.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptionsTables" xlink:href="ndrau-20200331.xsd#CommonStockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrantsTables" xlink:href="ndrau-20200331.xsd#CommonStockWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesTables" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" xlink:href="ndrau-20200331.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/InventoryDetailsNarrative" xlink:href="ndrau-20200331.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsDetails" xlink:href="ndrau-20200331.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsDetailsNarrative" xlink:href="ndrau-20200331.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CapitalStockDetailsNarrative" xlink:href="ndrau-20200331.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptionsDetails" xlink:href="ndrau-20200331.xsd#CommonStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrantsDetails" xlink:href="ndrau-20200331.xsd#CommonStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesDetails" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayable" xlink:label="loc_NDRAUStockPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_NDRAUStockPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_IncreaseDecreaseInLeaseLiability" xlink:label="loc_NDRAUIncreaseDecreaseInLeaseLiability" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NDRAUIncreaseDecreaseInLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayableForInvestorRelations" xlink:label="loc_NDRAUStockPayableForInvestorRelations" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NDRAUStockPayableForInvestorRelations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/NatureOfBusiness" xlink:title="00000007 - Disclosure - Nature of the Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/Inventory" xlink:title="00000009 - Disclosure - Inventory" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssets" xlink:title="00000010 - Disclosure - Fixed Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="00000011 - Disclosure - Accounts Payable and Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/ConvertibleNotes" xlink:title="00000012 - Disclosure - Convertible Notes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CapitalStock" xlink:title="00000013 - Disclosure - Capital Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptions" xlink:title="00000014 - Disclosure - Common Stock Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrants" xlink:title="00000015 - Disclosure - Common Stock Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingencies" xlink:title="00000016 - Disclosure - Commitments &amp; Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsTables" xlink:title="00000020 - Disclosure - Fixed Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="00000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptionsTables" xlink:title="00000022 - Disclosure - Common Stock Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrantsTables" xlink:title="00000023 - Disclosure - Common Stock Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesTables" xlink:title="00000024 - Disclosure - Commitments &amp; Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - Nature of the Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/InventoryDetailsNarrative" xlink:title="00000028 - Disclosure - Inventory (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsDetails" xlink:title="00000029 - Disclosure - Fixed Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsDetailsNarrative" xlink:title="00000030 - Disclosure - Fixed Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="loc_us-gaapAccruedInsuranceCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccruedInsuranceCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CapitalStockDetailsNarrative" xlink:title="00000032 - Disclosure - Capital Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptionsDetails" xlink:title="00000033 - Disclosure - Common Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrantsDetails" xlink:title="00000034 - Disclosure - Common Stock Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesDetails" xlink:title="00000035 - Disclosure - Commitments &amp; Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - Commitments &amp; Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>ndrau-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: Source; Value: 200644 03312020 10Q1.xfr; Date: 2020%2D05%2D13T17:42:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8008000C -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://endrainc.com/role/DocumentAndEntityInformation" xlink:href="ndrau-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/BalanceSheets" xlink:href="ndrau-20200331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/BalanceSheetsParenthetical" xlink:href="ndrau-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfOperations" xlink:href="ndrau-20200331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfStockholdersEquity" xlink:href="ndrau-20200331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfCashFlows" xlink:href="ndrau-20200331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/NatureOfBusiness" xlink:href="ndrau-20200331.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/Inventory" xlink:href="ndrau-20200331.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssets" xlink:href="ndrau-20200331.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/ConvertibleNotes" xlink:href="ndrau-20200331.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CapitalStock" xlink:href="ndrau-20200331.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptions" xlink:href="ndrau-20200331.xsd#CommonStockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrants" xlink:href="ndrau-20200331.xsd#CommonStockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingencies" xlink:href="ndrau-20200331.xsd#CommitmentsContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SubsequentEvents" xlink:href="ndrau-20200331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsTables" xlink:href="ndrau-20200331.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptionsTables" xlink:href="ndrau-20200331.xsd#CommonStockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrantsTables" xlink:href="ndrau-20200331.xsd#CommonStockWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesTables" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" xlink:href="ndrau-20200331.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/InventoryDetailsNarrative" xlink:href="ndrau-20200331.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsDetails" xlink:href="ndrau-20200331.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsDetailsNarrative" xlink:href="ndrau-20200331.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CapitalStockDetailsNarrative" xlink:href="ndrau-20200331.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptionsDetails" xlink:href="ndrau-20200331.xsd#CommonStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrantsDetails" xlink:href="ndrau-20200331.xsd#CommonStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesDetails" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapCash_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseCurrent_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssetsCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsAbstract_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayable" xlink:label="loc_NDRAUStockPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_NDRAUStockPayable_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayableMember" xlink:label="loc_NDRAUStockPayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NDRAUStockPayableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_NDRAUStockIssuedDuringPeriodSharesWarrantsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NDRAUStockIssuedDuringPeriodSharesWarrantsExercised_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_NDRAUStockIssuedDuringPeriodValueWarrantsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NDRAUStockIssuedDuringPeriodValueWarrantsExercised_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStockStock_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/NatureOfBusiness" xlink:title="00000007 - Disclosure - Nature of the Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/Inventory" xlink:title="00000009 - Disclosure - Inventory" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssets" xlink:title="00000010 - Disclosure - Fixed Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="00000011 - Disclosure - Accounts Payable and Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/ConvertibleNotes" xlink:title="00000012 - Disclosure - Convertible Notes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CapitalStock" xlink:title="00000013 - Disclosure - Capital Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptions" xlink:title="00000014 - Disclosure - Common Stock Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrants" xlink:title="00000015 - Disclosure - Common Stock Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingencies" xlink:title="00000016 - Disclosure - Commitments &amp; Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsTables" xlink:title="00000020 - Disclosure - Fixed Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="00000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptionsTables" xlink:title="00000022 - Disclosure - Common Stock Options (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrantsTables" xlink:title="00000023 - Disclosure - Common Stock Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesTables" xlink:title="00000024 - Disclosure - Commitments &amp; Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - Nature of the Business (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConvertibleNotesPayableConversionMember" xlink:label="loc_NDRAUConvertibleNotesPayableConversionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NDRAUConvertibleNotesPayableConversionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SeriesAPreferredStockConversionMember" xlink:label="loc_NDRAUSeriesAPreferredStockConversionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NDRAUSeriesAPreferredStockConversionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SeriesBPreferredStockConversionMember" xlink:label="loc_NDRAUSeriesBPreferredStockConversionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NDRAUSeriesBPreferredStockConversionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/InventoryDetailsNarrative" xlink:title="00000028 - Disclosure - Inventory (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsDetails" xlink:title="00000029 - Disclosure - Fixed Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember" xlink:label="loc_NDRAUPropertyLeaseholdAndCapitalizedSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_NDRAUPropertyLeaseholdAndCapitalizedSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_TAEUSDevelopmentAndTestingMember" xlink:label="loc_NDRAUTAEUSDevelopmentAndTestingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_NDRAUTAEUSDevelopmentAndTestingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsDetailsNarrative" xlink:title="00000030 - Disclosure - Fixed Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CapitalStockDetailsNarrative" xlink:title="00000032 - Disclosure - Capital Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptionsDetails" xlink:title="00000033 - Disclosure - Common Stock Options (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrantsDetails" xlink:title="00000034 - Disclosure - Common Stock Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesDetails" xlink:title="00000035 - Disclosure - Commitments &amp; Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - Commitments &amp; Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>ndrau-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: Source; Value: 200644 03312020 10Q1.xfr; Date: 2020%2D05%2D13T17:42:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8008000C -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Options to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayableMember" xlink:label="NDRAU_StockPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_StockPayableMember" xlink:to="NDRAU_StockPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_StockPayableMember_lbl" xml:lang="en-US">Stock Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConvertibleNotesPayableConversionMember" xlink:label="NDRAU_ConvertibleNotesPayableConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ConvertibleNotesPayableConversionMember" xlink:to="NDRAU_ConvertibleNotesPayableConversionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ConvertibleNotesPayableConversionMember_lbl" xml:lang="en-US">Shares issuable upon conversion of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SeriesAPreferredStockConversionMember" xlink:label="NDRAU_SeriesAPreferredStockConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SeriesAPreferredStockConversionMember" xlink:to="NDRAU_SeriesAPreferredStockConversionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SeriesAPreferredStockConversionMember_lbl" xml:lang="en-US">Shares issuable upon conversion of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SeriesBPreferredStockConversionMember" xlink:label="NDRAU_SeriesBPreferredStockConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SeriesBPreferredStockConversionMember" xlink:to="NDRAU_SeriesBPreferredStockConversionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SeriesBPreferredStockConversionMember_lbl" xml:lang="en-US">Shares issuable upon conversion of Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember" xlink:label="NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember" xlink:to="NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember_lbl" xml:lang="en-US">Property, leasehold and capitalized software</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_TAEUSDevelopmentAndTestingMember" xlink:label="NDRAU_TAEUSDevelopmentAndTestingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_TAEUSDevelopmentAndTestingMember" xlink:to="NDRAU_TAEUSDevelopmentAndTestingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_TAEUSDevelopmentAndTestingMember_lbl" xml:lang="en-US">TAEUS development and testing</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_DocumentAndEntityInformationAbstract" xlink:label="NDRAU_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_DocumentAndEntityInformationAbstract" xlink:to="NDRAU_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 50,000,000 shares authorized; 13,553,005 and 8,421,401shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayable" xlink:label="NDRAU_StockPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_StockPayable" xlink:to="NDRAU_StockPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NDRAU_StockPayable_lbl" xml:lang="en-US">Stock payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Series A Convertible Preferred Stock converted to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Series A Convertible Preferred Stock converted to common stock, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Series B Convertible Preferred Stock converted to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Series B Convertible Preferred Stock converted to common stock, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for note conversions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for note conversions, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Common stock issued for warrant exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="NDRAU_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="NDRAU_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Common stock issued for warrant exercise, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of vested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Stock to be issued, preferred dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock to be issued, consultant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Common stock, options and warrants issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayableForInvestorRelations" xlink:label="NDRAU_StockPayableForInvestorRelations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_StockPayableForInvestorRelations" xlink:to="NDRAU_StockPayableForInvestorRelations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_StockPayableForInvestorRelations_lbl" xml:lang="en-US">Stock payable for investor relations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Decrease (increase) in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_IncreaseDecreaseInLeaseLiability" xlink:label="NDRAU_IncreaseDecreaseInLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_IncreaseDecreaseInLeaseLiability" xlink:to="NDRAU_IncreaseDecreaseInLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Decrease in lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Increase in other asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net decrease in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash items:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income tax paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash items:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion of convertible notes and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConversionOfSeriesAConvertiblePreferredStock" xlink:label="NDRAU_ConversionOfSeriesAConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ConversionOfSeriesAConvertiblePreferredStock" xlink:to="NDRAU_ConversionOfSeriesAConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ConversionOfSeriesAConvertiblePreferredStock_lbl" xml:lang="en-US">Conversion of Series A Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConversionOfSeriesBConvertiblePreferredStock" xlink:label="NDRAU_ConversionOfSeriesBConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ConversionOfSeriesBConvertiblePreferredStock" xlink:to="NDRAU_ConversionOfSeriesBConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ConversionOfSeriesBConvertiblePreferredStock_lbl" xml:lang="en-US">Conversion of Series B Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsCommonStock" xlink:to="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xml:lang="en-US">Stock dividend payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of the Business</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Convertible Notes Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Capital Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:label="NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:to="NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:label="NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:to="NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments &amp; Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Capitalization of Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Earnings (Loss) Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_BeneficialConversionFeaturePolicyTextBlock" xlink:label="NDRAU_BeneficialConversionFeaturePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_BeneficialConversionFeaturePolicyTextBlock" xlink:to="NDRAU_BeneficialConversionFeaturePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_BeneficialConversionFeaturePolicyTextBlock_lbl" xml:lang="en-US">Beneficial Conversion Feature</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Operating lease liabilities maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_2_lbl" xml:lang="en-US">State of incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive shares excluded</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Anti-dilutive shares exluded from the calculation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares remaining available for issuance under the Omnibus Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Cumulative net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_WorkingCapitalDeficit" xlink:label="NDRAU_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_WorkingCapitalDeficit" xlink:to="NDRAU_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xml:lang="en-US">Insurance premium financing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_NumberOfOptionsExercised" xlink:label="NDRAU_NumberOfOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_NumberOfOptionsExercised" xlink:to="NDRAU_NumberOfOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NDRAU_NumberOfOptionsExercised_lbl" xml:lang="en-US">Number of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options cancelled or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price cancelled or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number warrants balance outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number warrants forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Number warrants expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number warrants balance outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number warrants outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2024 and beyond</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current obligations under lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_DocumentAndEntityInformationAbstract" xlink:to="NDRAU_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_NumberOfOptionsExercised" xlink:to="NDRAU_NumberOfOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_NumberOfOptionsExercised_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_PotentialequivalentsharesexcludedMember" xlink:label="NDRAU_PotentialequivalentsharesexcludedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_PotentialequivalentsharesexcludedMember" xlink:to="NDRAU_PotentialequivalentsharesexcludedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_PotentialequivalentsharesexcludedMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_WorkingCapitalDeficit" xlink:to="NDRAU_WorkingCapitalDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NDRAU_WorkingCapitalDeficit_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_StockPayable" xlink:to="NDRAU_StockPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_StockPayable_2_lbl" xml:lang="en-US">StockPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_2_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_NumberOfOptionsExercised" xlink:to="NDRAU_NumberOfOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_NumberOfOptionsExercised_3_lbl" xml:lang="en-US">NumberOfOptionsExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_2_lbl" xml:lang="en-US">Stock Options And Warrants Details 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>ndrau-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: Source; Value: 200644 03312020 10Q1.xfr; Date: 2020%2D05%2D13T17:42:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8008000C -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://endrainc.com/role/DocumentAndEntityInformation" xlink:href="ndrau-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/BalanceSheets" xlink:href="ndrau-20200331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/BalanceSheetsParenthetical" xlink:href="ndrau-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfOperations" xlink:href="ndrau-20200331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfStockholdersEquity" xlink:href="ndrau-20200331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/StatementsOfCashFlows" xlink:href="ndrau-20200331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/NatureOfBusiness" xlink:href="ndrau-20200331.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/Inventory" xlink:href="ndrau-20200331.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssets" xlink:href="ndrau-20200331.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/ConvertibleNotes" xlink:href="ndrau-20200331.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CapitalStock" xlink:href="ndrau-20200331.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptions" xlink:href="ndrau-20200331.xsd#CommonStockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrants" xlink:href="ndrau-20200331.xsd#CommonStockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingencies" xlink:href="ndrau-20200331.xsd#CommitmentsContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SubsequentEvents" xlink:href="ndrau-20200331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsTables" xlink:href="ndrau-20200331.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptionsTables" xlink:href="ndrau-20200331.xsd#CommonStockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrantsTables" xlink:href="ndrau-20200331.xsd#CommonStockWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesTables" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" xlink:href="ndrau-20200331.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ndrau-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/InventoryDetailsNarrative" xlink:href="ndrau-20200331.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsDetails" xlink:href="ndrau-20200331.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/FixedAssetsDetailsNarrative" xlink:href="ndrau-20200331.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ndrau-20200331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CapitalStockDetailsNarrative" xlink:href="ndrau-20200331.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockOptionsDetails" xlink:href="ndrau-20200331.xsd#CommonStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommonStockWarrantsDetails" xlink:href="ndrau-20200331.xsd#CommonStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesDetails" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" xlink:href="ndrau-20200331.xsd#CommitmentsContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_DocumentAndEntityInformationAbstract" xlink:label="loc_NDRAUDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NDRAUDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayable" xlink:label="loc_NDRAUStockPayable" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_NDRAUStockPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayableMember" xlink:label="loc_NDRAUStockPayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_NDRAUStockPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_NDRAUStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NDRAUStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_NDRAUStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NDRAUStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStockStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_StockPayableForInvestorRelations" xlink:label="loc_NDRAUStockPayableForInvestorRelations" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NDRAUStockPayableForInvestorRelations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_IncreaseDecreaseInLeaseLiability" xlink:label="loc_NDRAUIncreaseDecreaseInLeaseLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_NDRAUIncreaseDecreaseInLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_NDRAUConversionOfSeriesAConvertiblePreferredStock" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_NDRAUConversionOfSeriesAConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConversionOfSeriesBConvertiblePreferredStock" xlink:label="loc_NDRAUConversionOfSeriesBConvertiblePreferredStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_NDRAUConversionOfSeriesBConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="loc_us-gaapPaymentsOfDividendsCommonStock" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapPaymentsOfDividendsCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/NatureOfBusiness" xlink:title="00000007 - Disclosure - Nature of the Business">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/Inventory" xlink:title="00000009 - Disclosure - Inventory">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssets" xlink:title="00000010 - Disclosure - Fixed Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="00000011 - Disclosure - Accounts Payable and Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/ConvertibleNotes" xlink:title="00000012 - Disclosure - Convertible Notes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CapitalStock" xlink:title="00000013 - Disclosure - Capital Stock">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptions" xlink:title="00000014 - Disclosure - Common Stock Options">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:label="loc_NDRAUScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrants" xlink:title="00000015 - Disclosure - Common Stock Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:label="loc_NDRAUScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingencies" xlink:title="00000016 - Disclosure - Commitments &amp; Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_BeneficialConversionFeaturePolicyTextBlock" xlink:label="loc_NDRAUBeneficialConversionFeaturePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NDRAUBeneficialConversionFeaturePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsTables" xlink:title="00000020 - Disclosure - Fixed Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="00000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptionsTables" xlink:title="00000022 - Disclosure - Common Stock Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrantsTables" xlink:title="00000023 - Disclosure - Common Stock Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesTables" xlink:title="00000024 - Disclosure - Commitments &amp; Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - Nature of the Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_deiEntityIncorporationDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ConvertibleNotesPayableConversionMember" xlink:label="loc_NDRAUConvertibleNotesPayableConversionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NDRAUConvertibleNotesPayableConversionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SeriesAPreferredStockConversionMember" xlink:label="loc_NDRAUSeriesAPreferredStockConversionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NDRAUSeriesAPreferredStockConversionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SeriesBPreferredStockConversionMember" xlink:label="loc_NDRAUSeriesBPreferredStockConversionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NDRAUSeriesBPreferredStockConversionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_WorkingCapitalDeficit" xlink:label="loc_NDRAUWorkingCapitalDeficit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NDRAUWorkingCapitalDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/InventoryDetailsNarrative" xlink:title="00000028 - Disclosure - Inventory (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsDetails" xlink:title="00000029 - Disclosure - Fixed Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember" xlink:label="loc_NDRAUPropertyLeaseholdAndCapitalizedSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_NDRAUPropertyLeaseholdAndCapitalizedSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_TAEUSDevelopmentAndTestingMember" xlink:label="loc_NDRAUTAEUSDevelopmentAndTestingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_NDRAUTAEUSDevelopmentAndTestingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/FixedAssetsDetailsNarrative" xlink:title="00000030 - Disclosure - Fixed Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="loc_us-gaapAccruedInsuranceCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccruedInsuranceCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CapitalStockDetailsNarrative" xlink:title="00000032 - Disclosure - Capital Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockOptionsDetails" xlink:title="00000033 - Disclosure - Common Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_NumberOfOptionsExercised" xlink:label="loc_NDRAUNumberOfOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUNumberOfOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommonStockWarrantsDetails" xlink:title="00000034 - Disclosure - Common Stock Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" xlink:label="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ndrau-20200331.xsd#NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_NDRAUSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesDetails" xlink:title="00000035 - Disclosure - Commitments &amp; Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - Commitments &amp; Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801232928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,102,728<span></span>
</td>
<td class="nump">$ 6,174,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">373,254<span></span>
</td>
<td class="nump">116,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">174,935<span></span>
</td>
<td class="nump">113,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">121,951<span></span>
</td>
<td class="nump">130,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,772,868<span></span>
</td>
<td class="nump">6,535,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">237,015<span></span>
</td>
<td class="nump">236,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">389,004<span></span>
</td>
<td class="nump">404,919<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,398,887<span></span>
</td>
<td class="nump">7,176,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,444,035<span></span>
</td>
<td class="nump">1,708,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net of discount</a></td>
<td class="nump">38,402<span></span>
</td>
<td class="nump">298,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">68,608<span></span>
</td>
<td class="nump">66,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,551,045<span></span>
</td>
<td class="nump">2,072,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long Term Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">325,804<span></span>
</td>
<td class="nump">342,812<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long Term Liabilities</a></td>
<td class="nump">325,804<span></span>
</td>
<td class="nump">342,812<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,876,849<span></span>
</td>
<td class="nump">2,415,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 50,000,000 shares authorized; 13,553,005 and 8,421,401shares issued and outstanding</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">50,982,080<span></span>
</td>
<td class="nump">49,933,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_StockPayable', window );">Stock payable</a></td>
<td class="nump">78,836<span></span>
</td>
<td class="nump">43,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(48,540,234)<span></span>
</td>
<td class="num">(45,217,437)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">2,522,038<span></span>
</td>
<td class="nump">4,760,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">4,398,887<span></span>
</td>
<td class="nump">7,176,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_StockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_StockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798484448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,322,797)<span></span>
</td>
<td class="num">$ (2,748,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">21,586<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock, options and warrants issued for services</a></td>
<td class="nump">511,080<span></span>
</td>
<td class="nump">302,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">228,568<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use assets</a></td>
<td class="nump">15,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_StockPayableForInvestorRelations', window );">Stock payable for investor relations</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Decrease (increase) in prepaid expenses</a></td>
<td class="num">(256,505)<span></span>
</td>
<td class="nump">40,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_IncreaseDecreaseInLeaseLiability', window );">Decrease in lease liability</a></td>
<td class="num">(14,593)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(61,493)<span></span>
</td>
<td class="num">(14,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Increase in other asset</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="num">(258,878)<span></span>
</td>
<td class="num">(139,349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,088,367)<span></span>
</td>
<td class="num">(2,540,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(22,350)<span></span>
</td>
<td class="num">(5,239)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(22,350)<span></span>
</td>
<td class="num">(5,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="nump">39,238<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">39,238<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="num">(3,071,479)<span></span>
</td>
<td class="num">(2,545,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">6,174,207<span></span>
</td>
<td class="nump">6,471,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">3,102,728<span></span>
</td>
<td class="nump">3,925,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes and accrued interest</a></td>
<td class="nump">493,814<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ConversionOfSeriesAConvertiblePreferredStock', window );">Conversion of Series A Convertible Preferred Stock</a></td>
<td class="num">(452)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ConversionOfSeriesBConvertiblePreferredStock', window );">Conversion of Series B Convertible Preferred Stock</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Stock dividend payable</a></td>
<td class="nump">34,066<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">389,004<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 394,412<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ConversionOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ConversionOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ConversionOfSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ConversionOfSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_StockPayableForInvestorRelations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_StockPayableForInvestorRelations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801568080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,518,146<span></span>
</td>
<td class="nump">$ 1,773,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares exluded from the calculation of earnings per share</a></td>
<td class="nump">19,992,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,949,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance under the Omnibus Plan</a></td>
<td class="nump">2,281,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Cumulative net loss</a></td>
<td class="num">$ (48,540,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,217,437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_WorkingCapitalDeficit', window );">Working capital</a></td>
<td class="num">$ (2,221,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791317664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Warrant activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Warrants</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average Exercise Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term (Years)</b></p></td>
    </tr>
<tr>
    <td style="vertical-align: bottom; width: 57%"><font style="font-size: 8pt">Balance outstanding at December 31, 2019</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="vertical-align: bottom; width: 14%; text-align: right"><font style="font-size: 8pt">13,496,924</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><font style="font-size: 8pt">2.02</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 8pt">4.07</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Exercised</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">(45,101</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">)</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">0.87</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">4.70</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Expired</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">Balance outstanding at March 31, 2020</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2.03</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3.82</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">Exercisable at March 31, 2020</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2.03</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3.82</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802881760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares, authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares, issued</a></td>
<td class="nump">13,553,005<span></span>
</td>
<td class="nump">8,421,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares, outstanding</a></td>
<td class="nump">13,553,005<span></span>
</td>
<td class="nump">8,421,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares, issued</a></td>
<td class="nump">2,441.92<span></span>
</td>
<td class="nump">2,441.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="nump">2,441.92<span></span>
</td>
<td class="nump">2,441.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares, issued</a></td>
<td class="nump">121.58<span></span>
</td>
<td class="nump">121.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="nump">121.58<span></span>
</td>
<td class="nump">121.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639632848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 30,288<span></span>
</td>
<td class="nump">$ 23,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638572928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive shares</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Options to purchase common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,579,737</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,449,319</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Warrants to purchase common stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,496,924</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">31,603</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">362,568</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of Series A Preferred Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,806,805</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7,285,651</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of Series B Preferred&#160;Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">122,806</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">355,263</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Potentially dilutive shares excluded</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>19,992,774</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>24,949,725</b></font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634905824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020,
the Company issued an aggregate of 45,101 shares of its common stock upon warrant exercises valued at $39,238.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes all stock warrant
activity of the Company for the three months ended March 31, 2020:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Warrants</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average Exercise Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term (Years)</b></p></td>
    </tr>
<tr>
    <td style="vertical-align: bottom; width: 57%"><font style="font-size: 8pt">Balance outstanding at December 31, 2019</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="vertical-align: bottom; width: 14%; text-align: right"><font style="font-size: 8pt">13,496,924</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><font style="font-size: 8pt">2.02</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 8pt">4.07</font></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Exercised</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">(45,101</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">)</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">0.87</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">4.70</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-indent: 0.25in"><font style="font-size: 8pt">Expired</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">Balance outstanding at March 31, 2020</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2.03</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3.82</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">Exercisable at March 31, 2020</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2.03</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3.82</font></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791226064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2020 and December 31, 2019, current liabilities consisted
of the following:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Accounts payable</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">1,240,687</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">1,278,431</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued payroll</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">95,656</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">94,862</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued bonuses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">97,114</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">295,794</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued employee benefits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,750</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,750</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued interest</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,828</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9,738</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Insurance premium financing</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">23,950</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Total</b></font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>1,444,035</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>1,708,525</b></font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798158016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning | shares</a></td>
<td class="nump">3,449,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="nump">130,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_NumberOfOptionsExercised', window );">Number of options exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options forfeited | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options cancelled or expired | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending | shares</a></td>
<td class="nump">3,579,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options outstanding, exercisable | shares</a></td>
<td class="nump">856,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted | $ / shares</a></td>
<td class="nump">.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price exercised | $ / shares</a></td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price forfeited | $ / shares</a></td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price cancelled or expired | $ / shares</a></td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">2.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, exercisable | $ / shares</a></td>
<td class="nump">$ 4.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term outstanding, beginning</a></td>
<td class="text">8 years 3 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual term outstanding, granted</a></td>
<td class="text">2 years 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term outstanding, ending</a></td>
<td class="text">7 years 9 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term outstanding, exercisable</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_NumberOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_NumberOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791358304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock', window );">Common Stock Options</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock options are awarded to the Company&#8217;s
employees, consultants and non-employee members of the board of directors under the 2016 Omnibus Incentive Plan (the &#8220;Omnibus
Plan&#8221;) and are generally granted with an exercise price equal to the market price of the Company&#8217;s common stock at
the date of grant. The aggregate fair value of these stock options granted by the Company during the three months ended March 31,
2020 was determined to be $185,602 using the Black-Scholes-Merton option-pricing model based on the following assumptions: (i)
volatility rate of 116% to 119%, (ii) discount rate of 0%, (iii) zero expected dividend yield, and (iv) expected life of 10 years.
A summary of option activity under the Company&#8217;s Omnibus Plan as of March 31, 2020, and changes during the year then ended,
is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Options</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term (Years)</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%"><font style="font-size: 8pt">Balance outstanding at December 31, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,449,319</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">2.32</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">8.26</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">130,418</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.24</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2.01</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Cancelled or expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Balance outstanding at March 31, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3,579,737</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2.24</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7.79</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Exercisable at March 31, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">856,172</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4.77</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.20</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636034688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020 and December 31, 2019,
fixed assets consisted of the following:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Property, leasehold and capitalized software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">684,418</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">679,179</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">TAEUS development and testing</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">60,708</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">43,596</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated depreciation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(508,111</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(486,524</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fixed assets, net</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>237,015</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>236,251</b></font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the three months ended
March 31, 2020 and 2019 was $21,586 and $19,632, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790063392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management makes estimates that affect certain
accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments
or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company&#8217;s
consolidated financial statements include all accounts of the Company and its consolidated subsidiary and/or entities as of reporting
period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The accompanying
unaudited condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally
included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant
to such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily
indicative of the results that may be expected for the year ended December 31, 2020. The balance sheet at December 31, 2019 has
been derived from the audited financial statements at that date. For further information, refer to the financial statements and
footnotes thereto included in ENDRA Life Sciences Inc. annual financial statements for the twelve months ended December 31, 2019
included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 26, 2020.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company
considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid
investments with maturities of one year or less, when purchased, to be cash. As of March 31, 2020 and December 31, 2019, the Company
had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured
limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial
institutions and has determined the credit exposure to be negligible.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company&#8217;s
inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average
cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation
or obsolescence of inventory.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Capitalization of Fixed Assets</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company
capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one
year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3)
all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less
than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed
as incurred.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, &#8220;Revenue from Contracts with
Customers&#8221; (&#8220;ASC Topic 606&#8221;). This standard provides a single set of guidelines for revenue recognition to be
used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its
core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects
the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated
guidance effective January 1, 2018 using the full retrospective method. The new standard did not have a material impact on its
financial position and results of operations, as it did not change the manner or timing of recognizing revenue.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ASC Topic 606, in order to recognize revenue,
the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of
each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that
the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of
ASC Topic 606 did not have an impact on the Company&#8217;s operations or cash flows.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB Accounting Standards
Codification (&#8220;ASC&#8221;) Subtopic 730-10, &#8220;Research and Development&#8221;. Research and development costs are charged
to the statement of operations as incurred. During the three months ended March 31, 2020 and 2019, the Company incurred $1,518,146
and $1,773,498 of expenses related to research and development costs, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings (Loss) Per Common Share</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes earnings per share under
ASC Subtopic 260-10, &#8220;Earnings Per Share&#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss)
attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the
denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average
number of additional shares that could have been outstanding from securities convertible into common stock (using the &#8220;treasury
stock&#8221; method), unless their effect on net loss per share is anti-dilutive. There were 19,992,774&#160;and 24,949,725 potentially
dilutive shares, which include shares of common stock issuable upon the exercise or conversion of outstanding preferred stock,
stock options, warrants, and convertible notes, as of March 31, 2020 and&#160;December 31, 2019,&#160;respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The potentially dilutive shares, which are excluded
from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Options to purchase common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,579,737</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,449,319</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Warrants to purchase common stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,496,924</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">31,603</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">362,568</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of Series A Preferred Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,806,805</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7,285,651</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of Series B Preferred&#160;Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">122,806</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">355,263</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Potentially dilutive shares excluded</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>19,992,774</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>24,949,725</b></font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">Disclosures
about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance
sheet, where it is practicable to estimate that value.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In accordance
with ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; the Company measures certain financial instruments at
fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance
with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">Fair value
is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These
tiers include:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; <font style="background-color: white">Level 1, defined as
observable inputs such as quoted prices for identical instruments in active markets;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; <font style="background-color: white">Level 2, defined as
inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar
instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; <font style="background-color: white">Level 3, defined as
unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such
as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial assets are considered Level 3 when
their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one
significant model assumption or input is unobservable.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s
financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and
other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of
notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations
are the same as prevailing market rates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s 2016 Omnibus Incentive Plan
(the &#8220;Omnibus Plan&#8221;) permits the grant of stock options and other share-based awards to its employees, consultants
and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus
Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number
of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming
the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding
options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined
by the board. On January 1, 2020, the pool of shares issuable under the Omnibus Plan automatically increased by 3,202,280 shares
from 2,649,378 shares to 5,861,658. As of March 31, 2020, there were 2,281,921 shares of common stock remaining available for issuance
under the Omnibus Plan.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company records share-based compensation
in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use
of option-pricing models that require the input of highly subjective assumptions, including the option&#8217;s expected life and
the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes
option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expense recognized during
the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures.
The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable,
in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan
as described above.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Discount</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines if its outstanding convertible
promissory notes should be accounted for as liability or equity under ASC Topic 480, &#8220;Liabilities &#8212; Distinguishing
Liabilities from Equity.&#8221; ASC Topic 480 applies to certain contracts involving a company&#8217;s own equity, and requires
that issuers classify the following freestanding financial instruments as liabilities: mandatorily redeemable financial instruments,
obligations that require or may require repurchase of the issuer&#8217;s equity shares by transferring assets (e.g., written put
options and forward purchase contracts), and certain obligations where at inception the monetary value of the obligation is based
solely or predominantly on:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; A fixed monetary amount known at inception (for example,
a payable settleable with a variable number of the issuer&#8217;s equity shares with an issuance date fair value equal to a fixed
dollar amount);</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Variations in something other than the
fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the S&#38;P 500 and settleable with
a variable number of the issuer&#8217;s equity shares); or</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Variations inversely related to changes
in the fair value of the issuer&#8217;s equity shares (for example, a written put that could be net share settled).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_BeneficialConversionFeaturePolicyTextBlock', window );">Beneficial Conversion Feature</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the conversion feature of conventional convertible
debt provides for a rate of conversion that is below market value on the date of issuance, this feature is characterized as a beneficial
conversion feature (&#8220;BCF&#8221;). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 &#8220;Debt
with Conversion and Other Options.&#8221; In those circumstances, the convertible debt is recorded net of the discount related
to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company determines the instrument meets
the guidance under ASC Topic 480, the instrument is accounted for as a liability with a respective debt discount. The Company has
previously recorded debt discounts in connection with raising funds through the issuance of promissory notes. These costs are amortized
to noncash interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of
the unamortized amounts is immediately expensed. See Note 6, Convertible Notes, for further discussion on the Company&#8217;s accounting
treatment for the convertible notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial statements are
prepared using accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) applicable to a going concern,
which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited
commercial experience and had a cumulative net loss from inception to March 31, 2020 of $48,540,234. The Company had working capital
of $2,221,823 as of March 31, 2020. The Company has not established an ongoing source of revenue sufficient to cover its operating
costs and to allow it to continue as a going concern. The accompanying financial statements for the period ended March 31, 2020
have been prepared assuming the Company will continue as a going concern. The Company&#8217;s cash resources will likely be insufficient
to meet its anticipated needs during the next twelve months. The Company will require additional financing to fund its future planned
operations, including research and development and commercialization of its products.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the Company to continue as a going concern is dependent
on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable.
Management&#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and
borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.
As described further below under &#8220;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; the COVID-19 pandemic has impacted our business operations to some extent and is expected to continue to do so
and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. If the
Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce
the scope of or eliminate one or more of the Company&#8217;s research and development activities or commercialization efforts or
perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its
ability to successfully secure other sources of financing and attain profitable operations. There is substantial doubt about the
ability of the Company to continue as a going concern for one year from the issuance of the accompanying consolidated financial
statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In May
2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; ASU 2014-09 is a comprehensive revenue
recognition standard that superseded nearly all previous revenue recognition guidance under U.S. GAAP and replaced it with a principle-based
approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised
goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue
and cash flows arising from contracts with customers. The FASB has since issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12,
and ASU 2016-20, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim
and annual periods beginning after December 15, 2017. The standard can be adopted either retrospectively to each prior reporting
period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance
recognized at the date of initial application (the cumulative catch-up transition method). The Company has reviewed ASU 2014-09
and using the full retrospective method has determined that its adoption has had no impact on its financial position, results of
operations or cash flows. The Company adopted the provisions of this standard in the first quarter of fiscal 2018.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02,
&#8220;Leases.&#8221; ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance
sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning
after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for
capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial
statements. The Company evaluated the impact that the application of the new standard has on its consolidated financial statements
and related disclosures, and determined that it should record a total lease liability of $431,363, with a corresponding right of
use asset valued at $430,681. The Company adopted the provisions of this standard in the first quarter of fiscal 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued
by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did
not or in management&#8217;s opinion will not have a material impact on the Company&#8217;s present or future consolidated financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_BeneficialConversionFeaturePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_BeneficialConversionFeaturePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798510976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares, authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares, issued</a></td>
<td class="nump">13,553,005<span></span>
</td>
<td class="nump">8,421,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares, outstanding</a></td>
<td class="nump">13,553,005<span></span>
</td>
<td class="nump">8,421,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares, issued</a></td>
<td class="nump">2,441.92<span></span>
</td>
<td class="nump">2,441.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="nump">2,441.92<span></span>
</td>
<td class="nump">2,441.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares, issued</a></td>
<td class="nump">121.58<span></span>
</td>
<td class="nump">121.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="nump">121.58<span></span>
</td>
<td class="nump">121.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791263712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENDRA Life Sciences Inc. (&#8220;ENDRA&#8221;
or the &#8220;Company&#8221;) has developed and is continuing to develop technology for increasing the capabilities of clinical
diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions
in circumstances where expensive X-ray computed tomography (&#8220;CT&#8221;) and magnetic resonance imaging (&#8220;MRI&#8221;)
technology is unavailable or impractical.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENDRA was incorporated on July 18, 2007 as a
Delaware corporation.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENDRA Life Sciences Canada Inc. was organized
under the laws of Ontario, Canada on July 6, 2017, and is wholly owned by the Company.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798696320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded</a></td>
<td class="nump">19,992,774<span></span>
</td>
<td class="nump">24,949,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded</a></td>
<td class="nump">3,579,737<span></span>
</td>
<td class="nump">3,449,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded</a></td>
<td class="nump">13,451,823<span></span>
</td>
<td class="nump">13,496,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_ConvertibleNotesPayableConversionMember', window );">Shares issuable upon conversion of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded</a></td>
<td class="nump">31,603<span></span>
</td>
<td class="nump">362,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_SeriesAPreferredStockConversionMember', window );">Shares issuable upon conversion of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded</a></td>
<td class="nump">2,806,805<span></span>
</td>
<td class="nump">7,285,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_SeriesBPreferredStockConversionMember', window );">Shares issuable upon conversion of Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded</a></td>
<td class="nump">122,806<span></span>
</td>
<td class="nump">355,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_ConvertibleNotesPayableConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_ConvertibleNotesPayableConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_SeriesAPreferredStockConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_SeriesAPreferredStockConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_SeriesBPreferredStockConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NDRAU_SeriesBPreferredStockConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636049712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Options</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term (Years)</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%"><font style="font-size: 8pt">Balance outstanding at December 31, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,449,319</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">2.32</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">8.26</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">130,418</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.24</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2.01</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Cancelled or expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Balance outstanding at March 31, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3,579,737</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2.24</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7.79</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Exercisable at March 31, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">856,172</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4.77</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.20</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>37
<FILENAME>0001654954-20-005509-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-20-005509-xbrl.zip
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M<;H[VC;B<> =<1KRQ3R[CA.LP=T?_RQ*BX8]+ SB%*'9&?8M.>4D8-^2)Y;
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M X]C#,6"*A;(%Y!DYH)OE]R9RKZTUGC"Y8/*S-3.4E]-@J%B'J$*3>=NT]N
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MF2_+KA44.>+6D T>DCZ+-:9=E2<*^])_H,;WX -R*'-NWI53GG7E6H.N"FZ
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MLJD:-ZO7_O.FV^GWW/Z@8PT.DZT,L)J12NM5Y*^ /XHBEO=5PASV%=#?AL^
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MHTF;V*A^PE1-H';+.NVR(\I73VBU;)-""#NS;X+\15F3LLS.SOE3+V.M$-=
MT!3#Q.'<4O*E*(^-K2_GTKL6;J;N?)R XF7YG>&UE6_)?,C"Q6()&G7'R(N%
M,#85A<R[*3DR0BSFPO07/ A6OB9*![;4Z>7P(&95C:+OM!JUL9RI+6N\3,(L
M7:2\FDLJT3Q2Q+",[W12'1#01 0T\7(%E<@"%ITN6"YBB:-0S9AGE26*]Z2I
ME$1F(7J;T][RHJJ8XK=$%F&^J<G'DA(2FQ\+NMQF/MRHB3^[MJE%JJA+KJ:4
M1P4.T0D(-,/&E8H82<)XX@+R6_[$%U>'YH;-:1>KK"-(K0HJ[4MDQ<55+NU
MIK=AQ7/$A[Y1?IU5!,/\6"CQ*1;"]-'WLG85##&E+H5!0Q%E>*MCU\,45BSI
M+N-X1'4'8KRL/*8$-SZ1J308K'U>6.I>=.:W0-WJ-KH%5WZ.(Q=J\.L4TI1K
MWE:]KAP +"2J*MV>.+^5PX4+C:]WR(!C[7AD1?VMR=VV)9ZL<5'#19Y@AXL+
MNK$G/OHY921O0=*\G6Y7K-()2"+]<QX51-)B73];7LT!5S%H@NV.\7.Z%(_T
ME>=+2@6NWL@Y1P<-N^HC7[ZA5+E"H8;O/&^[S4;?[7K-ZC1_1Z;XY^HKV+<!
M'S)G-V;B4_X2\X= FT)F?JY1*0 T:U3]4+#G:1D&$4.6FBLU8.T\-!.EJ0<'
M>07'?+O#OO!.J.&9L?>6!=:2\JSB<2\Y7\LMR>4;O6[7';2]4F$*8I]:6> 1
M\6&.8!DRH/,YN<4$Q"I4JI0S&N)N@G_5NRA4ALVQ0NM/I7X/@RB>XN'+&>NS
M7 &8*H532GJ'K08D(:O6B\J\VK_(_"HG"=(?M0EFD^C\&ET-5N_"<_!V]Q?]
M.SM4P*/L<8S\%"@UF+$ZV7RB,G]EBLC;:O]X,=WC"<KY7+K'X-[2/5H=K][S
MBKE/"S-+J97%JM0-@D?!O%WZ1KO9=5N>G5&R,*!E^RI*Q:?P;<9./H^@W= *
M;U6"AU;%BWD *Y(-5N0#2)E_S@FX]YR M]OD!+P]V9R BK1<=6$NY%0,CJ7S
M(29^RYXSY 9&4V7!FC*:ME@%%#^Q4%Q6Z(R#";V969J,I0]2K$ZZ[+6R5XSL
M&9FT<!N@6L5(>U9LW)^C!9X%(TO=6Y(D48V:4T^2.&AN1+DN9+?<"-LR7YD;
M,1@L+OK>5ZZ$BJV6\R6<(^1** ?&&I4<]Y4K02!4Y$L4<_3N/5="X6*QQG'_
MN1(*AE*^A+/W7 E@/D1D]196XD*=?T!M#J@"+8#_@O41WB!E2EDCU6I)JD;!
M[;VXQNC^4C74Y5^1KE$)B'7NU,Y%96OLDJ9AF\4W)+/OED:D*W(U!OV]Y6KH
MS-1ROH:SMUR-94'C$E)6YEJ4E:[XBC*(V8BI4K^613B>9**%HLVQ2:V0K8J4
M$ZH0)5J.P]REMR8WQ/,D[VA'3H[BS+G#"FT,.'$>18#EGPC"GI(DG'TD2!!
M.R1)5.85+4R0J+26&83E"0U%2_E)T'<A8V%PT(R%P: 8BRZ>P8/.6!ALE;%0
M1$$N8Z%"LMQWQD+Y2/:<L5!:8&7&0NF-U1D+!?7D_M(6;"UV+4%F"R/"V!.7
M2-NE"!C?[+WD""QRD.7N36("JW?FJJZ@Q12"O'=TDX0"*^YORZ4]QOZ]MMO,
M^:>7MLW,Z4([A?X7OJ[LV>H&MT^*8Q8&^<NJT#G(?W)!_@JOWUI!_D9KXR"_
M5V]UMPGR>Y[K=3O;1/B=0F"_,@B]03R_JLE*3@FT8_DF0'"@>'X9.M7EJ-5M
MNZU.YZ#1?$='\FV=Y,#1_#Y%Z74D7]8AE*+YO0X]UWA@T7S33VSM1F&JP]BG
M=W]<?'_]=70-YQ^*SQ.*!KQ%=R>J$R)*B0GHL]Q2MVI2TO&[CDDRGQG; T-L
M8Y-_N"@BHJ:/IMQ+#,Y5%Q%$<533PTFGI.-IM6"H BEC%4BQE')0 +O.YVD4
M#.<I:'(XY1T9&32(<F]W^1A'B>"!XA0@VHN,&(-<N4*F42R_Q*JMDKMKQ<Q]
MT])7">0KMAK)!:5UL9)4 AC2W"$H4/,AJ9SAN:1%"T&A.X=6-(+N=]QNH[FJ
M#30#4\O+#=N;;[>"MEI H]>80*AL =W]!<'PO,$]MH+V&G8?Z NPR:93&5:6
MPA#=P3<(F*&\JN-5A$CD5]6;E:$ ZR:Z BZTS@?79Z\R'0Z?24 MY537!&PA
M^OKH\B^_+,V<<T8B#-.9C\?^Z[/&,_IYAI>N_#D'FM=<#9L: ]]H_&(F.-)Z
MV\Y[W&#,I82\QE\$*.H=-=)OG:^,8L1%].NSIM[X$"__1']PB-SC>( &NL?S
M,*LO[>U 422*9/EYWOO"RESYI .?\H:KM"[N^X@>_T$K?/]#AA<6&G$'@^2"
MXQO'!^2]NL8YN^1,?V?Z.R@@?ZB.1L<'Y5+.5D%%]AL:=B_^&]6@EX=ABG _
MXYS5&U)GZ+9_67="[UO5?-5T:<54"NV,;\GZ(8)T_8G!2GGY96.!L/.;@U_R
MA[[1P.*6VVX/W-9#VJ^W]ED_WVY3.R&T66\U'QXN#TQU_7JS>P](VK-PH>UA
MAVX4PHUZLQ-$ZV[P;VR;K[G'=8]@TZ/:^GR\5L-M>_TC@7^P;<*9MA_['IOU
MAK?S'D^'L90B_V!9J_;8">Z\P0?$3A]4ZLV9G<X;?*@;/!UVND33,L32"6SE
M3%F)9\XZ;_#!;G!/G+4FO M<,_E@VD-EIY;;Z0W<7JMW3*I;#>:F+I,=[)+'
M;WOUZKUU_6JGPH/OK?S01\-[_4[7]7KKNN4>.^>UZ[VC"J%#G'BGO@=JK>"\
M5Y3[D/O5 9/0]I)+MEEBFDJP/LFDM+U,HRKU0CE/I]J^H,,D>W&2$"=5 6NF
M.#!=XD^BCJ#1.5:%@G#5EGKEN9Z3H\[)40\Q.>KI+1R6TL$6S)@[Y^,\\),^
M.HFI#"1')@ YCR__JW5Z]%;$?B6:#PK).?_K?O*_R@Z))11?K9=HE:;3.W;N
MU@H M\B16?'%QMZ_Z+5W2<?Q6FY[T'4':WODCH:Y^SN+_3MH5BS<WRW+K+%I
MEMDCH/+]?W&G++9VO;&N(VW?A[ 7 7RP_+9U+-2=SW1OI''O\;:'A(XS5D_X
M,P\%J\>65ILF#3X1&GC!KNX](F7UFB_/1Y#/0.[O1X4X+8P<'['M>F_= ."C
M$'&;)G(^$3(X*P^;8_54 #RMSSP4(CRV('J_4=;KF0(>+#K.6#WASSP4K.Y!
M6NT8/-@JP_&)D +&!3J>VV^V'B%>#NWVW\77_WCQ?TSR;M7[^PFBG)ZPVT<:
M]Q.A@K.0.PNY4__, Q9R)F-^W?SU)2GG*G===6/%42D!C1]++Z(Q9K: 5H<C
M(\1I)JSCAW6*#37:_CR98/?0WP1@@=#U!-MOO]<ML-4H&\[CZ>1G6U ND^PY
M3>.P?.RF3^@+!0TH49,#N'OKWQ*<EW,9SY/,=7[[[1(;#_\>C*Z#*W@Q#*8!
M=P/UA]Q]=,3+N-P6/]>BO^5V.ST'IR]R4ON_ $@YA$((ZMR,N=["U5GK013@
M%$C.6P_OZ%7JS-UQ!_VN*X>\R?DFW"JUL'75G%]]2;5@[C9D,GS=^<PC03Z/
MLIBF2#3HS1X $*02(]C:U9]RVGP0C1+XI2J8*.S&R>T$NZ^VW$&GH2>+Y7:"
M4UUZ;F_0UT#\^QS^YG6KYN::42!82"%;JV;8LC43\N,,K!I'8/IVRW[3.',M
MR^&5L0%R,(BP:R^!0.76-+LA*F>$N3QR@^:5F16C^%96::<5;S7;QV\\?8!E
M[0F\W+(\M5#DIZG@@1+T,X%B>$9B4_:K->V*^=V9?T>BF4>ZF6_BZ7&[8_GS
MW0RO&Z"@<2QXW)4<]$(<,)V%P2C@UK]O>*8+D(HH%_3,L0H'B4S [J;4*9V(
M'H$ HAG&2<*U*=1$6,).\_,TR(HEIY+,==_AQ=LD,-16<P.-^4!EE^!\!V.D
M==D!'^"A[Z1E19WXUVO\4N?[@7H81RD-!L"3NHK@IA_S;$(<:(-J02T,(@:)
M1Q16H%ZUKR8&E#/\1G$8REDH04J-N@'[V(0>#F+HTP3)W+" XK!!&DVF8"(4
M(S8(#AY%>"='R^KYJ[D>T?Y8R@5 ZL772^=;#!3A]-M-QJ>:EU93\](2E4YK
M;PL ;]>[/=75^0FP[D5ELVEN39ZIP3IFUH*<T,8H4TQ,LW$2FJS"Q5OIN:)J
M'44XKSJOJ^:O;0Y8=26Y/ZM''E?=QM$+1CYK66PT\:+^O<6A5CI]-J<N]8;*
M'.ZOG;.\A;OGD??G[+7=QN ^.G3NZ:S7/]C=V_IM*9LD5-M[W!J>V^OLWH[A
MX!@_5@>)/6"\#>;:N@ZV$\+X[B ?#>,]L)]W[W!S<(RWR=@;BKLX>K"MRSP<
M9+:VD#\5Y'^+P4J]#Y3O_R+>/BUS,'![_8?&%K^)-'VMYK3I(:,\*9!'G#U4
M3GGA-3INJ[>1*K'ZJXN3O ][;E^*#IO)G$883H,HF,ZG!3?50SW#UJ#MMKV'
M)NV8IT;SA'WC0_BL' ?)T[;8)_90SZ3;=[N-W?NG'_A(XNBJ1JXT9@SK4![Y
MM=1J=MQ^XUZNI6-V##N ^^[#NGV:4*TD4,H1HB B,3#FX))T<I/C\GFKX3;[
M?5))GS=;KM?ON^B#GG&\,+Q[$FY>_' ^:OR>IF9.U:SO2QZLB0J)GI[.+/L$
MH\EE;'U(_&@4!RE%?T58/>=:SPSUO#>.CD@3J+_[=X[7Y.AJ94C:4>%H%6O%
M0T&UD&)0PCJL?(2Z!%A^SKP5/B(X+J\#,<%6-J,Y1<LY=R!A$KCV@V1*$?$%
M\U/-['7U3"5@R3S"@$T2SZ^N<Q%1S;P\S9)R+>8<./4IYE++XAI-M.3($P7J
M?)RLS2M7KB;C?*D._D81]B7!X)"3^B$&Q"D^!=]+Y\-_PDXXZH?CG?'0^7/9
M@BU;&*3X6R+P,I.35LLK!9&<QFW/Z)P!X<6XWQLZ:1JV"M" W)L2*%ZC]I\4
MIWO>ZH JW6G4G>]Z7&C5GEWG=\"(.G'<F0 BQD'6!22,_/0:-A7-4QDLH[Z#
M_@BHX$:-T>;@HTC@S2EF-]=D6(U0!31"L5"X@(+TVDR*K:*-+_,$IX)3T-.&
M+Q?#K-X.SSV/.'Q( .EYV9B!0R'YQ<-Q54A_-@<H1YC0(0CWUYR]H(;<JJ&W
M -YL#O<*Q:;MSHTM[+G8:\B^C00&K&KW;>1S5Q^Z]H&#?!U:=%1HL3#P%R^A
M=GV0&Z<^*4ST!7:XP3'7-*H;KT&:$LS!3S[*(()3"$..A@\%B+!(9BI8LJ4/
ME(,GS)-X?3U$/IYG#@U(QSFR=\XL3E2H=.%!J0&V.**9X$AESA6-]R5@\<L
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MM_P4M,J5+4ZJE&<_E7SR\22FFX[V;()7.;UF=+IU9SF.",L]2]V@8]2=\#K
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MH[]K&_W$$@GTMQ.&!:2WB^*1.UY3&CXZL<?/61)K+)+A@^,':&C?13'MWJY
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MO0S>/[:36*4.6CPMH!9'+W<Z:NS:\ALT2O=7X/45>NWUQG>#;]WWYK7,8 Y
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M&_%O&Q/6:B-<)!^-0U^"WNR3C;/8:OLKG0K$O9-;:_9%1GJ;3A=><4^D!SG
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MFM>?E32,D/ZL9']6LC\K*>:I/RMI^EG),EX\6[X)D@'$34*)MR"8/> 9M&Q
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M%P?(WY:#LK*@O='R87;Y^?X"/^,H81V(V/& LSR,'Q5,[%>R1SY= [9\Z],
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M#>$MX:P%,TOXR?.+(B4P[W@-,*[PW/\96P'_'(?2%[Q,"[&>X\/8P XIM4L
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M%33,O<=^D;)\%I<O?E0$.*!/OM-PMJBR5[>7*'J=\AX^9-5Y[ZVB&DY^]*^
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M)XFS,[Q(4LSE'KP7G%V^Y*F7I$$8>^GZ.L=+%GC31:LDBEAE\)M[HH;=X^<
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M7+M3\LGYF40D<;,X^<'YQ0US^IN__^,RRNCOO"QX)O2WY5<_.=^\/WYT]O8
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MR5!ZR\ZI1JQ]XJ^E%P1>6">6"![6_MAVM$5[FV?A%0\+SB!9FQ(BJP?[';X
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MF?)XQ\PG/']A%RK2;0"W^58<\$H4H57,L/H7]@>[@Z*_^7]02P$"% ,4
M"  :BZY0'U9N\_6*   [C 0 $@              @ $     ;F1R874M,C R
M,# S,S$N>&UL4$L! A0#%     @ &HNN4,PM(F>("@  <FL  !(
M     ( !)8L  &YD<F%U+3(P,C P,S,Q+GAS9%!+ 0(4 Q0    ( !J+KE Z
M950\N0L  &N3   6              "  =V5  !N9')A=2TR,#(P,#,S,5]C
M86PN>&UL4$L! A0#%     @ &HNN4,>I!LY;#P  >?$  !8
M ( !RJ$  &YD<F%U+3(P,C P,S,Q7V1E9BYX;6Q02P$"% ,4    "  :BZY0
MA4E]?(DO  !0$ , %@              @ %9L0  ;F1R874M,C R,# S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( !J+KE!F1;V=;"$   A? @ 6
M  "  1;A  !N9')A=2TR,#(P,#,S,5]P<F4N>&UL4$L%!@     &  8 D $
' +8" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791326784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments &amp; Contingencies</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Office Lease</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective January 1, 2015, the Company entered
into an office lease agreement with Green Court, LLC, a Michigan limited liability company, for approximately 3,657 rentable square
feet of space, for the initial monthly rent of $5,986, which commenced on January 1, 2015 for an initial term of 60 months. On
October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On
July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally
expiring on December 31, 2019, such that the lease now expires on December 31, 2024.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company records the lease asset and lease
liability at the present value of lease payments over the lease term. The lease typically does not provide an implicit rate; therefore,
the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease
payments. The Company&#8217;s discount rate for operating leases at March 31, 2020 was 10%. Lease expense is recognized on a straight-line
basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents
as they become payable based on the adoption of ASC Topic 842. The weighted-average remaining lease term is 4.67 years.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, the maturities of operating
lease liabilities are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Operating Lease</b></p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 88%"><font style="font-size: 8pt">2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">74,092</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">101,752</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">104,793</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">107,954</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2024 and beyond</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">111,192</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">499,784</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: amount representing interest</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(105,371</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Present value of future minimum lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">394,412</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: current obligations under leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">68,608</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Long-term lease obligations</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">325,804</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2020 and
2019, the Company incurred rent expenses of $30,288 and $23,188, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment and Consulting Agreements</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Francois Michelon</i></b> &#8211; Effective
May 12, 2017, the Company entered into an amended and restated employment agreement with Francois Michelon, the Company&#8217;s
Chief Executive Officer and Chairman of the board of directors. The term of the employment agreement runs through December 31,
2019 and continues on a year-to-year basis thereafter. The employment agreement provides for an annual base salary that is subject
to adjustment at the board of directors&#8217; discretion. The annual base salary in effect during the period covered by this Form
10-Q was $355,350. Under the employment agreement, Mr. Michelon is eligible for an annual cash bonus based upon achievement of
performance-based objectives established by the board of directors. Pursuant to Mr. Michelon&#8217;s employment agreement, in connection
with the closing of the Company&#8217;s initial public offering he was granted options to purchase an aggregate 339,270 shares
of common stock. The options have a weighted average exercise price of $4.96 per share of common stock and vest in three equal
annual installments beginning on May 12, 2018. Upon termination without cause, any portion of Mr. Michelon&#8217;s option award
scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change
of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the
entire unvested portion of the option award will terminate.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Mr. Michelon&#8217;s employment is terminated
by the Company without cause, Mr. Michelon will be entitled to receive 12 months&#8217; continuation of his current base salary
and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base
salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following
a change in control).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under his employment agreement, Mr. Michelon
is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 27, 2019, the Company entered into
an amendment to Mr. Michelon&#8217;s employment agreement to provide that (i) Mr. Michelon&#8217;s employment with the Company
will continue until terminated under the terms the employment agreements, and (ii) Mr. Michelon will each receive certain payments
if he is terminated by the Company without Cause (as defined in the employment agreement amendment) or he resigns for Good Reason
(as defined in the employment agreement amendment).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b><i>Michael Thornton</i></b> &#8211;
Effective May 12, 2017, the Company entered into an amended and restated employment agreement with Michael Thornton, the Company&#8217;s
Chief Technology Officer. The term of the employment agreement runs through December 31, 2019 and continues on a year-to-year basis
thereafter. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors&#8217;
discretion. The annual base salary in effect during the period covered by this Form 10-Q was $267,800. Under the employment agreement,
Mr. Thornton is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board
of directors. Pursuant to Mr. Thornton&#8217;s employment agreement, in connection with the closing of the Company&#8217;s initial
public offering he was granted options to purchase an aggregate 345,298 shares of common stock. The options have a weighted average
exercise price of $4.96 per share of common stock and vest in three equal annual installments beginning on May 12, 2018. Upon termination
without cause, any portion of Mr. Thornton&#8217;s option award scheduled to vest within 12 months will automatically vest, and
upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award
will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Mr. Thornton&#8217;s employment is terminated
by the Company without cause, Mr. Thornton will be entitled to receive 12 months&#8217; continuation of his current base salary
and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base
salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following
a change in control).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under his employment agreement, Mr. Thornton
is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 27, 2019, the Company entered into
an amendment to Mr. Thornton&#8217;s employment agreement to provide that (i) Mr. Thornton&#8217;s employment with the Company
will continue until terminated under the terms the employment agreements, and (ii) Mr. Thornton will each receive certain payments
if he is terminated by the Company without Cause (as defined in the employment agreement amendment) or he resigns for Good Reason
(as defined in the employment agreement amendment).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>David Wells</i></b> &#8211; On May 12,
2017, the Company entered into a consulting agreement with StoryCorp Consulting (&#8220;StoryCorp&#8221;), pursuant to which David
Wells provided services to the Company as its Chief Financial Officer. Pursuant to the consulting agreement, the Company paid to
StoryCorp a monthly fee of $9,000, and in May 2018 this monthly fee was increased to $9,540. Additionally, pursuant to the consulting
agreement, the Company granted to Mr. Wells a stock option to purchase 15,000 shares of common stock in connection with the closing
of the Company&#8217;s initial public offering, having an exercise price per share equal to $5.00 and vesting in twelve equal quarterly
installments, and, for so long as the consulting agreement was in place, granted to Mr. Wells a stock option to purchase the same
number of shares of common stock with the same terms on each annual anniversary of the date of the consulting agreement. In May
2018, the annual stock option amount was increased and on December 13, 2018, Mr. Wells was granted options to purchase an additional
35,000 shares of common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 13, 2019, the Company entered into an
employment agreement with David Wells that supersedes the consulting agreement between the Company and StoryCorp. The employment
agreement provides for an annual base salary of $230,000 and eligibility for an annual cash bonus to be paid based on attainment
of Company and individual performance objectives to be established by the Company&#8217;s board of directors (in 2019, the amount
of such cash bonus if all goals were achieved would be 30% of the base salary plus base fees paid to StoryCorp under the consulting
agreement). The employment agreement also provides for eligibility to receive benefits substantially similar to those of the Company&#8217;s
other senior executive officers.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the employment agreement, on May
13, 2019 Mr. Wells was granted stock options to purchase 56,000 shares of the Company&#8217;s common stock. The stock options have
an exercise price of $1.38 per share, and vest in three equal annual installments beginning on the first anniversary of the grant
date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white"><b><i>Litigation</i></b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">From time
to time the Company may become a party to litigation in the normal course of business. There are currently no legal matters that
management believes would have a material effect on the Company&#8217;s financial position or results of operations.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633434976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>July 2019 Notes</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 26, 2019 the Company conducted a private
placement offering in which the Company sold senior secured convertible promissory notes (the &#8220;July 2019 Notes&#8221;) and
warrants exercisable for shares of the Company&#8217;s common stock (the &#8220;July 2019 Warrants&#8221;) to accredited investors
for a purchase price approximately $2.8 million. The purchase price covered the purchase of $2,587,895 aggregate principal amount
of July 2019 Notes and July 2019 Warrants exercisable for an aggregate of 1,736,843 shares of common stock. The net proceeds to
the Company were approximately $2.5 million, after deducting placement agent fees and other offering expenses.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company sold the July 2019 Notes and July
2019 Warrants pursuant to a Securities Purchase Agreement, dated July 26, 2019, between the Company and each purchaser. The July
2019 Notes bore interest at a rate of 10% per annum until maturity on April 26, 2020. Interest was paid in arrears on the outstanding
principal amount on the three month anniversary of the issuance of the July 2019 Notes, and each three month period thereafter,
and finally on the maturity date. Holders of July 2019 Notes were entitled to convert principal and accrued, unpaid interest on
the July 2019 Notes into shares of common stock. The July 2019 Notes were convertible into common stock at a conversion price per
share equal to $1.49 and were initially convertible into 1,736,843 shares of common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each July 2019 Warrant entitles the holder to
purchase one share of common stock for an exercise price per share equal to $1.49. The July 2019 Warrants are exercisable for an
aggregate of 1,736,843 shares of common stock commencing immediately upon issuance and expire July 26, 2022. The July 2019 Warrants
provide for cashless exercise and customary anti-dilution protection. The terms of the Placement Agent Warrant (as defined below)
are the same as those of the July 2019 Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">National Securities Corporation (the &#8220;Placement
Agent&#8221;) acted as placement agent in the offering pursuant to a Placement Agent Agreement, dated July 9, 2019 (the &#8220;Placement
Agent Agreement&#8221;). Pursuant to the Placement Agent Agreement, the Company paid to the Placement Agent a commission of 10%
of the gross proceeds from the offering, reimbursed $30,000 of the Placement Agent&#8217;s expenses and issued to the Placement
Agent a warrant exercisable for 173,685 shares of common stock (the &#8220;Placement Agent Warrant&#8221;).&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The July 2019 Notes and July 2019 Warrants include
embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815-40, &#8220;Derivatives and
Hedging.&#8221; The estimated fair value of the derivative warrant instruments was calculated using a Black-Scholes valuation model.
At inception, the aggregate relative fair value of the 1,910,538 warrants issued to the investors and the Placement Agent in July
2019 was determined to be $1,993,714 using the Black-Scholes-Merton Option Pricing model with the following average assumptions:
(i) volatility rate of 111%, (ii) discount rate of 0%, (iii) zero expected dividend yield, and (iv) expected life of three years.
Out of such amount, $1,126,138 was recorded as debt discount upon issuance using allocation of proceeds.&#160;<font style="background-color: white">At
the issuance of the July 2019 Notes, the effective conversion price was analyzed at $0.84 per share of common stock and the market
price of the shares on the date of conversion was $1.54 per share. As a result, the Company recognized aggregate beneficial conversion
features of $1,440,638.</font>&#160;$1,147,257 was recorded as debt discount upon issuance of the July 2019 Notes using allocation
of proceeds.&#160;<font style="background-color: white">As a result, the Company recorded a note discount of $2,587,895 to account
for the funding cost of $314,500 and the relative fair values of the warrants&#8217; and the notes&#8217; beneficial conversion
features, which will be amortized as interest over the terms of the warrants and the notes or in full upon exercise of the warrants
and conversion of the notes.</font>&#160;During the three months ended March 31, 2020, the Company amortized $228,568 of such discount
to interest expense, and the unamortized discount as of March 31, 2020 was $3,858.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 11, 2019, the Company completed
an offering of its Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;), described below under Note 7.
In connection with the offering, the Company retired $1,919,008 aggregate principal amount of the July 2019 Notes and $24,184 in
accrued interest, which amounts were used by the noteholders to purchase an aggregate of 1,690.58 shares of Series A Preferred
Stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, the Company had a total
of $42,260 in principal amount of July 2019 Notes outstanding, and unamortized debt discount of $3,858, for a net balance of $38,402
amount of the July 2019 Notes remaining outstanding.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634361296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 1,240,687<span></span>
</td>
<td class="nump">$ 1,278,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="nump">95,656<span></span>
</td>
<td class="nump">94,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">97,114<span></span>
</td>
<td class="nump">295,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">5,750<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">4,828<span></span>
</td>
<td class="nump">9,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance premium financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Total</a></td>
<td class="nump">$ 1,444,035<span></span>
</td>
<td class="nump">$ 1,708,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790519040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments &amp; Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 74,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">101,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">104,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">107,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024 and beyond</a></td>
<td class="nump">111,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">499,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(105,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">394,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current obligations under lease</a></td>
<td class="nump">68,608<span></span>
</td>
<td class="nump">$ 66,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">$ 325,804<span></span>
</td>
<td class="nump">$ 342,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791226064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020 and&#160;December 31, 2019,
inventory consisted of raw materials and subassemblies to be used in the assembly of a TAEUS system. As of March 31, 2020, the
Company had no orders pending for the sale of a TAEUS system. <font style="background-color: white">As of March 31, 2020 and December
31, 2019, the Company had&#160;inventory valued at $174,935 and $113,442, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798516400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENDRA Life Sciences Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001681682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,504,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801915552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Stock Payable</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,422,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, amount at Dec. 31, 2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">$ 33,939,162<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (27,691,696)<span></span>
</td>
<td class="nump">$ 6,248,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,748,736)<span></span>
</td>
<td class="num">(2,748,736)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,422,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, amount at Mar. 31, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">34,241,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,440,432)<span></span>
</td>
<td class="nump">3,801,740<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">6,338.490<span></span>
</td>
<td class="nump">351.711<span></span>
</td>
<td class="nump">8,421,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, amount at Dec. 31, 2019</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">49,933,736<span></span>
</td>
<td class="nump">43,528<span></span>
</td>
<td class="num">(45,217,437)<span></span>
</td>
<td class="nump">4,760,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Series A Convertible Preferred Stock converted to common stock, shares</a></td>
<td class="num">(3,896.570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,520,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Series A Convertible Preferred Stock converted to common stock, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="num">(37,471)<span></span>
</td>
<td class="num">(37,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Series B Convertible Preferred Stock converted to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230.133)<span></span>
</td>
<td class="nump">234,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Series B Convertible Preferred Stock converted to common stock, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="num">(835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for note conversions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued for note conversions, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">493,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued for warrant exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_StockIssuedDuringPeriodValueWarrantsExercised', window );">Common stock issued for warrant exercise, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">39,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Stock to be issued, preferred dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,066)<span></span>
</td>
<td class="nump">34,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock to be issued, consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,322,797)<span></span>
</td>
<td class="num">(3,322,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="nump">2,441.920<span></span>
</td>
<td class="nump">121.578<span></span>
</td>
<td class="nump">13,553,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, amount at Mar. 31, 2020</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 50,982,080<span></span>
</td>
<td class="nump">$ 78,836<span></span>
</td>
<td class="num">$ (48,540,234)<span></span>
</td>
<td class="nump">$ 2,522,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639050000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 174,935<span></span>
</td>
<td class="nump">$ 113,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615223968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease liabilities maturities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Operating Lease</b></p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 88%"><font style="font-size: 8pt">2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">74,092</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">101,752</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">104,793</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">107,954</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2024 and beyond</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">111,192</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">499,784</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: amount representing interest</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(105,371</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Present value of future minimum lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">394,412</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: current obligations under leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">68,608</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Long-term lease obligations</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">325,804</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606871856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Fixed assets</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Property, leasehold and capitalized software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">684,418</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">679,179</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">TAEUS development and testing</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">60,708</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">43,596</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated depreciation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(508,111</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(486,524</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fixed assets, net</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>237,015</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>236,251</b></font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788022064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,518,146<span></span>
</td>
<td class="nump">$ 1,773,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">114,955<span></span>
</td>
<td class="nump">56,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,467,745<span></span>
</td>
<td class="nump">916,903<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,100,846<span></span>
</td>
<td class="nump">2,747,219<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(3,100,846)<span></span>
</td>
<td class="num">(2,747,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="num">(228,568)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">6,617<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses</a></td>
<td class="num">(221,951)<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(3,322,797)<span></span>
</td>
<td class="num">(2,748,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,322,797)<span></span>
</td>
<td class="num">$ (2,748,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (.29)<span></span>
</td>
<td class="num">$ (.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares - basic and diluted</a></td>
<td class="nump">11,508,843<span></span>
</td>
<td class="nump">7,422,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636049712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management makes estimates that affect certain
accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments
or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white"><u>Principles
of Consolidation</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company&#8217;s
consolidated financial statements include all accounts of the Company and its consolidated subsidiary and/or entities as of reporting
period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white"><u>Basis
of Presentation</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The accompanying
unaudited condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally
included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant
to such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily
indicative of the results that may be expected for the year ended December 31, 2020. The balance sheet at December 31, 2019 has
been derived from the audited financial statements at that date. For further information, refer to the financial statements and
footnotes thereto included in ENDRA Life Sciences Inc. annual financial statements for the twelve months ended December 31, 2019
included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 26, 2020.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white"><u>Cash
and Cash Equivalents</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company
considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid
investments with maturities of one year or less, when purchased, to be cash. As of March 31, 2020 and December 31, 2019, the Company
had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured
limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial
institutions and has determined the credit exposure to be negligible.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;<u>Inventory</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company&#8217;s
inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average
cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation
or obsolescence of inventory.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white"><u>Capitalization
of Fixed Assets</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Company
capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one
year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3)
all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less
than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed
as incurred.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue Recognition</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, &#8220;Revenue from Contracts with
Customers&#8221; (&#8220;ASC Topic 606&#8221;). This standard provides a single set of guidelines for revenue recognition to be
used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its
core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects
the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated
guidance effective January 1, 2018 using the full retrospective method. The new standard did not have a material impact on its
financial position and results of operations, as it did not change the manner or timing of recognizing revenue.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ASC Topic 606, in order to recognize revenue,
the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of
each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that
the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of
ASC Topic 606 did not have an impact on the Company&#8217;s operations or cash flows.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Research and Development Costs</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB Accounting Standards
Codification (&#8220;ASC&#8221;) Subtopic 730-10, &#8220;Research and Development&#8221;. Research and development costs are charged
to the statement of operations as incurred. During the three months ended March 31, 2020 and 2019, the Company incurred $1,518,146
and $1,773,498 of expenses related to research and development costs, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Net Earnings (Loss) Per Common Share</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes earnings per share under
ASC Subtopic 260-10, &#8220;Earnings Per Share&#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss)
attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the
denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average
number of additional shares that could have been outstanding from securities convertible into common stock (using the &#8220;treasury
stock&#8221; method), unless their effect on net loss per share is anti-dilutive. There were 19,992,774&#160;and 24,949,725 potentially
dilutive shares, which include shares of common stock issuable upon the exercise or conversion of outstanding preferred stock,
stock options, warrants, and convertible notes, as of March 31, 2020 and&#160;December 31, 2019,&#160;respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The potentially dilutive shares, which are excluded
from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Options to purchase common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,579,737</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">3,449,319</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Warrants to purchase common stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,451,823</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,496,924</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">31,603</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">362,568</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of Series A Preferred Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,806,805</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7,285,651</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon conversion of Series B Preferred&#160;Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">122,806</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">355,263</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Potentially dilutive shares excluded</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>19,992,774</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>24,949,725</b></font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><u>Fair Value Measurements</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">Disclosures
about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance
sheet, where it is practicable to estimate that value.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In accordance
with ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; the Company measures certain financial instruments at
fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance
with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">Fair value
is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These
tiers include:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; <font style="background-color: white">Level 1, defined as
observable inputs such as quoted prices for identical instruments in active markets;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; <font style="background-color: white">Level 2, defined as
inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar
instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; <font style="background-color: white">Level 3, defined as
unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such
as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial assets are considered Level 3 when
their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one
significant model assumption or input is unobservable.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s
financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and
other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of
notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations
are the same as prevailing market rates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Share-based Compensation</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s 2016 Omnibus Incentive Plan
(the &#8220;Omnibus Plan&#8221;) permits the grant of stock options and other share-based awards to its employees, consultants
and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus
Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number
of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming
the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding
options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined
by the board. On January 1, 2020, the pool of shares issuable under the Omnibus Plan automatically increased by 3,202,280 shares
from 2,649,378 shares to 5,861,658. As of March 31, 2020, there were 2,281,921 shares of common stock remaining available for issuance
under the Omnibus Plan.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company records share-based compensation
in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use
of option-pricing models that require the input of highly subjective assumptions, including the option&#8217;s expected life and
the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes
option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expense recognized during
the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures.
The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable,
in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan
as described above.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;<u>Debt Discount</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines if its outstanding convertible
promissory notes should be accounted for as liability or equity under ASC Topic 480, &#8220;Liabilities &#8212; Distinguishing
Liabilities from Equity.&#8221; ASC Topic 480 applies to certain contracts involving a company&#8217;s own equity, and requires
that issuers classify the following freestanding financial instruments as liabilities: mandatorily redeemable financial instruments,
obligations that require or may require repurchase of the issuer&#8217;s equity shares by transferring assets (e.g., written put
options and forward purchase contracts), and certain obligations where at inception the monetary value of the obligation is based
solely or predominantly on:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#9679; A fixed monetary amount known at inception (for example,
a payable settleable with a variable number of the issuer&#8217;s equity shares with an issuance date fair value equal to a fixed
dollar amount);</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Variations in something other than the
fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the S&#38;P 500 and settleable with
a variable number of the issuer&#8217;s equity shares); or</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Variations inversely related to changes
in the fair value of the issuer&#8217;s equity shares (for example, a written put that could be net share settled).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><u>Beneficial Conversion Feature</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the conversion feature of conventional convertible
debt provides for a rate of conversion that is below market value on the date of issuance, this feature is characterized as a beneficial
conversion feature (&#8220;BCF&#8221;). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 &#8220;Debt
with Conversion and Other Options.&#8221; In those circumstances, the convertible debt is recorded net of the discount related
to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company determines the instrument meets
the guidance under ASC Topic 480, the instrument is accounted for as a liability with a respective debt discount. The Company has
previously recorded debt discounts in connection with raising funds through the issuance of promissory notes. These costs are amortized
to noncash interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of
the unamortized amounts is immediately expensed. See Note 6, Convertible Notes, for further discussion on the Company&#8217;s accounting
treatment for the convertible notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Going Concern</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial statements are
prepared using accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) applicable to a going concern,
which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited
commercial experience and had a cumulative net loss from inception to March 31, 2020 of $48,540,234. The Company had working capital
of $2,221,823 as of March 31, 2020. The Company has not established an ongoing source of revenue sufficient to cover its operating
costs and to allow it to continue as a going concern. The accompanying financial statements for the period ended March 31, 2020
have been prepared assuming the Company will continue as a going concern. The Company&#8217;s cash resources will likely be insufficient
to meet its anticipated needs during the next twelve months. The Company will require additional financing to fund its future planned
operations, including research and development and commercialization of its products.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the Company to continue as a going concern is dependent
on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable.
Management&#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and
borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.
As described further below under &#8220;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; the COVID-19 pandemic has impacted our business operations to some extent and is expected to continue to do so
and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. If the
Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce
the scope of or eliminate one or more of the Company&#8217;s research and development activities or commercialization efforts or
perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its
ability to successfully secure other sources of financing and attain profitable operations. There is substantial doubt about the
ability of the Company to continue as a going concern for one year from the issuance of the accompanying consolidated financial
statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent Accounting Pronouncements</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In May
2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; ASU 2014-09 is a comprehensive revenue
recognition standard that superseded nearly all previous revenue recognition guidance under U.S. GAAP and replaced it with a principle-based
approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised
goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue
and cash flows arising from contracts with customers. The FASB has since issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12,
and ASU 2016-20, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim
and annual periods beginning after December 15, 2017. The standard can be adopted either retrospectively to each prior reporting
period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance
recognized at the date of initial application (the cumulative catch-up transition method). The Company has reviewed ASU 2014-09
and using the full retrospective method has determined that its adoption has had no impact on its financial position, results of
operations or cash flows. The Company adopted the provisions of this standard in the first quarter of fiscal 2018.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02,
&#8220;Leases.&#8221; ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance
sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning
after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for
capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial
statements. The Company evaluated the impact that the application of the new standard has on its consolidated financial statements
and related disclosures, and determined that it should record a total lease liability of $431,363, with a corresponding right of
use asset valued at $430,681. The Company adopted the provisions of this standard in the first quarter of fiscal 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued
by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did
not or in management&#8217;s opinion will not have a material impact on the Company&#8217;s present or future consolidated financial
statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6754878432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Jul. 18,  2007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">State of incorporation</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791230080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Current liabilities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%"><font style="font-size: 8pt">Accounts payable</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">1,240,687</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">1,278,431</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued payroll</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">95,656</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">94,862</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued bonuses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">97,114</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">295,794</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued employee benefits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,750</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,750</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accrued interest</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,828</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9,738</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Insurance premium financing</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">23,950</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Total</b></font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>1,444,035</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 8pt"><b>1,708,525</b></font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791324176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">$ (508,111)<span></span>
</td>
<td class="num">$ (486,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">237,015<span></span>
</td>
<td class="nump">236,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember', window );">Property, leasehold and capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">684,418<span></span>
</td>
<td class="nump">679,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=NDRAU_TAEUSDevelopmentAndTestingMember', window );">TAEUS development and testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 60,708<span></span>
</td>
<td class="nump">$ 43,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=NDRAU_PropertyLeaseholdAndCapitalizedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=NDRAU_TAEUSDevelopmentAndTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=NDRAU_TAEUSDevelopmentAndTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M77_X785=;^S._F/CBZ!JX-==J"]02P,$%     @ &8NN4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MK+W?M!-!Z^[N%O07R.P?4$L#!!0    ( !F+KE"VC@77_P(  &@+   8
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M(L/>2:'A9(CME>+F]0@2AYQNZ9OC232M"PY69!UOX#NX']W)>(O-+)50H*U
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MWOBS&<=L-!QVTP]B\S<N_@!02P,$%     @ &8NN4*GDL-BT 0  T ,  !@
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M/(/"(:=;^N9XEDWKHX,562<:^ +^:W>QP6(S2R4U&"?1$ MU3A^WI_,^QJ>
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M'E\V]K\VQ@-*V5WA"+7XP19#0NW#\1;/=AJSR?"FGW\06[YQ\0Y02P,$%
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MH/,O&_M?(SKP4I(;/T*M_V"+H:!VX?C)G\TT9I/AL)]_$%N^<?$74$L#!!0
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MG"<9NP2A&7.<,'R%V2\(YM67$'PKQ)'_1^?;]&0SPR32DW7TVW1;(-T42*-
M^J'$]%.)6YCK3T'8JJ<*3!.GR9(2!QTG>>5=!O:>QS=YAT_3_E.8IM.6G-'Y
MEXW]KQ$=^%1V5WZ$6O_!%D-"[<+QUI_--&:3X;"??Q!;OG'Q#U!+ P04
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M_C?6!L!4LAL<H0X_V&(H:$(\WN'936,V&<'V\P]BRS<N_P)02P,$%     @
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MK)_F;JZ[=M<MK&K[5IX,WQ.+?U!+ P04    "  9BZY0YX/2\U@"  #<!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q]56%OFS 0_2N([RO!& P1
M02J)IDW:I*I3M\].<@FH@)GMA.[?SS:44'#Z!>SCO7?O#G.D'>.OH@"0SEM=
M-6+C%E*V:\\3AP)J*AY8"XUZ<F*\IE)M^=D3+0=Z-*2Z\M!J%7DU+1LW2TWL
MB6<IN\BJ;.").^)2UY3_RZ%BW<;UW?? <WDNI YX6=K2,_P"^=(^<;7S1I5C
M64,C2M8X'$X;]]%?[V*--X#?)71BLG9T)7O&7O7F^W'CKK0AJ. @M0)5MRML
MH:JTD++Q=]!TQY2:.%V_JW\UM:M:]E3 EE5_RJ,L-F[L.D<XT4LEGUGW#89Z
M0M<9BO\!5Z@47#M1.0ZL$N;J'"Y"LGI0459J^M;?R\;<N_X)"0::G8 & AH)
M*O=GA& @!#<"_I2 !P*^$2+3K;X4TYL=E31+.>L<WK_=ENI#Y*^QZOY!!TVS
MS3/5'J&BUPQAG'I7+31@\AZ#)AC_(V*W1*" C!A/.1AM()N-'"T%/J;8+A&$
MS%PL(?=,!-9>!(8?3.L,8[L M@I@(X"G'I-9+WM(9"#-D,./?1S-RK7@" EP
M<L=/:/43+OP@',X,]9APFBA)$D3([!3LED"$$YP0%-HM159+D<72K/8\6F9"
ML9\@WYZ(6!,12Z+9@<G)HLE?<!SB%0KFQ=N0(?()OG?"8JNIV&(JGIF*EZD0
M0GZ,@EDF;_*-U\#/9GX*Y\ NC=2?P20ZCNA'I&?$+)[[ZVT_:6\R_=S_2?FY
M;(2S9U)-(#,G3HQ)4#Y7#^H%%>I7,VXJ.$F])&K-^X';;R1KAW^)-_[0LO]0
M2P,$%     @ &8NN4/2%W"JV 0  U0,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL?5/M;ML@%'T5Q ,4V[A)&]F6UDS3)JU2U&G;;V)?QZA\>$#B
M]NT+V+&\S-H?P[V<<S@'0S%H\VH[ (?>I%"VQ)US_8X06W<@F;W3/2B_TFHC
MF?.E.1';&V!-)$E!LB39$,FXPE41>P=3%?KL!%=P,,B>I63F_0F$'DJ<XFOC
MA9\Z%QJD*GIV@A_@?O8'XRLRJS1<@K)<*V2@+?&G=+>G 1\!OS@,=C%'(<E1
MZ]=0?&M*G 1#(*!V08'YX0)[$"((>1M_)DT\;QF(R_E5_4O,[K,<F86]%K]Y
MX[H2/V#40,O.PKWHX2M,>>XQFL)_APL(#P]._!ZU%C9^47VV3LM)Q5N1[&T<
MN8KC,*[D5]HZ(9L(V4Q(\_\2Z$2@-P0R.HM1/S/'JL+H 9GQ9_4LW(ET1_UA
MUJ$9SRZN^;36=R]5EC\6Y!*$)LS3B,F6F+\1^W\1=#M#B#<PN\A676213Q?\
M=).L"]!5 1H%\H5 GMZD&"&;"%'C'MO\D=[?1%F!I33/LQLW9'' X<(_,W/B
MRJ*C=OY?Q1-MM7;@)9,[?XLZ_\;F0D#KPG3KYV:\:6/A=#\](C*_Y.H#4$L#
M!!0    ( !F+KE!/FI[:# (  ,,%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;(V476^;,!B%_PKB?C4?-I"((*U,TR9M4M1IV[5#W@14@YGMA.[?
MSS84$>)5O<$?G/?X.08['[AXEC6 \EY:ULF=7RO5;Q&250TME0^\ATZ_.7'1
M4J6'XHQD+X >;5'+4!0$"6IIT_E%;N?VHLCY1;&F@[WPY*5MJ?C["(P/.S_T
M7R>>FG.MS 0J\IZ>X0>HG_U>Z!&:78Y-"YUL>.<)..W\C^&V3(W>"GXU,,A%
MWS-)#IP_F\'7X\X/#! PJ)1QH+JY0@F,&2.-\6?R].<E3>&R_^K^V6;760Y4
M0LG9[^:HZIV?^=X13O3"U!,?OL"4A_C>%/X;7(%IN2'1:U2<2?OTJHM4O)U<
M-$I+7\:VZ6P[C&\PF<K<!=%4$,T%(7ZS()X*XE4!&LELU$]4T2(7?/#$^+%Z
M:OZ)<!OKS:S,I-T[^TZGE7KV6D0DR-'5&$V:QU$3+36WBO)>$:>S!&F F2)R
M4D2V'M]0A"N*49-836<U'TB0A>%*5SIT.$M(A-U L1,HO@/"9,4S2LABG2A.
M@W E*UVR9)GNA@8[:;!C>R*W 7$:$(=!O,I#[D"3#.,P6^5QR-)-F&[<.(D3
M)W'@_.?SI$Z#]!UYTKO_( G28!WG7H5CLDE6,&AQG,SU]IV*<]-)[\"5/IGV
M_)PX5Z =@P>]-[6^4><!@Y,RW53WQ7BOC /%^^G*1/.]7?P#4$L#!!0    (
M !F+KE!7 H!DX $  &8$   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;'U4ZVZ;,!1^%<L/4(=+2!<!4D-5;=(F19W6_7;@<%%MS&PG=&\_7RBE"=H?
M;!]_WW<N/H=T%/)5M0 :O7'6JPRW6@][0E39 J?J3@S0FYM:2$ZU.<J&J$$"
MK1R),Q)N-@GAM.MQGCK;4>:I.&O6]7"42)TYI_+O 9@8,QS@=\-SU[3:&DB>
M#K2!GZ!_#4=I3F16J3H.O>I$CR34&7X(]D5L\0[PTL&H%GMD,SD)\6H/WZH,
M;VQ P*#45H&:Y0(%,&:%3!A_)DT\N[3$Y?Y=_<GE;G(Y406%8+^[2K<9OL>H
M@IJ>F7X6XU>8\MEB-"7_'2[ #-Q&8GR4@BGW1>59:<$G%1,*IV]^[7JWCOXF
MCB;:.B&<".%,,+[_1X@F0O1!<-4D/C*7ZB/5-$^E&)'TCS50VQ/!/C+%+*W1
MU<[=F6R5L5[R<+M-R<4*39B#QX0+3# CB%&?781K+@[A#3W\[*"X1>QVZQZB
MU20BQX^6 2;1ND"\*A [@?A3%9*K*GA,XC"]QP3;^RM4<8L*OB11>!4,63P/
M!]FX3E:H%.=>VT(LK/.P/(3V>:_L!S-$ON<_9/P$_J"RZ7J%3D*;YG%/7 NA
MP02YN3-MW9JAGP\,:FVW.[.7OO7]08MAFFHR_UKR?U!+ P04    "  9BZY0
MV@S>SD@"   C!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R%E=N.
MFS 417\%\0$#^ 9$)%)#5;52*T53M7UV$B>@ 4QM)TS_OK9A*#%N^Q+?]MEG
M'<?8Q<#%BZP84\%KVW1R&U9*]9LHDJ>*M50^\9YU>N7"14N5'HIK)'O!Z-D&
MM4T$XIA$+:V[<%?8N8/8%?RFFKIC!Q'(6]M2\6O/&CYLPR1\FWBNKY4R$]&N
MZ.F5?67J6W\0>A3-+N>Z99VL>1<(=MF&[Y)-F1N]%7ROV2 7_<!4<N3\Q0P^
MG;=A;(!8PT[*.%#=W%G)FL88:8R?DV<XIS2!R_Z;^P=;NZ[E2"4K>?.C/JMJ
M&V9A<&87>FO4,Q\^LJD>' 93\9_9G35:;DATCA-OI/T-3C>I>#NY:)26OHYM
MW=EV&%=(,H7Y \ 4 .: !/TS $X!T F(1C);ZGNJZ*X0? C$^&?UU)R)9 /U
M9I[,I-T[NZ:KE7KVO@,X+:*[,9HT^U$#EII'1;E6P#\FD0:8*8"7 MAXN(A/
M"/$;0*\!M ;HH8S,*6/4$*OIQB0 Q21SRBU]NC1#,/$#(2\0\@#E#M"HP8M$
M.2:8.#@>%<H(\,-@+PQ>PY#8@<'K-&F2( =FK0(Y3G/DIR%>&N*A21P:LLJ#
M4^P@E_\1/:"D7I34@^*<[7VZRH(RX)RM<BW*4YCY43(O2N9!@0Y*MLKB;LE:
M 6#^MSW)O2#Y"B2)W<.2KS\1A% ,L8/CT:5QA@%V@*+%=66>CR]47.M.!D>N
M],UG[Z<+YXIIS_A)5U?I%VL>-.RB3#?5?3'>V^- \7YZDJ+Y7=S]!E!+ P04
M    "  9BZY0LM.C99,"  !-"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6R-EF&OVB 4AO]*TQ]@H05;C9I,EV5+ML3<9=MG5-3FMJ4#U+M_/Z"]
M30MX6S]8H.\Y/,#)6U8/QE_%E5(9O)5%)=;A5<IZ&47B>*4E$3-6TTJ].3->
M$JFZ_!*)FE-R,D%E$<4 S*.2Y%6X69FQ/=^LV$T6>47W/!"WLB3\WY86[+$.
M8?@^\))?KE(/1)M532[T)Y6_ZCU7O:C+<LI+6HF<50&GYW7X"2YW$.L H_B=
MTX?HM0.]E -CK[KS[;0.@2:B!3U*G8*HQYWN:%'H3(KC;YLT[.;4@?WV>_8O
M9O%J,0<BZ(X5?_*3O*[#+ Q.]$QNA7QACZ^T71 .@W;UW^F=%DJN2=0<1U8(
M\Q\<;T*RLLVB4$KRUCSSRCP?S1N4MF'^@+@-B+L B#X,2-J Q J(&C*SU,]$
MDLV*LT? F].JB2X*N$S49A[UH-D[\TZM5JC1^R:>HU5TUXE:S;;1Q'W-4+%S
M%4G:22(%T%'$7HK8Q*->_#RS(!I):B25D8 9  !:)*.R 4WBI4E<FH5%TTAP
M;QH,FI_%,T$X($)>(N00I=9$6^1,!!.,$P"P1>0*,Q1#]&R+L!<(NT#626SQ
M5"!7^"'0W LT=\\,^>-3;WSJ+L@J\FTZK0)'90.:S$N3N32)19.YV^LIOS'5
M@&7A95FX++9!-)*L-TN,$)PM;)L8UPUX(/!;%G")L&U98"+2!.&0Z8F-0K?^
MYD\R^"T0NA[H5""<:(+CNB&1WP:AZX-.%4+7WZ!;A6.J(8W? J'' YT/%7(.
M$\9PAC.;9U0W)/)[(/28H%.'>"+1J*XABGK?=7W1^D'X):]$<&!271',A_S,
MF*0J)YBIG%=UM^LZ!3U+W4Q5FS<7G*8C6=U>WJ+N!KGY#U!+ P04    "  9
MBZY01K*50<$"  "["@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R-
MEF^OFC 4QK\*X0,(+7]:#)KH798MV1)SEVVOJU8E%RAKJ]Y]^Y6"#,LAN6^D
M+4_/[Q1[GIS\+N2;NG"NO?>JK-7*OVC=+(- '2Z\8FHA&EZ;-R<A*Z;-5)X#
MU4C.CG93508X#-.@8D7MKW.[MI/K7%QU6=1\)SUUK2HF_VYY*>XK'_F/A=?B
M?-'M0K#.&W;F/[C^V>RDF05#E&-1\5H5HO8D/ZW\#5INL=U@%;\*?E>CL=<>
M92_$6SOY>ESY89L1+_E!MR&8>=SX"R_+-I+)XT\?U!^8[<;Q^!']LSV\.<R>
M*?XBRM_%45]6/O6](S^Q:ZE?Q?T+[P^4^%Y_^F_\QDLC;S,QC(,HE?WU#E>E
M1=5',:E4[+U[%K5]WKLWY+$-WH#[#7C8$-D-00>RF7]BFJUS*>Z>[#Y^P]K_
M&"VQ^3:'=M%^"OO.)*_,ZFV-TR0/;FV@7K/M-'BD08,B,-$'!(806SS9CM,4
M#A"!.48V0#3FDQ@.$(,!8AL@?LJ .(?L-(G5U%83Q7$6H0P&)2 H 4#4 243
M$(K"&%&8DX*<%.!D#B>=<$(804 $F2)(Z"#(1Q$41%  @1P$_2@B Q$9@, .
M(IO^\PG)2$1@$ KA0@H!5.164CAAT21%HY2>43,UBP!4[*+ZR@Y'++R(YDA@
MZ6X0!D@3>X!$,P6.X I'$1#"K5!0-%,V"#8"!#@!<0L'%,UQ8!] @!%0MWH@
MT2P']@$$& %U2Z@7T:>+@&<,%,%N@  [H&XA]:*G*Q<OR%P=P::  %>@DSJ"
M1',G@IT! =9 )U<;$LU<;0S[ @9\@;I7&Q3-7 4,FP(&3(&Z5QL29:ZA!J/>
MH>+R;+LFY1W$M;8MVVAUZ,PVV/8>_^5=6_>=R7-1*V\OM.E@;)]Q$D)SDTNX
M,-?_8CK)85+RDVZ'Q(QEUTYU$RV:OE4,AGYU_0]02P,$%     @ &HNN4*5/
M6"*[ @  OPH  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULE9;=CILP
M$(5?!7'?@,V?B9)(R595*[72:JMMKYW$2= "IK:3;-^^MB%LUHRE[0U@<V8^
M&\9'L[AR\2)/C*G@M:E;N0Q/2G7S*)*[$VNHG/&.M?K-@8N&*CT4QTAV@M&]
M#6KJ",=Q'C6T:L/5PLX]BM6"GU5=M>Q1!/+<-%3\W;":7Y<A"F\33]7QI,Q$
MM%IT],A^,O7</0H]BL8L^ZIAK:QX&PAV6(9K--]@&V 5ORIVE7?/@=G*EO,7
M,_BV7X:Q61&KV4Z9%%3?+NR!U;7)I-?Q9T@:CDP3>/]\R_[%;EYO9DLE>^#U
M[VJO3LN0A,&>'>BY5D_\^I4-&\K"8-C]=W9AM9:;E6C&CM?27H/=62K>#%GT
M4AKZVM^KUMZO_9OB%@8'X"$ CP&)#8AZD%WY9ZKH:B'X-1#]Q^^H^<=HCO6W
MV9E)^RGL.[UXJ6<O*URB170QB0;-IM?@.\V;(M+91P2&$!L\"<=Y#B=(P#4F
M-D%RSR]2.$$*)DAM@O3=)K&SR5Z364W;0Y*TS$OL(64@*0-(B4/*)J081N0@
M(@<0J8/()XA/:89BSV\K0$X!<#*'4WQT*P1$$ "1.PCR440)(DH 43B($OKU
M&2(X@4DHAH]2#+"(>Y;B_X5YSBV:P@JW# :188XT/(NQAP0>WS7" ,DM!%!$
M/!SXE*,$2.'^*DA4EAX.; 8(<(.B=#F0R+<?V K0U N2.'8Y@&%X.; ?(, 0
MR,3">Q%Y7PB^DH,- 0&.0%P;'41NR?E(L"\@P!B(:Z. */$Y'(+- 0'N0":E
M/14EOB.$86? @#,0M[0!4>+[;A@V!0R8 G%+&Q!-.=%=_] P<;2=DPQV_-S:
MMNUN=NS.UMCV'V_ROK7[0<6Q:F6PY4IW,;;7.'"NF%Y+/-/E?]+=Y#BHV4&9
MQT(_B[ZEZ@>*=T.[&(T]Z^H?4$L#!!0    ( !J+KE#Q\&;'=0(  "4(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;(V6W8[;(!"%7\7R?=> \5^4
M1&H25:W42JNMMKTF"4FLM8T+)-Z^?0%[4R\>5\U%#/C,?&? !B\[(5_4A7,=
MO-95HU;A1>MV$47J<.$U4P^BY8VY<Q*R9MITY3E2K>3LZ(+J*B((I5'-RB9<
M+]W8HUPOQ5579<,?9:"N=<WD[PVO1+<*<?@V\%2>+]H.1.MER\[\.]?/[:,T
MO>B>Y5C6O%&E: +)3ZOP(U[L,+$!3O&CY)T:M0-;REZ(%]OY<ER%R#KB%3]H
MFX*9RXUO>5793,;'KR%I>&?:P''[+?LG5[PI9L\4WXKJ9WG4EU68A\&1G]BU
MTD^B^\R'@I(P&*K_RF^\,G+KQ# .HE+N/SA<E1;UD,58J=EK?RT;=^WZ.PD9
MPN  ,@20>P"F_PR(AX#X?P/H$$"]@*@OQ<W-CFFV7DK1!;)?WI;9IP@OJ)G]
M@QUTD^WNF>E19O2VCA%=1C>;:-!L>@T9:<A[Q7:JB+/WDMU4DOV51,;CW2@!
MC1(7'X_B<5; "6(P0>P2T+''V"NTEZ1.TO0>*2H(3*$@A4XI*/$PO28983#"
M63+#24!. G!2CY, ')H5,<Q)04X*<+REW:0 )RL2"G,RD),!G-SC9%..^<VM
M3PYR\@D'(^1Q\@F'%D66S]13@)P"J*?P.,6$\P&C),XP#,((?H/1%(7]D@;1
MF!47E&+BOZ5H\@J@&3<S^PD&W&#?#9ZX2?/47^_M(!N;25,\]_QB>-_ !#!$
M?$-D0HI)DOL[X1;249)C_Q&,1MNO/4"_,7DN&Q7LA38[N=MO3T)H;G*B!S,-
M%W-FWSL5/VG;S$Q;]@=7W]&B'0[EZ/YEL/X#4$L#!!0    ( !J+KE"TJB-G
MX $  &8$   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;'U466[;,!"]
M"L$#A-H2NX8D('91M$ +&"F:?M/2:$&XJ"1MI;<O%T51;*$_(CE\[\W"&>6C
M5"^Z S#HE3.A"]P9,^P(T54'G.H[.8"P-XU4G!I[5"W1@P):>Q)G)(FB!\)I
M+W"9>]M1E;D\&]8+."JDSYQ3]7</3(X%CO&;X:EO.^,,I,P'VL)/,+^&H[(G
M,JO4/0>A>RF0@J; C_'ND#F\!SSW,.K%'KE,3E*^N,.WNL"1"P@85,8I4+M<
MX ",.2$;QI])$\\N'7&Y?U/_XG.WN9RHAH-DO_O:= 7>8E1#0\_,/,GQ*TSY
MW&,T)?\=+L LW$5B?522:?]%U5D;R2<5&PJGKV'MA5_'<'._G6CKA&0B)#/!
M^OX?(9T(Z3O!5Y.$R'RJGZFA9:[DB%1XK(&ZGHAWJ2UFY8R^=O[.9JNM]5*F
M<9J3BQ.:,/N 21:8>$80JSZ[2-9<[),;>O+1P>$6L=FL>TA7DT@]/UT&N/FT
M+I"M"F1>(/M0A>RJ"@'SX#$B8*)DN[U*Y1:5I/$"%8(AB^?AH%K?R1I5\BR,
M*\3".@_+8^*>]\J^MT,4>OY=)DS@#ZK:7FATDL8VCW_B1DH#-LCHSK9U9X=^
M/C!HC-MN[%Z%U@\'(X=IJLG\:RG_ 5!+ P04    "  :BZY09X$JMOU=  #?
M6P$ %    'AL+W-H87)E9%-T<FEN9W,N>&UL[;UY<]S8E2_X=]]/@?#([Y$1
M8%;N2Y6[(BA**JN[JL0G2O9T3,P?R$R0A)692 -(473,AY^SW@5+,JE2N?N]
MZ&BW+9+ Q5W./>OOG/.GLJRB+]O-KOS7/]Q7U?[[[[XK5_?I-BE[^3[=P5]N
M\V*;5/!C<?==N2_29%W>IVFUW7PW[/>GWVV3;/>'Z+#+_GY(K_+#KOK7/XP&
MDS_\^*<R^_%/U8^O\M5AF^ZJ*-FMH]>[*JL>H[<['C/+=]%%5-XG15K^Z;OJ
MQS]]A^_P>Z/HEWQ7W9?PSCI=U__Z2U+THM$@CH;]8;_YQ\=H,&[_VQ/3J3\N
M3[Q/[[*R*A)X[]=DFS:>^O75^\OHY^PVC6Y66;I;I24,NNIU?OS#X[XQR*!_
M\;\Z7[A.BRS'":^C5TG5>%>WP_S+O[0M^A+&6-,X;S;)7?VOM\FF;"Z)%WX%
M+Q7)!E:S3K]$_YX^UI_K]_N#Z1S^,ZS_Y>I0%/3)K%S!"/^1)D7G_"\N!L.+
MT:!K$OEV"Y1R4^6K3W%T0^02O3M4906'F.T:"Y+7WF2;M(BNX'-W>=&8^*_Y
M[B)9K5)X!IY8\],=([W>IL4=?"CZJ<@?JGN<T#[9-8:LBD/7/K[^$GT \BDS
MHGD^S8Y';[;)9A.]/)39+BT;UT*W1#;W?;K/BPJG=E,EU:'Q^'\T+Y9^YCZ%
MSW2LQ%Z,"G9G566?4SRV1#_;^?@J+V ^=)-BFE$:Y7 $R!4*/,=U8W]>O3YR
M>M&OA^VR>2I <A>CV6*ZZ+PN/LV]@5\V-N$H:Y"WY<ZUOO^_&K1ZE<,5V95
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MFK$Y@?S7[C82+ZP=GDL\@R,!D9ZQM>N=?Y&2&7)'UU0IB;</?WJXSU;W47E
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M:A'#MBT,.L:S&[9]]C5<TP$Q1O]0;6*98?\V#/_N*Z4T!U]2 )?J'!-6@)!
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M0<D5*B9^&RE3I\"!=2P^25Q!.T ]+$+O4CB\ S,8&]OEO VIV]6Z(XE]=)P
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M)2(XV)]P2FIV;0L.]^KX.U!+ P04    "  :BZY0G9OADVH#  !X&   #P
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M0WM*\W2JB/W9K-=[?5M7+ZH\OX&V!W$O:;TW;:^QW?2__ =02P,$%     @
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M77(U_&[-"&X?+I5]?,8P]>[^D=*AWV+-<'VX.L/4WPAS=0*]_0%02P,$%
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M%_CL"U!+ 0(4 Q0    ( !F+KE ?(\\#P    !,"   +              "
M 0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !F+KE GZ(<.@@   +$    0
M              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M&8NN4,W;'VOO    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ &8NN4)E<G",0!@  G"<  !,
M ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  9BZY0ALEZ
M5Z\"  #8"@  &               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ &8NN4*"(IMX"!   5A(  !@
M ( !W0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !F+
MKE"5%EJYDP(  $P*   8              "  140  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  9BZY0MHX%U_\"  !H"P  &
M        @ '>$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ &8NN4+X\,LVV!   P!8  !@              ( !$Q8  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !F+KE"06ET48 0  (44   8
M              "  ?\:  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  9BZY0##E>O+ !  #2 P  &               @ &5'P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ &8NN4'9@7@2U 0
MT@,  !@              ( !>R$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( !F+KE"IY+#8M $  - #   8              "  68C
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  9BZY0%-;F
M?+0!  #2 P  &0              @ %0)0  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( !F+KE"FEBI6M $  -(#   9
M  "  3LG  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M&8NN4"V,K)"V 0  T@,  !D              ( !)BD  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  9BZY0N6/L2;,!  #1 P  &0
M            @ $3*P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( !F+KE !'PX=M $  -(#   9              "  ?TL  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ &8NN4#8(B02T 0
MT@,  !D              ( !Z"X  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  9BZY0:)3DXK8!  #2 P  &0              @ '3
M,   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !F+KE B
MY%JAM $  -(#   9              "  < R  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ &8NN4"VN)V-[ @  <PD  !D
M     ( !JS0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !F+KE"CNP-=MP$  -(#   9              "
M 1,_  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ &8NN
M4+/?WB&W 0  T@,  !D              ( ! 4$  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  9BZY0%OYI>\0!   V!   &0
M        @ 'O0@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( !F+KE O<$B:?0(  %L(   9              "  >I$  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ &8NN4.>#TO-8 @  W 8
M !D              ( !GD<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  9BZY0](7<*K8!  #5 P  &0              @ $M2@
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !F+KE!/FI[:
M# (  ,,%   9              "  1I,  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ &8NN4%<"@&3@ 0  9@0  !D
M ( !74X  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  9
MBZY0V@S>SD@"   C!P  &0              @ %T4   >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !F+KE"RTZ-EDP(  $T*   9
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M970S-BYX;6Q02P$"% ,4    "  :BZY09X$JMOU=  #?6P$ %
M    @ %J8   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  :BZY0
MTZ.JTDX"  !D"P  #0              @ &9O@  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( !J+KE"=F^&3:@,  '@8   /              "  1+!  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  :BZY0[)9%4(T!  "1%@  &@
M            @ &IQ   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  :BZY07 T#FIP!   *%P  $P              @ %NQ@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     +0 M "T,   [R      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791341376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>COVID-19</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The COVID-19 outbreak, which the World Health
Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to issue &#8220;stay-at-home&#8221;
or similar orders, and enact restrictions on the performance of &#8220;non-essential&#8221; services, public gatherings and travel.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beginning in March 2020, we undertook temporary
precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring most employees
to work remotely, pausing all non-essential travel worldwide for our employees, and limiting employee attendance at industry events
and in-person work-related meetings, to the extent those events and meetings are continuing. To date we do not believe these actions
have had a significant negative impact on our operations. However, these actions or additional measures we may undertake may ultimately
delay progress our developmental goals or otherwise negatively affect our business. In addition, third-party actions taken to contain
its spread and mitigate its public health effects of COVID-19 may negatively affect our business.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Paycheck Protection Program</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the period ended Mach 31, 2020,
the Company issued a U.S. Small Business Administration (&#8220;SBA&#8221;) Paycheck Protection Program Note (the &#8220;Note&#8221;)
to First Republic Bank (the &#8220;Lender&#8221;) for a loan in the amount of $308,600.00 (the &#8220;Loan&#8221;) under the Paycheck
Protection Program (&#8220;PPP&#8221;) promulgated under the Coronavirus Aid, Relief and Economic Security Act of 2020. The Loan
bears interest at a rate per annum of 1.00%. The term of the Loan is two years, ending April 22, 2022 (the &#8220;Maturity Date&#8221;).
No payments are due on the Loan until seven months from April 22, 2020, the date of first disbursement of the Loan (the &#8220;Deferment
Period&#8221;), but interest will accrue during the Deferment Period. Following the Deferment Period, the Company must pay monthly
principal and interest payments on the outstanding principal balance of the Loan amortized over the term of the Loan (the &#8220;Loan
Payments&#8221;), unless forgiven in whole or in part in accordance with the PPP regulations. These repayments will begin following
the Deferment Period and until the Maturity Date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may apply to the Lender for the
Loan to be forgiven partially or fully if the funding received is used during the 8-week period following disbursement for payroll
costs, covered rent, and covered utilities, provided that at least 75% of the forgiven amount has been used for payroll costs.
Forgiveness is based on the Company&#8217;s maintaining, or quickly rehiring, employees and maintaining applicable salary levels.
Forgiveness will be reduced if full-time headcount declines, or if salaries and wages decrease. No assurance is provided that the
Company will obtain forgiveness of the Loan in full or in part.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may prepay the principal of the
Loan at any time without incurring any prepayment charges. The Company may prepay 20% or less of the unpaid principal balance at
any time without notice. If the Company prepays more than 20% and the Loan has been sold on the secondary market, the Company must
provide the Lender with written notice, pay all accrued interest and comply with the other requirements described in the Note for
such repayment.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not provide any collateral or
personal guarantees for the Loan, nor did the Company pay any facility charge to the government or to the Lender.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Note also provides for customary events
of default, including, among others, events of default relating to failure to make payment or comply with the covenants contained
in the Note and related loan documents, defaults on any other loan with the Lender, defaults on any loan or agreement with another
creditor (if the Lender believes the default may materially affect the Company&#8217;s ability pay the Note), failure to pay any
taxes when due, bankruptcy, breaches of representations, judgment, reorganization, merger, consolidation or other changes in ownership
or business structure without the Lender&#8217;s prior written consent, and material adverse changes in financial condition or
business operation. Upon an event of default the Lender may require immediate payment of all amounts owing under the Note, collect
all amounts owing from the Company, or file suit and obtain judgment.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock Issued</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Subsequent to the period ended March 31, 2020,&#160;the Company issued
a total of 929,650 shares of common stock&#160;upon&#160;the conversion of&#160;an aggregate of&#160;808.796 shares of Series A
Convertible Preferred Stock at the request of&#160;its&#160;holder.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Subsequent to the period ended March 31, 2020 the Company issued
a total of 22,099 shares of common stock to a vendor for services which were valued at $40,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638709680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2020, the authorized capital of
the Company consisted of 60,000,000 shares of capital stock, consisting of 50,000,000 shares of common stock with a par value of
$0.0001 per share and 10,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company has designated 10,000
shares of its preferred stock as Series A Preferred Stock and 1,000 shares of its preferred stock as Series B Preferred Stock,
and the remainder of 9,989,000 shares remain authorized but undesignated.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, there were 13,553,005
shares of common stock, 2,441.92 shares of Series A Preferred Stock, and 121.578 shares of Series B Preferred Stock issued and
outstanding, and a stock payable balance of $78,836.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020,
the Company issued 4,520,982 shares of its common stock upon the conversion of 3,896.570 shares of its Series A Preferred Stock,
and 234,080 shares of its common stock upon the conversion of 230.133 shares of its Series B Preferred Stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020,
the Company issued 331,441 shares of its common stock upon the conversion of $493,847 principal amount of, and in respect of accrued
interest on, July 2019 Notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020,
the Company issued 45,101 shares of its common stock upon warrant exercises valued at $39,238.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>December 2019 Offering of Series A Preferred Stoc</i></b><i>k<b>,
Common Stock and Warrants</b></i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 11, 2019, the Company completed
a private placement offering in which the Company sold 6,338.49 shares of its Series A Preferred Stock and 904,526 shares of its
common stock, along with warrants (the &#8220;December 11, 2019 Warrants&#8221;) exercisable for an aggregate of 8,190,225 shares
of common stock, for approximately $7.9 million of gross proceeds. The offering was made pursuant to a Securities Purchase Agreement
(the &#8220;Purchase Agreement&#8221;), dated as of December 5, 2019, between the Company and the investors. Pursuant to the Purchase
Agreement, each investor elected whether to receive shares of Series A Preferred Stock or shares of common stock in the offering.
The Company used approximately $1.9 million of the net proceeds from the offering to repay debt represented by July 2019 Notes
and plans to use the remaining net proceeds for working capital and general corporate purposes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the closing of the offering,
the Company filed a Certificate of Designations of Series A Convertible Preferred Stock (the &#8220;Series A Certificate of Designations&#8221;)
with the Secretary of State of the State of Delaware setting forth the rights and preferences of the Series A Preferred Stock.
Each share of Series A Preferred Stock has a $1,000 issue price (the &#8220;Issue Price&#8221;). Dividends accrue on the Issue
Price at a rate of 6.0% per annum and are payable to holders of Series A Preferred Stock as, when and if declared by the Company&#8217;s
Board of Directors. Shares of Series A Preferred Stock, including accrued but unpaid dividends, are convertible into common stock
at a conversion price of $0.87 per share. The conversion price is subject to proportional adjustment for certain transactions relating
to the Company&#8217;s capital stock, including stock splits, stock dividends and similar transactions. Holders of shares of Series
A Preferred Stock vote with the holders of common stock and are entitled to a number of votes equal to the number of shares of
common stock into which such holder&#8217;s shares of Series A Preferred Stock are then convertible. Holders of Series A Preferred
Stock are entitled to a liquidation preference in the event of any liquidation, dissolution or winding up of the Company based
on their shares&#8217; aggregate Issue Price and accrued and unpaid dividends thereon. Holders may convert their shares of Series
A Preferred Stock into common stock at any time and the Company has the right to cause each holder to convert their shares of Series
A Preferred Stock if at any time (i) the simple average of the daily volume-weighted average price of Common Stock for 10 consecutive
trading days is greater than $1.74 (as adjusted for stock splits, stock dividends and similar transactions) and (ii) there is then
an effective registration statement registering under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
the resale of the shares of common stock issuable upon such conversion of Series A Preferred Stock (the &#8220;Series A Forced
Conversion Conditions&#8221;).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The simple average of the Daily VWAP (as defined
in the Series A Certificate of Designations) for the 10 consecutive trading days from January 8, 2020 to January 22, 2020, inclusive,
was $1.82, satisfying the first Forced Conversion Condition. On January 27, 2020, the SEC declared effective the Company&#8217;s
Registration Statement on Form S-3 (File No. 333-235883) registering under the Securities Act the resale of the shares of common
stock issuable upon the conversion of Series A Preferred Stock, shares of common stock issued in the offering, and shares of common
stock issuable upon the exercise of December 11, 2019 Warrants and December 11, 2019 Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each December 11, 2019 Warrant entitles the
holder to purchase a share of common stock for an exercise price equal to $0.87. The December 11, 2019 Warrants are exercisable
commencing immediately upon issuance and expire on the date five years after the date of issuance, unless earlier terminated pursuant
to the terms of the December 11, 2019 Warrant. If, during the term of the December 11, 2019 Warrants, the Series A Forced Conversion
Conditions are met, the Company may deliver notice thereof to the holders of the December 11, 2019 Warrants and, after a 30-day
period following such notice, any unexercised December 11, 2019 Warrants will be forfeited. The December 11, 2019 Warrants provide
for cashless exercise only if there is no effective registration statement registering under the Securities Act the resale of the
shares of Common Stock issuable upon exercise of the December 11, 2019 Warrants. As described in the preceding paragraph, the Series
A Forced Conversion Conditions have been met with respect to the December 11, 2019 Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Securities Purchase Agreement, dated December
5, 2019, includes customary representations, warranties and covenants. In connection with the offering, the Company paid to the
placement agent a commission of 8.0% of the gross proceeds from the offering, will reimburse up to $35,000 of the placement agent&#8217;s
documented expenses and issued to the placement agent and its designees warrants exercisable for an aggregate of 327,606 shares
of Common Stock (the &#8220;Series A Placement Agent Warrant&#8221;). The terms of the Series A Placement Agent Warrant are the
same as those of the December 11, 2019 Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Series A Preferred Stock Deemed Dividend,
Beneficial Conversion Calculation</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After factoring in the relative fair value of
the warrants issued in conjunction with the Series A Preferred Stock, the effective conversion price is $0.45 per share, compared
to the market price of $0.90 per share on the date of issuance. As a result, a $4,208,612 beneficial conversion feature was recorded
as a&#160;deemed dividend&#160;in the consolidated statement of operations because the Series A Preferred Stock is immediately
convertible, with a credit to additional paid-in capital. The relative fair value of the warrants issued with the Series A Preferred
Stock of $2,766,941 was recorded as a reduction to the carrying amount of the preferred stock in the consolidated balance sheet.
The value of the warrants was determined utilizing the binomial option pricing model using a term of 5 years, a volatility of 114%,
a risk-free interest rate of 1.64%, a 6% rate of dividends, and a call multiple of 2.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>December 2019 Offering of Series B Preferred
Stock and Warrants</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 19, 2019, the Company completed
a private placement offering in which the Company sold 351.711 shares of its Series B Preferred Stock and warrants (the &#8220;December
19, 2019 Warrants&#8221;) exercisable for an aggregate of 426,316 shares of the Company&#8217;s common stock to the investors for
approximately $405,000 of gross proceeds. The Company plans to use the net proceeds from the offering for working capital and general
corporate purposes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the closing of the offering,
the Company filed a Certificate of Designations of Series B Convertible Preferred Stock (the &#8220;Series B Certificate of Designations&#8221;)
with the Secretary of State of the State of Delaware setting forth the rights and preferences of the Series B Preferred Stock.
The Series B Preferred Stock has substantially the same rights and preferences as the Series A Preferred Stock, except for a different
conversion price and trading price of common stock at which the Series B Preferred Stock becomes subject to automatic conversion.
Each share of Series B Preferred Stock has a $1,000 issue price (the &#8220;Issue Price&#8221;). Dividends accrue on the Issue
Price at a rate of 6.0% per annum and are payable to holders of Preferred Stock as, when and if declared by the Company&#8217;s
Board of Directors. Shares of Series B Preferred Stock, including accrued but unpaid dividends, are convertible into Common Stock
at a conversion price of $0.99 per share of common stock. The conversion price is subject to proportional adjustment for certain
transactions relating to the Company&#8217;s capital stock, including stock splits, stock dividends and similar transactions. Holders
of shares of Series B Preferred Stock vote with the holders of common stock and are entitled to a number of votes equal to the
number of shares of common stock into which such holder&#8217;s shares of Series A Preferred Stock are then convertible. Holders
of Series B Preferred Stock are entitled to a liquidation preference in the event of any liquidation, dissolution or winding up
of the Company based on their shares&#8217; aggregate Issue Price and accrued and unpaid dividends. Such liquidation preference
of Series B Preferred Stock holders is on a pari passu basis with holders of Series A Preferred Stock. Holders may convert their
shares of Series B Preferred Stock into common stock at any time and the Company has the right to cause each holder to convert
their shares of Series B Preferred Stock in the event that (i) the average of the daily volume-weighted average price of Common
Stock over any 10 consecutive trading days is greater than $1.98 (as adjusted for stock splits, stock dividends and similar transactions)
and (ii) there is then an effective registration statement registering under the Securities Act the resale of the shares of Common
Stock issuable upon such conversion of Preferred Stock (together, the &#8220;Series B Forced Conversion Conditions&#8221;).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The average daily VWAP requirement of the Series
B Forced Conversion Conditions relating to daily volume-weighted average price of our Common Stock has not yet been satisfied.
On January 27, 2020, the SEC declared effective the Company&#8217;s Registration Statement on Form S-3 (File No. 333-235883) registering
under the Securities Act the resale of the shares of common stock issuable upon the conversion of Series B Preferred Stock and
upon the exercise of December 19, 2019 Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each December 19, 2019 Warrant entitles the
holder to purchase a share of common stock for an exercise price equal to $0.99. The December 19, 2019 Warrants are exercisable
commencing immediately upon issuance and expire on the date five years after the date of issuance, unless earlier terminated pursuant
to the terms of the December 19, 2019 Warrant. If, during the term of the December 19, 2019 Warrants, the Series B Forced Conversion
Conditions are met, the Company may deliver notice thereof to the holders of the December 19, 2019 Warrants and, after a 30-day
period following such notice, any unexercised December 19, 2019 Warrants will be forfeited. The December 19, 2019 Warrants provide
for cashless exercise in the event there is no effective registration statement registering under the Securities Act the resale
of the shares of common stock issuable upon exercise of such December 19, 2019 Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Securities Purchase Agreement, dated December
19, 2019, includes customary representations, warranties and covenants. In connection with the closing of the offering, the Company
paid to the placement agent in the offering a commission of approximately 8.0% of the gross proceeds from the offering and issued
to the placement agent and its designees warrants exercisable for an aggregate of 14,211 shares of common stock (the &#8220;Series
B Placement Agent Warrant&#8221;). The terms of the Series B Placement Agent Warrant are the same as those of the Warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Series B Preferred Stock Deemed Dividend,
Beneficial Conversion Calculation</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After factoring in the relative fair value of
the warrants issued in conjunction with the Series B Preferred Stock, the effective conversion price is $0.03 per share, compared
to the market price of $1.36 per share on the date of issuance. As a result, a $11,165 beneficial conversion feature was recorded
as a deemed dividend in the consolidated statement of operations because the Series B Preferred Stock is immediately convertible,
with a credit to additional paid-in capital. The relative fair value of the warrants issued with the Series B Preferred Stock of
$364,355 was recorded as a reduction to the carrying amount of the preferred stock in the consolidated balance sheet. The value
of the warrants was determined utilizing the binomial option pricing model using a term of 5 years, a volatility of 118%, a risk-free
interest rate of 1.75%, a 0% rate of dividends, and a call multiple of 2.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802211536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 21,586<span></span>
</td>
<td class="nump">$ 19,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790593952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number warrants balance outstanding, beginning | shares</a></td>
<td class="nump">13,496,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number warrants granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number warrants exercised | shares</a></td>
<td class="num">(45,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number warrants forfeited | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Number warrants expired | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number warrants balance outstanding, ending | shares</a></td>
<td class="nump">13,451,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number warrants outstanding, exercisable | shares</a></td>
<td class="nump">13,451,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted | $ / shares</a></td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price exercised | $ / shares</a></td>
<td class="nump">.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price forfeited | $ / shares</a></td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price expired | $ / shares</a></td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, exercisable | $ / shares</a></td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning', window );">Weighted average remaining contractual term outstanding, beginning</a></td>
<td class="text">4 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual term outstanding, granted</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted average remaining contractual term outstanding, ending</a></td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual term outstanding, exercisable</a></td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NDRAU_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWarrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NDRAU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>62</ContextCount>
  <ElementCount>261</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>15</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://endrainc.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Common Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommonStockOptions</Role>
      <ShortName>Common Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommitmentsContingencies</Role>
      <ShortName>Commitments &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://endrainc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://endrainc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://endrainc.com/role/FixedAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://endrainc.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Common Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommonStockOptionsTables</Role>
      <ShortName>Common Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommonStockOptions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommonStockWarrants</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments &amp; Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommitmentsContingenciesTables</Role>
      <ShortName>Commitments &amp; Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommitmentsContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Nature of the Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>Nature of the Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/NatureOfBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Inventory (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/InventoryDetailsNarrative</Role>
      <ShortName>Inventory (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/FixedAssetsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Fixed Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/FixedAssetsDetailsNarrative</Role>
      <ShortName>Fixed Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/FixedAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Capital Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>Capital Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/CapitalStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Common Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommonStockOptionsDetails</Role>
      <ShortName>Common Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommonStockOptionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommonStockWarrantsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Commitments &amp; Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommitmentsContingenciesDetails</Role>
      <ShortName>Commitments &amp; Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommitmentsContingenciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ndrau-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Commitments &amp; Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://endrainc.com/role/CommitmentsContingenciesDetailsNarrative</Role>
      <ShortName>Commitments &amp; Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://endrainc.com/role/CommitmentsContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ndrau-20200331.xml</File>
    <File>ndrau-20200331.xsd</File>
    <File>ndrau-20200331_cal.xml</File>
    <File>ndrau-20200331_def.xml</File>
    <File>ndrau-20200331_lab.xml</File>
    <File>ndrau-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
